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Abstract
TP53 is the most commonly mutated gene in all human cancers [Vogelstein, 1990] and co­
ordinates many of the cellular responses to DNA damage. It is vitally important therefore that we gain 
a better understanding of the function and regulation of p53. Since a major consequence of p53 
mutation is cancer, a disease of complex multicellular organisms, the best system to study the real 
complexities of p53 function and regulation is in vivo. Accordingly we have proposed to use gene 
targeting in ES cells to create genetically altered strains of mice to enable a range of studies of p53 
regulation and function. Given the importance of p53 in human disease processes, it is perhaps 
surprising that there have been relatively few p53 reporter mouse strains described. Heretofore few 
p53 reporter mouse strains have been described and these have been based upon un-targeted, often 
artificial, repeated p53 response elements in constructs that integrate at random [Komarova et al., 
1997, Gottlieb et al., 1997, Vasey et al., 2008, Briat and Vassaux, 2008]. Such random integration is 
known to be associated with loss of fidelity resulting from positional effects and thus it is unlikely that 
any of these provide authentic reporting of p53 activity. The ideal solution might be to target a p53 
responsive gene using a knock-in approach, preferably in a gene that was exclusively activated by 
p53, eliciting a specific response program (cell cycle arrest/senescence/apoptosis) and which also 
does not display any haploinsufficiency. This project was based on such a strategy.
In order to study p53 activation and consequence(s) in the gastrointestinal tract we aim to 
generate novel transgenic mice which would contain fluorescent reporters in the downstream target 
genes of p53 activation in both of p53s main responses to DNA damage (apoptosis and cell cycle 
arrest). The resulting dual apoptosis/cell cycle arrest p53-reporter mice would allow a unique 
opportunity to visualise not only that p53 was activated but what responses p53 had induced. 
Furthermore, as visual technology advances these mice, or second generation mice with newer 
fluorescent proteins with improved bioimaging properties (such as increased tissue penetration and 
brightness), could also be used in real-time analyses of p53 responses to DNA damage or other 
stimuli, as well as for long term monitoring of gene-regulation during cancer development.
In addition, we aim to address fundamental questions regarding the regulation of p53 again 
using such gene targeting technology for in vivo studies. Importantly it is not yet known whether the
i
p53-mediated up-regulation of its essential negative regulator Mdm2 is absolutely required for 
viability. Therefore we intend to make two transgenic mouse strains which lack either the Mdm2 P1 
(constitutive) promoter or the p53 RE sites within the Mdm2 P2 (inducible) promoter. Studies of these 
mice are likely to have a profound impact on the field of cancer biology and normal development.
ii
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1 Introduction
1.1 Introduction to p53
The TP53 tumour suppressor gene is a critical part of the damage control pathways 
that prevent the development of cancer. The importance of p53 is highlighted by the fact that 
TP53 has the greatest number of cancer-associated mutations of any known gene and is 
mutated directly in approximately half of all human cancers [Vogelstein, 1990, Hollstein et al., 
1991]. Furthermore, in many cancers that retain wild-type p53, p53 is inactivated indirectly by 
up-regulation of genes (such as MDM2 - see Section 1.4.1) whose products play a part in 
p53 regulation [Vogelstein et ai., 2000, Lane, 1992, Oliner et al., 1992].
Of the known p53 mutations 27,580 are somatic mutations and 597 are germline 
mutations (IARC TP53 DATABASE, publicly available at http://www-p53.iarc.fr/) and see 
[Petitjean et al., 2007]. Mutations in p53 have an unusual bias towards missense mutations 
(amino acid substitutions) totalling >73% of all p53 mutations. This differs when compared 
with other tumour suppressor genes such as Rb and APC; in which the most frequent types of 
mutations are deletions, insertions and nonsense mutations [Hussain and Harris, 2006, 
Vousden and Lu, 2002]. The missense mutations in p53 might lead to a gain of function 
mutant p53 protein being produced which switches the tumour suppressor effect of p53 to 
oncogenic [Lane and Benchimol, 1990, Hussain and Harris, 2006]. Some examples of an 
oncogenic gain of function in p53 are the p53His175 and p53Gly281 mutants which attenuate 
p53’s transcriptional activation of p73 (another tumour suppressor gene) [Strano et al., 2000].
p53 is highly conserved between a variety of species which allows easy extrapolation 
of data gathered from animals. Further, many of the mutations of the p53 protein are in 
residues that are also highly conserved between diverse species [Hollstein et al., 1991]. In 
fact 28% of mutations affect only six residues [Vousden and Lu, 2002], all of which occur in 
the sequence specific DNA binding domain and thus prevent p53 from acting as a 
transcriptional activator in the wild-type manner (see Figure 1.1.1). Mutants in p53 are 
thought to further hinder wild-type p53 by behaving in a dominant-negative manner when the 
functional tetramer of p53 is formed [de Vries et al., 2002, Petitjean et al., 2007]. However 
many tumours that harbour point mutations in p53 also show loss of heterozygosity (LOH) 
(common in other tumour suppressor genes such as Rb) where the wild-type allele is
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completely deleted, implying that the dominant-negative effect is incomplete and further 
mutations are required for the tumour to progress [Vousden and Lu, 2002].
P53 175245 248r-249273 282
!■!
<--------------------------------------------------------------►
95.1% of mutations
|lransactivation Domains ^^Sequence-specific DNA binding 
(Nuclear export signals ^^Nuclear-localisation signals 
1 ~ [proline rich ^^Oligomerisation domain
Figure 1.1.1: p53 structure and location of tumour-associated mutations.
Taken from [Vousden and Lu, 2002]. Almost all point mutations in p53 occur in the 
sequence-specific DNA binding domain (shown in orange) and 28% of these mutations occur 
in the 6 highlighted residues. The transactivation domain (blue) has two activation domains, 
AD1 residues 1-42, and AD2 residues 43-63 [Zhu et a!., 2000],
Since it was first described in 1979 [Linzer and Levine, 1979, Lane and Crawford, 
1979] p53 has been widely investigated with almost 60,000 papers published to date, 
however despite considerable advances in knowledge there are still gaps in this competitive 
field of cancer research. This project proposes to investigate novel areas of p53 regulation, 
activation, function and consequences with particular reference to the intestinal gut epithelium 
and to generate novel tools with which to do this. Therefore, the normal intestinal epithelium 
will be introduced next.
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1.2 The normal intestine
1.2.1 Structure - crypt architecture
The epithelia of the small intestine are arranged into multiple deep folds inside the gut 
wall with finger like protrusions penetrating the gut lumen. These invaginations are called 
crypts and the protrusions are called villi and several crypts provide cells for one villus. Unlike 
the small intestine, only crypts are present in the colon [Yen and Wright, 2006] (see Figure 
1.2.1 & Figure 1.2.2). These differences reflect the roles of the small and large intestine; the 
villi provide a large surface area suitable for secretion of enzymes that aid digestion and for 
absorption of nutrients, while the large intestine is the last part of the digestive system and 
acts to store solid waste and absorb the remaining water (discussed briefly in [Nicholl et al., 
1985] and [Sama and Otterson, 1989]). Cells migrate from the crypt base to the villus tip 
where they are shed into the gut lumen and die due to detachment-induced-apoptosis (also 
called anoikis). This process takes 2-3 days to complete in the mouse and is the source of 
one of the most rapid turnover rates in mammalian tissues [Tsubouchi, 1983, Watson and 
Pritchard, 2000, Brittan and Wright, 2004].
Epithelial stem cells (located at the base of the crypts) are pluripotent and can 
continually divide to provide new cells to re-populate the gut surface [Marshman et al., 2002, 
van der Flier and Clevers, 2009] (see Figure 1.2.1 & 1.2.2). Daughter cells migrate up 
towards the luminal surface and undergo further divisions and differentiate into specialised 
cell types such as absorptive enterocytes, goblet cells and enteroendocrine cells [Marshman 
et al., 2002, Stamataki et al., 2011]. Enterocytes are simple columnar cells that represent the 
majority of cells in the intestinal lining; they have a glycocalyx surface coat and microvilli on 
their apical edge which increases the surface area [Marsh et al., 1971]. The main role of 
enterocytes is to help digestion and to absorb nutrients from the gut lumen. Goblet cells 
secrete mucus, a viscous material which protects the gut lining from mechanical damage, 
while enteroendocrine cells are very rare and secrete hormones [Sancho et al., 2004, 
Stamataki et al., 2011]. A fourth type of cell lineage in the small intestine, the paneth cells are
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located among the stem cells and contribute to innate immunity by secreting antimicrobial 
peptides when exposed to bacteria [Ayabe et al., 2004].
Villus
Crypt
Figure 1.2.1: The small intestine.
A) Schematic diagram of the small intestine illustrating the position of the stem cells amongst the 
paneth cells. Stem cells are thought to divide asymmetrically providing one replacement stem cell 
and one daughter cell to go on dividing and differentiating to populate the gut surface, with all the 
different cell types. B) Photo of mouse small intestine (x40 objective) to complement the 
schematic. Villi and crypts may appear differently, depending on how the tissue was cut.
The well defined characteristics of this highly organised tissue make the gut an 
attractive model system to study. The position of a cell within a crypt (or villus) indicates its 
age, its proliferative capabilities and its lineage [Rotten and Ellis, 2006]. Until very recently it 
was speculated that the stem cells were located towards the base of the crypts in cell 
positions 4-6 or 1-2 (small intestine and colon respectively - see Figure 1.2.1 & Figure 1.2.2) 
[Rotten et al., 1997a]. However the position of these stem cells had been determined from 
indirect experimental evidence as there were no direct biochemical or molecular markers to 
accurately identify the position of the stem cells [Rotten et al., 1997a, Watson and Pritchard,
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2000], In the search for this elusive “sfemness" marker, Barker et al. hypothesised that since 
the Wnt signalling pathway played such an important role in both physiological and 
pathophysiological proliferation of the intestine, it could be reasoned that out of the 80 or so 
genes involved in this pathway a small subset might be solely expressed in the stem cells 
[Barker and Clevers, 2007]. Indeed, one of these, Lgr5 (leucine-rich-repeat-containing G- 
protein-coupled receptor 5) was subsequently identified and shown to be expressed only in 
the crypt base columnar (CBC) cells of the small intestine and at the base of the colonic 
crypts [Barker et al., 2007]. Barker et al. then developed an elegant transgenic mouse 
system to determine whether the Lgr5+ expressing cells could be self-renewing, long lasting 
and produce all the different cell types in the intestinal epithelium - three of the criteria for 
“stemness’’. To demonstrate this, the mice generated had a Tamoxifen inducible Cre located 
in the Lgr5 locus, and a Rosa26-LacZ with a stop sequence (between loxP sites) which 
prevented ubiquitous expression of LacZ in the absence of Cre recombinase [Soriano, 1999]. 
Upon administration of Tamoxifen, only Lgr5 expressing cells would produce Cre 
recombinase which would then excise the stop sequence and permanently switch on LacZ 
expression in those cells. LacZ expression allowed Barker et al. to perform lineage analysis 
which demonstrated that the Lgr5+ cells were pluripotent and capable of self-renewal. The 
Lgr5+ cells were also very long lasting, the pattern at 60 days post Tamoxifen treatment was 
the same as 5 days post treatment, illustrating that they were labelling genuine stem cells 
[Barker et al., 2008]. Similar genetic and phenotypic analysis was performed for another 
potential “sternness" marker gene, Bmi1, which demonstrated it to be another bone fide stem 
cell marker [Sangiorgi and Capecchi, 2008]. The Bmi1 positive cells were located underneath 
the traditional stem cell position, but above the Lgr5 expressing cells indicating that there may 
be more than one pool of adult stem cells within the small intestine [Freeman, 2008]. These 
two sub-populations of intestinal stem cells may compensate for each other following 
exposure to genotoxic stress or other damage, allowing a mechanism for the intestine to 
replenish its stem cell population and recover from injury [Tian et al., 2011].
While morphologically similar there are major differences between the small and large 
intestine with respect to their ability to develop tumour. Cancers of the small intestine are 
rare, accounting for less than 5% of all gastrointestinal tumours [Haselkorn et al., 2005]. The
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dramatic increase in colorectal cancer over small bowel tumours cannot be simply explained 
by size differences between the two organs since, the small intestine is much longer than the 
large intestine and has a larger absorptive area and yet the incidence of colorectal cancer is 
still higher than the incidence of the small bowel cancer. This may suggest that the cells in 
the colon are more prone to tumourigenesis and therefore it would be of importance to 
consider the difference(s) in p53 activity between the small and large bowel to examine 
whether this could account for the differences in tumour susceptibility.
Since we aim to generate transgenic reporter mice, henceforward the information in 
this report is directly relevant to the mouse gut, although due to the highly conserved nature 
of the p53 response it is possible to extrapolate data through to human responses.
Colon
Differentiation VJ V--
Figure 1.2.2: The colon
A) Schematic representation of a colonic crypt, stem cells are shown in yellow at the base of the 
crypt. B) Photo of colon (x40 objective) to complement diagram. In the colon there are no villi, 
instead the crypts flatten off forming the crypt table, where cells will undergo anoikis.
1.2.2 Development of the mouse gut
It takes about 18-21 days (varies depending on mouse strain) for a fertilised mouse 
egg to complete embryogenesis and become a viable neonate. During this time the egg must
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divide, implant, undertake and complete gastrulation, neurolation, organogenesis and limb 
formation if it is to be successful in its bid to survive. One prominent developmental biologist, 
Lewis Wolpert, is commonly quoted as saying ‘The most important event in your life is not 
birth, marriage, or death, but gastrulation’ [Wolpert, 1991]. Gastrulation is a particularly 
important stage of embryogenesis, because it dramatically alters the morphology of the 
embryo and creates all three germ layers of the embryo: ectoderm, mesoderm and 
endoderm, producing the first mesodermal cells (cells that will go on to induce and maintain 
neuronal development) [Tam and Beddington, 1987].
The main reference source of information for this section of the report is from a book 
by Kaufman and Bard [Kaufman and Bard, 1999]. Gut development begins at 6.5 d.p.c. 
(days post coitum) when the differentiating egg cylinder orientates itself, showing evidence of 
an embryonic axis as the primitive streak forms, Gastrulation continues as the primitive 
streak bulges and forms the amniotic bud (7 d.p.c.) and as the neural plate enlarges and 
forms head folds (7.5 d.p.c.). At this stage the foregut pocket begins to form and is clearly 
visible by 8 d.p.c. The hind-gut undergoes little development as the rest of the embryo takes 
shape. Later in embryogenesis (15 d.p.c.) the first evidence of villi and intestinal glands 
appear, however there is still little differentiation in the rectum. Cell proliferation is limited to 
the base of the invaginations that form during this stage [Sancho et al., 2004]. At 16 d.p.c. 
there is a large number of well formed villi and the mucosa begins to differentiate and there is 
early evidence of intestinal glands forming within the sub-mucosa. The small intestine also 
massively increases in size, so that by 17 d.p.c. there are gross changes in histological 
appearance although the hind-gut remains virtually unchanged. At 18 d.p.c. the mouse 
embryo is almost fully formed, long whiskers are visible and the morphology of the gut has 
become more reminiscent of an adult. The mucosal lining has differentiated; large numbers 
of goblet cells (filled with a homogenous eosinophilic material) have developed in the large 
intestine and the hind-gut. The duodenum has filiform projections (villi) which will develop 
more during postnatal development. By the time a mouse is born, all the basic tissue 
structure and cell types are present in the gastrointestinal tract, however the gut still must 
acquire post-natal immunity to its new environment (mucosal lining becomes populated with a
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T-cell pool [Williams et al., 2006]) and continue to grow in order to digest adult food post- 
weaning.
In the first few weeks following birth the invaginations in the small intestine which 
contain the proliferative cells deepen into mature crypts, while the crypts in the colon deepen 
further [Sancho et al., 2004], The crypts increase steadily in number as the gut develops into 
its final structure (see Figure 1.2.3).
The expression of p53 in the intestine during mouse embryogenesis has been 
previously examined by in situ hybridisation. Strong labelling of all cells in the stratified 
epithelium was detected at 14.5 d.p.c (before formation of villi), while by 16 d.p.c. the labelling 
was concentrated within the crypt (villi were formed). The cells of the submucosa had only 
low levels of p53 mRNA [Schmid et al., 1991]. The authors noted that while p53 is strongly 
expressed in all tissues early in embryogenesis, once organogenesis commences, varied 
tissue-specific p53 expression patterns can be observed. In general, in cells undergoing 
terminal differentiation (for example, those cells forming the villi), p53 mRNA expression 
declined [Schmid et al., 1991]. Could the absence of p53 expression along the length of the 
villi account for the differences observed between the crypt and the villus in response to 
whole body y-radiation and other genotoxic stresses (as discussed in Section 1.2.6)7
Figure 1.2.3. Postnatal development of the gut.
Taken from [Sancho et al., 2004] illustrating the progression into the final structure of the adult 
gut tissue, following invagination of the crypts and elongation of the villi.
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1.2.3 Cell cycle progression - in the intestine
Cell proliferation in the adult mouse (and human) is limited to within the intestinal 
crypts [Rotten, 1998, Strater et al., 1995]. The stem cells were traditionally thought to divide 
asymmetrically, providing one replacement stem cell and one daughter cell to migrate up the 
crypt and differentiate, thus maintaining cell numbers [Marshman et al., 2002], However, it 
has been demonstrated recently that this is not the case. In fact, most stem cell divisions are 
symmetrical and thus stem cell fate is not pre-determined [Snipped et al., 2010]. Also, the 
segregation of chromosomes in stem cells appears to be random [Escobar et al., 2011], 
adding weight to the theory of a dynamic stem cell niche whereby “sternness” is restricted to 
the cells at the base of the crypt and cell fate is arbitrarily assigned depending on the cell 
position [Simons and Clevers, 2011]. Therefore the stem cells within the intestinal crypts are 
intrinsically a clonal population which overtime results in the extinction of all cell lines except 
one (also know as clonal succession or neutral drift) [Kim and Shibata, 2002, Snipped et al., 
2010]. This may have implications for cancer biology as clonal succession is usually a 
cancerous trait and therefore perhaps it allows an opporiunity for “silent” mutations to 
accumulate.
Cell cycle progression does not occur outside the crypt. When migrating cells enter 
the villus they become trapped in the Gi phase of the cell cycle because of down regulation of 
the growth promoters cyclin D1 and cyclin-dependent kinase 2 (Cdk2) [Chandrasekaran et al., 
1996, Watson and Pritchard, 2000]. The cells remain in Gi phase until they reach the tips of 
the villus and are then shed into the gut lumen. Proliferation never occurs in the normal villus, 
it is strictly confined to the crypt where it is carefully controlled and monitored for genetic 
mutations.
1.2.4 Apoptosis - unstressed intestine
Apoptosis is limited to within the crypt and villus tip. Very low levels of apoptosis 
occur normally in the proliferative region of the small intestine and apoptosis occurs even less 
frequently in the upper region of the colonic crypt (the intercrypt table - not associated with 
stem cells) [Rotten, 1998, Merritt et al., 1994, Rotten et al., 1997b]. This apoptosis, in
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apparently normal tissue, is referred to as "spontaneous11 since the identity of the true stimulus 
(if any) is unknown. Spontaneous apoptosis rates do not differ between wild-type and p53 
null animals [Merritt et al., 1994, Rotten et al., 1994], suggesting that the process is p53 
independent.
The absence of spontaneous apoptosis in colonic stem cells has been investigated 
by generating Bcl-2 null mice. BcI-2{~ mice have similar levels of apoptosis inside the small 
intestine when compared to their wild-type counterparts, but greatly increased apoptosis in 
the large intestine [Merritt et al., 1995]. Furthermore, the increase in apoptosis was observed 
in the stem cell region of the colonic crypt (cell positions 0-2). Bcl-2 is an anti-apoptotic 
protein, which is conserved between diverse species (C. eiegans homolog ced-9) and acts 
by interaction with other Bcl-2 family members such as pro-apoptotic Bax and Bak [Danial 
and Korsmeyer, 2004]. Indeed Ba/fv' mice have reduced amounts of spontaneous apoptosis 
in the colonic intercrypt table and increased crypt cell number and levels of mitosis compared 
with the wild-type (deletion of Bak had no affect in the small intestine) [Duckworth and 
Pritchard, 2009]. However, BaxA mice show similar levels of apoptosis as wild-type mice in 
the crypt, indicating that Sax is not important in normal colonic epithelial homeostasis, 
whereas Bcl-2 and Bak expression are ([Watson and Pritchard, 2000, Duckworth and 
Pritchard, 2009] and as discussed in detail in Section 1.4.5).
One theory attempting to explain the relatively high expression of Bcl-2 in the colonic 
crypts, but not in the small intestinal crypts, suggests that this favours repair of DNA damage 
in the event of a mutation rather than pushing cells to commit suicide. This cell survival 
strategy (instead of implementing apoptosis) may have evolved because the large bowel is 
exposed to more genotoxic molecules than the small bowel (due to a longer transit time) and 
thus it may be impractical (and risky since cell division can also induce mutations) to keep 
replacing damaged or mutated cells [Potten et al., 2002]. If colonic stem cells are allowed to 
accumulate genetic defects (by failed repair of DNA damage) then this provides one 
explanation for the increase in tumour malignancies in the colon.
The second kind of apoptosis seen in the unstressed gut is at the villus tip where 
terminally differentiated cells are shed into the lumen. This process is also called anoikis or 
detachment induced cell death DICD. Cells only appear morphologically apoptotic once they
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have lost cell anchorage [Shibahara et al., 1995], however apoptosis is initiated once cells 
reach the luminal surface by activation of the “executioners of apoptosis” notably caspase-3 
[Grossmann et al., 2002]. This priming of cells to apoptose may be due to a decrease in pro- 
survival proteins like Bcl-2 and an increase in pro-apoptotic Bcl-2 family members like Bax 
and Bak. Though studies where Bcl-2 was over expressed in villus epithelial cells indicated 
that there did not appear to be an effect on cell shedding [Watson and Pritchard, 2000, 
Coopersmith et al,, 1999]. Other pro-apoptotic signals such as transforming growth factor p 
(TNF-P) are expressed and are known to induce apoptosis and detachment [Grossmann et 
al., 2002, Rotten et al., 1997b]. Shedding appears to be p53 independent as it is a normal 
part of gastrointestinal homeostasis and is presumably unaltered in p53 null mice.
Apoptosis never occurs along the length of the villus in the normal unstressed 
intestine [Watson and Pritchard, 2000, Grossmann et al., 2002]. Cell death along the villus is 
associated with disease. Expression of a dominant negative N-cadherin (an adhesion 
molecule) along the entire crypt-villus axis causes spontaneous apoptosis along the length of 
the villus resulting in a Crohn’s like inflammatory disease [Hermiston and Gordon, 1995]. 
Death is caused by anoikis from the loss of adhesion molecules [Hermiston and Gordon, 
1995, Grossmann, 2002] indicating cells in the villi do contain the apoptotic machinery and 
are able to implement it. This does not tell us, however, if it is p53 dependent.
1.2.5 Stress induced apoptosis in the intestine
Apoptosis in response to stress (such as DNA damage) is limited to within the crypt. 
Shedding at the villus tip seems to be unaffected and there is no cell death along the villus 
length [Marshman etal., 2001, Watson and Pritchard, 2000],
Genotoxic damage induced by ionising radiation can result in massive cell death 
(even at relatively low doses of irradiation) in the small intestinal crypts and an attenuated 
apoptotic response in the colonic crypts [Merritt et al., 1994]. The acute apoptotic response 
(in the first few hours) was shown to be exclusively dependent on p53, since p53 null mice 
had this response completely abrogated [Merritt et al., 1994]. However, deletion of p53 
actually sensitises cells to the later responses to y-radiation, which occurred because of
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catastrophic errors in mitosis 24 hours after exposure to higher doses of irradiation (>8 Gy) 
[Merritt et al., 1997, Kirsch et a!., 2010].
A lower level of apoptosis in the colonic crypts may be due to the pro-survival actions 
of the anti-apoptotic protein Bcl-2. Bcl-2 was expressed in the stem cells of the colonic crypt 
(cell positions 0-2) but was absent from the small intestine, causing the colonic cells to be 
more resistant to spontaneous and stress induced apoptosis [Merritt et al., 1995], When Bcl- 
2"/' mice and wild-type mice had their apoptotic levels compared following exposure to 
ionising-irradiation it was found that there was similar levels of apoptosis in the small 
intestine, but that the Be]-!'1" mice had much higher levels of apoptosis in the colonic crypts 
[Coopersmith et al., 1999] indicating that Bcl-2 (an anti-apoptotic protein) is having a 
protective effect in the colon. Forced over-expression of Bcl-2 in the small intestine can in 
part counteract the p53-dependent apoptotic response to DNA damage, by delaying onset of 
apoptosis and reducing the total amount of apoptosis two-fold [Coopersmith et al., 1999].
Bax, a pro-apoptotic member of the Bcl-2 family appears to have redundant roles in 
the p53-dependent apoptotic response to DNA damage [Watson and Pritchard, 2000]. Bax'~ 
mice behaved indistinguishably from wild-type mice when administered with enterotoxin 5- 
fluorouracil (5FU- perturbs RNA metabolism including biosynthesis of deoxyribonucloetides 
by thymidylate synthase) or exposed to y-radiation [Pritchard et al., 1999]. However, whilst 
there were no significant differences observed between the two mouse strains following 
genotoxic stress, the authors noted that there may be a general trend in the Bax'1' mice to 
have decreased apoptosis overall. Nonetheless, the data indicate that Bax only plays a minor 
role in the regulation of DNA damage induced apoptosis in the intestinal epithelium. On the 
other hand deletion of Bak, (another pro-apoptotic member of the Bcl-2 family) significantly 
reduced the amount of apoptosis in the colonic (but not small intestinal) epithelia when 
exposed to y-radiation which indicates a non-redundant role for Bak in the DNA damage 
response in this tissue [Duckworth and Pritchard, 2009].
The only publication to date, which has shown stress-induced cell death along the 
entire length of the villus was Coopersmith et al. in 1999 who induced apoptosis by ischemia- 
reperfusion [Coopersmith et al., 1999]. Briefly; mice had their superior mesenteric artery 
clipped to occlude blood flow for 20 minutes and then the clip was removed to allow blood to
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re-enter the intestines. The resulting apoptosis was greater in the differentiated, non­
proliferating villi cells then the cycling, non-differentiated crypt cells, presumably because the 
cells along the villi are located further away from the submucosal blood vessels and hence 
suffer more from prolonged hypoxic effects. Indeed, reflecting this assumption, apoptotic 
levels where the highest in the upper region of the villi. Comparison with p53 null animals 
showed that ischemia-reperfusion-induced apoptosis was p53 independent [Coopersmith et 
al., 1999]. However, Puma (a pro-apoptotic protein that can be up-regulated by p53 [Nakano 
and Vousden, 2001]) knock-out mice had a significantly attenuated apoptotic response under 
the same experimental setting when compared to wild-type mice and p53-null mice [Wu et al., 
2007]. Therefore Puma would appear to have a p53-independent role in detecting oxidative 
stress in the intestine and in initiating cell death.
1.2.6 Why don’t some cells die?
Apoptosis does not occur along the length of the villi in response to radiation-induced 
DNA damage or as a result of many chemotherapeutic drugs or cytotoxic agents [Watson and 
Pritchard, 2000, Merritt et al., 1994]. One explanation for the lack of apoptosis might be that 
these cells do not proliferate however studies where enterocytes are forced back into the cell 
cycle by targeted expression of SV40 large T antigen does not appear to increase their 
radiosensitivity [Coopersmith and Gordon, 1997]. Although, the loss of p53 function as a 
consequence of the transforming ability of SV40 large T antigen confounds interpretation of 
these results. Another explanation for this might simply be that p53 is not induced - however 
as this report will go on to demonstrate even when p53 is induced in cells on the villi they 
remain refractory to apoptosis. So why don’t cells along the villi die? The villus and crypt 
receive similar levels of radiation yet there is rarely any apoptosis observed in the intestinal 
villus cells [Marshman et al., 2001]. This bizarre biological phenomenon is part of the puzzle 
that will hopefully be explained by the use of transgenic mouse models (see Aims).
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1.3 Cancer in the intestine
1.3.1 Colorectal tumouriaenesis
In 2004 colorectal cancer had the second highest incidence in Europe (13.2%, after 
lung cancer at 13.3%) and was the second commonest cause of cancer related death 
(203,700 total deaths after lung at 341,800} [Boyle and Ferlay, 2005]. So any discoveries 
made that would help to understand the development of colorectal cancer would be of 
relevance to a large number of cancer patients.
Cancer progression is a multi-step process involving accumulation of aberrant genetic 
changes by which cells acquire dominant oncogenic properties and loose recessive tumour 
suppressive capabilities [Hanahan and Weinberg, 2000]. Clinicians use histopathological 
alterations to classify types and stages of the disease, for example small benign adenoma 
versus large metastatic cancers. Colorectal carcinomas arise from the epithelia of the colon 
and have the best documented histopathological progression of all human cancers (discussed 
in [Weinberg, 2006]). This is in part due to the large incidence of colorectal cancer in the 
western world and also to the relative accessibility of the colon through colonoscopy. The 
data suggests that most colorectal carcinomas originate from existing benign tumours which 
develop initially following the loss of a tumour suppressor gene, coupled with mutational 
activation of an oncogene. It takes a further four or five mutations or deletions of 
predominately tumour suppressor genes (such as p53) for the nascent tumour to then 
develop into a malignant cancer (see Figure 1.3.1) [Weinberg, 2006, Fearon and Vogelstein, 
1990].
The use of linkage analysis and LOH studies on a small sub-population of individuals 
who suffered from a heritable colon cancer syndrome called familial adenomatous polyposis 
(FAR) enabled the discovery and cloning of the APC (adenomatous polyposis coll) gene in 
1991 [Varesco, 2004, Groden et al., 1991, Vogelstein et al., 1989]. APC is a tumour 
suppressor gene (part of the Wnt signalling pathway), the loss of which is associated with the 
initiation of hyperplasic growth in the epithelium of the colon [Korinek et al., 1998].
15
Other consistent early events in colorectal tumourigenesis include; activation of the 
proto-oncogene K-ras (occurs in over one third of all human colorectal cancer cases, [Bos et 
al., 1987, Forrester et al., 1987]), loss of genetic stability (as identified by accumulation of 
ubiquitous somatic mutations in simple repeated sequences [Shibata et al., 1994]) and DNA 
hypomethylation [Goelz et al., 1985] (impacts on global gene expression which is important if 
it effects TSGs and thus perhaps further reduces genetic stability [Razin and Riggs, 1980]).
Figure 1.3.1 illustrates a typical genetic model for colon carcinoma progression, 
although it is thought that the overall accumulation of mutations, rather than the order by 
which an individual acquires mutations, is more important for the development of cancer 
[Fearon and Vogelstein, 1990].
DNA
Loss of ARC Hypomethylation Activation Loss of Loss of Other
Of K-ras 18qTSG p53 Alterations
Normal
Epithelium
Hyperplastic
Epithelium
Early Intermediate
Adenomas Adenomas
Late Carcinoma
Adenomas _
Figure 1.3.1: Genetic model for colon carcinoma progression.
Adapted from [Fearon and Vogelstein, 1990]. Tissues from various stages of colorectal 
cancer had its DNA examined for loss of heterozygosity (LOH) at chromosomal markers 
[Vogelstein et al., 1989]. The chromosomal regions with frequent LOH were considered to be 
harbouring Tumour Suppressor Genes (blue text) and some of these have since been 
identified (APC and p53) while others remain unclear (18q TSG, also known as DCC (simply 
Deleted in Colon Cancer DCC - is separate from other TSGs in the 18q region such as 
SMAD2 and SMAD4 [Lassus et al., 2001])). DNA hypomethylation is thought to contribute to 
genetic instability while K-ras drives cell proliferation.
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1.4 Further introduction to p53
1.4.1 Activation of p53- an overview
p53 can become activated in response to a wide variety of stimuli including genotoxic 
stress, hypoxia and aberrant growth signalling [Vogelstein et al., 2000, Vousden, 2002], Each 
of these stimuli inhibits the degradation of p53 leading to a rapid increase in p53 levels. In 
“resting" cells p53 is usually kept low in abundance and in an inactive form by the 
antagonising activities of Mdm2 and Mdmx (also known as Mdm4) [Blattner, 2008]. Mdm2 
(Murine double-minute 2) is an E3 ubiquitin ligase which can bind to the transactivation 
domain of p53, hampering p53’s ability to act as a transcription factor and can target p53 (and 
itself) for degradation by the proteasome [Brooks and Gu, 2006, Vousden, 2002], The ability 
of Mdm2 to ubiquitylate p53 requires its RING finger domain to be intact [Honda et a!., 1997]. 
Mdmx, a closely related protein, can also bind to and block the transactivation domain of p53 
through the conserved p53-binding N-terminal region present on both MDM proteins [Shvarts 
et al., 1996] (and see Figure 1.4.1). Mdm2 and Mdmx also share homology with the RING 
finger domain (at the C-terminal), however, Mdmx lacks the E3 ubiquitin ligase activity of 
Mdm2 [Marine and Jochemsen, 2005]. Mdm2 and Mdmx are able to interact and form 
heterodimers through their mutual RING finger domains [Tanimura et al., 1999] which may 
contribute to Mdm2 stability by interfering with Mdm2 auto-ubiquitination and thus allows p53 
to be efficiently degraded [Stad et al., 2001]. There are two main lines of thought regarding 
the outcome of the formation of Mdm2/Mdmx-p53 complexes; 1) Mdmx contributes to p53 
degradation by stimulating ubiquitination [Linares et al., 2003] and 2) Mdmx prevents the 
Mdm2 mediated nuclear export of p53 thus preventing transport to the proteasome and the 
subsequent proteolysis [Jackson and Berberich, 2000]. The second theory would only appear 
to hold true in experimental settings when there is a massive excess of Mdmx over Mdm2, 
which could then compete for p53 binding [Marine and Jochemsen, 2005].
Interestingly - as Mdm2 mediates p53 degradation - Mdm2 is also a transcriptional 
target of p53, creating a negative feedback loop that ensures low levels of p53 are maintained 
in “resting" cells [Kubbutat and Vousden, 1998, Blattner, 2008, Harris and Levine, 2005].
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Until very recently it was suggested that in contrast to Mdm2, Mdmx did not appear to have 
any p53 responsive elements (p53 REs) in its promoter region nor was it thought to be up- 
regulated by p53 [Marine and Jochemsen, 2005]. However it is now known that HDMX and 
the murine homolog Mdmx both have a consensus p53 binding site within the first intron 
(similar to Mdm2 - see Figure 1.4.3) which is responsive to p53 [Phillips et al., 2010, Li et al., 
2010],
Mdm2
p53-binding NLS NES Acidic ZF
■ II I"
RF NoLS
Mdmx
p53-binding Acidic ZF RF NoLS
Figure 1.4.1: Mdm2 (mouse or human) versus Mdmx (mouse) protein structure.
Adapted from an image available at http://D53.free.fr/p53 info/mdm familv.html information 
from [Marine and Jochemsen, 2005]. Blue is N-terminal p53-binding domain, NLS is nuclear 
localisation signal, NES nuclear exclusion signal, grey is the acidic region, yellow is the zinc 
finger domain, pink is the RING finger domain and red is the nucleolar localisation signal.
The control of p53 by Mdm2 and Mdmx is essential for life. Deletion of Mdm2 in mice 
causes them to die early in embryogenesis, and this phenotype is completely rescued on a 
p53 null background [Montes de Oca Luna et al., 1995, Jones et al., 1995]. Similarly, Mdmx 
null mice also die early in embryogenesis (7.5 d.p.c) and this phenotype is also rescued 
through the deletion of p53 [Parant et al., 2001]. Whilst Mdm2'/' mice die at 3 d.p.c from 
increased p53-dependent apoptosis, MdmxA mice die at 7.5 d.p.c by aberrant p53-dependent 
growth arrest, thus demonstrating that deregulated p53 activity appears to be the cause of 
death in these mice and suggests that Mdm2 and Mdmx have distinct roles in the regulation 
of p53. Attempts have been made to delay embryo death in these Mdm2~l~ or Mdmx'1' mice by
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deleting downstream p53 targets, such as Bax and p21 [Chavez-Reyes et al., 2003]. On a 
Bax null background MdmZ^ mice survived marginally longer (3 d.p.c to 6.5 d.p.c) and the 
mechanism of death switched from excessive apoptosis to growth arrest. Mdmx^ mice did 
not have any increased survival following deletion of p21, however, the cause of death was 
initiated by apoptosis rather than cell cycle arrest. The different mechanisms of action and 
functional properties of Mdm2 and Mdmx may become important in the intestinal gut 
epithelium; where there is a distinct difference in outcome of p53 activation along the crypt- 
villus axis (see Section 1.2.6).
In a stressed cell, following DNA damage, p53 rapidly accumulates. This is attributed 
to p53 rescue from proteasome degradation rather than de novo synthesis and is 
predominately due to disruption of the interaction between p53 and its negative regulators 
[Blattner, 2008]. Lesions in the DNA are thought to be recognised by members of the PI3-K 
kinsase family including; ATM (ataxia telangiectasia mutated), ATR (ATM-rad3-related) and 
DNA-PK (DNA-dependent protein kinase). ATM and DNA-PK appear activated following 
DNA double stranded breaks - as caused by ionising-radiation - whilst ATR is required for 
repair of stalled replication or DNA cross-links - as can be induced by UV-irradiation 
(reviewed in [Zhou and Elledge, 2000]). As discussed previously, Mdm2 is a gene which is 
essential for the control of p53 (at least during early development) and many of the responses 
to differing types of DNA lesion converge on Mdm2 as a means of liberating p53 [Blattner, 
2008]. Indeed following their activation all three PI3-K kinases can phosphorylate Mdm2 in a 
way that causes its functional inactivation and/or destabilisation [Mayo et al., 1997, Maya et 
al., 2001, Shinozaki et al., 2003]. Destabilisation of the Mdm2 protein was initially speculated 
to be due to accelerated Mdm2 auto-ubiquitination [Stommel and Wahl, 2004] however later 
mouse models have demonstrated that auto-ubiquitination is not required for degradation of 
Mdm2 in vivo [Itahana et al., 2007]. Mdm2 degradation may instead be regulated by other E3 
ligases (such as SCFp'trcp [Inuzuka et al., 2010]) as well as the deubiquitinating enzyme 
HAUSP (Herpesvirus-associated ubiquitin-specific protease) [Meulmeester et al., 2005]. In 
addition, ATM and ATR can both phosphorylate p53 at serine 15 which blocks the ability of 
Mdm2 to bind to the transactivation domain of p53 [Lakin et al., 1999]. DNA-PK can also 
inactivate genes that would normally phosphorylate critical parts of the Mdm2 degradation
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loop such as GSK-3 (glycogen synthase kinase 3) which further prevents p53 degradation 
[Blattner et a!., 2002, Kulikov et al., 2005, Boehme et al., 2008] (see Figure 1.4.2).
Yet another mechanism for p53 stabilisation is the sequestration of Mdm2 into the 
nucleolus by a protein called ARF (19ARF in mice and 14ARF in humans - based on the 
molecular weight of each protein) reviewed in [Zhang and Xiong, 2001], ARF was discovered 
as an alternative reading frame in tumour suppressor gene p16INK4A (mouse and human) and 
becomes triggered in response to oncogenic activity [Sherr, 1998]. Each of the mechanisms 
described here allows the rapid accumulation of p53 without synthesising new protein. 
Transcriptional regulation of p53 would create a delay in the DNA-damage response 
pathways and there is also a high risk - as the DNA is damaged - of perhaps producing a 
mutated non-functional p53 protein [Blattner, 2008].
Following stabilisation, p53 is activated and regulated by post-translational 
modifications [Appella and Anderson, 2001, Olsson et al., 2007], The outcome of p53 
activation depends on a wide range of factors; the type of tissue, the state of the cell, if the 
cell has other oncogenic changes, the type and severity of the stress stimuli and the presence 
or absence of p53-independent death or survival signals that cooperate with p53 [Vousden, 
2006]. p53 can inhibit tumour development by initiating a number of responses including 
reversible changes to induce cell cycle arrest and irreversible changes implementing 
apoptosis and cell senescence [Vousden and Lu, 2002]. What response p53 induces 
depends on which target genes it up regulates [Vousden, 2002], p53 is thought to be able to 
control which downstream targets it up-regulates via promoter selection and binding with 
transcriptional co-activators (ASPP for example drives p53 to the induction of cell death 
[Samuels-Lev et al., 2001]). Promoter recognition and selection are controlled by a number of 
different mechanisms, one being post-translational modifications such as phosphorylation and 
acetylation [Vousden, 2002, Vousden, 2006]. The consensus DNA binding motif for p53 
responsive elements (p53 REs) consists of a repeated 10bp 5’-PuPuPuC(A/T)(T/A)GPyPyPy- 
3’ palindromic half site separated by 0-13bp [el-Deiry et al., 1992]. Genome wide searches 
for this motif using computer algorithms have suggested that more than 4000 genes contain a 
p53-binding site, while more recent studies using stress activation have placed a lower figure 
on this of approximately 1500 genes [Smeenk et al., 2008, Vousden, 2006].
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Figure 1.4.2: Model of regulation of p53 stability.
Adapted from [Kubbutat and Vousden, 1998], In response to DNA damage p53 is regulated 
by many pathways [Fisher, 2001]. Upstream genes such as DNA-PK (DNA-dependent 
protein kinase) and ATM (Ataxia Telangiectasia Mutated) sense specific DNA lesions and 
activate key players in the DNA damage response network, for example by phosphorylating 
p53 so it no longer binds to Mdm2 [Blattner, 2008]. Once liberated from its negative 
regulators, p53 levels rapidly accumulate in cells leading to p53-mediated cell cycle arrest or 
apoptosis [Vousden, 2006].
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Since so many genes have the potential to be involved in a p53 dependent DNA- 
damage response it is critical that we evaluate each of the major responses to p53 activation 
and determine which downstream p53 target genes are induced in our tissue of interest - the 
gastrointestinal tract. Below is an outline of the major responses to p53 activation, (regulation 
of p53 by Mdm2, senescence, cell cycle arrest and apoptosis) and in the case of cell cycle 
arrest and apoptosis a review of the downstream targets of p53 which could be used as a 
reporter in the intestinal gut epithelia.
1.4.2 Regulation of p53 by Mdm2: the P1. P2 conundrum
Mdm2 is an important proto-oncogene which is often up regulated in tumours where 
cells retain wild-type p53 [Oliner et ai., 1992] and also in tumours lacking wild-type p53, 
illustrating Mdm2 has both p53-dependent and p53-independent functions [Ganguli and 
Wasylyk, 2003]. This is highlighted in the gene structure and promoter layout in Mdm2 (see 
Figure 1.4.3). Mdm2 has 12 exons that can create multiple splice variants and two promoter 
regions; P1 is located upstream of exon 1 and is responsible for basal expression while P2 is 
located in intron 1 just before exon 2 and has two p53 responsive elements (p53-REs). The 
P1 and P2 promoters produce different transcripts of Mdm2 but both promoters can produce 
both of the major isoforms of Mdm2 [Saucedo et al., 1999]. These are the full length p90MDM2 
which is capable of binding and inactivating p53, initiated from the first ATG in exon 3 and a 
shorter protein, p76MDM2 initiated from the ATG in exon 4, which is missing part of the p53 
binding domain. p76MDM2 can act in a dominant negative manner to inhibit p90MDM2 from 
degrading p53 (reviewed in [Iwakuma and Lozano, 2003]).
When transcripts from the P1 and P2 promoters were compared using a S1 nuclease 
protection assay, it was discovered that levels of RNA from P1 or P2 promoters did not 
change between p53 wild-type mice or p53 null mice [Mendrysa and Perry, 2000]. However 
when mice were exposed to 5 Gy of whole body y-irradiation, there was a marked p53- 
dependent increase in the P2 promoter RNA levels; most dramatically there was a 32-fold 
increase of P2 transcripts in the spleen. Therefore p53 would appear to only up-regulate 
Mdm2 in vivo under conditions of stress - perhaps indicating that as cells in culture
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continually produce Mdm2 from the P2 promoter that they are under some unidentified stress. 
Curiously, in p53 null mice there was still some 10-30% of the total Mdm2 RNA originating 
from the P2 promoter, indicating that other transcription factors must be able to bind to the P2 
promoter [Mendrysa and Perry, 2000].
Wild-type Mdm2
ATG (p90) ATG (p76)
Figure 1.4.3: Structure of Mdm2 (mouse and human) gene.
Adapted from [Chang et a!., 2004] and [Iwakuma and Lozano, 2003]. Mdm2 has 12 exons 
(shown in green boxes) and two promoter regions (indicated by arrows; P2 has two p53 
Responsive Elements). Transcripts from the human P1 promoter skip exon 2 - murine 
transcripts do not. The two start codons are also shown, the one in exon 3 codes for the long 
p90 isoform of Mdm2 while the one in exon 4 codes for the shorter protein p76. In MDM2 (the 
human gene) there is a third promoter region, called P3 in the third intron of this gene [Liang 
and Lunec, 2005]. It is thought p53 is able to bind to and down-regulate the P3 promoter 
expression when MDM2 levels are elevated, dampening levels of MDM2 and providing yet 
another feedback loop in this complex system.
Indeed, transcription factor binding sites (TFBS) other than p53 have been reported 
within the P2 promoter region including; IECS, AP-1, Ets A, Ets B and AP-4 [Truong et al., 
2005, Ku et al., 2009, Ries et al., 2000, Phelps et al., 2003, Zhou et al., 2009] and these are 
discussed next. The AP-1 and Ets sites have been shown to play a role in inducing Mdm2 
through the Ras/Raf/MEK/MAP kinase pathways. In experiments where constitutively 
activated Ras is over-expressed in cultured cells there is a 5-8 fold increase in P2 promoter 
activity which is independent of p53 and completely abrogated in P2 promoters with mutations 
within either or the AP-1 or Ets B sites [Ries et al., 2000, Truong et al., 2005]. In addition, in 
breast cancer cell lines elevated HDM2 levels were also partly associated with this composite 
AP-1 Ets B site [Phelps et al., 2003]. Furthermore Fli-1 (an Ets transcription factor -
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implicated in the progression of Friend Murine Leukemia Virus (F-MuLV)-induced 
erythroleukemia) was shown to bind to the Ets A site and up-regulate Mdm2 in a Ras/p53 
independent fashion in vivo [Truong et al., 2005], Mdm2 may also be induced by oxidative 
stress via the AP-1 site in cardiac myocytes, where Mdm2 is speculated to act as a 
cardioprotective agent [Pikkarainen et al., 2009].
Another p53-independent role for Mdm2 has been suggested in the development of 
germinal centre (GC) B cells where Mdm2 is up-regulated by IFN regulatory factor 8 (IRF8) 
[Zhou et al., 2009]. GC B cells are cells actively undergoing DNA double strand breaks (DSB) 
in order to rearrange immunoglobulin genes as part of gene diversification in the specific 
pathogen immune response - however despite undergoing DSB these cells do not up- 
regulate p53. IRF8, a transcription factor which is expressed in differentiating myeloid, 
dendritic and B cells, has been shown to bind to an IECS site within Mdm2 intron 1. IRF8 
binding allowed p53-independent up-regulation of Mdm2 which is suggested to prevent p53 
up-regulation and protect the GC B cells from p53 induced cell cycle arrest and/or apoptosis.
Another TFBS within the Mdm2 P2 region is an AP-4 site located downstream of the 
second p53 RE site [Ku et al., 2009, Phelps et al., 2003]. AP-4 binding (with other cofactors) 
has been shown to down-regulate MDM2 in human colorectal carcinoma cells [Ku et al., 
2009].
The p53-independent TFBS within the P2 promoter may provide one explanation for 
the low level expression of Mdm2 from the P2 promoter in p53 null mice reported by 
[Mendrysa and Perry, 2000]. Indeed other research groups have also demonstrated that p53 
is dispensable for low level expression from the P2 promoter in human astrocytic glioma cells 
[Dimitriadi et al., 2008]. P2 promoter transcripts are important as they are about 8 times more 
efficiently translated than transcripts from the constitutively active counterpart [Landers et al., 
1997]. The reduction in translation efficiency of the P1 promoter is due in part to two 
upstream open reading frames (uORFs) present in transcripts which are inhibitory to 
downstream translation [Brown et al., 1999, Jin et al., 2003], The induction of Mdm2 by p53 
results in accumulation of Mdm2 protein following genotoxic stress which may enable a rapid 
return to “resting” ce\\ levels of p53 once the stress stimulus is removed [Blattner, 2008] which
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could prevent further uncontrolled and perhaps deadly action from p53 [Stommel and Wahl, 
2005] or for some other unknown function (discussed in Section 1.4.1).
The P1, P2 promoter layout in Mdm2 does present an interesting biological question 
and a unique opportunity to discover more about the regulation of one of the most important 
tumour suppressor genes - p53. Would deletion of either the P1 or P2 promoter of Mdm2 
affect this complex regulatory loop and how would such affects be manifested/ ie what would 
the phenotype, if any, of such alterations be? Presumably a P2-Mutant mouse (which is 
unresponsive to p53) could develop normally as basal expression of Mdm2 would still be 
present; although it is likely that there will be occasional stresses even during normal 
development (such as ROS (reactive oxygen species) and oxidative stresses) which might 
require p53 induction. Assuming that the P2-Mutant mice survive embryogenesis, would 
basal expression of Mdm2 be enough to deal with genotoxic stress such as ionising-radiation 
or indeed just normal encounters with general stresses? Or would the mice be prone to 
tumour development? Or even might they be resistant to tumour formation? A P1-Null 
mouse might be even more interesting; would it develop normally or die in embryogenesis? 
And if it does survive to birth how would it deal with different cellular stresses? It may be 
important then that other tumour suppressor genes play a role in controlling levels of Mdm2. 
For example the PTEN (phosphatase and tensin homolog deleted from chromosome 10) 
tumour suppressor gene down-regulates Mdm2 expression through the P1 promoter in a p53- 
independent fashion [Chang et al., 2004], which could become even more important in a P2 
deleted mouse.
To our knowledge, no such mice have yet been created. Part of this project then 
would be to create one or both of these mice. Data from these animals would be likely to 
have a significant impact in the field of cancer biology regardless of the phenotype of these 
mice.
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1.4.3 Cellular senescence
Cellular senescence is when a cell irreversibly enters cell cycle arrest (reviewed in 
[Pazolli and Stewart, 2008] and [Funayama and Ishikawa, 2007]). Senescent cells are 
characterised by an enlarged and flattened morphology which is often accompanied by 
senescence-associated (3-galactosidase (SA-p-gal) activity [Dimri et al., 1995]. Senescent 
cells may also have condensed chromatin [Funayama and Ishikawa, 2007]. Cells can enter 
senescence because of replicative stress (known as replicative senescence (RS)) or through 
other distinct stress signals such as oncogenic activity, loss of tumour suppressor genes, 
excessive DNA damage and oxidative stress (known as stress induced senescence (SIS)) 
[Pazolli and Stewart, 2008].
RS is triggered by telomere (a long repetitive region at the end of chromosomes) 
shortening as a result of repeated cell cycles. Cells have an “internal clocking” mechanism - 
the telomeres which protect the coding sections of the chromosome - thus they have a limit 
on the number of proliferation cycles they can undertake (50-70) [Hayflick and Moorhead, 
1961]. Eventually, in cells which lack endogenous telomerase (an enzyme which can extend 
the telomeres) the telomeres become critically short, and the result is aberrant chromosome 
fusions in an attempt to repair the chromosomes. Such alterations are recognised as DNA 
damage which is detected by the kinases ATM and Chk2 [Serrano and Blasco, 2001], ATM 
and Chk2, as discussed in Section 1.4.1 can stabilise and activate p53, which can in turn 
activate genes involved in the senescence response - namely p21 which goes on to induce 
Rb and ultimately senescence [Funayama and Ishikawa, 2007] (see Figure 1.4.4). Mice 
deficient in telomerase in their epithelial cells had a lower incidence of papillomas than wild- 
type mice, suggesting that telomere shortening and senescence can have a protective effect 
in tumourigenesis [Gonzalez-Suarez et al., 2000], Conversely, a second line of thought is 
that senescent cells may actually promote tumourigenesis (in relation to aging) through 
interactions in the tissue microenvironment which promote growth of surrounding 
preneoplastic cells [Krtolica et al., 2001].
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Figure 1.4.4: The signalling pathways that lead to cellular senescence.
Taken from [Funayama and Ishikawa, 2007]. Whilst upstream changes are still undefined, 
downstream changes are usually dependent on tumour suppressor genes p53 and Rb. 
Inactivation of either gene appears to be sufficient for MEFs to evade cellular senescence 
[Harvey et al., 1993, Sageetal., 2000].
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1.4.4 Cell cycle arrest- d21 (CDKNIa)
CDKNIa (cyclin-dependent kinase inhibitor 1a) or p2icip1/Waf1 (from hereon referred to 
as p21) was the first p53 target gene discovered with a role in celi cycle arrest [el-Deiry et al., 
1993]. It encodes a potent cyclin-dependent kinase inhibitor which represses cell cycle 
progression [Harper et al., 1993] and is involved in both the G1/S and G2/M checkpoint 
responses to DNA damage [Cartel and Tyner, 1999] (see Figure 1.4.5). Interestingly, whilst 
p21 does bind to and inhibit a wide range of cyclin and cdk (cyclin dependent kinases) 
complexes including; cyclin D1-Cdk4, cyclin E-Cdk2, cyclin A-Cdk2, and cyclin A-Cdc2, p21 
may also act as an assembly factor for cyclin D1-Cdk4 at low concentrations [LaBaer et al., 
1997]. At high concentrations of p21 (as would be induced upon p53 activation) the 
stimulatory effects are switched to inhibitory and thus prevent entry of the cell into the cell 
cycle [Zhang et al., 1994, Levine, 1997]. The paradoxical activity of cell cycle inhibitor p21 to 
also act a stimulator of early G1 phase of the cell cycle does not appear to be essential for 
normal cell function - as p21 null mice developed normally [Deng et al., 1995].
The ability of p53 to induce cell cycle arrest also lays with two other genes, GADD45 
(growth arrest and DNA damage-inducible protein 45) and 14-3-3o [Olsson et al., 2007]. 14- 
3-3o sequesters cyclinB1-CDK1 complexes in the cytoplasm preventing their nuclear import, 
while GADD45 destabilises CDC2/cyclinB which ultimately induces G2/M arrest in cells with 
DNA damage [Olsson et al., 2007, Vogelstein et al., 2000].
p21 null mice developed normally and were fertile but were prone to renal failure 
[Deng et al., 1995] and eventually succumbed (average age 16 months) to spontaneous 
tumour development [Martin-Caballero et al., 2001]. There is also evidence of p21 
haploinsuffciency. Studies have shown that p2T/_ and p21+/' mice developed more tumours 
and in a wider spectrum than p21+/+ mice when exposed to a single 4 Gy dose of y-irradiation 
at two weeks of age [Jackson et al., 2003]. p21/' mice also had a much higher incidence of 
tumour metastasis, indicating p21 may function as an anti-metastatic agent. However, this 
phenotype is not nearly as severe as that displayed by p53-null mice (average age of tumour 
development 6 months [Donehower et al., 1992]) which thus argues that p21 is not 
responsible for all p53’s tumour suppressor activity [Fisher, 2001]. Certainly lack of p21 does
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not affect p53 dependent cell death in the intestine [Brugarolas et al., 1995], nor can loss of 
p21 rescue Mdm2 null lethality during embryogenesis [Montes de Oca Luna et al., 1997]. p21 
deficiency does, however, compromise radiation-induced cell cycle arrest [Brugarolas et al., 
1995],
p21 is induced in the colonic and small intestinal crypts in response to DNA damage. 
This process is p53-dependent as demonstrated by studies of p53 null mice in which no p21 
induction occurs in response to ionising radiation [Wilson et al., 1998]. p21 was also induced 
in a p53-dependent manner in response to chemically induced DNA damage in the small 
intestine (using 5-fluorouracil, 5-FU) [Pritchard et al., 1998]. Since p21 is essential for p53- 
induced G1 cell cycle arrest, and p21’s expression in the Gl tract is dependent on p53, p21 
appears to be an ideal downstream reporter for p53-mediated cell cycle arrest in the intestinal 
gut epithelia.
Period during 
which the cell is 
responsive to 
growth signals
Figure 1.4.5: The cell cycle clock.
Taken from [Weinberg, 2007] G1, S, G2 and M refer to first gap, DNA synthesis, second gap 
and mitosis. Restriction (R) point is the time when a cell must commit to continuing with DNA 
synthesis, it is also up to this point that a cell remains sensitive to mitogenic growth factors.
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Unlike p53, mutations in the p21 tumour suppressor protein are rare in human 
cancers [Shiohara et al., 1994], indicating that p21 may have redundant roles in the p53 
response - for example p53 may up-regulate GADD45 and/or 14-3-3o to compensate for loss 
of p21, or p53 may induce apoptosis instead - so that mutations in p53 itself are far more 
detrimental [Lozano and Zambetti, 2005]. In addition to p53, several other factors can 
activate the transcription of p21 (reviewed in [Gartel and Tyner, 1999]). However, since in 
response to DNA damage p53’s main downstream target in cell cycle arrest seems to be p21 
- and p21 appears to be essential for p53-depenedent G1 arrest (reviewed in [Levine, 1997]) 
-p21 would appear to serve as an ideal p53-responsive reporter gene.
1.4.5 Apoptosis - an overview
Apoptosis, or programmed cell death, is a vital component of the maintenance of 
healthy multicellular organisms. Apoptosis occurs in response to a wide variety of stimuli 
including cellular stresses such as DNA damage or viral infection and is tightly controlled by a 
variety of pro- and anti-apoptotic proteins (reviewed in [Danial and Korsmeyer, 2004, Taylor et 
al., 2008]). A cell undergoing apoptosis has a very distinct morphology; the cell shrinks, its 
chromosomes condense, the nucleus fragments, the cellular membranes bleb and form small 
apoptotic bodies which are removed by phagocytes [Kerr et al., 1972]. It is the organised 
removal of cell debris and the prevention of an unwanted immune response that defines 
apoptosis from another type of cell death called necrosis [Savill and Fadok, 2000]. Apoptosis 
is a very rapid process and can be completed within a few hours after initiation which makes it 
particularly difficult to detect in vivo [Walker et al., 1988].
Apoptosis can be stimulated intracellularly or extracellularly but both pathways 
converge at the mitochondrial membrane where members of the Bcl-2 protein family compete 
to control the release of cytochrome c [Danial and Korsmeyer, 2004, Chipuk and Green, 
2008]. The Bcl-2 protein family is divided into three subclasses based on their areas of Bcl-2 
like homology (BH domains) (see Figure 1.4.6) [Willis and Adams, 2005, Puthalakath and 
Strasser, 2002]. The anti-apoptotic members (Bcl-2, BcI-Xl Mcl-1, A1 and others) contain all 
four areas of homology BH1-4, the “multidomain” pro-apoptotic members (Bax and Bak)
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contain BH1-3 and finally the BH3-only pro-apoptotic members Puma and Noxa (among 
others) contain only BH3 domains [Huang and Strasser, 2000, Shibue and Taniguchi, 2006]. 
At the mitochondrial outer membrane (MOM), under normal conditions, the anti-apoptotic Bcl- 
2 family members such as Bcl-2 and Bci-xi block apoptosis by preventing the oligomerisation 
of Bax and Bak. However, after receiving death signals from the BH3-only proteins, Bax or 
Bak migrate to the MOM where, following oligomerisation and the subsequent formation of 
homodimers, they can insert themselves into the membrane and create channels which allow 
the release of cytochrome c. It is thought to be the balance of Bcl-2 pro- versus anti-apoptotic 
family members on the MOM which determines whether to prevent or to allow release of inter­
membrane space (IMS) proteins including cytochrome c [Chipuk and Green, 2008]. The 
release of IMS proteins from the mitochondria is called mitochondrial outer membrane 
permeabilization (MOMP) [Danial and Korsmeyer, 2004] and Bax or Bak are essential to 
inducing apoptosis in this way (also referred to as the intrinsic cell death pathway) [Cheng et 
al., 2001, Zong et al„ 2001].
Following cytochrome c release, it is bound by Apaf-1 (apoptotic protease activating 
factor) through their mutual WD40 domains. The caspase recruitment domains (CARD) on 
Apaf-1 are usually bound by its WD40 domains, so once cytochrome c has bound to the 
WD40 domains the CARD sites become dislodged [Danial and Korsmeyer, 2004]. In the 
presence of ATP/dATP Apaf-1/cytochrome c can then recruit pro-caspase-9 through the 
CARD-CARD interactions between Apaf-1 and pro-caspase-9 [Li et al., 1997]. Pro-caspase- 
9, an initiator caspase, is able to auto-activate within the resulting structure, termed the “the 
wheel of death” but also known as the apoptosome [Chinnaiyan, 1999]. Activated caspase-9 
can then go on to cleave and activate executioner caspase-3 which triggers the caspase 
cascade which will ultimately result in the death of the affected cell (see Figure 1.4.7) [Hill et 
al., 2003].
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Figure 1.4.6: The Bcl-2 family.
Image taken from [Taylor et a!., 2008]. The B-cell lymphoma-2 (Bcl-2) family proteins have 
very important roles in the regulation of apoptosis and are divided into three groups; the anti- 
apoptotic proteins Bcl-2, Bcl-XL, Bcl-W, Mcl-1, Bcl2A1 and Bcl-B, the pro-apoptotic 
“multidomain” proteins Bax, Bak and Bok, and the pro-apoptotic BH3-only proteins Bik, Hrk, 
Bim, Bad, Bid, Puma, Noxa and Bmf (see text for further details).
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MAMMALS
Figure 1.4.7: The intrinsic apoptotic pathway.
Taken from [Danial and Korsmeyer, 2004] illustrating the similarities and divergence between 
C. elegans and the mammalian intrinsic death pathways. EGL-1 and a subset of the BH3- 
only proteins bind to and inactivate anti-apoptotic proteins CED-9 and Bcl-2. This leaves 
CED-4 free to activate CED-3 and Bax/Bak able to release cytochrome c from the 
mitochondria, allowing the formation of the apoptosome which activates the effector 
caspases. It is the effector caspases like caspase-3 (a homologue of CED-3) that trigger the 
caspase cascade and ultimately the death of the cell.
The extrinsic death pathway is activated by so called death receptors including, the 
tumour necrosis factor receptor (TNF-R) family and Fas [Danial and Korsmeyer, 2004], Both 
TNF-R and Fas have a common cytoplasmic region called the "death domain” and following 
binding with their ligands TNF-a and FasL respectively, the death domain binds and activates 
an associated protein termed FADD (Fas-associated death domain protein) [Boldin et al., 
1996, Muzio et al., 1996]. The resulting complex, DISC (death-inducing-signalling-complex) 
activates the initiator caspases; pro-caspases -8 and -10 which then go on to activate the 
executioner caspases -3, -6 & -7 independently of the intrinsic mitochondrial pathway (see 
Figure 1.4.8). The executioner caspases trigger the caspase cascade which leads to the 
morphological changes associated with apoptosis [Taylor et al., 2008]. Caspase-8 also
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catalyses Bid activation (a Bcl-2 BH3-only pro-apoptotic family member) which then 
translocates to the mitochondria [Gross et al., 1999] resulting in Bax/Bak activation and 
cytochrome c release [Willis and Adams, 2005]. Bid activation thus connects the death 
receptor pathway with the intrinsic mitochondrial apoptotic pathway and hence amplifies pro- 
apoptotic signals [Danial and Korsmeyer, 2004, Shelton et al., 2009].
A third pathway which activates the caspase cascade and apoptosis is the granzyme 
B pathway (See Figure 1.4.8) [Taylor et al., 2008], T-cells and Natural killer (NK) cells can 
eliminate transformed tumour cells or cells infected with a virus by delivering granules, 
containing perforin and serine proteases called granzymes, to the cytosol of their targets 
[Martinvalet et al., 2008], Perforin can form pores in the cells plasma membrane facilitating 
granzyme B entry into the cell. Granzyme B can cleave caspase-3 and BH3-only protein Bid 
(thus activating it) [Alimonti et al., 2001], whereupon this pathway converges with the other 
apoptotic pathways. Granzymes A and B can also induce caspase-independent death (not 
discussed in this report) [Danial and Korsmeyer, 2004].
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Figure 1.4.8: Caspase activation pathways.
Image taken from [Taylor et a!., 2008]. The caspase cascade and cell death can be triggered 
in three (not necessarily exclusive) ways. 1) The extrinsic pathway 2) the intrinsic pathway 
and 3) the granzyme B pathway (see text for details). Importantly the intrinsic pathway relies 
on Bax/Bak oligomerisation and the formation of channels in the mitochondrial membrane to 
allow the release of cytochrome c which then goes on to form the apoptosome and caspase 9 
auto-activation, whereas the extrinsic pathway and granzyme B pathway can also activate the 
executioner caspases independently of the mitochondria.
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1.4.5.1 Apoptosis - downstream p53 targets
The tumour suppressor gene TP53 can initiate the intrinsic and extrinsic apoptotic 
pathways by up-regulating specific genes following its activation. For example p53 can up- 
regulate death receptor KILLER/DR5 in response to DNA damage induced by 
chemotherapeutic agents or by ionising radiation [Wu et al., 1999, Wu et al., 1997], 
KILLER/DR5 activates the extrinsic death pathway once it is bound by its death ligand TRAIL 
(TNF-related apoptosis inducing ligand) in a similar manner to the Fas/TNF-R death receptors 
(see Section 1.4.5). p53 can also up-regulate CDIP (cell death involved p53-target), in 
response to genotoxic stress [Brown et al., 2007], CDIP induces apoptosis in a caspase-8 
dependent manner that implicates it in the extrinsic death pathway. In the mitochondrial 
intrinsic cell death pathway p53 can up-regulate key players such as; Bcl-2 pro-apoptotic 
protein family members Bax, Bid, Noxa and Puma in response to DNA damage.
The process of p53 induced apoptosis is far more complicated than just activating 
genes that promote apoptosis - as p53 does not always up-regulate the same pro-apoptotic 
target genes in every cell type or under every type of stimuli (for example DNA damage, 
hypoxia, oncogenic stress, UV light, free radicals etc) [Vousden, 2006]. p53, in fact, up-
regulates a wide range of downstream target genes which often have redundant or 
cooperative roles in apoptosis. Since a large number of these target genes belong to the pro- 
apoptotic “club” and due to the complicated nature of how these gene interact under different 
conditions, there is not yet one p53 target gene that can account for the whole apoptotic 
response [Vousden and Lu, 2002]. In addition, p53 can act independently of transcription and 
initiate apoptosis by acting like a BH3-only protein in the cytoplasm of cells [Vousden, 2006]. 
In summary, the p53-dependent apoptotic pathways are very complex with tissue specific and 
stress specific responses which make it imperative that the unique properties of each 
candidate gene are examined when selecting between them to act as a reliable reporter for 
p53 activation in the gastrointestinal tract. Below the candidate genes Bax, Puma, Noxa and 
Bid are discussed.
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1.4.5.2 The Multidomain Bcl-2 Proteins: Bax (and Bak)
Bax is a multidomain member of the Bcl-2 family [Cory et al., 2003, Danial and 
Korsmeyer, 2004] and is transcriptionally up-regulated by p53 [Wu and Deng, 2002] although, 
surprisingly (as expression of Bax (and Bak) is associated with apoptosis in rats and humans 
[Bowen et al., 2005]), it appears to play only a minor role in DNA damage induced apoptosis 
in the intestinal gut epithelia of mice [Pritchard et al., 1999, Watson and Pritchard, 2000]. 
Therefore, Bax would not appear to be the best candidate gene to act as a p53-responsive 
reporter gene in the gastrointestinal tract. Since the multidomain Bcl-2 proteins are required 
to create the pores in the outer mitochondrial membrane which initiates MOMP and 
cytochrome c release, the upstream BH3-only proteins cannot initiate apoptosis without them 
(the multidomain Bcl-2 family proteins) [Zong et al., 2001, Cheng et al., 2001, Wei et ai., 
2001]. Therefore, if Bax is not responsible for the induction of apoptosis in the intestinal gut 
epithelia then perhaps other Bcl-2 multidomain proteins are.
Bak - one potential candidate - is not thought to be, nor has it yet been identified as 
a transcriptional target of p53 [Cory et al., 2003] instead Bak is transcriptionally up-regulated 
by IFN-Gamma [Ossina et al., 1997] and thus would not be a good candidate as a reporter 
gene for p53 activation in the gut.
Bax and Bak are activated and controlled either directly or indirectly by BH3-only 
proteins [Fletcher and Huang, 2008, Willis and Adams, 2005, Willis et al., 2007]. Indirect 
activation occurs by displacement of Bak from Bcl-2 pro-survival members (Mci-1 and Bcl-xL) 
by BH3-oniy proteins such as Noxa [Willis et al., 2005]. Direct activation of Bax/Bak occurs in 
a two step process involving "sensitizer" BH3-only proteins like Bad, which bind to and 
inactivate the anti-apoptotic Bcl-2 members and "activators” (for example Bid) which bind 
Bax/Bak at the mitochondrial outer membrane to induce cell death [Willis and Adams, 2005, 
Zinkel, 2008], Evidence also exists for protein-protein interactions between p53 and Bax/Bak 
in the cytoplasm of cells whereby p53 acts in a transcription-independent manner (similar to 
the BH3-only protein Bid) to initiate apoptosis [Chipuk et al., 2004, Pietsch et al., 2007].
To determine whether the roles of Bax and Bak are mutually exclusive, knock-out 
mice have been generated. Mice lacking either Bax or Bak develop normally with only minor
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aberrations in apoptosis, whilst doubly deficient mice rarely survive to birth (only 10% survive 
embryogenesis) [Lindsten et al., 2000], This indicates that Bax and Bak have overlapping 
(presumably partially redundant) roles in apoptosis during embryogenesis. Such studies 
seem to indicate that Bak may compensate in the absence of Bax in the intestine, and/or that 
Bax and Bak complement each other in their mechanism of action [Degli Esposti and Dive, 
2003], In a closely related tissue (the stomach) both Bax and Bak regulate ionising radiation 
induced apoptosis in proliferative regions of gastric epithelia [Przemeck et al., 2007]. This 
has yet to be investigated in detail in the epithelium of the gastrointestinal tract, but research 
into the endothelial cells shows Bax and Bak play non-redundant roles in response to 
ionising-radiation [Rotolo et al., 2008], In summary the multidomain Bcl-2 family members do 
not appear to be good reporters of p53 activity. The next section of this report focuses on the 
BH3-only proteins which act upstream of Bax/Bak to induce apoptosis.
1.4.5.3 The BH3-Only Proteins: Puma, Noxa and Bid
The BH3-only members of the Bcl-2 family are a diverse group of pro-apoptotic 
proteins, including: Bim, Bmf, Hrk, Bad, Puma, Noxa and Bid (among others see Figure 
1.4.6). Characteristically, the only area of homology that BH3-only proteins share is the BH3 
domain (see Section 1.4.5). The BH3 domain is a short 9-16 amino acid sequence that forms 
(with surrounding residues) an amphipathic helix capable of binding the anti-apoptotic Bcl-2 
family members [Huang and Strasser, 2000].
BH3-only proteins are either absent or inactive in an unstressed cell. However, in 
response to various cellular stress stimuli, each BH3-only protein plays a unique role in 
inducing programmed cell death [Shibue and Taniguchi, 2006] (see Figure 1.4.9). Bim and 
Bmf, for example, are cytoskeletal proteins that contribute to anoikis when there is a 
disruption of the cytoskeleton [Puthalakath et al., 2001]. BH3-only proteins can be regulated 
by post-translational modifications, including phosphorylation. For example, Bad undergoes 
phosphorylation in the presence of growth factors [Zha et al., 1996, Bergmann, 2002] which 
renders it inactive. However upon de-phosphorylation (caused by the lack of appropriate 
growth factors) Bad becomes active and exerts its pro-apoptotic effects.
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Puma, Noxa and Bid are a subset of BH3-only proteins up-regulated by tumour 
suppressor gene TP53 in response to DNA damage [Wu and Deng, 2002, Sax et al., 2002]. 
Since Puma, Noxa and Bid are all transcriptional targets of p53; these genes are potential 
candidates to be used as a p53-responsive reporter gene. The suitability of Puma and Noxa 
as p53-reporter genes is discussed first; followed by Bid.
The role of Puma and Noxa in p53-mediated apoptosis is not fully understood. The 
reason(s) why p53 recruits either Puma or Noxa (or both) to instigate cell death remain(s) to 
be elucidated. Several lines of evidence collectively indicate that the contribution of Puma 
and Noxa to p53-mediated apoptosis is determined by cell type and cell state [Vousden, 
2006]. Studies using Puma and Noxa knock-out mice have been used to further investigate 
the respective roles of each protein; these will be discussed below.
Mice lacking either Puma and/or Noxa were generated to test whether or not the p53- 
dependent roles of these two proteins in apoptosis overlap [Michalak et al., 2008]. These 
mice developed normally (with respect to their appearance, behaviour and health) and did not 
appear to be susceptible to tumour development (no tumours seen in mice up to a year old). 
In contrast, mice deficient in p53 developed a wide range of tumours and most had died by 6 
months of age [Donehower et al., 1992] (and see Section 1.4.4). Mice doubly deficient in 
Puma and Noxa, whilst not susceptible to tumour formation, did however show an impaired 
apoptotic response in several tissues and cell types [Michalak et al., 2008]. In all of the cell 
types examined, Puma (rather than Noxa) consistently played a major role in inducing 
apoptosis. Indeed, following DNA damage in mature T and B cells in the spleen, Puma alone 
was responsible for inducing cell death in a p53-dependent manner. In other cell types, such 
as cultured thymocytes and mouse embryonic fibroblasts (MEFs) expressing oncogene E1A, 
Noxa also contributed to apoptosis [Shibue et al., 2006, Shibue et al., 2003]. Interestingly, 
MEFs lacking Puma (or both Puma and Noxa) and expressing oncogene E1A did not undergo 
apoptosis even at very high doses of y-irradiation (50 Gy) whilst pdd'1' MEFs were still 
vulnerable [Michalak et al., 2008]. Presumably this is because p53''' MEFs cannot induce cell 
cycle arrest; hence the cells die iater (24 hours after irradiation) from catastrophic errors in 
mitosis.
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Figure 1.4.9: Different stress conditions activate different BH3-only protein responses.
Adapted from [Puthalakath and Strasser, 2002] and [Cory et al., 2003]. BH3-only proteins 
are shown in blue text. Bim and Bid can activate Bax/Bak directly (as can Puma and p53) 
[Willis and Adams, 2005] and Bid has been shown to be up-regulated in some tissues by p53 
(including the intestine) [Sax et al., 2002]. Bim and Bmf reside in separate cytoskeletal 
compartments and Bmf is released during anoikis [Puthalakath et al., 2001]. Noxa and 
Puma are up-regulated by tumour suppressor gene p53 [Wu and Deng, 2002].
Deletion of both Puma and Noxa in some cell types (thymocytes and fibroblasts 
expressing oncogene E1A) completely recaptured a p53-null phenotype during the early 
apoptotic response to DNA damage; demonstrating their importance in p53-dependent cell
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death [Michalak et al., 2008]. There are additional roles for p53 in the apoptotic response 
apart from inducing Puma and Noxa. For example, p53_/' mature B cells did not undergo any 
apoptosis in response to DNA damage whilst Puma^ and Noxa’7' mature B cells still 
underwent some apoptosis. p53 must therefore have other unidentified target genes in 
mature B cells that play a role in apoptosis in these cells. Similarly, Puma and Noxa have 
apoptotic roles that don’t rely on p53 activation and these p53-independent roles are 
discussed next.
Both Puma (p53 upregulated modulator of apoptosis) and Noxa (Latin for damage 
[Oda et al., 2000]) can act in a p53-dependent and independent manner to induce apoptosis 
[Jeffers et al., 2003]. It has been demonstrated that Puma plays a role in p53-independent 
cell death of primary thymocytes, including death induced by the addition of glucocorticoids 
(mechanism of death unknown [Wyllie, 1980]) or by serum deprivation [Jeffers et al., 2003, 
Han et al., 2001]. Puma also has p53-independent roles in inducing apoptosis as a result of 
ischaemia-reperfusion in the intestine [Wu et al., 2007] and in chronic colitis [Dirisina et al., 
2011]. In contrast Noxa appears to only play a p53-independent role under hypoxic 
conditions. During hypoxia Noxa is up-regulated by hypoxic-inducible factor 1 a (HIF-1a) and 
contributes to cell death by generation of reactive oxygen species (ROS) [Kim et al., 2004],
Puma and Noxa, just like many other p53 inducible genes, have a consensus p53 
REs in their promoter regions (see Section 1.4.1) that allow them to be transcribed by p53 
[Oda et al., 2000, Nakano and Vousden, 2001], However, Puma and Noxa differ in the mode 
of induction by p53. Whilst Puma requires both trans-activation domains of p53 to be intact 
for activation either domain seems to be sufficient for the induction of Noxa [Cregan et al., 
2004]. The differential regulation of Puma and Noxa is thought to provide a mechanism for 
the differences observed in expression and activation of the two genes [Shibue and 
Taniguchi, 2006].
An important difference between Puma and Noxa is in their ability to bind to other Bcl- 
2 family members. Puma potently binds to all the Bcl-2 pro-survival family members whereas 
Noxa is more selective, binding only to Mcl-1 and (weakly) A1 [Fletcher and Huang, 2008, 
Chen et al., 2005] (see Figure 1.4.10). Puma may also directly activate Bax on the 
mitochondrial membrane to induce cytochrome c release [Cartron et al., 2004], however the
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evidence for this remains controversial [Fletcher and Huang, 2008]. Noxa acts mainly 
through Bak (rather than Bax) but cannot directly activate either Bak or Bax [Letai et al., 
2002], Noxa can, however, displace Bak from Mcl-1, leaving Bak “free” (i.e. Bak which is no 
longer bound to its negative regulators Mcl-1 and Bcl-xL) in the cell, ready to induce cell death 
upon a further stimulus [Willis et al., 2005].
Puma / Bim
Figure 1.4.10: BH3-only proteins can have selective or ‘promiscuous’ binding.
Adapted from [Fletcher and Huang, 2008], BH3-only proteins are shown in blue text. Puma 
and Bim are “promiscuous”, binding to and neutralising all pro-survival Bcl-2 family members. 
Bad, tBid and Noxa are more selective. Bad binds with Bcl-2, Bcl-w and Bcl-xL tBid binds 
Bcl-xL and Mcl-1 while Noxa neutralises Mcl-1 and A1.
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Puma and Noxa have different roles and mechanisms of action in the induction of 
apoptosis. Puma can be described as an "effector”, whereas Noxa is a “sensitizer” (see 
Section 1.4.5.2). Each of the unique properties of Puma and Noxa should be taken into 
consideration when choosing between the two genes to act as a reliable reporter for p53 
activation in the gastrointestinal tract. For instance, since Puma has many p53-independent 
activities, its suitability as a true p53 reporter gene could be called into question. As Noxa 
acts as a sensitizer towards cell death, it may not be the gene of choice to be an accurate 
reporter of apoptosis. The role of Puma and Noxa in the gastrointestinal tract in response to 
DNA damage will now be discussed in an attempt to further evaluate their suitability as p53 
reporter genes.
There is evidence that Noxa plays a role in p53-mediated apoptosis in the 
gastrointestinal tract based on the analysis of Noxa and p53 knockout animals [Shibue et al., 
2003], When wild-type mice, Noxa knockout mice and p53 knockout mice were each 
exposed to 10 Gy of x-ray-irradiation to induce DNA damage and had their jejunums 
harvested for analysis of apoptosis 6 hours later, it was observed that apoptosis was induced 
in the crypt region of the small intestine of the wild-type animals in the expected manner (see 
Section 1.2.5). Mice lacking Noxa showed a two-fold reduction of apoptosis, but in p53 
knockout mice this acute apoptotic response in the small intestine was completely abrogated 
[Shibue et al., 2003]. Therefore, the apoptosis seen in the small intestine is completely p53- 
dependent (in agreement with previous studies [Merritt et al., 1994]), thus since Noxa only 
contributes to apoptosis in the small intestine when p53 is present, Noxa must have been 
induced, or otherwise activated by p53. However, Noxa cannot be the only target gene p53 
up-regulates in response to DNA damage in the gastrointestinal tract as apoptosis still 
occurred in Noxa knockout mice. Noxa may share responsibility for inducing apoptosis with 
other genes [Nakajima and Tanaka, 2007, Fei et al., 2002] (such as Puma and B/d-discussed 
later in this section) and perhaps one of these would be better suited as a p53-responsive 
reporter gene. Noxa would not seem to be an ideal reporter gene for the apoptotic arm of the 
p53 response to DNA damage as the expression of Noxa does not always correlate with 
either p53 status or with the induction of apoptosis [Fei et al., 2002].
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It has been demonstrated that Puma plays a major role in DNA damage induced 
apoptosis in the intestinal gut epithelium [Qiu et al., 2008]. Recent research into the 
regulators of gastrointestinal syndrome has implicated Puma as a key regulator of 
radiosensitivity. Radiotherapy is one commonly used method for treating cancer, however a 
major limitation in radiotherapy is gastrointestinal toxicity caused by the radiation. Mice that 
receive a y-irradiation dose of greater than 14 Gy die at 7-10 days after treatment from 
damage to the small intestine [Komarova et al., 2004]. The lethal damage is initiated by a 
massive p53-dependent apoptotic response [Merritt et al., 1994] and cell death continues to 
occur later as a result of aberrations in cell division which are p53-independent [Merritt et al., 
1997]. As Puma is a downstream apoptotic target of p53 activation [Nakano and Vousden, 
2001], Puma knockout mice were generated to investigate whether Puma plays a role in the 
DNA damage induced apoptosis in the small intestine.
It has been shown in wild-type mice that Puma was rapidly up-regulated in response 
to a range of doses of y-irradiation (8-18 Gy) in an exclusively p53-dependent manner [Qiu et 
al., 2008]. The induction of Puma (and p53) was contained within the crypt region of the 
small intestine, specifically in cell positions 0-6 (associated with the speculated stem cell 
position and progenitor cells [Potten et al., 1997a, Barker et al., 2007] - and see Section 
1.2.1). As expected, Puma knockout mice underwent less irradiation induced apoptosis in the 
small intestine than the wild-type mice. At low doses of y-irradiation (8 Gy) apoptosis was 
blocked to a similar degree between Puma knockout mice and p53 knockout mice during 
early stages (4 hours) after treatment. However, later on (24 hours) or when higher doses of 
Y-irradiation were used (>15 Gy), p53 knockout mice showed higher levels of apoptosis than 
the Puma knockout mice. One explanation for this difference in apoptotic rates between 
Puma knockout and p53 knockout mice could be that p53 knockout mice fail to activate the 
cell cycle arrest gene p21, hence there is a profound increase in cell proliferation in these 
mice. The increased cell proliferation accelerates the rate of gastrointestinal syndrome and 
consistent with this, p53 knockout mice die 3.5 days earlier than wild-type mice following 
exposure [Qiu et al., 2008, Komarova et al., 2004], Puma knockout mice were, however, 
significantly protected against gastrointestinal syndrome, surviving approximately 50% longer 
than the wild-type mice. As Puma is up-regulated by p53 and is responsible for much of the
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p53-dependent apoptotic response in the small intestine it would seem to be an ideal p53- 
responsive reporter gene.
One research group have already used p53 REs found in the Puma promoter region 
to examine the expression of p53/Puma in vivo [Briat and Vassaux, 2008]. Brait and Vassaux 
designed a construct that contained four copies of the human Puma p53 RE, upstream of a 
minimal promoter that drove the expression of the Firefly Luciferase (Luc) gene to generate 
the p53RE-Luc reporter mice. These mice were examined using bioluminescence imaging 24 
hours prior to and 24 hours post administration of the chemotherapeutic drug, Doxorubicin 
(Dox), and it was found that luciferase activity was increased (by 4-fold) in the lower 
abdominal region in male (but not female) mice. Dox is thought to prevent DNA and RNA 
synthesis by interaction with nucleic acids [Momparler et al., 1976] making it a useful cancer 
therapy however Dox is also known to be very toxic to the testes [Yeh et al., 2009]. The 
p53RE-Luc transgenic mice provide a reliable indication of where p53/Puma is being 
activated in response to Dox testicular toxicity, which is thought to be caused by oxidative 
stress and cellular apoptosis (dependent on p53). Whilst the p53RE-Luc transgenic mice are 
a useful system to test drug toxicity, these mice do not report genuine endogenous Puma or 
p53 activity. The pro-nuclear injection method used to create these mice means that the 
p53RE-Luc construct has been randomly integrated into the host DNA and expression is thus 
subject to positional bias [Ittner and Gotz, 2007]. In addition, there are 4 REs, whilst in the 
endogenous Puma promoter only 2 are present [Nakano and Vousden, 2001]. One way of 
overcoming both of these problems is by generating a knock-in reporter mouse that would 
contain a reporter construct inside the actual Puma gene, thus reporting genuine Puma 
activation.
The third p53-inducible BH3-only gene we are examining for suitability as a p53- 
responsive reporter gene is Bid. Bid (BH3 interacting death agonist) is an interesting BH3- 
only gene as it is involved in both the intrinsic and the extrinsic cell death pathways (see 
Figure 1.4.9). Briefly, as described previously in Section 1.4.5, engagement of the death 
receptors Fas or TNF-R1 leads to the formation of DISC. DISC recruits caspase-8 through 
interaction with FADD [Boldin et al., 1996, Muzio et al., 1996]. Caspase-8 is rapidly activated 
(probably by autocatalysis within the protein complex [Cryns and Yuan, 1998]) and in turn
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activates other caspases, triggering the caspase cascade. Activated caspase-8 also cleaves 
full length cytoplasmic Bid (p22) into a truncated active fragment known as tBid (p15) [Li et 
al., 1998]. tBid translocates to the mitochondria [Gross et al., 1999] where it can bind to and 
inactive Bcl-2 pro-survival family members Bcl-xL and Mcl-1 [Fletcher and Huang, 2008] as 
well as directly activate Bax/Bak [Willis and Adams, 2005, Walensky et al., 2006]. The 
balance of Bcl-2 family proteins, in this case, shifts towards pro-apoptotic Bcl-2 family 
members and consequently allows the release of cytochrome c from the inter-membrane 
space of the mitochondria [Danial and Korsmeyer, 2004]. tBid thus connects the activation of 
the death receptors Fas/TNF-R1 which is an essential part of the extrinsic apoptotic pathway 
with the rapid release of cytochrome c and hence activation of the intrinsic mitochondrial 
apoptotic pathway [Luo et al., 1998, Li et al., 1998].
Bid knockout mice were generated to examine the role of Bid in inducing apoptosis in 
vivo. Bid deficient mice developed normally, but whilst wild-type mice died within 4 hours 
following an injection with an antibody that binds Fas as a result of hepatic apoptosis and 
haemorrhagic necrosis, Bid null mice survived [Yin et al., 1999]. This suggests that Bid is 
critical for hepatocyte apoptosis induced by activation of the death receptors Fas/TNF-R1 
[Yin, 2000]. Other cell types such as MEFs and thymocytes do not strictly require Bid to 
induce apoptosis in response to treatment in culture with an anti-Fas antibody [Yin et al., 
1999]. However, Bid deficiency effectively delayed onset of apoptosis in MEFs and 
thymocytes (following activation of the Fas/TNF-R1 pathway) implying that whilst Bid is not 
essential in these cell types for initiation of apoptosis, it does contribute pro-apoptotic signals. 
It has been suggested that the activation of the mitochondrial pathway (and hence cleavage 
of Bid) following death receptor engagement is only essential in inducing apoptosis in certain 
cell types, also called type II cell lines [Scaffidi et al., 1998]. Hepatocytes might therefore 
belong to this class of cells [Yin et al., 1999].
Whilst Bid’s involvement in the extrinsic death pathway in type II cells has been well 
characterised [Yin et al., 1999], its role in DNA damage induced apoptosis remains 
controversial. In some studies Bid deficient MEFs and myeloid progenitor cells (isolated from 
Bid knockout mice) were less susceptible to a variety of DNA damaging reagents than wild- 
type cells [Sax et al., 2002, Zinkel et al., 2005, Kamer et al., 2005], whereas another study
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showed no role for Bid in DNA damage induced apoptosis [Kaufmann et al., 2007]. 
Nonetheless, Bid is up-regulated by p53 in response to y-radiation in the colonic epithelium 
and in splenic red pulp [Sax et al., 2002]. Bid was also up-regulated in a p53 dependent 
manner in Campthothecin (a chemotherapy drug) treated neurones [Jacobs et al., 2007], It is 
worth mentioning that although there may be a minor role for full length Bid in apoptosis 
[Goonesinghe et al., 2005], tBid is far more potent at inducing mitochondrial dysfunction and 
cytochrome c release [Li et al., 1998, Luo et al., 1998, Yin et al., 1999], therefore to induce 
apoptosis it is generally accepted that Bid has to be cleaved into tBid [Shelton et al., 2009].
In addition to Bid being cleaved by caspase-8 as part of the death receptor pathway 
[Li et al., 1998], Bid can also be cleaved by calpains, Granzyme B, cathepsins [Yin, 2006] and 
other executioner caspases (caspase-3 and caspase-2) [Bonzon et al., 2006, Shelton et al., 
2009]. Bid, however, cannot be cleaved into tBid by p53 directly, so how Bid up-regulation by 
p53 contributes to the induction of apoptosis is uncertain. In neurones the death receptor 
pathway becomes activated as part of treatment with Campthothecin [Jacobs et al., 2007] 
thus caspase-8 is recruited and can readily go on to cleave and activate Bid. Therefore, in 
Campthothecin treated neurones Bid cleavage appears to be an upstream event in MOMP 
(mitochondrial outer membrane permeabilization see Section 1.4.5). in contrast, in the 
colonic epithelium there is no known death receptor activation during y-radiation, therefore 
p53 up-regulated Bid can only be cleaved once executioner caspases are present implying 
that Bid cleavage is a downstream event. In the case of the colonic epithelium, Bid may act 
to amplify cell death signals, irreversibly committing cells to death in a “feed forward" loop 
[Shelton et al., 2009]. Whether Bid acts as an initiator of MOMP consistent with its role in the 
death receptor pathways or as a sensitizer which may be the case in the colon seems to 
depend on the cell type and the type of DNA damaging agent used.
Interestingly, an analysis of Bid expression by in situ hybridisation in wild-type mice 
and p53 null mice showed that Bid was induced in a p53-dependent manner in response to 
ionising radiation in the transverse colon, but not in the small intestine [Fei et al., 2002]. Bid 
was, however, constitutively expressed in p53+/+ mice small intestine, but not in small intestine 
of p53'!' mice or in the colon. Since cells in the small intestine more readily undergo 
apoptosis than cells in the colon [Merritt et al., 1995], it is possible that Bid expression
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contributes to the increased sensitivity in the small intestine. However, as Bid is expressed 
constitutively in the small intestine (albeit in a p53-dependent fashion) it cannot be used as an 
indication of p53 activation of apoptosis, which would be an essential property to any gene 
selected to be part of our p53-responsive reporter system. In addition, Bid may not be an 
ideal p53-responsive reporter gene as Bid is also a critical part of the death receptor pathway 
which may or may not be involved in the response to DMA damaging agents.
A final consideration, when deciding between Puma, Noxa and Bid as p53-responsive 
reporter genes, is to examine their status in colorectal cancer. If these genes are important in 
the development of cancer in the intestine it is likely they will be either mutated or have an 
altered expression pattern in the cancerous tissue when compared to healthy tissue. Indeed, 
Puma was highly expressed in human colorectal carcinomas when compared with normal 
tissue [Kim et al., 2007] and Bid was either over-expressed which was associated with good 
prognosis or lost altogether which when combined with over expression of Puma was 
associated with the worst prognosis for patient survival [Sinicrope et al., 2008]. Noxa 
expression did not have any association with the development of colorectal cancer [Jansson 
et al., 2003]. Since Puma and Bid can be over-expressed during tumour development in the 
intestine, this could appear to conflict with a positive role in apoptosis. However, it may also 
be interpreted as; the cancer has evolved to uncouple Puma and Bid from their apoptotic 
responses (perhaps via up-regulation of the pro-survival Bcl-2 family members) hence their 
levels become elevated to compensate. As Bid can also be lost altogether then this may 
indicate a further need for the cancer to bypass its apoptotic properties in order to progress. 
This data might suggest that Puma and Bid play a more important role in this tissue then 
Noxa - as they are manipulated during tumour development, whilst Noxa is not. However, as 
these types of studies are not directly related to the p53-dependent apoptotic response to 
DNA damage, it is unclear how relevant such data is when making a decision of which gene 
to use as a p53-responsive reporter.
Before selecting a downstream marker for p53-mediated apoptosis in the gut some of 
the discrepancies would need to be resolved. Puma expression, for example, when 
examined by two groups showed either no up-regulation [Fei et al., 2002] or rapid up- 
regulation [Qiu et al., 2008] in response to ionising radiation. Since both groups used in situ
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hybridisation as a detection method and the mice used were on a C57BL/6 genetic 
background in both cases it is unclear how these two very different results arose. One 
explanation might be that Fei et al could have looked at the whole gut, including the sub­
mucosa and endothelial cells (the literature does not specify what cells were examined for 
staining) whereas Qiu et al specifically focused on the epithelial crypt cells in the small 
intestine. Qiu et al also performed real-time PCR and western blotting to confirm that Puma 
expression which further supports their conclusions. In conclusion, therefore, it appears that 
Puma is the best candidate gene to compliment p21 in a dual cell cycle arrest/apoptosis p53- 
responsive reporter system.
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1.5 Genetic manipulation
1.5.1 Gene-trapping: a public resource
Gene-trapping is a high-throughput approach to inserting mutations into genes. 
Gene-trap mutagenesis can be used to randomly generate loss-of-function genes in 
undifferentiated ES cells whilst simultaneously introducing a reporter to monitor endogenous 
gene expression [Skames et al., 2004]. Genes are “trapped” in ES cell lines by introduction 
of a vector (that contains a reporter gene (like LacZ) and a selectable marker (typically 
neomycin- which confers resistance to G418 an amino-glycoside antibiotic)) by either 
retroviral infection or electroporation [Stanford et al., 2001], These cell lines are then 
screened using a PCR based technique called 5’RACE (5’ rapid amplification of cDNA ends 
[Schramm et al., 2000]) which provides a sequence tag to BLAST (Basic Local Alignment 
Search Tool) and identify the gene affected (including novel genes) [Stryke et al., 2003]. 
Gene-trap mutagenesis overcomes some of the difficulties associated with more traditional 
mutation methods (such as x-ray, chemical mutation and gene-targeting) since it will only 
report endogenous gene expression and requires no previous knowledge of the genomic 
sequence. Gene-trapping can also be scaled up and used intensively to generate large 
libraries of gene-trapped ES cells [Skarnes et al., 2004].
These libraries can be searched through the IGTC (International Gene-Trap 
Consortium) website (httD://www.Qenetrap.ora/1 [Nord et al., 2006] and cell lines are often 
available to the research community on a cost recovery basis from the MMRRC (Mutant 
Mouse Regional Resource Centers). The MMRRC acts as a repository for ES cell lines (and 
mouse strains), with many groups donating their mutated alleles (for example SIGTR, Sanger 
Institute Gene Trap Resource and BayGenomics) for use in creating transgenic mice [Stryke 
et al., 2003]. It is hoped that with use of multiple vectors (containing new designs to 
overcome insertion bias [Skarnes et al., 2004]) and different vector delivery methods 
(retroviral infection vs electroporation) that the genome will become saturated with gene-traps 
and thus there will eventually be an ES cell line available for almost every gene [Stanford et 
al., 2001].
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There are three main gene-trap strategies exploiting different vector designs; the 
enhancer, promoter and gene-trap (see Figure 1.5.1) [Stanford et al., 2001]. As described 
above all vectors will have a reporter gene of some kind and a selectable marker, which can 
be the same thing, for example [3-geo is a fusion protein between (3-galactosidase (from LacZ) 
and neomycin [Friedrich and Soriano, 1991]. The enhancer-trap contains its own promoter 
which will, if it has inserted near to an enhancer region become active when the endogenous 
gene is activated. However, this does not always lead to the gene being disrupted (often 
genes can splice around the vector creating a truncated protein that may contain partial 
function) hence enhancer-traps often create hypomorphic mutations rather than nulls and as 
such are not widely used in the creation of knock-out mice [Stanford et al., 2001],
The promoter-trap has essentially the same structure as the enhancer-trap, except it 
is promoterless, which changes its functionality. For promoter traps to mutate a gene and 
successfully report that genes expression it must insert into an exon, thus creating a fusion 
transcript of the upstream endogenous gene with the vectors reporter. This has the 
advantage of almost always creating a mutation (usually null) but the disadvantage of low 
trapping frequency, as the probability of integrating in an exon is relatively low, since introns 
are generally much longer than exons [Stanford et al., 2001].
The last of these three strategies, utilising the gene-trap vector tries to overcome both 
these disadvantages. The gene-trap vector contains a splice acceptor upstream of a 
promoterless reporter and thus once integrated can be activated from the endogenous 
promoter from within the introns of genes. This design creates a fusion protein between the 
upstream coding region of the endogenous gene and the reporter (commonly |3-geo) 
simultaneously interrupting the gene and reporting its expression (see Figure 1.5.2) [Stanford 
et al., 2001]. Gene-trap vectors have a relatively high trapping frequency and a high 
probability of causing a null mutation, especially if integrated towards the 5’ ends of genes. 
There is a strong bias for gene-traps to insert in the 5’ ends of genes with retroviral infection 
[Friedrich and Soriano, 1991]). A disadvantage of this kind of gene-trap is it requires the gene 
to be expressed in undifferentiated ES cells, meaning genes that are important later on in 
development will not be targeted.
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Figure 1.5.1: The basic trap vectors.
Taken from [Stanford et a!., 2001], A) The enhancer-trap vector B) The gene-trap vector and 
C) The promoter-trap vector. See text for details.
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When generating transgenic animals one of the rate limiting steps is the development 
of a carefully planned targeting construct, since it requires in-depth knowledge of the gene’s 
structure and sequence and is very labour intensive [Stanford et al., 2001]. Large libraries of 
gene-trapped ES cells have been developed and these enable researches to rapidly identify 
candidate ES cell clones with a gene-trap for their gene of interest. The idea being to provide 
the research community with low-cost, easily available, pre-targeted ES cell lines which can 
be used to produce knock-out mice [Skarnes et al., 2004, Stryke et al., 2003, Hansen et al., 
2003]. Several research groups have used such gene-trapped ES cell clones and have 
demonstrated that this system can accurately report endogenous gene expression whilst 
simultaneously mutating the gene it has integrated into [Skarnes et al., 1992, Stoykova et al., 
1998], Our project would therefore use the public gene-trap libraries to identify ES cell lines 
with a gene-trap in the p53-responsive genes p21 and Puma to demonstrate in principle that 
this knock-in approach can report authentic expression of both these genes.
Spiood transcript 
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pA
Nature Raviaws | Genetics
Figure 1.5.2: p-geo gene-trap vector.
Taken from [Stanford et al., 2001]. The fusion transcript created by vector integration into a 
gene’s intronic region generates a fusion protein consisting of a truncated protein from the 
endogenous gene X and /3-geo (a fusion of the lacZ gene and neomycin 
phosphotransferase).
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Gene-trap technology cannot be used to insert subtle mutations, such as those 
required when creating either an Mdm2 P1 or P2 promoter-less mouse. Therefore the next 
section of this report discusses BAG clones and how (and why) we plan to use them as rich 
sources of DNA for generating the arms of homology and for sequencing the P2 region of 
Mdm2.
1.5.2 BAG clones
Bacterial Artificial Chromosomes or BAG Clones are large fragments of genomic DNA 
that have been spliced into a bacterial plasmid, such as F-Factor plasmids in E.Coli 
[O'Connor et al., 1989]. They can accept and maintain > 300Kb DNA fragments, acting as a 
method of storing and easy amplification of genomic DNA [Shizuya et al., 1992].
Gene-targeting in ES cells uses homologous recombination to target a specific locus, 
the efficiency of which can be determined by regions of homology in the targeting vector to 
genomic DNA. Identical sequences maximise the targeting efficiencies and different mouse 
strains can make a substantial difference to homologous recombination frequencies [te Riele 
et al., 1992]. Equally the construction of a vector to specifically target and mutate/delete 
either the P1 or the P2 locus of Mdm2, leaving the rest of the gene intact and functioning 
normally requires the exact sequence at and around these loci.
The mouse genome project was based on the C57BL/6J mouse strain while the first 
ES cells were derived from 129 strains leading to the majority of gene targeting being carried 
out in these substrains or from crosses between 129 mice and other inbred strains [Adams et 
al., 2005]. Thus it is important to have the exact sequence of Mdm2 and surrounding regions 
(+/- 5Kb) in the 129Sv mouse strain for a successful targeting event.
A 129Sv BAG library resource exists and is available to view alongside the C57BL/6J 
genome in Ensembl browser [Adams et al., 2005]. Three BAG clones span the Mdm2 region 
(see Figure 1.5.3) and the two larger fragments were selected to sequence the P2 region of 
Mdm2 and facilitate generation of a targeting vector. Following the same logic further BAG 
clones will be ordered to facilitate construction of the p21 and Puma knock-in reporter mice. 
These bMQ BAG clones (bMQ-305J12 and bMQ-81N13) were generated by partial digestion
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of genomic DNA with Sau3A1 and cloned into a pBACe3.6 linearised (by BamHI) vector thus 
recreating a BamHI site at the point of integration (Clones and information ordered from 
GeneServices Ltd).
11702 Mb 
'Forward st land
Gonsligined elements
11706 Mb 117.10 Mb 117.14 Mb 117 IB Mb 117
---------------------------------------216.03 Kb -------------------------------------------------------------------------------
I I I I III I II I llll Illllllll I I III llllllllll lllllll III
I—I--------------I------Hf M ■ I—I
ENSMUSESTQ0000000 7461 > ENSMUSESTG00000007462 >
i——'——
Cpm >
EN SML) STpOOOOOS 5120 >
AC 13213& 4 1 206712 > AC 133019.3 1 12^45
00^1
<Vbm2 < Sfc35e3
< Ml m2 
* NR 003027.1
im- u h
< EN SMU SESTGOOOOCOO 74 71
< Nup107
I IIH-IIIMIHWH
< ENSMUSESTGOOO
___________________________________________________ < ENSMUSESTG000000074;
bAO-3^P9 | { | bMdB1n13q1kTir bMO-BBSCB
bMQ-263124 bMQ- 305J12
fcfvo-sejopio 1 bMQ263i24 pi kSP6 !bMQ-317C8ibfvC^61N13j
*
bM3317cCt| plkSFB ^MO- 106K9 '
fcfvO&Inn p!KSP6 bMQ3B0piPq1kT7 bMO 116M15
»
bMQ
4
bMQ305j12q1kT7 bMQI 16m15q 1kT7 bMQ116m15
■ 4
tMQ32Bp0g q1kT7 bMQ343a00 plkaSP5®
bMQ-343A9 bMO3&5c06 ql kT7
bMQ343a00.q1 kaT7 bMO-449120
»
6MCM49i20q1kT7
l
bM0449j19q1kT7
M
□M31O6k09 41k:
bMO-292JB
bMQ292j06q1k'
'21603 Kb ' Ffeverse strand
11702 Mb 11706 Mb
lEnsemb Novel Pseudogene 
I Common Known Protetncoding 
iRNAgene (Knownl 
|EST gene
117.10 Mb ________ 117.14 Mb___________ 11718 Mb
lEnsembl Known Protein Coding 
Havara Known Protein coding
117
Figure 1.5.3: Ensembl screen shot of AB2.2 129Sv DNA BAC clones available over the 
Mdm2 region.
Three clones cover Mdm2 and surrounding sequence, bMQ-305J12 (pink), bMQ-81N13 
(green) and bMQ-343A9 (pink) colours indicate direction [Adams et a!., 2005]. 
http://www.ensembl.org/Mus musculus/contiaview?reaion=10&vc start=11700743 7&vc end
=117223468 website.
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1.5.3 Creation of transgenic mice: a brief overview
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Figure 1.5.4: Creation of transgenic mice from ES cells.
Adapted from [Babinet and Cohen-Tannoudji, 2001], Mouse pictures adapted from 
vmw. istockohoto. com See text for details.
Figure 1.5.4 illustrates the sequence of events leading to the generation of a self- 
renewing homozygous mutant mouse colony. ES cell lines (usually derived from a 129 strain 
of mice, which have an agouti coat [Adams et al., 2005]) are grown and kept in a pluripotent 
state and targeted through various means to genetically modify the cells, for example by 
retroviral infection with a vector containing a gene-trap or a point mutation. The successfully 
targeted cells are selected for and isolated (by means of selectable markers (resistance to
56
Introduction
drugs) or other phenotypic screens (e.g. (3-gai assay - targeted cells turn blue) which are 
then harvested and injected into a recipient blastocysts (of a different strain with a different 
coat colour - commonly C57BL/6J which are black). The blastocysts are implanted into a 
pseudo-pregnant surrogate mother and chimaeric mice are born containing two distinct 
genetic cell populations and hence, depending upon the ratios of the genetic contribution from 
each strain, may have patches of fur in different colours (black/brown). Chimaeras are mated 
with normal mice (of the recipient blastocyst genotype e.g. C57BL/6J) and genetic 
modifications that have entered the germ cells (i.e. ova or sperm cells) will produce 
heterozygous mice with all agouti coats (shown as brown in Figure 1.5.4). Heterozygotes are 
then inter-crossed to produce a homozygous population, known as the founder colony 
[Babinet and Cohen-Tannoudji, 2001].
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Aims
This project aims to examine the regulation of p53 function with a focus on the bowel 
and in particular on the small intestine. There are three components to this;
Firstly, p53 induces apoptosis in the crypt but not in the villi of the smalt intestine. In 
circumstances where p53 is induced on the villi, these cells do not apoptose (see Figure 
3.1.7). Thus as the cells differentiate along the crypt villus axis, they become refractory to 
p53 mediated apoptosis. It is not clear whether this is because p53 is up-regulated but not 
activated or alternatively, p53 is up-regulated and activated BUT, p53 activity is suppressed 
(for example by expression of a negative regulatory gene such as MDM2 or MDMX). We 
therefore propose to characterise the expression of p53 target genes and regulatory genes 
along the crypt-villus axis in vivo in the presence and absence of apoptogenic stimuli.
Secondly, as stated above, to examine p53 activity and regulation we will be using 
surrogate indicators (target gene expression) to monitor p53 activity. Therefore we propose 
to develop a reporter mouse based upon a p53-responsive gene or genes to facilitate 
measurements of p53 activation in vivo.
Thirdly, we know that MDM2 is an essential negative regulator of p53 and that an 
autoregulatory feedback loop exists between these genes. In response to p53 activation by 
genotoxic and other stresses, p53 promotes up-regulation of MDM2 expression. We want to 
investigate whether and if so, to what extent, the ability of p53 to up-regulate MDM2 
contributes to p53 regulation in vivo. To accomplish this we propose to generate two strains 
of transgenic mice which would contain either a deletion in the Mdm2 constitutive (P1) 
promoter or mutate the p53 RE within the p53-responsive Mdm2 (P2) promoter.
These aims will enable us to gain a better understanding of the regulation of p53 
activity and we will use the tools we propose to generate to examine the bowel in the first 
instance. This is important in cancer since loss of p53 function is a critical event in 
carcinogenesis. Cells can compromise p53 partially or completely as part of the process of 
tumour development and progression. Our hypothesis is that cells in the bowel may be able 
to take advantage of an intrinsic ability displayed by villus cells to p53 expression.
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The main emphasis, of this project, is on the development of a dual reporter system 
using in vivo technologies; as such the first task is to identify downstream targets of p53 
activation in both its apoptotic and ceil cycle arrest functions with relevance to the intestine. 
Once suitable targets have been selected our second aim is to generate gene-trapped LacZ 
reporter mice by taking advantage of public gene-trap resources. The ultimate aim would be 
to develop a dual fluorescent apoptosis/cell cycle arrest p53 reporter system which would 
have wide-reaching applications in cancer research and for studying normal development.
We envision using these mice in the first instance to define the long standing 
molecular phenomenon occurring in intestinal gut epithelium, in which cells on the villi display 
an uncoupling from the apoptotic actions of p53. Why is there this apparently black and white 
switch in the cells behaviour? This has implications for cancer progression, if cells have the 
ability at some point in their lifespan to resist the tumour suppressor activities of p53, a 
relapse into this state in a stem cell position would allow for easier tumour progression.
The last aim is to create the Mdm2 P1-Null or P2-Mutant mouse strains. Mdm2 is an 
essential negative regulator of p53, which is itself up-regulated by p53 in response to stress 
(such as DNA damage). It has not yet been determined whether or not this regulation is 
critical to the action/s of p53 or indeed if it is critical in vivo during embryogenesis or normal 
physiological homeostasis. As the P2 promoter region is a p53 RE and a constitutive 
promoter (P1) is also present in the Mdm2 gene this displays an exciting opportunity to define 
the regulation of one of the most important tumour suppressor genes; p53.
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2 Materials and Methods
Materials and Methods
2.1 Bacteria
2.1.1 Strains used and basic maintenance
A table of all the bacterial strains used in this project is shown below, including details 
of each strain’s genotype and general uses (see Table 2.1.1). For general cloning TOP10 
bacteria were most frequently used, whilst different strains of bacteria were required for 
different/specialised purposes. For example when unmethylated DNA was required for 
downstream applications (such as a DNA digest with a Dcm sensitive restriction enzyme 
SexAl) a dam'/dcm' competent Escherichia coli strain was used to generate the DNA. For 
more complex cloning exercises which included large DNA constructs (>20 kb) with very 
repetitive DNA MAX Efficiency® Stbl2 E. coli were the preferred option (since this strain had 
its recombination genes inactivated when grown at 30°C - hence the DNA was more stable). 
Some of the more common E. coli genotypes are explained in Table 2.1.2.
All bacterial work was carried out using aseptic techniques. E. coli were grown in 
Luria Broth (Sigma-Aldrich) liquid media that was prepared by adding 25 g/L of Luria Broth 
(formulation 10 g/L tryptone, 5 g/L yeast extract and 10 g/L NaCh) to distilled water and was 
sterilised by autoclaving at 122°C. Any appropriate antibiotics were added at their 
recommended working concentration (see Table 2.1.3) once the solution had cooled. Solid 
media was prepared using the same method and formulation but with the addition of 15 g/L of 
agar (Formedium - derived from seaweed) and antibiotics were added at ~ 50°C.
E. coli were initially propagated in small starter cultures and then diluted 1:100 for 
larger culture volumes. To set up a starter culture, an individual bacterial colony was picked 
from an LB-agar plate (containing either recombinant clones or known plasmids of interest), 
inoculated into small 5 ml liquid cultures (containing an appropriate antibiotic) in 14 ml sterile 
Falcon 2059 tubes and incubated overnight at 37°C with vigorous shaking (~230 rpm). 
Larger scale E. coli culture was inoculated into a conical flask that was at least five times the 
size of the culture volume (to ensure adequate aeration) and grown overnight at 37°C with 
vigorous shaking (-230 rpm).
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Table 2.1.1: Complete table of all Escherichia constrains used.
Strain Source Genotype Uses
One Shot® Invitrogen F" mcrA A(mrr-hsdRMS-mcrfZC) Routine
TOP10 #C4040 <p80/acZAM15 A/acX74 recA1 araD139 cloning
A(ara-/ea) 7697 ga/U ga/K rpsL (StrR)
enc/A1 nupG A'
DH5a Invitrogen F- cp80/acZAM15 A(/acZYA-argF)U 169 Routine
recA1 endAI hsdRWfa, mk+) phoA supEAA cloning
t/7/-1 gyrA96 re/A1 K
XLI-Blue Strata gene recA1 endA1 gyrA96 thi-1 hsdR17 supE44 Routine
#200130 relA1 lac [F' proAB laclqZAM15 Tn10 cloning
(Tetr)]. HQ DNA
SURE Agilent e14“ (McrA~) A(mcrCB-hsdSMR-mrr)111 Cloning
Technologies endA\ supEAA t/7/-1 gyrA96 re/A1 lac recB DNA with
recJ sbcC umuC::Tn5 (Kanr) uvrC [F’ proAB non-
/aclqZAM15 Tn10 (Tetr)] standard
structures
CopyCutter Epicenter F- mcrA A(mrr-hsdRMS-mcrBC) Cloning
EPI400 Biotechnologies cp80d/acZAM15 AlacXJA recAl endA1 unstable
# C400CH10 araD139 A(ara, leu)7697 ga/U ga/K A' rpsL DNA
nupG tonA ApcnB dhfr.
MAX Invitrogen F' mcrA A(mcrBC-hsdRMS-mrr) recA1 Cloning
Efficiency® #10268-019 endA‘\ Ion gyrA96 thi supEAA re/A1 A A(/ac- unstable
Stbl2 proAB) DNA
dam/dcm' New England ara-14 leuB6 fhuA31 /acY1 fsx78 glnVAA Cloning
Competent Biolabs galK2 gafT22 mcrA dcm-6 hlsGA rfbD1] DNA free
E. coli #C2925 R(zgb2W::TnW) Tets endA'l rspL136 (StrR) of Dam
“C2925S” dam 13;.TnO (CamR) xylA-5 mf/-1 f/?/-1 and Dcm
mcrB1 hsdR2 methylation
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Table 2.1.2: Common Escherichia coli genotypes and their associated phenotypes.
Genotype Phenotype
hsdR Efficient transformation of unmethylated DNA from PCR amplifications
mcr/\, Restriction minus - efficient transformation of methylated DNA
mrr-sdRMSmcrBC
/acZAM15 For blue/white colour screening of recombinant clones
e/ic/A1 Endonuclease deficient ~ increased plasmid yield and quality
recA1 recB recJ Recombination deficient - increased DNA stability
pcnB Plasmid copy number - modified version of the gene allows high copy
number to be induced (CopyCutter EPI400)
Table 2.1.3: Selective antibiotics.
Each antibiotic was prepared as a concentrated stock solution, which was sterilised by 
filtration and then aliquoted and stored at -20°C. *Except for the “C2925” strain where the 
final concentration used is 30 pg/yi.
Antibiotic Source Reconstituted Stock Typical working
in solution concentration
Ampicillin Sigma-Aldrich h2o x 1000 100 pg/pl
Kanamycin Sigma-Aldrich h2o x 250 50 pg/pl*
Chloramphenicol BDH biomedical Ethanol x 1000 20 pg/pl
For long term storage of E. coli a freshly grown “saturated” overnight culture was 
mixed 1:1 with 50% glycerol and kept at -80°C. Frozen E, coli were revived by scraping off 
some of the frozen glycerol stock with an inoculation loop (without allowing the contents to 
thaw) and streaking this out onto an LB-agar plate which is then incubated overnight at 37°C 
or until individual colonies have become visible.
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2.1.2 Introduction of plasmid DNA into bacterial cells
2.1.2.1 Transformation by heat shock in chemicaliy competent bacteria
Chemically competent E. coli strains were obtained from commercial sources (see 
Table 2.1.1) and were used according to manufacturer’s guidelines. The basic method is 
outlined next (for One Shot® TOP10) followed by the strain-to-strain optimised variations.
One Shot® TOP10 E. coli were used for routine cloning. For each transformation 
reaction, 50 pi of chemically competent E. coli were thawed slowly on ice in a 2 ml screw cap 
tube. Once the cells had thawed either 10 pg of control plasmid such as pUC19 DNA or 
known plasmids of interest or 2-5 pi of a DNA ligation mixture was added. The transformation 
reaction was mixed by gentle swirling of the tube and/or gentle flicking (not by pipetting) and 
incubated on ice for 30 minutes. The transformation mix was then heat shocked at 42°C for 
exactly 30 seconds (without shaking) followed by a further incubation on ice for 2 minutes (it 
is this stage of the protocol which is often optimised depending on bacterial strain, vessel 
type, and reaction volume - see Table 2.1.4). 250 pi of SOC (Super Optimal broth with 
Catabolite repression - see Table 2.1.5 for formulation) medium was then added and the cells 
allowed to recover by incubation for 1 hour at 37°C with shaking (-230 rpm). The 
transformation mixture was then spread onto LB-agar plates containing selective antibiotics 
and incubated overnight at 37°C to allow the growth of transformants. In order to ensure the 
growth of individual colonies (for picking and screening of recombinant clones) typically 10% 
and 90% of the total transformation mixture volume were spread onto LB-agar plates. 
Transformation efficiency (colony forming units per pg of pUC19 DNA) was calculated to 
determine whether the transformation was performed satisfactorily (see Table 2.1.4 for the 
specified transformation efficiency of each strain used).
XL1-Blue cells were used when better quality and quantity of DNA was required for 
downstream applications (such as transfection into mammalian cells) and/or when the DNA to 
be transformed was a previously made plasmid (i.e. not DNA from ligation reactions). The 
XL1-Blue transformation protocol was essentially the same as the basic method detailed 
above for One Shot® TOP10 E. coli except only 10 pi of competent cells was used per 
transformation reaction and the heat shock was for 45 seconds.
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Table 2.1.4: Summary of Escherichia coli chemical transformation protocols.
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One Shot® TOP10 50 30 2 ml 250 370 1 x 10
XL1-Blue 10 45 2 ml 290 370 1 x 10b
CopyCutter EPI400 50 30 2 ml 250 370 1 x 10'
MAX Efficiency® Stbl2 100 25 14 ml 900 300 1 x 10y
‘02925” 50 30 2 ml 950 370 1-3x10°
The CopyCutter EPI400 E. coli strain was used to transform unstable DNA constructs 
since it contains a modification which allows it to grow plasmid DNA at a low copy number 
(which can be induced to high copy number in liquid culture by 4 hour incubation in the 
presence of the CopyCutter Induction Solution). The transformation protocol was the same as 
for One Shot® TOP10 cells.
MAX Efficiency® Stbl2 cells were also used for cloning unstable or otherwise difficult 
to transform DNA constructs. The transformation protocol differs from the One Shot® TOP10 
cells, most notably the cells are grown at 30°C to suppress recombination, including 
incubation of the LB-agar plates. For each transformation 100 pi of cells were gently pipetted 
into pre-chilled 14 ml Falcon 2059 tubes. Ligation reactions were diluted 1:5 in TE buffer 
(Qiagen, formulation 10 mM Tris (pH 8.0), 1 mM EDTA) and 1 pi of this was added gently to 
the cells. 50 pg of pUC19 DNA was used for the control reaction. Heat-shock (still at 42°C) 
was performed for only 25 seconds and 900 pi of SOC medium (pre-heated to 30°C) was 
added. Recovery was at 30°C for 90 minutes in a shaking incubator.
“C2925” a damVdcm' competent E. coli strain were used to produce DNA free of 
Dam and Dcm methylation. The transformation protocol was almost the same as the One 
Shot® TOP10 cells, except 950 pi SOC media was used with more vigorous shaking during
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recovery (~250 rpm). Note, the working concentration of kanamycin in this strain was 30 
pg/pl (rather than 50 pg/pl listed in Table 2.1.3) and the LB-agar plates were made up 
accordingly.
2.1.2.2 Generation of electrocompetent bacteria
Electrocompetent E. coli were prepared using aseptic technique by the following 
method. A single colony of the desired E. coli strain was inoculated into 5 ml LB medium 
(plus any appropriate antibiotic) and incubated overnight at 37e>C, with shaking (300 rpm). 2.5 
ml of this starter culture was then inoculated into 500 ml of LB medium and incubated at 
37°C, with shaking at 300 rpm, until an OD600 nm of 0.5 to 0.7 was reached which typically 
takes 3-4 hours. Cells were then chilled in an ice water bath for 10-15 minutes before 
proceeding with harvesting. From this point on all centrifugation steps were performed at 2°C 
and all reagents/equipment were kept pre-chilled on ice. Cells were harvested in a 500 ml 
centrifuge bottle in a Sorvall RC 5C Plus (Du Pont) Centrifuge at 3000 x g for 20 minutes. 
The supernatant was poured off immediately and the cells washed with 500 ml of ice-cold 
water by re-suspending initially with 5 ml (to ensure a single cell suspension), then the 
remaining water was added. The cell suspension was mixed well before being harvested as 
before. The wash with 500 ml of ice cold water was repeated once more then the cells were 
re-suspended in 40 ml of 10% (v/v) glycerol. The cell suspension was transferred into a 
narrow bottom 50 ml Falcon tube and was harvested in an Eppendorf Centrifuge 5804R at 
3000 x g for 10 minutes. The supernatant was promptly poured off and the cells re­
suspended 1:1 with 10% glycerol (the volume of the pellet was estimated by eye - usually 
around 500 pi). The electrocompetent E. coli were then aliquoted 50 pl/1.5 ml micro­
centrifuge tube and rapidly frozen either on dry ice (preferable, when available) or snap frozen 
in liquid nitrogen. The cells were stored at -SO^C until needed.
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2.1.2.3 Transformation by electroporation
Electro-transformation of E. coli by high voltage was performed using a Bio-Rad 
Gene Pulser II. Electroporation cuvettes (Bio-Rad) had a 0.1 or 0.2 cm gap and were 
recycled by a simple washing protocol between transformations (see below). SOC media 
was prepared in advance and was sterilised by autoclaving (see Table 2.1.5). The electro­
transformation procedure was performed as follows; competent cells were thawed on ice and 
1-2 pi of pre-chilled ligation mixture was added (or 10 pg of pUC19 control plasmid DNA). 
The transformation reaction was then carefully transferred to avoid air bubbles into an ice- 
cold electro-cuvette. The outside of the cuvette was wiped to be free of condensed moisture 
before being placed into the Bio-Rad Gene Pulser II and a single pulse was delivered (see 
Table 2.1.6 for specifications). Immediately following pulse delivery, 1 ml of chilled SOC 
medium was added to the cuvette and the transformation mix was gently re-suspended 
before being transferred to a chilled 2 ml screw cap tube. The cell suspension was then 
incubated for an hour at 37°C (or 90 minutes at 30°C for MAX Efficiency® Stbl2 cells) with 
shaking (~230 rpm). The transformation mixture was then plated out onto LB-agar plates, as 
with the chemically competent E. coli transformation protocol. Using this protocol ceils 
typically produced transformation efficiencies of > 1 x 108'9 cfu/pg pUC19 DNA.
Washing of the electro-cuvettes was performed by five complete rinses with H2O an 
acid soak in 0.2 M HCI for 10 minutes, then a further five complete rinses with 70% ethanol. 
Following a final rinse with 70% ethanol, the liquid was decanted under a sterile hood and 
allowed to air dry for about an hour. The cap of the cuvette was replaced and the electro­
cuvette was ready to use again.
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Table 2.1.5: Formulation of Super Optimal broth with Catabolite repression (SOC) 
medium.
SOC medium /L Source
0.5% Yeast Extract 5g BD Biosciences
2% Tryptone 20 g BD Biosciences
10 mM NaCI 2 ml of 5 M BHD AnalaR
2.5 mM KCI 2.5 ml of 1 M AnalaR NORMAPUR
10 mM MgCI2 10 ml of 1 M BDH AnalaR
10 mM MgS04 10 ml of 1 M BDH AnalaR
20 mM Glucose 20 ml of 1 M Formedium
Table 2.1.6: Specifications for Electroporation.
Gap size (cm) 0.1 0.2
Capacitance (pF) 25 25
Resistance (Q) 200 200
Voltage (kV) 1.5 2.4
Pulse (kV/cm) 15 12
Expected time constant (ms) 4.6 4.6
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2.2 Yeast
2.2.1 Strain used and basic maintenance
The Saccharomyces cerevisiae strain YPH501 was used for cloning in this project to 
take advantage of the homologous recombination machinery in yeast. YPH501 (kindly 
provided by Dr Antonius Plagge, the University of Liverpool) is a diploid strain and its 
genotype is ura3-52, /ys2-801amber, ade2-101ochre, frp1-delta63, ft/'s3-delta200, /eu2-delta1. 
All yeast work was carried out using aseptic techniques.
Yeast were grown in either rich or minimal media depending on the experimental 
requirements. For convenience, stock solutions of each of the major components of the 
media were prepared in H20 and sterilised separately, see Table 2.2.1.
Table 2.2.1: Yeast media components.
YEP broth and glucose solutions were sterilised by autoclaving at 122°C. The YNB-AA, 
adenosine and the amino acids were sterilised by filtration.
Media component Source Stock
solution
Working
concentration
YEP broth Formedium X 5 30 g/L
Glucose Formedium X 10 2% (w/v)
YNB-AA Formedium X 10 6.9 g/L
Adenosine (hemisulfate salt) Sigma-Aldrich X 125 40 pg/pl
L-histidine Formedium X 120 20 pg/pl
L-leucine Formedium X 120 60 pg/pl
L-lysine Formedium X 120 30 pg/pl
Rich media YPD (yeast extract, peptone, dextrose) was used to grow S. cerevisiae 
when there was no need for selection (for example during preparation of LiAc competent cells 
for transformation - see Section 2.2.2. Liquid media was prepared by diluting the x5 YEP 
broth (formulation 10 g/L yeast extract, 20 g/L peptone) and x10 glucose to x1 working
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concentration in water. YPD-agar was prepared by autoclaving 2% agar (in water) in 85% of 
the total final volume. Once the agar solution had cooled to ~50°C the x5 YEP broth and x10 
glucose stock solutions added, mixed thoroughly and poured into Petri dishes.
Minimal media used to select for recombined plasmids was composed of YNB-AA 
(yeast nitrous base without amino acids) supplemented with glucose and x1 nutrients. In 
order for the YPH501 strain to grow in minimal media it must be supplemented with the 
nutrients adenosine, L-histidine, L-leucine, L-lysine, L-tryptophan and uracil (see Table 2.2.1). 
However, since our selection protocol relied upon the reintroduction of both a functional URA3 
and trp1 gene, uracil and L-tryptophan were not included (sometimes known as Ura/Trp- 
dropout media/plates). Liquid minimal media was prepared as follows; the x10 YNB-AA, the 
x10 glucose and appropriate stock amino acids solutions were added together to a suitable 
container (typically a 50 ml Falcon tube) and then the solution was diluted to x1 working 
concentration with sterile water and mixed well before use. The minimal-agar plates were 
prepared as follows; 2% agar in water was autoclaved in 80% of the total final volume and 
allowed to cool to ~50°C. Once cooled the concentrated YNB-AA, glucose and amino acids 
solutions were added to a final concentration of x1 and the minimal-agar mixed thoroughly 
before pouring.
S. cerevisiae were propagated using similar microbiological techniques as for E. coli 
(see Section 2.1.1). Starter cultures, each in 5 ml of liquid media (either rich or minimal), 
were inoculated with individual yeast clones from an agar plate and incubated at 30°C with 
shaking (230rpm). S. cerevisiae that were grown in rich media would typically reach 
stationary during an overnight culture (12-16 hours) however yeast cells that were grown in 
minimal media generally took longer (2-3 days).
For long term storage of yeast strains, S. cerevisiae were grown to late-iog or early- 
stationary phase of growth and 1 ml placed into a sterile 1.5 ml screw cap micro-centrifuge 
tube. 80 pi of DMSO (dimethyl sulphoxide) was added (8% v/v) and the solution mixed and 
frozen at -80°C. Recovery from frozen stocks was essentially the same as for E. coli strains, 
a small volume of yeast cells were scraped from the frozen stock (without allowing the 
contents to thaw) and re-streaked onto an appropriate agar plate.
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2.2.2 Co- transformation of yeast with lithium acetate
Competent S. cerevisiae cells were generated for co-transformation as follows; an 
overnight yeast culture was diluted into 50 ml of YPD-media to an OD600 nm of 0.2 and 
incubated at 30°C with shaking (-230 rpm) until an OD600 of 0.5-1 was reached which 
typically takes 3-4 hours. The cells were then transferred into a 50 ml Falcon tube and 
harvested by centrifugation at 1500 x g for 10 minutes at room temperature (RT). The 
supernatant was discarded and the pellet re-suspended in 10 ml of water and harvested as 
before. This wash step was followed by a further wash in 10 ml of 100 mM lithium acetate 
(LiAc (BD biosciences, Clontech)), before the cells were finally re-suspended in 250 pi 100 
mM LiAc. These cells were then competent and ready to use immediately (although they 
could be stored on ice for a few hours).
The other components of the co-transformation shown in Table 2.2.2, were then 
prepared. The herring testes carrier DNA (BD biosciences, Clontech) was denatured just 
before use by performing two rounds of boiling (100°C for 5 minutes) and rapid cooling (in ice 
water for a few minutes). The shuttle vector DNA and donor DNA were prepared in advance 
(see Sections 2.3.9, 2.6.1 & 3.3.5.6 for details) and the PEG solution was prepared on the 
day of use by diluting a 50% PEG solution (BD biosciences, Clontech) with 1 M LiAc and 
water.
Table 2.2.2: Co-transformation mix components.
Component Amount Source
Competent yeast cells 50 pi See above
lOmg/ml Herring testes carrier DNA (denatured) 5 pi BD biosciences, Clontech
Shuttle vector DNA 500 ng To be generated by user,
Donor DNA 500 ng unique to each reaction.
PEG solution (100 mM LiAc, 40% PEG) 300 pi BD biosciences, Clontech
Once ready, all components of the co-transformation reaction were placed together in 
a 1.5 ml screw cap micro-centrifuge tube and vortexed briefly prior to incubation at 30°C for 
30 minutes (with shaking -230 rpm). The cell mixture was then heat shocked for exactly 15
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minutes at 42°C with gentle vortexing every 3 minutes. 100 |jl of the transformation mix was 
then spread onto Ura/Trp-dropout agar plates and incubated at 30°C for 2-3 days until 
individual yeast clones were visible.
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2.3 DNA extraction methods
2.3.1 Basic small scale isolation of plasmid DNA using alkaline lysis and PCI
The plasmid DNA extracted using the low-cost/low-quality-DNA method detailed 
below, was used to screen recombinant clones (not for sequencing) and typically yielded 
between 30-50 pg DNA from a 4 ml liquid culture, of adequate quality for analysis by 
restriction digest (see Section 2.6.1 for details). This basic protocol has the benefit of being 
capable of isolating DNA quickly from many clones at once, allowing for rapid screening. All 
reagents were prepared in advance (see Table 2.3.1) and for ease and speed were 
dispensed during the protocol using a multi-pipetter (muitipette®p/t/s, Eppendorf). All DNA, 
regardless of the method used to generate it, was stored at -20°C.
Plasmid DNA isolation was performed as follows; E. coli overnight cultures were 
harvested in 2 ml micro-centrifuge tubes in an Eppendorf centrifuge 5415 at 6800 x g for 5 
minutes at RT (4 ml of liquid culture per pellet). The cell pellet was re-suspended in 200 pi of 
GTE solution by vortexing, and then 200 pi of lysis buffer was dispensed into each tube, 
followed in quick succession by 200 pi of K+Ac" solution and 500 pi of PCI (24:25:1). The 
tubes were sealed and mixed manually by inversion for 5 minutes and then centrifuged at 
maximum speed for 10 minutes. The aqueous phase was promptly transferred into a fresh 
1.5 ml micro-centrifuge tube containing 500 pi of isopropanol (VWR) and mixed well before 
being incubated at RT for 5 minutes. The precipitated DNA was then harvested by 
centrifugation at maximum speed for 10 minutes. DNA pellets were washed thoroughly by 
adding approximately 1 ml of 70% ethanol and vortexing to ensure that the pellet was 
dislodged and moving freely in the solution. The samples were centrifuged briefly and the 
supernatant carefully decanted. The pellet was air-dried for 5-10 minutes (or until the white 
pellet became clear/translucent in appearance) and the DNA was re-suspended in 20 pi of TE 
buffer + RNase A. Optionally, to help the DNA dissolve, the DNA solution could be incubated 
for 30-60 minutes in a 37°C water-bath, with occasional vortexing. In general 2 pi of a 1:10 
diluted (in H20) DNA solution was sufficient for analysis.
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Table 2.3.1: Composition of buffers for basic plasmid DNA isolation
GTE, lysis buffer and K*Ac solution were stored at RT. The lysis buffer was heated up in a 
37°C water-bath before use to dissolve any precipitated SDS. PCI (24:25:1) was stored at - 
20°C and defrosted in a 37°C water-bath before use. TE buffer + RNase A was stored at 4- 
8°C.
Solution Composition Source
GTE (re-suspension buffer) 50 mM Glucose AnalaR
25 mM tris (pH 7.4) Calbiochem
1 mM EDTA (pH 8.0) Sigma-Aldrich
Lysis buffer (AKA buffer P2) 1 % SDS (w/v) VWR
200 mM NaOH VWR
K+Ac‘ solution (neutralisation buffer) 3 M KAc BDH Biochemical
11.5% Glacial acetic acid (v/v) MERCK
PCI (24:25:1) 24: Phenol VWR
25: Chloroform VWR
1: Isoamylalcohol VWR
TE buffer + RNase A 10 mM Tris.Cl (pH 8.0), 1 mM
EDTA QIAGEN
10 pg/ml RNase A Sigma
2.3.2 Small scale, high quality preparation of plasmid DNA
When small quantities of high quality, clean DNA were required for downstream 
applications (such as for DNA sequencing), the QIAprep spin Miniprep kit (QIAGEN) was 
used to isolate plasmid DNA. The kit is based on alkaline lysis (similar to the previous 
method - see Section 2.3.1), but DNA is extracted by binding in high salt to a silica 
membrane. The silica membrane is held within a column (QIAprep spin column), has a 
detachable collection tube (called a catch-tube) and is optimised for use in a standard bench- 
top centrifuge. Plasmid DNA isolation was performed according to the manufacturer’s 
guidelines and typically yielded 5-20 pg DNA from 4 ml of an overnight E. co//culture.
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Table 2.3.2 lists the reagents provided by all the QIAGEN plasmid DNA preparation kits used 
in this project.
Briefly, the protocol was as follows; after harvesting the bacterial cells in a 2 ml micro­
centrifuge tube by centrifugation at 6800 x g for 5 minutes at RT, the pellet was re-suspended 
in 250 pi of buffer PI. 250 pi of buffer P2 was added to the cell suspension and mixed 
thoroughly by inverting the tube 4-6 times to lyse the bacterial cells. 350 pi of buffer N3 was 
added to neutralise the reaction (within 5 minutes) and the samples were centrifuged for 10 
minutes at maximum speed at RT. The supernatant (cleared lysate) was then applied to a 
QIAprep spin column and centrifuged for 30-60 seconds. The flow through was discarded 
and 500 pi of buffer PB was added to the column and centrifuged for 30-60 seconds. The 
flow through was discarded and the column washed by adding 750 pi of buffer PE and 
centrifuging for 30-60 seconds. The flow through was discarded and the column was 
centrifuged again for 1 minute to remove any residual wash buffer. The QIAprep spin column 
was then placed into a fresh 1.5 ml micro-centrifuge tube and 30-50 pi of H20, or X 0.1 TE 
buffer was added carefully directly to the silica membrane. The column was left to stand for 
1-5 minutes and then centrifuged for 1 minute. The concentration of DNA and its purity was 
determined using a UV spectrophotometer (see Section 2.4.1).
2.3.3 Medium scale, high quality preparation of plasmid DNA
The QIAGEN-tip 100 kit (QIAGEN) was used to isolate larger quantities (75-100 pg) 
of high quality plasmid DNA. The basis of the kit was briefly as follows; a modified alkaline 
lysis procedure was used on the bacterial cells followed by clearing the lysate by 
centrifugation. The cleared lysate was then applied to a single use QIAGEN anion-exchange 
resin (in a gravity-flow column) which bound the DNA under low salt and appropriate pH 
conditions. The resin was then washed to remove contaminants, such as RNA and proteins, 
and the DNA was eluted from the resin in a high-salt buffer. To concentrate and de-sait the 
DNA, DNA was precipitated with isopropanol and then washed in 70% ethanol. The plasmid 
DNA prepared by this midiprep protocol was of high quality and could be used to transfect 
mammalian cells.
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Table 2.3.2: Composition of buffers from QIAGEN Plasmid DNA preparation kits...
... used in this project, including QIAprep spin miniprep kit, QIAGEN-tip 100 kit (midiprep) and 
QIAGEN-tip 2500 EndoFree Plasmid Mega kit.
Solution Composition
Buffer P1 (re-suspension buffer) 50 mM Tris.CI (pH 8.0), 10 mM EDTA (pH 8.0), 100
pg/ml RNase A
Buffer P2 (lysis buffer) 1% SDS (w/v), 200 mM NaOH
Buffer P3 (neutralisation buffer) 3 M potassium acetate (pH 5.5)
Buffer N3 (neutralisation buffer) Confidential - proprietary component of kit
Buffer PB (binding buffer) Confidential - proprietary component of kit
Buffer PE (wash buffer) Confidential - proprietary component of kit
Buffer FWB2 (QIAfilter wash buffer) 1 M potassium acetate (pH 5.0)
Buffer ER (endotoxin removal buffer) Confidential - proprietary component of kit
Buffer QC (wash buffer) 1 M NaCI, 50 mM MOPS (pH 7.0), 15% isopropanol
(v/v)
Buffer QF (elution buffer) 1.25 M NaCI, 50 mM Tris.CI (pH 8.5), 15 %
isopropanol (v/v)
Buffer QN (elution buffer) 1.6 M NaCI, 50 mM MOPS (pH 7.0), 15% isopropanol
(v/v)
f E buffer 10 mM Tris.CI (pH 8.0), 1 mM EDTA
Plasmid DNA was prepared according to the manufacturers guidelines, albeit with 
some minor modifications as detailed below. A 25 ml culture of E. coli was grown overnight 
from a starter culture (see Section 2.1.1) and was harvested by centrifugation at 4500 x g, 
4°C for 60 minutes (different from handbook). The bacterial cell pellet could be frozen at this 
point at ^O^C indefinitely, or could be processed directly with the protocol as follows; the 
pellet was re-suspended with 4 ml of buffer P1. 4 ml of buffer P2 was added and the cell 
suspension mixed thoroughly by inverting the sealed tube 4-6 times. The lysis reaction was 
performed for 5 minutes at RT before neutralisation by adding 4 ml of chilled buffer P3. This
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was mixed immediately by inverting the sealed tube 4-6 times and then left to incubate on ice 
for 15 minutes. The lysate was then centrifuged at 20,000 x g for 30 minutes at 4°C. The 
supernatant was removed promptly into a fresh centrifuge tube, before being mixed and 
centrifuged again. A QIAGEN-tip 100 resin column was equilibrated by adding 4 ml of buffer 
QBT and once the centrifugation steps were complete the supernatant was applied to the 
column and allowed to enter the resin by gravity flow. The QIAGEN-tip 100 containing the 
bound plasmid DNA was then washed twice with 10 ml buffer QC before the DNA was eluted 
with 5 ml buffer QF (which was heated to 65°C when larger constructs were being prepared - 
40-50 kb). The plasmid DNA was precipitated by adding 3.5 ml of RT isopropanol. The 
following steps differ from the handbook; the 8.5 ml isopropanol/DNA solution was mixed well 
and then divided up into 1.5 ml micro-centrifuge tubes and harvested by centrifugation at 
14,000 x g for 30 minutes at 4°C. The pellets were washed with 70% ethanol (at RT) before 
being pooled together and centrifuged at 13,000 x g for 10 minutes. The ethanol was 
carefully decanted and DNA pellets air dried for 5-10 minutes before being re-suspended in 
50-75 pi of X 0.1 TE buffer. The concentration of DNA and its purity was determined using a 
UV spectrophotometer (see Section 2.4.1).
2.3.4 Medium scale preparation of DNA from very low copy number plasmid
The QIAGEN-tip 100 kit could also be used to isolate high quality plasmid DNA from 
very low copy number plasmids (such as BAG clones, which typically only have one copy per 
cell). The basis of the procedure is basically the same as for the previous method, except 
larger volumes are used and there is an additional precipitation with isopropanol prior to 
loading the QIAGEN-tip 100. The plasmid DNA was prepared using the manufacturer’s 
guidelines, with some minor modifications and typically yielded 20-100 pg DNA.
Plasmid DNA isolation was as follows; for very low-copy number plasmids a 500 ml 
LB culture was grown overnight from a starter culture (see Section 2.1.1) and was harvested 
by centrifugation in a 500 ml centrifuge bottle at 6000 x g for 15 minutes at 4°C. The pellet of 
bacterial cells was re-suspended in 20 ml of buffer P1, then mixed (by inverting the sealed 
tube) with 20 ml buffer P2 and left for 5 minutes at RT. 20 ml of chilled buffer P3 was added
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and mixed immediately by inverting tube 4-6 times to neutralise the lysis reaction followed by 
incubation on ice for 30 minutes. The mixture was then centrifuged at 4500 x g for 1 hour at 
4°C (modified from handbook) and the supernatant (containing plasmid DNA) was promptly 
and carefully removed. The DNA was precipitated by mixing the supernatant with 42 ml of RT 
isopropanol and the DNA pellet was harvested by centrifugation as before. The DNA pellet 
was re-suspended in approximately 500 pi of TE buffer and brought to a final volume of 5 ml 
with buffer QBT. At this point the QIAGEN-tip 100 was equilibrated with 4 ml of buffer QBT 
and the protocol continued as for the normal midiprep method (see Section 2.3.3).
2.3.5 Large scale, high quality preparation plasmid DNA (with endotoxin
removal)
When large quantities of high quality, ultra-pure transfection grade DNA were 
required, then a QIAGEN-tip 2500 EndoFree Megaprep kit was used to isolate the plasmid 
DNA. This kit was based on the same principles as the QIAGEN-tip 100 kit, except the 
bacterial cell lysate was cleared by filtration (not centrifugation). The procedure was 
performed according to the manufacture’s guidelines, with some minor modifications and 
typically yielded 1.5-2.5 mg DNA.
Plasmid DNA was isolated as follows; a 500 ml LB culture was grown overnight from 
a starter culture (see Section 2.1.1) and was harvested by centrifugation in a 500 ml 
centrifuge bottle at 6000 x g for 15 minutes at 4°C. The pellet of bacterial cells was re­
suspended in 50 ml of buffer P1, then mixed (by inverting the sealed tube) with 50 ml P2 
buffer and left for 5 minutes at RT. The lysis reaction was neutralised by adding 50 ml of 
chilled buffer P3 followed by vigorously inverting the tube 4-6 times. There was no incubation 
on ice, instead the lysate was poured straight onto a QIAfilter Mega-Giga cartridge (which 
was already screwed into a 500 ml glass bottle and connected to a vacuum source) and 
allowed to incubate at RT for 10 minutes. The vacuum source was then switched on until all 
the liquid had been pulled through the filter. 50 ml of buffer FWB2 was then added to the 
QIAfilter and stirred gently with a spatula. The vacuum source was switched back on, until 
the liquid had been pulled through completely. Once the lysate had been filtered, 12.5 ml of
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buffer ER was added to the 500 ml glass bottle and mixed by inverting the bottle 
approximately 10 times. The endotoxin removal reaction was then incubated on ice for 30 
minutes, during which time, a QIAGEN-tip 2500 was equilibrated by adding 35 ml of buffer 
QBT. The filtered lysate was then applied to the column and allowed to enter by gravity flow. 
The column was washed with 200 ml total of buffer QC. The remainder of the protocol was 
modified from the handbook and continued as follows; the DNA was collected in a 50 ml 
Falcon tube by eluting with 30 ml of buffer QN. The DNA was then precipitated by adding 21 
ml of RT isopropanol, mixed well and harvested by centrifugation at 4500 x g for 1 hour at 
4°C. The supernatant was carefully decanted and the pellet re-suspended in 7 ml of 
endotoxin-free RT 70% ethanol. The DNA and ethanol solution was then aliquoted out 
between 1.5 ml sterile screw cap micro-centrifuge tubes, and centrifuged at 13,000 x g for 10 
minutes at RT. Following centrifugation the pellets were pooled together in one tube and 
centrifuged again at maximum speed for 1 minute. The supernatant was removed, without 
disturbing the pellet and allowed to air-dry for 10-20 minutes. The DNA was then re-dissolved 
into a suitable volume of TE buffer. The concentration of DNA and its purity was determined 
using a UV spectrophotometer (see Section 2.4.1).
2.3.6 Fast, small scale isolation of veast/plasmid DNA by mechanical lysis
Very small amounts (~ pg) of plasmid DNA were isolated from yeast cells (along with 
contaminating genomic DNA) using the rapid mechanical lysis protocol detailed below. The 
DNA extracted was suitable for PGR and transformation of bacterial cells.
5 ml starter cultures of individual yeast clones were grown in selective media for 2-3 
days as described in Section 2.2.1. 1.5 ml of this yeast culture was then harvested in a 1.5 ml 
micro-centrifuge tube by centrifugation at 13,000 x g for 10 seconds (at RT). The supernatant 
was decanted and the pellet re-dissolved in the remaining liquid. To the sample 200 pi of 
VLB (yeast lysis buffer - see Table 2.3.3 for formulation) and 200 pi of PCI (24:25:1) were 
added. Small acid-washed glass beads (Sigma-Aldrich) were also added up to the interface 
(~ 0.3 g). The tubes were sealed and the samples vortexed vigorously for 2 minutes. 
Following mechanical lysis, the samples were centrifuged at 13,000 x g for 5 minutes at RT.
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100 pi of the aqueous phase was retained and stored at -20°C while another 100 pi of the 
aqueous phase was transferred to a fresh pre-chilled 1.5 ml tube and the DNA was 
precipitated by adding 30 pi of 3 M sodium acetate (pH 5.2) and 200 pi of ice-cold 100% 
ethanol. The solution was mixed and left to stand in a -20°C freezer for at least an hour 
(could be left overnight) and then was centrifuged for 10 minutes at maximum speed (13,000 
x g). The supernatant was decanted and the pellet washed in 200 pi of ice-cold 70% ethanol. 
The sample was briefly centrifuged again and the supernatant removed, allowing the pellet to 
air dry for 2-5 minutes before re-suspending in 20 pi of TE buffer + RNase A. The DNA was 
then checked by PCR and/or transformed into E. coli.
Table 2.3.3: Formulation of (VLB) yeast-lysis-buffer.
YLB was prepared by dissolving the Tris.CI in 80 ml H20 and then the pH was adjusted to pH 
8.0 with HCI. The remaining components were added and the solution was mixed well using 
a stir bar, with heating to 37°C. YLB was stored at RT, but was heated to 37°C and mixed 
again before each use.
Component /100 ml Source
10 mM Tris.CI (pH 8.0) 0.1211 g Calbiochem
1 mM EDTA (pH 8.0) 200 pi of 0.5 M Sigma-Aldrich
100 mM NaCI 0.5844 g VWR
1% SDS (w/v) 5 ml of 20% (w/v) VWR
2% Triton X 100 (v/v) 2 ml of 100% (v/v) Sigma-Aldrich
2.3.7 Isolation of genomic DNA from whole animal tissue
The protocol is essentially as described in Sambrook [Sambrook et al., 2000]. Briefly, 
frozen liver from a 129SvEv mouse strain was ground with a pestle and mortar then aliquoted 
(approximately 0.2 g per tube) and placed in 500 pi of genomic DNA preparation lysis buffer 
(50 mM Tris (pH 8.0), 100 mM EDTA and 0.5% SDS (w/v)) with 250 pg proteinase K (Sigma- 
Aldrich) (final concentration 5 pg/pl) and left overnight at 55°C. The next day, DNA was 
extracted using an organic solvent-based extraction method. The cell lysate was mixed with
80
Materials and Methods
500 nl phenol and left for an hour with gentle shaking. Following centrifugation (5 minutes, 
13,000 x g) the aqueous phase was transferred to a fresh tube and mixed with 500 pi PCI 
(24:25:1) for 5 minutes by inverting the tubes (without vortexing) then centrifuged again as 
before. The aqueous phase was transferred into a fresh tube and the DNA was precipitated 
by adding 50 pi 3 M sodium acetate (pH 6.0) and 500 pi of 100% ethanol to each tube. This 
was mixed (by inverting the tubes) for 1 minute then centrifuged for 10 minutes (13,000 x g). 
The supernatant was removed and the pellet was washed with 70% ethanol. The DNA pellet 
was re-suspended in TE buffer + RNase A. The concentration of DNA and its purity was 
determined using a UV spectrophotometer (see Section 2.4.1).
2.3.8 Isolation of genomic DNA from mammalian cells
Genomic DNA was isolated from mammalian tissue cultured cells by using essentially 
the same protocol as described above in Section 2.3.7. The only major difference was that 
cells in culture were harvested initially from their plastic tissue culture flasks using trypsin as 
described in Section 2,9.1. A cell pellet of about 5 x 106 cells was typically re-suspended in 
500 pi of the genomic DNA preparation lysis buffer with 5 pg/pl of proteinase K, where upon 
this method rejoins the previous protocol.
2.3.9 Extraction of DNA from agarose gels
DNA products were extracted from agarose gels using the GENECLEAN Turbo Kit 
(Qbiogene) according to the manufacturer’s instructions. The DNA yield from the kit was 
typically 70-90% for DNA products 1-8 kb in length, but could be markedly less for larger or 
smaller DNA products. The DNA isolated using the GENECLEAN kit was suitable for many 
downstream applications including sequencing and molecular cloning.
DNA extraction was performed as follows; appropriate DNA bands were excised from 
the agarose gel and agarose gel plugs were placed in 1.5 ml micro-centrifuge tubes with 100 
pi of GENECLEAN turbo salt solution per 0.1 g of agarose gel. This was then incubated in a 
water bath set to 55°C for ~ 10 minutes, until the agarose gel had melted completely. A 
cartridge with a glass-milk membrane was placed inside a second tube which was used to
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collect the flow through (called a catch-tube) and the DNA/gel/salt solution was then applied 
over the membrane (no more than 600 pi at a time) and centrifuged for 10 seconds. The flow 
through was run over the membrane a second time, along with any remaining DNA/gel/salt 
solution. The liquid was then discarded since the DNA was bound to the membrane. The 
membrane was washed by adding 500 pi of GENECLEAN turbo wash solution over the 
column then centrifuged for 10 seconds. Flow-through was discarded and then the column 
was centrifuged for a further 4 minutes at 13,000 x g (to dry the membrane). The column, 
containing the DNA was then put into a fresh 1.5 ml micro-centrifuge tube with a detachable 
lid (provided in the kit) and 20 pi of H20 was applied directly to the membrane, incubated for 5 
minutes at RT and then centrifuged for 1 min at 13,000 x g. The final eluate contains the 
purified DNA fragment. In order to estimate the yield, 10% of the eluted sample was analysed 
on another agarose gel (see Section 2.4.2 for further details).
2.3.10 Purification of DNA from enzymatic reactions
The GENECLEAN Turbo kit could also be used to purify DNA after enzymatic 
reactions. For example, during cloning exercises where two restriction enzymes were 
required to cut a particular DNA fragment, but which had incompatible buffers; a faster, liquid 
version of the GENECLEAN reaction was performed. This protocol is much the same as 
described previously in Section 2.3.9 except the DNA reaction to be cleaned had X 5 (v/v) 
GENECLEAN turbo salt solution added to it, prior to loading onto a GENECLEAN column.
Larger quantities of DNA (> 10 pg) were purified by a phenol/chloroform extraction as 
follows; an equal volume of PCI (24:25:1) was added to the DNA containing solution and 
mixed thoroughly. The DNA/PCI mixture was then centrifuged at maximum speed (~ 13,000 
x g) for 30 seconds at RT. The aqueous phase was promptly transferred to a fresh 1.5 ml 
sterile screw cap micro-centrifuge tube. An equal volume of TE buffer (QIAGEN) was added 
to the organic phase and mixed thoroughly and then centrifuged as before. The aqueous 
phases were combined together and an equal volume of chloroform was added and mixed. 
The DNA/chlorofomn solution was centrifuged as before and the aqueous phase was 
transferred into another fresh 1.5 sterile screw cap micro-centrifuge tube. The DNA was then
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precipitated by adding 2.4 volumes of 100% absolute (molecular biology grade) ethanol 
(Sigma-Aldrich). The sample was mixed and centrifuged at maximum speed for 10 minutes. 
The supernatant was removed under a sterile hood (if required), and the DNA pellet allowed 
to air dry for 5-10 minutes (or until the pellet became colourless/transparent) before being re­
suspended in an appropriate buffer, at an appropriate concentration. The purity and yield of 
the DNA was either examined by UV spectroscopy or by agarose gel electrophoresis (see 
Section 2.4).
2.3.11 Purification of DNA sequencing reactions (qenCLEAN 96 Well)
DNA sequencing reactions for use on the MegaBACE capillary sequencer were 
cleaned up to remove contaminating excess dyes by using the genCLEAN 96 Well Dye 
Terminator Removal Kit (Genetix). The procedure was performed according to a slightly 
modified version of the manufacturer’s guidelines as follows; the genCLEAN plate was 
equilibrated to RT and once warmed, the buffer was removed by placing the genCLEAN plate 
onto a wash plate and then centrifuging it in a Sorvall Legend RT+ centrifuge at 910 x g for 5 
minutes. The wells were then washed twice with 100 pi of H20 by loading the water with a 
multi-channel pipetter (Eppendorf) and centrifuging as before. The genCLEAN plate was then 
placed onto the collection plate and the DNA samples were loaded carefully into the wells 
directly onto the gel matrix. Any unused wells were loaded with water to prevent drying 
during centrifugation. The samples were then collected by a final centrifugation step, for 6 
minutes at 1000 x g. The unused wells were loaded with 100 pi water and the genCLEAN 
plate was stored in the fridge for use later. These samples were then ready for analysis on 
the MegaBACE capillary sequencer - see Section 2.7.2.6 for further details.
2.3.12 Extraction of DNA from 96-well plates
DNA was extracted from ES cells in 96-well plates in order to screen for positive 
clones by mini-Southern blot analysis or PCR. The method briefly utilised freeze/thaw 
technique to crack open the cellular membranes, followed by an overnight digestion with 
proteinase K to remove proteins and cellular debris. The DNA was then precipitated with ice-
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cold ethanol, washed 2-3 times in 70% ethanol, dried and re-suspended in a restriction digest 
cocktail. The yield using this method was variable (1-15 pg), but was usually sufficient for 
analysis by mini-Southem blot.
DNA was extracted in detail as follows; one duplicate ES cell plate (see Section 
2.9.2.2.5) was taken from the -80°C freezer (after being frozen for at least 3 hours) and 
allowed to warm up to RT for 5 minutes. Once defrosted 50 pi of mini-Southern lysis buffer 
(MSLB - see Table 2.3.4) was added per well using a multi-channel pipette. The plate was 
then sealed using masking tape (Tessa) and was placed into a Tupperware box with a well 
fitting lid and wet paper towels to reduce evaporation whilst it was incubated overnight at 
60°C.
Table 2.3.4: Formulation of Mini-Southern lysis buffer (MSLB).
MSLB without proteinase K was frozen at -20°C in 5.4 ml aliquots (sufficient for x1 96-well 
plate). Proteinase K was prepared as a 10 mg/ml (x 10) stock solution and also frozen at - 
20°C in 0.7 ml aliquots. For use, 0.6 ml of Proteinase K was added fresh to the rest of the 
MSLB once defrosted.
Component /50 ml Source
10 mM Tris (pH 7.8) 500 pi of 1 M Calbiochem
10 mM EDTA (pH 8.0) 1 ml of 0.5 M Sigma-Aldrich
10 mM NaCI 100 pi of 5 M VWR
0.5% Sarcosyl 5 ml of 5% BDH
H20 45 ml -
1 mg/ml proteinase K [ADD FRESHLY] 0.6 ml of 10 mg/ml Sigma-Aldrich
The following day the plate was removed from the incubator and was centrifuged 
briefly to remove the condensation form the lid. At this stage if PCR was to be performed on 
the samples, 5 pi was removed and placed into another duplicate 96-well PCR plate. The 
PCR-duplicate plate was then sealed with an adhesive sticker and the proteinase K heat- 
inactivated by boiling the samples at 95°C for 10 minutes. Once boiled the PCR-duplicate 
plate was labelled and stored at -20°C until required. Continuing with the main DNA
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extraction protocol; DNA was precipitated by gently adding 100 pi of ice-cold 100% molecular 
biology grade, 200 proof, ethanol (Sigma-Aldrich) per well. The plate was then incubated at 
RT for 30 minutes. Precipitated DNA adhered to the polystyrene wells of the tissue culture 
vessel, therefore after 30 minutes the plate was gently inverted onto layers of blue roll towel 
and allowed to drain. The DNA was then washed 2-3 times with 100 pi of 70% ethanol. After 
the final wash the plate was left to dry completely as any residual ethanol could impede the 
restriction digest reaction. In order to help the ethanol dry from the plate (typically this 
requires 15-30 minutes) the lid was removed and the plate placed into a 37°C bacterial 
incubator.
Table 2.3.5: Restriction reaction cocktail.
40 ijI was required per sample. A master mix was prepared for all the samples by multiplying 
the 40 pi reaction by n, where n - number of samples + 10. For example a 96-well plate 
would be x 106.
Component /40 pi Source
X 1 NEBuffer 4 pi of x 10 NEB
100 pg/ml BSA 0.4 pi of x 100 NEB
1 mM Spermidine 0.04 pi of 1 M Sigma-Aldrich
50 pg/ml RNase (DNase-free) 0.2 pi of 10 mg/ml Sigma-Aldrish
15-20 units restriction enzyme Varies NEB
H20 Up to final volume
Whilst the ethanol was evaporating from the wells the restriction digest cocktail was 
prepared (see Table 2.3.5). Once the plate was completely dry, 35 pi of restriction digest 
cocktail was added to each well using a multi-channel pipette and the contents of each well 
was mixed by pipetting up and down ~ 10 times. Tips were changed between each row to 
avoid cross-contamination. The plate was sealed with tape and incubated overnight at the 
appropriate temperature for the restriction enzyme being used in a Tupperware box with wet 
paper towels. Once the digestion was complete the plate could be stored at -20°C until 
required.
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2.4 Analysis of DNA
2.4.1 Determining the purity and concentration of DNA/RNA by UV
spectroscopy
DNA concentration and purity were determined using a UV spectrophotometer 
(BioPhotometer, Eppendorf) as follows; 1 pi of sample was diluted 1:100 with DNA re­
suspension buffer (usually water or X 0.1 TE buffer), mixed well and transferred into UV 
cuvette (Eppendorf). Re-suspension buffer without any DNA added was used as a blank. 
The BioPhotometer determines the concentration of the DNA using the equation; 
Concentration (fjg/ml) = (A26o reading - A32o reading) x dilution factor x 50 fjg/ml, since a DNA 
solution of 50 pg/ml has an absorbance of 1 at A26o (this is adjusted for turbidity - A320). Total 
yield was determined as; Yield (fjg) = Concentration (fjg/^l) x total volume (ijI). The purity of 
DNA was estimated from the A26o/ A280 ratio, where pure DNA has a value of 1.8, though 
values from 1.7-2 are accepted as high quality DNA. A value of less than 1.8 is indicative of 
protein contamination and a value of 2.0 is thought to be pure RNA (see 
http://www.promeQa.eom/paQuide/chaD9.htm#title1.a).
The concentration and purity of RNA was determined using a similar method. 2 pi of 
sample was diluted 1:30 with water and mixed well. High quality RNA should have an A260/ 
A280 ratio of 2.0, however it was also necessary to run an agarose gel to qualitatively assess 
the RNA quality - see below.
2.4.2 Agarose gel electrophoresis
Agarose gel electrophoresis was used to separate, purify and estimate the yield of 
DNA fragments ranging from 100 bp to 15-20 kb. An agarose gel was prepared to an 
appropriate concentration (see Table 2.4.1) in TAE buffer (40 mM Tris-Base, 1 mM EDTA (pH 
8.0) 1.142% Glacial acetic acid). Gensieve LE agarose (Flowgen) was typically used, unless 
the DNA fragment of interest was to be extracted later for molecular cloning exercises (see 
Section 2.3.9), in which case SeaKem®GTG® agarose (Lonza) was used instead. The
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agarose solution was melted in a standard microwave oven, on full power for 2-4 minutes with 
occasional swirling. Once fully dissolved the agarose solution was then allowed to cool to ~ 
50°C before being supplemented with 0.5 pg/ml ethidium bromide (Roche) and poured into a 
sealed gel cast, with comb, to set. Once set, the comb and sealing tape were gently and 
carefully removed and the gel (in the supporting cast) was submerged (~ 1 mm over the 
surface of the gel) in TAB buffer inside a suitably sized electrophoresis tank. All DNA 
samples to be run were supplemented with 10% (v/v) orange G loading buffer (50% glycerol 
with sufficient orange G dye (BDH) to produce a bright orange colour) and were loaded 
carefully into the wells along with a DNA marker (either 100 bp DNA ladder (NEB) or 1 kb 
DNA ladder (Invitrogen) - as stated).
Table 2.4.1; Appropriate concentration of agarose gels for different sized DNA
fragments.
% agarose
(w/v)
Effective resolution of
DNA fragments (kb)
0.5 > 12
0.7 1-12
1.0 0.5-8
1.2 0.2-5
2 1 <
Electrophoresis was run in horizontal gel units (Scie-Plas) by applying a voltage of 1- 
10 V/cm across the gel until the desired band separation had taken place. Since ethidium 
bromide was included in the agarose gel, DNA bands could be visualised as the samples 
were being run by placing the gel onto a High Performance UV-transilluminator (UVP). A 
picture was recorded digitally using a Kodak EDAS 290 and edited in Adobe Photoshop.
The yield of DNA fragments was estimated from the agarose gel, by comparing the 
intensity of the band of interest with the intensity of a band of known amount of DNA. The 
lower limit of what DNA could be visualised by eithidium bromide under a UV light was ~ 5-10 
ng of DNA, whilst the upper limit to accurately predict the yield was ~ 200-500 ng. Estimating
87
DNA yield using this method was helpful when low concentration of DNA were expected, such 
as after a GENECLEAN (see Sections 2.3.9 & 2.3.10), since a UV spectrophotometer was not 
accurate at those ranges.
Agarose gel electrophoresis was also used to qualitatively assess the quality of RNA 
samples. The method was essentially the same as described above with the exception that 
the electrophoresis tank, gel cast and gel comb were soaked in 1 M HCI for an hour and then 
washed with copious amounts of RNase/DNase free water before use. A 1% general 
purpose agarose gel was prepared and run with 200-500 ng of each RNA sample 
(supplemented with Orange G loading buffer) including the 1 kb DNA marker. A digital 
photograph was taken and the RNA quality was assessed based on the presence and ratios 
of the two rRNA subunit bands, 28S and 18S. The large subunit (28S) should contain 
approximately twice as much double stranded RNA than the smaller subunit (18S); therefore 
in an un-degraded RNA sample there should be two sharp bands at - 2:1 ratio. In a 
degraded, or partially degraded RNA sample there is usually a shift in the 2:1 ratio towards a 
1:1 ratio (since the larger subunit degraded faster) and other non-specific bands, or even a 
smear might be present on a gel. The presence of a separate smear towards the top of the 
gel is usually indicative of genomic DNA contamination.
2.4.3 Southern blotting
Southern blotting was used for screening of ES cell colonies in order to identify a 
successful targeting event. Briefly; DNA was extracted from the potential clones and was 
digested overnight with a restriction endonuclease enzyme (see Section 2.3.12) which would 
produce a digest pattern that could differentiate between wild-type and correctly targeted 
DNA. The digested DNA was run on an agarose gel (described above) and then the DNA 
was transferred by capillary action onto a nitrocellulose membrane, where it was immobilised 
by UV irradiation. The membrane was then probed with a short (300-700 bp) radioactively 
labelled DNA sequence unique to the fragment of interest. The probed membrane was then 
exposed to X-ray film in order to detect any radioactive signal. A correctly targeted ES cell
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colony would show both the wild-type and the expected recombined size shift in the DNA 
digest pattern and would therefore be worth investigating further.
The Southern blotting protocol described here was based on [Sambrook et al., 2000]. 
Following DNA extraction and digestion from the ES cell colonies in the duplicate 96-well 
plates, samples were run on a 0.7% agarose gel. Included with the samples was the 1 kb 
DNA ladder, a wild-type control (10 pg of genomic DNA, digested with the same restriction 
enzyme as the samples) and an equivalent of a 0.1 and 0.01 copy number of the gene of 
interest used as positive control (from the linearised plasmid containing the DNA fragment 
corresponding to the probe DNA). Once the gel had been run a digital photograph was taken 
with a ruler on the UV transilluminator to record the ethidium bromide staining pattern (to 
determine whether there was complete digestion of DNA samples and approximate DNA 
yield).
The gel was prepared for transfer by several washes in buffers which denatured, 
depurinated and neutralised the DNA (see Table 2.4.2). The washes were performed as 
follows; 45 minute wash with agitation in denaturing buffer with buffer being replaced every 15 
minutes, 5 minute wash in 0.2 N HCl with agitation, followed by brief rinse with water and 
finally 45 minute wash in 3 changes of neutralisation buffer. Meanwhile the DNA 
nitrocellulose membrane (HyClone), Whatman papers and paper towels were cut to the 
appropriate size. The nitrocellulose membrane was soaked for at least 20 minutes in H2O, 
followed by soaking in 10 X SSC prior to use. Once the washes were complete the gel was 
placed briefly into 10 X SSC whilst the transfer apparatus was assembled. The Southern blot 
transfer apparatus was set up as shown in Figure 2.4.1. Once set up the apparatus was 
wrapped in cling-film to provide stability and reduce evaporation. Transfer was performed for 
16-24 hours overnight.
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Table 2.4.2: Composition of Southern blotting buffers.
Buffer Composition Source
Denaturing buffer 1.5 M NaCI VWR
0.5 N NaOH VWR
Neutralisation buffer 1 M Iris (pH 7.4) Calbiochem
1.5 M NaCI VWR
20 X SSC (pH 7.0) 3 M NaCI VWR
0.3 M Sodium citrate Sigma-Aldrich
Pre-hybridisation mixture 1 M NaCI VWR
10% Dextran sulphate PKChemicals
1% SDS VWR
Glass plate
Stack of paper towels
Pyrex 
glass dish.
10XSSC
3 mm Whatman paper 
2 sheets cut to size of gel
Nitrocellulose membrane
IU Upside down gel cast
Gel - upside down with parafilm borders
"Wick" - 3 mm Whatman paper 
2 sheets cut to width of gel with 
overhang
Figure 2.4.1: Southern blot transfer apparatus.
Once the transfer was complete the apparatus was disassembled and the back of 
each nitrocellulose membrane was marked to indicate which gel it was and where the first 
well was. If desired, to check the efficiency of the DNA transfer, the old agarose gel could be 
re-stained with ethidium bromide and photographed with UV light for comparison. Re-staining 
was performed by immersing the gel in a 0.5 pg/ml solution of ethidium bromide for 30
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minutes with agitation; the gel was rinsed briefly in water to remove any excess ethidium 
bromide before examination. The nitrocellulose membranes were air-dried on a clean sheet 
of Whatman paper for 10-15 minutes and the DNA was then immobilised onto the 
nitrocellulose membrane by exposure to UV irradiation (using a UV cross-linker). The 
membranes at this point could be wrapped up in foil and stored for several months at 4°C. To 
continue with the protocol the dried membranes were soaked in 1 M NaCI for at least 30 
minutes to ensure that the entire membrane had been completely wetted. In the meantime, 
the pre-hybridisation mixture (pre-hybe mix), hybridisation bottles, and hybridisation oven 
were all heated to 65°C. When ready, the nitrocellulose membranes were then transferred 
into the hybridisation bottle with 25 ml of pre-hybe mix. Two membranes could be placed into 
one chamber by using special mesh screens to separate them. The membranes were 
incubated in pre-hybe mix at 65°C with circular turning for at least 3 hours - typically this was 
performed overnight.
Ahead of commencing the screening experiments the probe sequence had been 
carefully designed and tested. For most screens the probe sequence was 300-700 bp long 
and was designed outside of the DNA targeting construct to prevent detecting false positive 
results. A draw back of this strategy, however, was that it would not detect random 
integration events and therefore a second screen was planned on any promising clones to 
address this. The probe itself was generated by PCR using primers designed by primer- 
BLAST (see Section 2.7.1) and was cloned by TA-cloning into vector pCR2.1 (see Section 
2.6.6.1) and checked by sequencing (see Section 2.7.2.7). The probe was then liberated 
from vector pCR2,1 by performing a restriction digest (see Section 2.6.1) which was run on an 
agarose gel (see Section 2.4.2) and then the correct DNA fragment was extracted from the 
agarose gel by using the GENEclean turbo kit (see Section 2.3.9). 10% of the gene-cleaned 
product was run on another agarose gel to determine the concentration. The probe was then 
ready to be radioactively labelled.
The probe was radioactively labelled using the Amersham Megaprime DNA Labelling 
System RPN1604 according to the manufacturer’s instructions as follows; in a 0.2 ml PCR 
tube 50 ng of probe DNA was added to 5 pi of primer mix and was brought to a final volume 
of 26 pi with H20. The mixture was boiled in a PCR machine for 5 minutes, allowed to cool to
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RT and centrifuged briefly. Next the following components were added, 4 pi of dATP, 4 pi of 
dTTP, 4 pi of dGTP and 5 pi of reaction buffer. Then in the radiation room, behind the 
Perspex radiation screen 5 pi of 32P labelled dCTP {Easy Tides Deoxycytidine 5’- 
triphosphate, [a-32P] 250 pCi (9.25 mBq) in 25 pi from Perkin Elmer) is was added, followed 
by 2 pi of Klenow (a DNA polymerase). The reaction was mixed by gentle pipetting and was 
then incubated at 37°C for 45 minutes. Whilst the reaction was taking place the G-50 
sephadex separation column was prepared using a glass Pasteur pipette , which had been 
partly obstructed with a small amount of siliconised glass wool (Sigma-Aldrich) and filled with 
swollen G-50 sephadex beads ("-50% (w/v) G-50 sephadex in water). Once the labelling 
reaction had finished the tubes were placed briefly on ice (at least 2 minutes) before being 
prepared for the column.
The radioactive labelling reaction was prepared for column purification by adding 20 
pi of Orange G and 20 pi of dextran blue (HWM £ 2 MD). The solution was mixed by careful 
pipetting and was then loaded drop-wise onto the column. The eluate was collected in a 1.5 
ml micro-centrifuge tube. Water was then added drop-wise (in 200 pi increments) and the 
blue droplets (containing the probe) were collected (typically 400 pi) in a separate screw cap 
top tube. A 2 pi aliquot of the probe was then used to measure the radioactivity in a liquid 
scintillation counter (PACKARD, 1500 TRI-CARB)). The specific activity (dpm/pg) of the 
probe was determined in order to calculate the volume necessary to achieve 1 x 106 dpm/ml 
(a total of 2.5 x 107 dpm was required for 25 ml). Salmon sperm DNA (Sigma-Aldrich) at a 
final concentration of 100 pg/ml was then added to the probe and the tube was boiled for 10 
minutes, promptly incubated on ice for at least 5 minutes prior to being added to the pre-hybe 
mix with the nitrocellulose membranes. The hybridisation reaction was performed overnight 
in gently rotating hybridisation bottle(s) placed in hybridisation oven at 65°C.
The following morning the membranes were removed from the hybridisation bottle(s) 
and two quick washes in 2 X SSC were performed, followed by two 15 minute washes in 2 X 
SSC on a rocker at RT. The next two washes were in 2 X SSC, 0.1% SDS buffer and were 
performed inside a sealed Tupperware box in a shaking (60 rpm) 65°C water-bath (buffer was 
pre-heated). The final washes were in 0.1 X SSC at RT for 5 minutes on the rocker. The 
membranes were wrapped in cling-film and exposed to X-ray film (Kodak Biomax MS Film) in
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a cassette with an intensifying screen at -80°C for 3-4 days. All reagents for radioactive 
labelling, unless otherwise stated were from Amersham. All film related paraphernalia was 
made by Kodak but sourced from Sigma-Aldrich.
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2.5 Plasmids and Bacterial Artificial Chromosomes
(BAC)
Table 2,5.1: Plasmids.
Name Description (Accession #) Source
pACN Contained a self-excision neomycin
cassette (AF169416)
Dr Antonius Plagge
pBluescript II SK(+) Basic cloning vector Fermentas
pcDNA3 Basic mammalian expression vector Invitrogen
pcDNA3-WTp53 Murine wild-type p53 cDNA cloned into
pcDNA3
Dr Lorna Warnock
pCR2.1 TA-cloning vector - for cloning Taq
amplified PCR products
Invitrogen
pCR-XL-TOPO TA-cloning vector - for cloning tong (3-
10 kb) Taq amplified PCR products
Invitrogen
pE2-Crimson-N1 Encodes for far-red fluorescent protein
E2-Crimson
Clontech
pEGFP-N1 Encodes red-shifted variant of GFP -
suitable for N-fusions (U55762)
Clontech
pGL4.11 Promoter-less luciferase reporter Promega
pKO Scrambler NTKV- Contained negative selectable marker Stratagene
1902 Thymidine kinase.
pmCherry Source of pmCherry cDNA Clontech
pRAY-Cre Contains self-excision cassette with
neomycin and URA3 (AJ627603)
Dr Antonius Plagge
pRS414 Yeast-E. coli shuttle vector with TRP1
marker (U03448)
Dr Antonius Plagge
pUC19 Control plasmid Invitrogen
94
Materials and Methods
Table 2.5.2: Bacterial Artificial Chromosomes (BAC).
All BAC clones were sourced from Geneservice Ltd and contained segments of 129Sv/Ev 
genomic DNA, in vector pBACe3.6. These BAC clones carried resistance to 
chloramphenical.
Name Gene of
Interest
Size (bp) Chromosome Start Finish
bMQ-305J12 Mdm2 164210 10 117059258 117223468
bMQ-81N13 Mdm2 112123 10 117007437 117119560
bMQ-262p22 p21 102673 17 29198745 29301418
bMQ-44e41 p21 99063 17 29194941 29294004
bMQ-397h22 Puma 118745 7 16837560 16956305
bMQ-207e13 Puma 163875 7 16879773 17043648
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2.6 Enzymatic manipulation of DNA
2.6.1 Restriction endonuclease digestion
Digestion of DNA was performed with restriction endonucleases, according to the 
manufacturer’s instructions. All restriction endonucleases and buffers were purchased from 
New England Biolabs (NEB), unless otherwise stated. Plasmid DNA was digested either for 
diagnostic purposes (to identify correctly targeted recombinant clones) or for cloning 
exercises (i.e. for ligation reactions). Typically, for diagnostic digests, 0.5-1 pg of plasmid 
DNA was digested in a 20 pi volume containing 5-10 units of restriction enzyme 
supplemented with an appropriate X 1 buffer and if necessary X 1 BSA (final concentration of 
100 pg/ml) - see Table 2.6.1 for reaction components. The digestion was incubated for at 
least 2 hours (generally 3-4 hours) at the manufacturers recommended temperature (usually 
37°C). The DNA digest patterns were then analysed by agarose gel electrophoresis (see 
Section 2.4.2).
When DNA was prepared for ligation reactions, the same basic set-up as described 
above was applied, however, to ensure that there was sufficient DNA for the ligation 
reactions, (especially for DNA inserts < 300bp) up to 10 pg of plasmid DNA was digested. 
The digestion reaction was typically performed in a larger reaction volume (30-500 pi), with a 
longer incubation time (3 hours to overnight) and with X 10 excess enzyme (10 U/pg) to allow 
for complete digestion of the DNA. It was the volume of the enzyme which determined the 
final reaction volume since the enzyme content was not permitted to exceed 10% (v/v) (no 
more then 5% (v/v) glycerol) to reduce non-specific cutting (also called star activity). The 
digested DNA was then usually subjected to further enzymatic manipulation (de- 
phosphatising reaction - see Section 2.6.2, and/or blunting reaction - see Section 2.6.3) 
before being run on a GTG® (genetic technology grade) agarose gel and purified - see 
Section 2.4.2 & Section 2.3.9.
When a double digest was required (i.e. digestion with two restriction enzymes) the 
most suitable compatible buffer was chosen according to the manufacturer’s guidelines to 
allow both enzymes a minimal activity of 75%. In the cases where no suitable compatible
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buffer was available, the sequential digestion was performed by extracting the DNA after the 
first restriction digest using the liquid GENECLEAN protocol as described in Section 2.3.10 
followed by the second restriction digest..
Table 2.6.1: Components of a restriction endonuclease reaction.
Reaction component Concentration/Amount
Plasmid DNA ~ 0.5-10 pg
NEBuffer X 1
BSA X 1 (100 pg/ml)
Restriction endonuclease ~ 10 U/pg
Water Up to the final volume
2.6.2 Vector De-phosphorvlation (Antarctic phosphatase reaction)
Antarctic phosphatase (NEB) was used to catalyse the removal of 5’ phosphate 
groups from DNA and in doing so, reduce the probability of vector self-ligation and 
consequently the amount of vector background in cloning experiments. The procedure was 
performed according to the manufacturer’s guidelines as follows; once the backbone vector 
DNA (1-5 pg) had been digested with the desired restriction enzyme (see Section 2.6.1) the 
reaction mix was supplemented with 1/10th volume of X 10 Antarctic phosphatase buffer. 1 pi 
of Antarctic phosphatase (5 units) was then added and mixed by vortexing for 2-3 seconds. 
The sample was centrifuged briefly and incubated at 37°C for 15 minutes for 5’ extensions or 
blunt-ends, or 60 minutes for 3’ extensions. Antarctic phosphatase was inactivated by 
heating to 65°C for 5 minutes or alternatively by adding 1/10th volume orange-G loading buffer 
and proceeding straight away with GTG® agarose gel electrophoresis (see Section 2.4.2).
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2.6.3 Blunting DNA ends (with DNA polymerase I. large (Klenow) fragment)
DNA polymerase I, large (Klenow) fragment (NEB) was used to fill-in 5’ overhangs 
and to remove 3' overhangs from DNA following restriction endonuclease reactions (see 
Section 2.6.1) to create a blunt-ended DNA product. Creating a blunt-ended DNA product 
was useful in some cloning exercises when there were no compatible cohesive end restriction 
sites available or when particular restriction sites needed to be removed for downstream 
cloning steps. The protocol was performed according to the manufacturer’s instructions as 
follows; a 100 pi restriction enzyme reaction (in any X 1 buffer) was supplemented with 33 pM 
of each dNTP and 1 U of Klenow per pg DNA. The solution was mixed well by vortexing, 
briefly centrifuged and then was incubated at 25°C for 15 minutes. The reaction was 
promptly stopped by adding EDTA to a final concentration of 10 mM and incubating at 75°C 
for 20 minutes. The solution was then allowed to cool slowly before adding 1/10th volume 
orange-G loading buffer and running the sample on a GTG® agarose gel (see Section 2.4.2).
2.6.4 Ligation of DNA fragments
DNA ligation reactions were performed with T4 DNA ligase (multiple sources, 
Ambion, Invitrogen, and NEB) according to the manufacturer’s protocols. All T4 DNA ligases 
worked equally well, the choice of which enzyme to use was decided by availability at the time 
of the experiment. The Ambion T4 DNA ligase was routinely used for cloning in our 
laboratory, however this product was discontinued and our stock run out towards the end of 
this project. There was a small supply of the Invitrogen T4 DNA ligase available which was 
used before replacing and continuing with the NEB T4 DNA ligase.
The basic method of each ligation reaction remained relatively unchanged between 
each supplier and was set up as follows; the components of the ligation reaction were placed 
together in a 0,2 ml PCR tube (see Table 2.6.2) to a final volume of 10 pi (for Ambion and 
Invitrogen T4 DNA ligase) or 20 pi (for NEB T4 DNA ligase). The reaction was then mixed by 
vortexing for 2-3 seconds and centrifuged briefly before incubation at the appropriate 
temperature for overnight or longer. For cohesive end ligation reactions Ambion and 
Invitrogen supplied T4 DNA ligases were incubated at 14°C, whereas for blunt-end ligation
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reactions they were incubated at IG^C. The NEB T4 DNA ligase was always incubated at 
16°C and did not require additional supplementation with HCC and ATP for blunt-end DNA 
ligation reactions. Once the ligation reaction had been incubated sufficiently a small volume 
(1-5 pi) of the reaction was used in the transformation of competent E. coli - see Section 
2.12.
Table 2.6.2: Components of a ligation reaction.
*Only added to blunt-end DNA ligation reactions with T4 DNA ligase from Ambion/lnvitrogen.
Component Final concentration
Vector DNA 50 ng
X 10 ligase buffer X 1 (could precipitate in storage so was warmed to 37°C before
use and mixed well by vortexing)
Ligase 1 unit
*Hexamine cobalt chloride 1.5 pM
(HCC)
*ATP 0.5 mM
Insert DNA At least 1:1 molar ratio of vector: insert DNA however typically
aim for much higher insert concentration (1:3-1:10 ratio)
In addition to the desired ligation reaction, two control reactions were also routinely 
performed. The control reactions included the vector DNA with and without T4 DNA ligase in 
the appropriate buffer with any supplements (e.g. HCC/ATP). Neither of the control reactions 
contained any insert DNA; hence neither of these control reactions should produce any 
bacterial colonies in a transformation reaction. The presence of bacterial colonies on the first 
control (with ligase) may indicate an inefficient de-phosphorylation reaction (see Section 
2.6.2), whilst the presence of bacterial colonies on the second control (without ligase) might 
suggest an incomplete DNA digest (contamination with uncut plasmid DNA).
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2.6.5 Annealing linkers and adaptors
Linkers and adaptors are short (8-14 bp) fragments of double stranded DNA that can 
be used to introduce new restriction endonuclease sites into a plasmid. Linkers are blunt 
ended whereas adaptors create cohesive ends. This project only used adaptor- 
oligonucleotides; however the principle behind both linkers and adaptors was the same. The 
first step was to pick a suitable restriction enzyme site to adapt and then carefully design the 
oligonucleotide sequences to introduce the desired new restriction enzyme site (see Figure 
2.6.1). The oligonucleotides were obtained from Eurofin MWG Operon with a 5’ phosphate 
modification which allows for the formation of phosphodiester bonds between the de- 
phosphorylated backbone vector and the adaptor.
The adaptors were annealed by mixing the two oligonucleotides together (0.2 pg 
each) in 0.1 X TE buffer in a 1.5 ml micro-centrifuge tube to final volume of 25 pi. The tube 
containing the reaction was centrifuged briefly and placed into recently boiled water ~ 90°C. 
The water (and reaction) was allowed to cool slowly down to RT, before being moved into a 
fridge to cool further to - 4-8°C. The oligonucleotides would have annealed during the 
temperature gradient and 2 pi was then used in a ligation reaction.
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| Spel
_22_ a. ii J£iL_
?Vv>fI5tI\. ActagtAACGTTgaga gaCTAGT ^WV/JCV 
\lJtU \[jTGATCaTTGCAAGtctGtgatcA VJvJJ \P
Oligonucleotide 1: ctagtAACGTTgagaga 
Oligonucleotide 2: ctagtctctcAACGTTa
Figure 2.6.1: An example of a design of adaptor oligonucleotides.
The Spel site was chosen to be adapted to an Acll site. The adaptor was designed to 
complement the 5’ overhang left by digestion with restriction endonuclease Spel. The Acll 
site is introduced (shown in orange font) and non-specific bases are added to increase the 
amount of homology between the two oligonucleotides (in this case there will be 13 bp of 
overlapping double stranded DNA sequence). In this example the Spel site was maintained, 
however the Spel site could have been destroyed by designing the oligonucleotides 
differently.
2.6.6 TA-cloninq
2.6.6.1 A-tailing reaction (for cloning into pCR2.1 & pCR-XL-TOPO)
Cloning into the vectors pCR2.1 or pCR-XL-TOPO (Invitrogen) is based upon the 3’ 
A-tail overhang created by Taq DNA polymerase during a PCR reaction (see Section 2.7) for 
successful ligation (called TA-cloning). Therefore, it was necessary to add this 3’ A-tail 
overhang to the blunt-ended PCR products created by Phusion DNA polymerase. Briefly, the 
first step of the A-tailing reaction was to remove or inactivate any remaining Phusion DNA 
polymerase. This was because Phusion had 3’ to 5’ exonuclease activity and hence any 
residual enzyme would continue to remove the desired A-tail. The next step was incubation 
(in a suitable buffer) with excess dATPs and Taq DNA polymerase to attach the 3’ A-tails.
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There were three different methods for achieving the first important step of reducing 
the activity of Phusion; the first two protocols simply allowed the enzyme to become less 
efficient at removing the A-tails which fresh Taq DNA polymerase enzyme adds either by 
leaving the initial Phusion DNA polymerase PCR reaction overnight at 4°C or by heat-treating 
the reaction instead. The third method removed the Phusion DNA polymerase completely. 
Heat-treating was performed by incubating the Phusion PCR reaction at 98°C for 20 minutes 
immediately after completion of the PCR reaction. The reaction was then allowed to cool 
slowly before proceeding with the A-tailing reaction. Alternatively Phusion could be removed 
completely from the PCR reaction by performing a liquid GENECLEAN for purification of DNA 
(see Section 2.3.10). This third method was the most robust and was therefore the preferred 
option when multiple samples were being prepared simultaneously. However for successful 
ligations this required a high PCR product yield due to loss of PCR product during multiple 
purification steps (recovery rate was typically 70-90%).
The A-tailing reaction was then performed as follows; to the old PCR reaction 
(typically in 50 pi) 1 pi of 10 mM dATPs and 1 pi of Taq DNA polymerase (10 units) were 
added, mixed well and centrifuged briefly before incubation at 72°C for 20 minutes. When the 
DNA had been purified by liquid GENECLEAN, the reaction was performed as described 
above, except the reaction needed to be supplemented with X 1 Taq DNA polymerase buffer. 
Once the A-tailing reaction was completed the PCR products were then run on a GTG® 
agarose gel, and the DNA extracted for downstream cloning steps.
2.6.6.2 Topoisomerase reaction (cloning into pCR-XL-TOPO)
The TOPO® XL PCR cloning kit was purchased from Invitrogen and was used to 
clone long (3-10 kb) PCR products into the pCR®-XL-TOPO vector. The pCR®-XL-TOPO 
vector was supplied linearised with single 3’ T overhangs for TA-cloning and was also 
covalently bound to topoisomerase, which catalysed the ligation of DNA fragments. The 
reaction was performed according to the manufacturer’s instructions as follows; 4 pi of gel 
purified PCR product (DNA concentration was between 2-40 ng/pl - estimated by agarose gel 
electrophoresis see Section 2.4.2) was added to 1 pi of linearised pCR®-XL-TOPO vector
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and mixed gently. After 5 minutes of incubation at RT, 1 gl of the 6 X TORO® Cloning Stop 
Solution was added and mixed gently. The tube containing the reaction was then briefly 
centrifuged and placed on ice. 1-2 pi of the topoisomerase reaction was then used 
immediately in the transformation of competent E. coli.
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2.7 Amplification of DNA by Polymerase Chain
Reaction (PCR)
2.7.1 Standard Procedures and Optimisation
DNA fragments of interest were amplified using two suitable primers and a 
thermostable DNA polymerase (such as Taq or Phusion). A standard reaction (in 25 pi) 
contained an enzyme at the manufacturer’s recommended working concentration with the 
supplied buffer, 800 pM dNTPs (GE Healthcare), 0.05 pg of each primer and the appropriate 
amount of template DNA (typically 10 ng of BAG clone or 0.1 pg of genomic DNA) (see Table 
2,7.1). Once all components of a PCR reaction were mixed they were placed in a thermal 
cycler (Px2 Thermal Cycler, Thermo. Electron Corporation) and appropriate cycle conditions 
were used (see Table 2.7.2). Following a number of cycles (typically 30) the specific DNA of 
interest was amplified sufficiently for visualisation by UV light once stained with ethidium 
bromide in an agarose gel (see Section 2.4.2). In PCR reactions where the DNA product was 
to be used in molecular cloning, additional optimisation was required to increase specificity 
and reduce the introduction of random mutations. This was accomplished in two stages; i) a 
temperature gradient was performed for the annealing temperature and ii) the number of 
cycles performed was reduced to the minimum required.
For standard, relatively short PCR products (up to 2 kb), A-Tailing reactions (see 
Section 2.6.6.1) and for screening bacterial colonies (see Section 2.7.2.4) Taq DNA 
polymerase (NEB) was used. Alternatively, when screening was performed on genomic DNA, 
JumpStart Taq DNA polymerase (Sigma-Aldrich) was used. The use of JumpStart Taq DNA 
polymerase markedly reduced non-specific products because the enzyme was only activated 
once heated to its optimal temperature (heat-denaturing antibody hot start).
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Table 2.7.1: Standard components of a PCR reaction.
Component 125 pi
Standard buffer X1
dNTPs 200 pM each
Primers 0.05 pg each
DNA polymerase 0.5-1 units
DMSO (optional) 3%
Template DNA 50-250 ng of high complexity DNA (genomic)
1 pg-10 ng of low complexity DNA (plasmids)
Table 2.7.2: Standard cycle conditions for DNA polymerases Phusion and Taq.
Phusion High-Fidelity Taq DNA polymerase JumpStart Taq DNA
DNA polymerase (NEB) polymerase
Initial
denaturisation 98°C 30 sec 95°C 30 s 94°C 2 minutes
15-35 cycles
Denaturisation 98°C 10s 95°C 30 s 94°C 30 s
Anneal 50-65°C 30 s 50-65°C 30 s 55-68°C 30 s
Extend 72°C 15-30 s/kb 68°C 60 s/kb 72°C 2 minutes
Final 5-10
extension 72°C minutes 68°C 5 minutes 72°C 5 minutes
Hold 4°C 4°C 4°C
For all molecular cloning or on longer more difficult to amplify DNA templates, PCR 
reactions were performed with Phusion (Hot Start) High-Fidelity DNA polymerase (NEB). 
Phusion was supplied with two buffers, a high-fidelity standard buffer and a second buffer for 
use with GC-rich or difficult to amplify DNA templates. A standard procedure was 
implemented such that, if a PCR reaction failed using the standard reaction buffer, the GC- 
rich buffer was used instead with a further addition of 3% DMSO if the reaction continued to
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fail. PCR reactions which failed even after supplementation with DMSO were abandoned or 
new primers were designed.
Primers were designed using Primer3 (http://frodo.wi.mit.edu/primer3/) or Primer- 
BLAST (http://www.ncbi.nlm.nih.Qov/tools/primer-blast/index.cai7LINK LOC=BlastHome) and 
were usually 18-25 nt in length, with a GC content between 40-70% and a melting 
temperature (Tm) close to 60°C. When PrimerS could not find suitable primers or when 
specific mutations/start sites were required the oligonucleotides were designed manually and 
analysed on Primer3 to check their properties. All oligonuleotides were synthesised by 
Eurofms MWG Operon (http://www.eurofinsdna.com/home.html) and were reconstituted in
h2o.
2.7.2 Specialised PCR techniques
2.7.2.7 PCR-mediated mutagenesis
PCR was used to introduce useful sequences (such as unique restriction sites, point 
mutations and nuclear localisation signals) at the ends of PCR products. The desired 
sequence (up to a maximum of ~80 bp) was added to the 5’ end of oligonuleotides and would, 
provided that there was sufficient homology at the 3’ end of the primer to perform the reaction, 
be incorporated into the new PCR fragment see Figure 2.7.1. The appendage of additional 
sequence to the 5’ end of primers does not affect the properties of the original PCR reaction - 
hence all site-directed mutagenesis PCR reactions were optimised as described previously in 
Section 2.7.1. A 5’-GAGA cap was also included in the primer design in order to protect the 
integrity of the desired sequence.
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Fse,'SaM 5' I ggccggccgtcgacT
primer
Pact
primer 9
Primers have desired 
sequences - to be 
incorporated during 
the POP reaction - 
added to the 5' end
First round of PCR
I GGCCGGCCGTCGAC1 I
AATTAATT I
Further rounds of PCR
▼
5' iGGCCGGCCGTCGAC 1 ITTAATTAA I
rCCGGCCGGCAGCTG I
Figure 2.7.1: Schematic diagram of an example of PCR-mediated mutagenesis.
Adapted from [Watson et a!., 2007]. The addition of the restriction enzymes sites Fsel-Sall, 
and Pad to the PCR product was achieved as follows. Primers were designed to include Id- 
25 nt of complementary sequence to the template DNA and the desired sequences were 
included on the 5’ end of the primers (as well as a 5’-GAGA protective cap, not shown here). 
The PCR reaction was carried out as described in Section 2.7.1 and following further rounds 
of PCR the final product contained the new modifications, in this case the restriction enzyme 
sites Fsel-Sall and Pad.
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2,7.2.2 Fusion PCR
Fusion (or overlap extension) PCR is a technique which enables the accurate joining 
of two individual PCR products to produce one larger combined PCR product. In order to 
‘fuse’ the two PCR products together they must have a short (-15-40 bp) overlapping DNA 
sequence at the relevant 5' or 3’ end of the PCR fragment. The overlapping sequence can 
either exist within the DNA template or be added on through PCR-mediated mutagenesis (see 
Section 2.7.2.1). The procedure is carried out in two stages, briefly the first stage amplifies 
and purifies the two starter PCR products individually and the second stage mixes these two 
templates together for a further round of PCR - which creates the fused product (see Figure 
2.7.2).
A typical fusion PCR reaction was performed as follows; after careful planning, and 
primer design the two initial PCR reactions were optimised and performed as described in 
Section 2.7.1. The products from these PCR reactions were then separated and purified by 
agarose gel electrophoresis (see Section 2.4.2) and DNA gel extraction (Section 2.3.9). 10% 
of the gel-purified DNA product was run on another agarose gel to estimate the concentration 
of the DNA. The two DNA products were mixed at a 1:1 molar ratio and this DNA mixture 
was then used as the template DNA for the final round of PCR.
Table 2.7.3: Standard components of a fusion PCR reaction.
Component /50 pi
HF or GC-rich buffer X1
dNTPs 400 pM each
Very end primers 0.1 pg each
Phusion DNA polymerase 1 units
DMSO (optional) 3%
Template DNA 25-37.5 pi of DNA mixture (-20-200 ng)
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PCR reaction 1
J-
The first round of 
PCR amplifies and 
purifies the two 
starter products 
which go on to be 
the template DNA 
for the next reaction
4-
The second round of 
PCR uses the first 
round PCR products 
as a template These PCR 
products anneal 
together where 
there is homology 
(15-40 bp overlap) 
and through further 
rounds of PCR, 
produce the fused 
final product
Figure 2.7.2: A schematic diagram of fusion PCR
In the first round of PCR the two starter products which are to be joined together are amplified 
separately. In this example the overlap region (shown in grey) is added on to each starter 
product by PCR-mediated mutagenesis (see Section 2.7.2.1). Once purified the two starter 
PCR products are mixed together in a 1:1 molar ratio and become the template DNA for the 
next PCR reaction. The two templates anneal together where there is overlapping sequence 
homology (shown as dotted red lines) and act as primers from the join region, to begin to 
create the desired fused PCR product. The very end primers are also included and after 
several more cycles of PCR (typically 20-30) the full length fused PCR product is produced.
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The final round of PCR was performed in 50 pi and unlike normal PCR reactions the 
template DNA contributed to 50-75% of the total reaction volume (see Table 2.7.3). The PCR 
reaction was performed according to the Phusion DNA polymerase specifications listed in 
Table 2.7.2, typically 20-30 cycles of PCR were required to generate the full length PCR 
product. Fusion PCR was used to join together DNA fragments from different templates, to 
introduce specific site mutations and to overcome difficulties in amplifying large PCR products 
from problematic regions of DNA.
2.7.2.3 Manual hot start PCR
Hot start PCR is used to minimise contamination with non-specific DNA products and 
to reduce the formation of primer dimers. Non-specific products could be a particular problem 
when genomic DNA was used as a template, or when the primers were designed in a 
repetitive region of DNA. Non-specific products are often result of non-specific priming at 
lower temperatures and one method to reduce this background is to only add the DNA 
polymerase once the PCR reaction has been heated to its denaturisation temperature 
(typically 95°C or 98°C) - called a hot start PCR.
Most commercially available DNA polymerases can be supplied bound to an antibody 
which prevented the non-specific activity of the polymerase at lower temperatures until the 
antibody becomes denatured (for example JumpStart Taq DNA polymerase). However, these 
hot start enzymes are more expensive and so in some cases it was preferred to perform a 
manual hot start. A manual hot-start was performed by mixing all the components of the PCR 
reaction together, except for the DNA polymerase, and heating the mixture to the 
denaturisation temperature optimised for that DNA polymerase (in the case of Taq DNA 
polymerase from NEB, this temperature was 95°C). Once heated the tubes are quickly 
supplemented with 0.5 units of DNA polymerase (the stock enzyme was diluted to a suitable 
concentration, for example 0.5 units/pl to simplify the task of pipetting). The reaction then 
continued as for a normal PCR reaction.
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2.7.2A Bacterial colony PCR
PCR was used to screen bacterial colonies from LB agar plates directly using a 
technique called bacterial colony PCR. Briefly, bacterial colonies were selected and dipped 
into a pre-prepared tube containing the PCR reaction. The remaining bacteria (still attached 
to the inoculation loop) were then inoculated into a 5 ml LB starter culture and grown at 37°C 
overnight with shaking for expansion and DNA mini-prep. This technique requires a robust 
PCR reaction for successful screening, with a good positive control, which has been 
optimised as described in Section 2.7.1 in advance of screening.
Bacterial colony PCR was performed as follows; a PCR master mix was prepared for 
the number of colonies to be screened (plus a positive and negative control) assuming that 
the bacterial colony would take up approximately 1 p! volume, using Taq DNA polymerase 
(NEB). The PCR master mix was then aliquoted into labelled PCR tubes and kept chilled on 
ice whilst separate tubes containing 5 ml LB (plus appropriate antibiotic) were prepared and 
labelled. Next, one bacterial colony was selected from the LB-agar plate (containing the 
recombinant clones to be screened), and was picked using an inoculation loop and aseptic 
technique. The loop, with the bacteria attached, was then dipped 2-3 times very carefully into 
the PCR reaction tube before being shaken much more vigorously into the LB starter culture 
tube. The PCR reaction was then performed as described in Section 2.7.1 and analysed by 
agarose gel electrophoresis (see Section 2.4.2).
2.7.2.5 Yeast Colony PCR
PCR was performed on yeast cells to screen for positive recombinant clones. The 
method was very similar to the bacterial colony PCR described above, except for an 
additional initial heat denaturisation step. The protocol was performed as follows; 2-3 days 
previously a master yeast plate was generated by spreading individual yeast clones onto 
another minimal yeast agar plate with a grid. One master yeast plate containing 20-30 
colonies was usually sufficient for screening, since the majority of clones were expected to be 
positive due to the double selection protocol (see Section 2.2). Once the yeast colonies had 
grown into thick patches a sterile toothpick was used to gently scrape the surface of each
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patch. The toothpick was then transferred to a 0.2 ml PCR tube containing 10 pi of H20 and 
shaken to dislodge the yeast cells. The yeast cell mixture was then heated to 90°C for 10 
minutes; in the meantime a PCR master mix was prepared using Phusion Hot Start DMA 
polymerase as described in Section 2.7.1. The PCR reaction was then aliquoted into PCR 
tubes and kept on ice. After the 10 minute incubation the yeast/H20 mixture was vortexed 
well and 1 pi was transferred into each PCR reaction. Yeast colony PCR reactions were 
mixed by pipetting since the samples could not be centrifuged once the yeast cells had been 
added. The PCR was performed as described in Section 2.7.1 for 30 cycles and then 
analysed by agarose gel electrophoresis (see Section 2.4.2).
2.7.2.6 Sequencing reaction (MegaBACE)
The DYEnamic™ ET dye terminator cycle sequencing kit (MegaBACE™) was used 
to perform short sequencing reactions (150-400 nt in length) when there were many different 
clones to screen and multiple reactions to perform. The sequencing reaction was performed 
according to a slightly modified version of the manufacturer’s instructions as follows; the 
plasmid DMA to be sequenced was diluted to a concentration of 1 pg / 11 pi in H20 (not TE 
buffer since the EDTA could sequester important metal cofactors). Master mixes were then 
prepared for each primer (see Table 2.7.4 for reaction components) and were aliquoted into 
the wells of a 96-well plate. 0.5 pg of the desired template DNA in 5.5 pi was then added to 
each corresponding well. Once all the reagents had been prepared the 96-well plate was 
sealed and the cycling programme described in Table 2.7.5 was performed.
Table 2.7.4: Components of a standard MegaBACE sequencing reaction.
Component /10pl
DYEnamic ET reagent premix 4 pi
Primer (5 pM) 0.5 pi
DNA template 5.5 pi (0.5 pg)
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Table 2.7.5: Standard cycling parameters of a MegaBACE sequencing reaction.
25 cycles
Denaturisation 95°C 20 s
Anneal 50°C 15s
Extend 60°C 1 minute
Following completion of the sequencing reaction excess dye and other contaminants 
were removed from the reaction mixture by using a genCLEAN 96 Well Dye Terminator 
Removal Kit (Genetix) - see Section 2.3.11 for details. The sequence details were obtained 
by using the Cimarrun 3.12 software within the MegaBACE sequence analyser and were 
exported as a text document in FASTA format.
2.1.2.7 Sequencing (Eurofins MWG Operon/GATC)
For longer, higher quality DNA sequencing reads (up to 1100 nt) DNA samples were 
outsourced for sequencing. The two companies used in this project to perform this service 
were Eurofins MWG Operon and GATC Biotech. The DNA samples were prepared for 
sequencing following instructions on the company websites summarised in Table 2.7.6.
Table 2.7.5: DNA sample preparation for sequencing at Eurofins MWG Operon and 
GATC Biotech.
The information in this table was taken directly from the company websites.
Eurofins MWG Operon GATC Biotech
Purified plasmid DNA 50-100 ng/pl in minimum volume 30-100 ng/pl in 20 pi (sufficient
of 15 pi (per reaction) for 8 reactions)
Primers 15 pmol, sent pre-mixed with 10 pmol/pl in 20 pi (sufficient for
template DNA 8 reactions)
Purified PCR product 2-10 ng/pl in minimum volume of 10-50 ng/pl in 20 pi (sufficient for
15 pi (per reaction) 8 reactions)
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2.8 Bioinformatics
2.8.1 Basic Local Alignment Search Tool (BLAST)
BLAST is a search tool hosted by the National Center for Biotechnology Information 
(NCBI), used to align nucleotide or protein sequences and to statistically analyse how similar 
they are. In this project BLAST was generally used to compare data from DNA sequencing 
against either a database (for example the mouse genomic plus transcript database) or my 
own input material (for example vector DNA sequences). Specialised BLAST tools, such as 
primer-BLAST were also used to help design primers - see Section 2.7.1.
Website: http://blast.ncbi.nlm.nih.aov/Blast.cai?CMD=Web&PAGE TYPE=BlastHome
2.8.2 Identification of transcription factor binding sites (MAPPER)
MAPPER (Multi-genome Analysis of Positions and Patterns of Elements of 
Regulation) is an online search engine used to identify putative transcription factor binding 
sites (TFBS) within a DNA sequence [Marinescu et al., 2005]. It had extensive TFBS 
databases for several species including human and mouse and matches were displayed with 
straightforward access to the recognition model, statistical alignment scores and binding 
factor information (including the organism and structural class).
Part of this thesis was to design a mutated version of the Mdm2 P2 promoter region 
so that the P2-mutant would lose its ability to be bound and up-regulated by p53, but would 
be unaffected at any other, validated or speculated, TFBS. The MAPPER resource was used 
to help design the specific base changes in the P2 promoter region by monitoring for the 
deletion or introduction of TFBS as well as to verify that the p53 REs were no longer 
detectable. Briefly the task was performed as follows; the wild-type Mdm2 p53 RE DNA 
sequence +/- 40 bp was searched for putative TFBS, which were then recorded by exporting 
the graphical display and data summary sheet. Next, based on the consensus binding site for 
p53, various positions along each of the Mdm2 p53 REs were mutated in order to disrupt 
them. The modified sequence (at first only containing 2 nucleotide substitutions) was then
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run through the MAPPER search engine to confirm whether or not the p53 REs were still 
present. The number of nucleotide substitutions was steadily increased, starting with the 
most conserved positions (to be more effective at disrupting the p53 consensus binding sites), 
until the minimum number of base alterations that would theoretically prevent p53 binding was 
discovered. Attention was then focused on reducing non-specific effects such as 
deletion/introduction of other TFBS within the region that could potentially lead to confounding 
variables and make the results difficult to interpret. This was accomplished through 
systematically altering each base substitution to minimise its local effects. MAPPER was 
used to search for TFBS between each round of mutations and through a process of trial and 
error, combined with some educated deduction from using the recognition models available 
on MAPPER, the optimum sequence was derived. That is, the sequence that had the 
smallest number of mutations, which successfully prevented p53 binding whilst altering as few 
other TFBS within the region as possible.
Since the P2-mutant sequence was to be ultimately used in the generation of a 
transgenic mouse line, one final consideration to be included in the designing process was to 
introduce a restriction endonuclease site (or delete one) for screening purposes. Therefore 
once the optimum sequence had been defined, the sequence was further analysed (using 
NEBcutter - see Section 2.8.6) to see if any restriction enzyme sites had been introduced by 
chance, and if not, whether one could be incorporated without compromising any of the 
previously optimised features.
Website: http://mapper.chip.org
2.8.3 Splice site prediction tool
The splice site prediction tool was used to identify putative splice acceptor sites within 
a given DNA sequence [Reese et al., 1997], Specifically, for this thesis, this tool was used to 
determine whether the point mutations designed for the disruption of the p53-REs within the 
Mdm2 P2 promoter region had introduced any additional splice acceptor sites (compared with 
the wild-type Mdm2 P2 promoter region).
Website: http://www.fruitfiv.orq/seq tools/splice.html
115
2.8.4 Translation tool (ExPASv)
The ExPASy translation tool is hosted by the Swiss Institute of Bioinformatics (SIB) 
and was used to translate nucleotide sequences into their corresponding amino acid code. 
The tool was particularly helpful when checking whether a fused DNA sequence was in-frame 
and also for determining whether or not an unwanted DNA mutation was silent, that is the 
change in DNA sequence did not result in an altered protein sequence.
Website: http://web.exDasv.ora/translate/
2.8.5 Reverse complement
The reverse complement tool was used to convert DNA sequences into their reverse 
complement counterparts, which was helpful for many basic DNA sequence manipulation 
exercises, such as reversing primers and compiling vector DNA sequences. Another useful 
aspect of the reverse complement programme, although not its intended purpose, was that 
the tool removed all document formatting. Document formatting such as paragraphing and 
the inclusion of numbers or spaces was often present in downloaded DNA sequences and 
was a nuisance since it made searching for a particular DNA sequence (for example a primer 
or the start of a gene) within a sequence in Microsoft Word almost impossible. Formatting was 
removed using this tool as follows; the desired formatted version of the DNA sequence was 
entered and run through the reverse complement tool twice. The first round was sufficient to 
remove the formatting however the sequence will be its reverse complement; therefore a 
second round was performed on the output of the first round to revert the DNA sequence 
back to its original ‘forward’ configuration.
Website: http://www.bioinformatics.ora/sms/rev comp.html
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2.8.6 Restriction site mapping (NEBcutter)
The NEBcutter, restriction site mapping tool was used to analyse DNA sequences for 
the presence (and absence) of restriction enzyme sites [Vincze et al., 2003]. NEBcutter was 
essential when designing DNA cloning strategies to check for available restriction sites and to 
determine which restriction endonucleases should be avoided (for example if they cut 
elsewhere in a critical region of the DNA). Restriction mapping was also important for 
designing screening strategies, for example during routine recombinant clone diagnostic 
digests (see Section 2.6.1) and Southern blotting (see Section 2.4.3)
Website: http://tools.neb.com/NEBcutter2/
2.8.7 Chromatogram analysis (Sequence Scanner)
The Sequence Scanner Software v1.0 was downloaded from Applied Biosystems and 
was used to open chromatogram files with the extension ,ab1 from sequencing reactions 
performed by GATC Biotech. The software contained a helpful search function and 
adjustable scale bars which enabled fast and detailed inspection of the sequencing reactions’ 
raw format. These features were helpful when there was an apparent mutation in a DNA 
sequence, since the ‘mutated’ nucleotide could be located quickly (using the Find option and 
pasting in the aligned sequence just prior to the mutation - sequences were aligned in 
BLAST- see Section 2.8.1) and were examined closely by adjusting the scale to determine 
whether the mutation was real or just a base miscall. Confirmed mutations were dealt with on 
a case by case basis to decide what impact the mutation might have (if any).
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2.9 Mammalian Cells
2.9.1 Cell lines used and cell culture
Cell culture was carried out in Class II safety cabinets using aseptic technique. Cells 
were grown at 370C, in 5% C02 in a humidified incubator and all reagents were pre-warmed 
to 37°C. A summary of the cell lines used in this project and their growth medium is listed in 
Table 2.9.1. A detailed description of each cell line and its maintenance is provided next.
H1299 is an immortalised, p53 null, human non-small cell lung carcinoma cell line. 
H 1299s were routinely passaged 1:10 at 100% confluency. Subculture of cells was 
performed as follows. Once cells reached the desired confluency (typically took 2-3 days) the 
old media was removed and the cells washed with Dulbecco’s phosphate buffered saline 
(DPBS - Sigma-Aldrich) see Table 2.9.2 for appropriate volumes. Trypsin-EDTA (Sigma- 
Aldrich) solution was then applied evenly to the cells, by gentle tilting of the culture vessel to 
ensure adequate coverage, and the cells returned to the incubator for 2-5 minutes. Once the 
cells were becoming detached from the cell culture vessel, confirmed by microscopy, the 
trypsin was inactivated by adding at least x1 volume of growth media. The cells were then 
pipetted vigorously to ensure a single cell suspension and replaced into fresh culture vessel/s 
at the appropriate cell density with new media.
H1299 cells were frozen for long term storage in liquid nitrogen as follows; once the 
cells were in a single cell suspension (see above) the cells were then harvested by 
centrifugation at 300 x g for 5 minutes at RT. The cell pellet was then gently re-suspended in 
x 1 freezing media (see Table 2.9.3) at 1-2 x 106 cells/ml and dispensed in 0.5 ml aliquots into 
cryovials. The cryovials were then packaged into polystyrene containers and placed into a - 
80°C freezer, to freeze slowly. After at least 24 hours the cryovials were moved into liquid 
nitrogen storage.
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Table 2.9.1. Summary of cell lines used and the composition of each cell lines’ growth 
medium.
*These cell lines required high quality (HQ) FBS - see text for details. (3-mercaptoethanol 
(Sigma-Aldrich #M6250) was prepared as a x 100 stock solution in ESQ-PBS which was 
sterilised by filtration and stored at 4°C. ESGRO® LIE (Millipore #ESG1107) was prepared 
as a x 1000 stock solution in ES cell media and stored at 4°C in aliquots.
Cell line Source Base medium Supplements
H1299 Laboratory
stock
RPMI-1640
(Sigma-Aldrich)
10% FBS (Sigma-Aldrich)
Wild-type MEF Laboratory
stock
DMEM HEPES
modification
(Sigma-Aldrich #06171)
10% FBS (Sigma-Aldrich)
2 mM L-glutamine (Invitrogen)
p53 null MEF Laboratory
stock
As above As above
Double null MEF Laboratory
stock
As above As above
*SNL76/7 The
Wellcome
Trust
Sanger
Institute
KnockOut DMEM
(Invitrogen #10829018)
7% HQ FBS (HyClone/Invitrogen)
2 mM L-glutamine
*AB2,2 The
Wellcome
Trust
Sanger
Institute
As above 15% HQ FBS (Invitrogen)
2 mM L-glutamine
1 x 10'4 M (3-Mercaptoethanol
1000 units/ml LIF
*AM0998 IGTC As above 15% HQ FBS (HyClone)
2 mM L-glutamine
1 x 10'4 M (3-mercaptoethanol
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Table 2.9.2: Appropriate volumes of DPBS, trypsin, gelatin and media to add to each 
culture vessel.
Culture Vessel Volume of Volume of Volume of Volume of
DPBS (ml) Trypsin gelatin media
Multiwell 96-well 0.1 25 pi 70 pi 200 pi
plates 48-well 0.3 100 pi 200 pi 300 pi
24-well 0.5 250 pi 500 pi 1 ml
6-well 5 0.5 ml 3 ml 5 ml
Dishes 6 cm 5 0.5 ml 3 ml 5 ml
10 cm 5 1 ml 7 ml 10 ml
15 cm 10 3 ml 12 ml 12 ml
Flasks T25 5 1ml 3ml 5 ml
T75 10 2 ml 10 ml 10 ml
T175 10 3 ml 15 ml 25 ml
Table 2.9.3: Formulation of the freezing media used in this project
Cell line/s Freezing media components Source
H1299, wild-type MEF, p53
null MEF, double null MEF
x 1 freezing media
90% FBS
10% DMSO
Sigma-Aldrich #F9665
Sigma-Aldrich #D5879
SNL76/7, AM0998, AB2.2
x 2 freezing media
80% high quality (HQ) FBS
20% HQ DMSO
HyClone/Invitrogen
Sigma-Aldrich #D2650
96-well plates of ES cells
x 2 freezing media
40% ES cell media
40% HQ FBS
20% HQ DMSO
See Table 2.9.1
Invitrogen
Sigma-Aldrich #D2650
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Frozen cell lines were thawed and growth re-established as follows; the cryovial/s 
containing the desired cell line were removed from liquid nitrogen storage and the caps of the 
cryovials were loosened slightly (to prevent the vials from exploding). These vials were then 
placed into a 37°C water bath to defrost. Once all the ice inside the cryovial had melted the 
contents of the tube was transferred into a 15 ml Falcon tube and 10 ml of media was added 
drop-wise in order to slowly acclimatise the cells. The cell solution was then centrifuged at 
300 x g, for 5 minutes and the old media (containing DMSO) was removed. The cell pellet 
was gently re-suspended in an appropriate volume of growth media and transferred into a 
fresh cell culture vessel.
Mouse embryonic fibroblasts (MEFs) had been previously generated by our 
laboratory. Three different genotypes of MEFs were used in this project, including wild-type 
MEFs, p53 null MEFs and double null MEFs (pSS'7", Mdm2'/"). MEFs were split at 80-90% 
confluence at varying split ratios, reflecting their relative growth rates. Wild-type MEFs 
generally grew slower than either of the mutant cell lines and were only split 1:4, whereas the 
mutant cell lines (particularly the double nulls) grew very fast and could be split 1:12. 
Subculture, freezing and thawing of MEFs was performed as for H1299s.
SNL76/7 mouse embryonic fibroblasts were obtained from The Wellcome Trust 
Sanger Institute and were used as a feeder layer for embryonic stem (ES) cells. SNL 76/7 
cells are used because they produce Leukemia inhibitory factor (LIF) which maintains the ES 
cells in a pluripotent state [Williams et al., 1988] and also these cells contain a neomycin 
cassette and hence are resistant to drug selection by G418. SNL76/7 cells were grown on 
pre-gelatinised cell plates. Cell culture vessels were pre-gelatinised by coating the cell 
culture surface area with an appropriate amount of 0.1% gelatin solution (see Table 2.9.2 for 
volumes) for 2 hours, the 0.1% gelatin solution was then aspirated just before use. 0.1% 
gelatin solution was prepared by adding 0.5 g of porcine gelatin (Sigma-Aidrich #G1890) to 
500 ml of H20 with enough phenol red (BHD) to create a bright yellow colour. The 0.1% 
gelatin solution was sterilised by autoclaving and was stored at RT.
SNL76/7 cells required a high quality fetal bovine serum (FBS) for the best results. 
Serum quality had been determined previously by The Wellcome Trust Sanger Institute, who 
kindly provided us with the batch numbers of the highest quality serum. For our early
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experiments (growing ES cell line AM0998) HQ FBS was purchased from HyClone, whereas 
for the later experiments HQ FBS was sourced from Invitrogen. SNL76/7 cells were 
passaged at 80% confluence and split 1:10. The method of sub-culture was as for H1299 
cells with the exception that SNL76/7 cells were washed twice with DPBS (rather than only 
once) with an ES cell optimised formulation of DPBS (HyClone #SH30850.02) and different 
0.25% trypsin-EDTA solution (Sigma-Aldrich #14049). From hereon ES cell quality (ESQ) 
DPBS and 0.25% trypsin-EDTA solution will be referred to as ESQ-PBS and ESQ-trypsin 
respectively. Freezing and thawing SNL76/7 cells was performed as for H1299 cells except 
SNL76/7 cells were frozen 1:1 feeder cell medium to x 2 freezing medium (see Table 2.9.3).
2-3 days
2-3 days
T75 into j
Freeze
5 vials
Thaw vial of SNL76/7 Feeder cells *
Split 1:10
Expand into^^Bi 
x5T175 T175
Split 1:10 move up to T75 and T175 flasks
Freeze down in useful amounts of cells 
4.2x10® cells/0.5 ml aliquot
For x1 10 cm dish orx1 6-well plate
1.26x107 cells/1 ml aliquot
For x3 10 cm dish
Harvest and irradiate feeders
Use 3 ml ESQ-trypsin and inactivate with r 
27 ml ES cell media. x5 T175 flasks will fit 
into x3 50 ml Falcons (which is all that will 
fit in the GammaCell-irradiator)
Take small aliquot to count cells!
Figure 2.9.1: Flow diagram of the method used to generate large batches of mitotically 
inactivated feeder layers.
See text for further details.
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In order to act as a feeder layer for the ES cells, SNL76/7 cells were required to be 
mitotically inactivated; this was performed by exposing the cells to very high doses of y- 
radiation and this next section describes how the feeder layers were prepared. Feeder layers 
were prepared in batches as follows; x 5 T175 flasks of 80% confluence SNL76/7 cells were 
harvested as described previously, with the exception that the ESQ-trypsin solution was 
inactivated in x 10 feeder layer cell media (see Figure 2.9.1). Once harvested, the cells were 
pooled together in x 3 50 ml Falcons and were exposed to 60 Gy y-radiation (GammaCell 
irradiator with a 137Cs source dose rate 2.6 Gy/min). This mitotically inactivates the cells so 
that they can be used as feeder layers for the ES cells. A small aliquot of cells was taken to 
be counted. The irradiated feeder layer cells were then centrifuged at 300 x g for 5 minutes 
and were re-suspended in a suitable volume of feeder layer media to create useful aliquots of 
cells when frozen 1:1 feeder cell medium to x 2 freezing medium. For use with ES cells y- 
SNL76/7 cells were plated onto pre-gelatinised plates at the densities listed in Table 2.9.4. 
The feeder layers were allowed to settle and attach to the culture vessels for at least 1 day 
prior to use with ES cells, although slightly older feeders were preferred (5~7 days old) since 
the cells should have flattened nicely and any contamination would be obvious. Feeders 
older than 10 days were not used. From this batch method, you would expect to generate 
approximately 10 cryovials with 1.26 x 107 y-SNL76/6 cells/vial which should be sufficient for 
one round of ES cell targeting.
Table 2.9.4: Volumes and densities for plating irradiated feeder layers.
Cell culture vessel Volume Density
Multiwell plates 96-well (flat) 200 pi 1x10° cells/ml
24-well 1 ml 3.5x10° cells/ml
6-well 2 ml 3.5x10° cells/ml
Dishes 6 cm 4 ml 3.5x10° cells/ml
10 cm 12 ml 3.5x10° cells/ml
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AM0998 was a p21 gene-trapped ES cell line generated by The Wellcome Trust 
Sanger Institute which we requested from the international gene-trap consortium (IGTC) and 
see Section 3.2.1. AB2.2 is an untargeted, undifferentiated ES cell line with a 129$t/E\/ 
genetic background which is available upon request from The Wellcome Trust Sanger 
Institute. ES cells were grown on mitotically inactivated feeder layers (see above for 
preparation of feeder layers) and consequently growth of ES cells must always be well co­
ordinated with the availability of high quality feeder layers. Therefore before embarking on ES 
cell growth it is essential to determine when and what feeder layers will be required and to 
have them prepared at least a day in advance. ES cells were routinely sub-cultured every 
other day and their media was changed on alternate days, thus ES cells required daily 
attention. Since we intended to use these ES cells to generate transgenic mouse lines it was 
extremely important to maintain the ES cells in an undifferentiated state. Reflecting the 
importance of maintaining our ES cells in a pluripotent state, in our later experiments the 
media was also supplemented with exogenous LIE at 1000 U/ml. Subculture of ES cells was 
performed as for SNL76/7 cells, with the notable difference that the ES cell media was 
changed 3-4 hours prior to passaging.
ES cell lines were frozen in a similar manner to the SNL76/7 cells except instead of 
being frozen in polystyrene boxes the cryovials were frozen in an isopropanol container. The 
isopropanol container was initially at RT when the cells were placed inside, then it was 
transferred to the -80°C freezer. The isopropanol controlled the rate at which the temperature 
dropped, which allowed the cells temperature to drop slower (than the polystyrene box 
method) at approximately 1°C per minute and was hence better for acclimatising the cells and 
maintaining cell viability. For long term storage the cells were transferred to liquid nitrogen. 
The method of thawing ES cells was essentially the same, with the minor provision that 
thawing of ES cells was always performed at the end of the day and the media was always 
changed first thing in the morning. This was to limit the detrimental effects of any residual 
DMSO in the media.
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2.9.2 Introduction of DNA into mammalian cells
2.9.2.1 Transfection using GeneJuice
GeneJuice™ (Novagen) was used to transiently transfect mammalian cells with 
plasmid DNA. GeneJuice contains a non-toxic cellular protein and novel polyamine which 
allows for highly efficient non-toxic entry of DNA into treated cells. Transfection was 
performed on 50-60% confluent H1299 or p53 null MEF cells in triplicate wells of a 48-well 
plate. The procedure was performed according to the manufacturer’s instructions essentially 
as follows; the DNA was pipetted and mixed together first in sterile 1.5 ml screw-cap micro­
centrifuge tubes (one tube per condition). Next the GeneJuice, which was used at a 3:1 ratio 
with the DNA (3 pi of GeneJuice to 1 pg of DNA), was added to the serum free media and 
mixed by vortexing, then left to incubate at RT for 5 minutes. After incubation the 
GeneJuice/serum free media was added carefully to the DNA mixture and the reaction 
components were mixed well by flicking the tubes. Once mixed the tubes were centrifuged 
briefly and left to incubate at RT for 20 minutes. The contents of each tube were then very 
gently pipetted up and down and 15 pi was added drop-wise across the surface of the well 
being treated. Once all the wells had been treated the 48-well plate was then tilted back and 
forth and side to side (not by swirling) in order to aid distribution of the transfection reagents 
within the media. The transfected cells were then left in the tissue culture incubator for at 
least 24 hours before continuing with analysis (for example performing a luciferase assay see 
Section 2.13.8).
2.9.2.2 Stabie transfection of embryonic stem cells using electroporation
There are four major steps involved in the successful targeting of ES cells. These are 
DNA preparation; cell preparation, the electroporation itself and the subsequent selection and 
expansion of positive clones and these are described below.
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2.9.2.2.1 Preparation of DNA
Each electroporation required approximately 15-25 pg of targeting DNA, therefore to 
guarantee sufficient DNA for at least two attempts 60 pg of targeting construct DNA was 
digested overnight as described previously in Section 2.6.1 in order to linearise it. In the 
morning, 500 ng of the digested DNA was analysed on an agarose gel alongside 500 ng of 
the uncut DNA to confirm that complete digestion had taken place. The DNA was then 
extracted using the phenol/chloroform method described in Section 2.3.10 with precautions 
taken to ensure that the DNA was kept sterile once it was precipitated. The DNA was re­
suspended in 60 pi of sterile ESQ-PBS (approximately 1 pg/pl) and the DNA concentration 
and quality was checked by using a UV spectrophotometer. One final check on the DNA was 
performed by running a further 500 ng sample of the precipitated DNA on an agarose gel 
(with an uncut control) to confirm that everything appeared as expected. Preparation of the 
DNA was usually performed a few days ahead of the planned ES cell electroporation to allow 
time for all the quality control checks to be made. DNA was stored at -20°C until required, 
although storage for more than a few days was avoided.
2.9.2.2.2 Preparation of cells
Figure 2.9.2 provides an overview to the ES cell targeting strategy, including 
expected cell culture times, amount of feeder layers required and screening/expansion plans. 
Prior to the day of electroporation, the ES cell population was expanded from the initial 
thawed vial of AB2.2 cells, on three 10 cm dishes. One of these dishes was frozen (see 
Section 2.9.1) for use in future targeting events whilst the remaining two dishes (at 80% 
confluence) were utilised for the electroporation as follows; 3-4 hours before electroporation 
the ES cells media was changed to fresh ES cell medium. The media on the nine 10 cm 
feeder layer dishes, where the targeted ES cells were to be seeded post-electroporation, was 
also changed to ES cell media. The ES cells were then harvested as described in Section 
2.9.1 and the cells from two 10 cm dishes were combined into a single 15 ml tube (10 ml 
total). A 500 pi aliquot of cells was taken to be counted before the cells were centrifuged at 
300 x g for 5 minutes. The old media was removed and the cell pellet was gently re­
suspended in a suitable volume of ESQ-PBS to achieve a density of 1.1 x 107 cells/ml (two 10
126
Materials and Methods
cm dishes typically yielded enough AB2.2 cells for 2-3 electroporations). The cells were then 
ready to be electroporated.
2.9.2.2.3 Electroporation of ES cells
Electroporation of mammalian cells was performed using a Bio-Rad Gene Pulser II 
with Capacitance Extender. The electrode chamber was connected to the output jack on the 
Gene Pulser il Unit Control Panel which was the main panel - not to the Pulse Controller II 
Front Panel which was used for high voltage transformation of bacterial cells. Single use 0.4 
cm gap electroporation cuvettes were prepared by adding 0.9 ml of cells (1 x 107 cells) and ~ 
25 p! of DNA solution (25 pg of DNA as prepared above). The cuvette was placed into the 
electrode chamber, the Gene Pulser II was set at 230 V, 500 pF and a single pulse was 
delivered. Following exposure to a single pulse, the cuvettes were incubated at RT for 5 
minutes and then the cells were transferred from the cuvettes into a 15 ml Falcon tube. The 
cuvettes were washed out 2-3 times with more ESQ-PBS and contents collected together in 
the 15 ml Falcon tube. The total volume in the tube was then brought up to 9 ml with ESQ- 
PBS and the cells were very gently pipetted up and down before 1 ml was placed into each 
10 cm feeder layer dish. Each dish was then gently swirled in a figure of eight pattern to 
evenly distribute the cells, before being returned to the incubator. Electroporation was 
generally performed late in the evening so that selection protocols could be commenced in 
the morning of day 2 (36 hours post-electroporation) since this allowed maximum time for the 
ES cells to settle and attach before changing the media.
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2 days
2 daysSplit 1:3
Freeze
Plate out
Electroporate (iocm]x2
24-36 hours later 
start selection
Thaw vial of AB2.2 ES Cells
11 da]^ - change media every day for the first 4 
days, then only every other day thereafter
if cells are positive for Mini- 
Southern continue with
yjfct 24'W8>i
Southern analysis --------
Thaw doubly positive clones
«------------- - ----------------------- Extract DNA and perform 
further Mini-Southern 
analysis/PCR sequencing
3-4 days
Aim to get two 75-90% 
confluent wells of a 6-well 
plate one for freezing and 
one for divided use
Figure 2.9.2: Flow diagram for ES cell targeting strategy.
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2.9.2.2A Selection of positive clones
Selection of recombinant clones was started 36 hours post electroporation once the 
majority of the ES cells had settled and attached to the feeder layers. Since correctly 
targeted homologous recombination events are relatively rare, both positive and negative 
selections were used to increase the probability of selecting correctly targeted clones. 
Positive selection was based on resistance to G418 (Calbiochem), an aminoglycoside 
antibiotic, to which resistance is conferred after integration of the neomycin cassette (the 
positive selection marker). However, positive selection alone does not discriminate against 
random recombination events (integration at non-specific loci) therefore negative selection 
was also used and was based on the presence of the viral protein thymidine kinase (TK - the 
negative selectable marker) that renders ES cells sensitive to Ganciclovir (Sigma-Aldrich) an 
antiviral drug. Ganciclovir is a harmless nucleoside analogue unless it is phosphorylated by 
the viral protein thymidine kinase whereupon it becomes incorporated into replicating DMA 
and causes cell cycle arrest and eventual death of the affected cells.
For convenience both selection agents were prepared as concentrated stock 
solutions and were diluted into the ES cell media just before use. G418 was used at a 
working concentration of 300 pg/ml and was prepared as a X 100 stock solution in ESQ-PBS. 
Ganciclovir was used at a working concentration of 2 pM and was prepared as a X 1000 
stock solution. Initially Ganciclovir powder was dissolved in a small volume (10%) of 0.1 M 
HCI before being brought to the final desired volume (to create a X 1000 stock) with ESQ- 
PBS. Both solutions were sterilised by filtration and stored at 4°C.
Selection was performed over a 10-11 day period as follows; plates were re-fed daily 
with fresh ES cell media plus G418 and Ganciclovir for the first four days, then only every 
other day thereafter. Colonies became visible around days 5-7 and most of the debris from 
dead cells was gone by day 10. In our experience each 10 cm plate had 100 + colonies and 
most appeared undifferentiated when examined briefly under a microscope. Picking of 
colonies was started on day 10 of selection and usually continued for 2-3 days. 1-2 hours 
before picking colonies the old feeder layer medium on the 6 x 96-well feeder layer plates was 
removed and replenished with 100 pi of fresh ES cell media (it was not necessary to maintain 
selection once colonies had been picked). Just prior to commencing picking 30 pi of ESQ-
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trypsin was added per well of a 96-well round bottom sterile tissue culture plate. Picking ES 
cell colonies was then performed as follows; working with one plate at a time, the ES ceils 
were washed twice with 5 ml ESQ-PBS and then the plate was flooded with 8 ml of ESQ- 
PBS. A p20 pipette was set to 10 pi and a fresh box of sterile 1-10 pi pipette tips was used, 
so that each tip corresponded to a well of the 96-well plate. ES cell colonies were picked off 
the feeder layer one at a time and tips were changed between colonies to keep track of which 
wells had been used and to avoid cross-contamination (i typically picked 72 colonies/30 
minutes).
Once all the desired colonies had been picked (often not from a full plate to select 
only the best colonies from each of the 9 x 10 cm plates) they were returned to the incubator 
to trypsinize for a further 15 minutes. The trypsin was then inactivated by adding 70 pi of ES 
cell media to each well by using a multichannel pipette. The colonies were broken up into a 
single cell suspension by triturating the contents of each well with 35-40 pipette strokes. Tips 
were changed between each row to prevent cell line cross-contamination. The single cell 
suspensions were then transferred onto a new 96-well feeder layer plate and returned to the 
incubator for 48 hours before the media was changed. Following the initial 48 hours, which 
allowed the ES cells to settle and attach to their new feeder layer, the media was changed on 
the ES cells daily until more than 90% of the wells were turning the media yellow overnight 
(this typically took 3 days). When the majority of the wells appeared ready, the next step was 
to generate a master plate which would be frozen to preserve the cell lines and to create two 
duplicate plates for DNA screening purposes.
2.9.2.2.5 Generation of master plates and expansion of ES cells for DNA
A master plate was generated as follows: 3-4 hours prior to freezing/expansion the 
ES cells were re-fed with fresh ES cell media. Two gelatin coated plates were also prepared 
to create the duplicate plates. Feeder layers were not required for the duplicate plates since 
those cells were only to be used for DNA extraction and screening purposes therefore it did 
not matter if they became differentiated. Working with one plate at a time, each row was 
washed twice with 100 pi of ESQ-PBS, and then 25 pi of ESQ-trypsin was added. Once all 
the rows in the plate had been prepared the plate was returned to the incubator for 15 
minutes. While the cells were trypsinising, 150 pi of ES cell media was added to the gelatin
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coated plates. Following incubation, 25 pi of ES cell medium was added per well and 
pipetted up and down for 35-40 strokes to triturate the cells. 50 pi of 96-well plate x 2 
freezing medium (see Table 2.9.3 for formulation) was then added per well and pipetted a 
further 5-10 strokes. 20 pi of the ES cell suspension was then transferred into each 
corresponding well of the duplicate plates before returning the plates to the incubator. The 
media was changed on the duplicates after 48 hours and then daily (or more frequently if 
required) until more than 90% of the wells turned the medium yellow overnight.
Meanwhile the master plate was prepared by gently pipetting 100 pi of sterile mineral 
oil (Sigma-Aldrich) overlay on to the remaining cell suspension in the original 96-well plate. 
The master plate was then sealed carefully with extreme-temperature resistant tape (Tessa) 
and packed into a polystyrene box before being transferred to a -80°C freezer. Cells should 
be viable at -80°C for several months, although for long term storage plates should be 
transferred to the gas phase of liquid nitrogen.
The duplicate plates were also frozen once the majority of wells (> 90%) were 
confluent (this typically took 3 days). This was performed as follows; duplicate plates were 
removed from the incubator and wells washed twice with 100 pi of ESQ-PBS before sealing 
the plates with tape and freezing at -80°C. These cells were used for DNA extraction, using 
the protocol described in Section 2.3.12.
2.9.3 Exposure of mammalian cells to v-irradiation
Mammalian cells were exposed to y-irradiation for two purposes in this thesis; to 
generate feeder layers (described previously in Section 2.9.1) and to induce p53 up- 
regulation in cells to examine the subsequent protein expression. In the latter case, cells 
were grown to approximately 90-100% confluence in T25 flasks and then were exposed to 6, 
20 or 60 Gy of y-irradiation (or mock treated) in a GammaCell irradiator (dose rate 2.6 
Gy/minute). T25 flasks were used since three could fit inside the GammaCell irradiator when 
standing upright. Cells were mock treated by simply standing their T25 flasks upright for the 
same length of time as the cells that were irradiated. When cells received a 60 Gy dose, 
because of the technical complication (T25 flasks only fitted inside the machine whilst upright)
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irradiation was delivered in 5 minute pulses with a 5 minute recovery time in-between. 
Following treatment cells were then either stained for expression of p-galactosidase (P-gal) 
(Section 2.13.7) or were harvested for analysis by western blotting (Section 2.10).
132
Materials and Methods
2.10 Protein extraction and analysis
2.10.1 Protein sample preparation and quantification (Bradford assay)
Protein samples were prepared from tissue culture cell pellets as follows; the desired 
cell pellets were harvested as described previously in Section 2.9.1. Once the cell pellets had 
been collected they were washed twice with DPBS before being centrifuged (300 x g, 5 
minutes, RT) and the DPBS removed. Cell pellets could be processed straight away, or 
stored at -80°C and defrosted on ice before use.
Protein was extracted from the cell pellets as follows; once the pellets had defrosted 
cells were then re-suspended on ice in the appropriate amount of SLIP buffer supplemented 
with protease inhibitors (see Table 2.10.1 for composition of SLIP buffer and Table 2.10.2 for 
information on protease inhibitors), lysed on ice for 10 minutes and centrifuged at maximum 
speed (16,000 x g) at 4°C for 10 minutes. The supernatant was transferred to a fresh pre­
chilled 1.5 ml micro-centrifuge and kept on ice.
In the meantime protein standards were prepared by dissolving bovine serum 
albumin (BSA) in SLIP buffer to create the following dilutions; 20, 10, 5, 2.5, 1.25, 0.625, 
0.3125 mg/ml. 2 pi of standard or sample was added to 1 ml of Bradford reagent (BioRad - 
diluted 1 in 5 in water before use) and vortexed briefly. The addition of protein to the Bradford 
reagent results in a colour change in the dye, Coomasie Brilliant Blue G-250, which can be 
measured by a shift in the absorbance at 595 nm. The absorbance of the known protein 
standards was measured first using the BioPhotometer (Eppendorf) to create a standard 
curve and protein concentration of samples determined based on the calibrated 
spectrophotometer and recorded. Samples were then prepared to a concentration of 25 
pg/20 pi in sample buffer (see Table 2.10.1) and stored at -80°C.
An alternative version of the Bradford assay, a micro-Bradford assay, was performed 
when low protein yields were expected, for example for a luciferase assay (see Section 
2.13.8). A micro-Bradford assay was essentially the same as the regular assay described 
above except the following protein standards were created in the passive lysis buffer (PLB - 
Strategene); 5, 2.5, 1.25, 0.625, 0.3125, 0.156, 0.078 mg/ml and 5 pi of standards/samples
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was added to 1 ml of Bradford reagent. Once the spectrophotometer (Eppendorf 
Biophotometer) was calibrated the samples were then measured and the protein 
concentration estimated as before. For a luciferase assay, protein samples did not need to 
be prepared in sample buffer.
Table 2.10.1: Composition of protein buffers.
Solution Composition Source
Standard lysis and 50 mM HEPES (pH 7.5) Calbiochem
immunoprecipitation Buffer 150 mM sodium chloride VWR
(SLIP buffer) 10% glycerol Sigma-Aldrich
0.1% triton X-100 Sigma-Aldrich
0.5 mg/ml bovine serum albumin Fluka
Protein sample buffer 0.25 M Tris (pH 6.8) Calbiochem
8% sodium dodecyl sulphate (SDS) VWR
40% glycerol Sigma-Aldrich
4 mg/ml bromophenol blue Sigma-Aldrich
1 % p-mercaptoethanol Sigma-Aldrich
Tris-glycine electrophoresis 25 mM Tris Calbiochem
buffer (running buffer) 220 mM glycine Fisher
0.1% SDS VWR
Transfer buffer 25 mM Tris Calbiochem
192 mM glycine Fisher
20% methanol BHD
PBS/Tween 0.065 M Na2HP04 Sigma-Aldrich
0.015 MNaH2P04xH20 Sigma-Aldrich
0.075 M NaCI VWR
0.1% Tween 20 Sigma-Aldrich
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Table 2.10.2: Protease inhibitors.
All protease inhibitors except PMSF (Fluka) were purchased from Roche and were stored in 
aliquots at -80°C. PMSF was prepared fresh on the day.
Protease inhibitor Reconstituted Stock Working
in solution concentration
Aprotinin (A) h2o X 1000 2 pg/ml
Leupeptin (L) h2o X 1000 0.5 pg/ml
Pepstatin (P) Methanol X 1000 1 pg/ml
Soybean Trypsin Inhibitor (STI) H20 X 1000 100 pg/ml
Phenylmethylsulphonyl fluoride (PMSF) Ethanol X 100 1 mM
2.10,2 Western blotting
Western blotting is used to identify and quantitate specific proteins using specific 
antibodies. Briefly, protein samples are first resolved by SDS-PAGE (sodium dodecyl 
sulphate polyacrylamide gel electrophoresis) using the Mini-PROTEAN®-3 system (BioRad). 
Once resolved the protein samples were transferred onto a Hybond ECL nitrocellulose 
membrane (GE Healthcare) which could then be probed with an antibody specific for the 
protein of interest.
SDS-PAGE was performed as follows; the resolving gel mixture (see Table 2.10.3) 
was prepared at an appropriate percentage and poured into a glass cassette sandwich and 
allowed to set for approximately 40 minutes. In order to prevent the gel from drying out, 
remove bubbles and to ensure a flat surface, 1 ml of water was added immediately to the top 
of the glass cassette once the gel had been poured. After the gel had set, the water was 
shaken off and the stacking gel applied. The stacking gel comb was then gently and quickly 
inserted into the stacking gel and checked for air bubbles which might appear under the wells. 
The stacking gel was then left to polymerise for a further 40 minutes.
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Table 2.10.3: Components of SDS-PAGE gels.
The percentage of acrylamide can be varied to produce different densities of resolving gel. 
Low percentage gels (6%) were for resolving high molecular weight proteins such as p-geo 
(150 kDa) whereas high percentage gels (12%) were for resolving low molecular weight 
proteins such as p21 (21 kDa).
Component Source SDS'PAGE resolving gel SDS-PAGE
6% 12% stacking gel
h2o - 5.8 ml 4.3 ml 7.225 ml
40% acrylamide mix VWR 1.5 ml 3 ml 1.275 ml
1.5 M Tris (pH 8.8) Calbiochem 2.5 ml 2.5 ml -
1 M Tris (pH 6.8) Calbiochem - - 1.25 ml
10% SDS VWR 0.1 ml 0.1 ml 0.1 ml
10% ammonium peroxosulfate BDH 0.1 ml 0.1 ml 0.1 ml
10% TEMED (N,N,N\N’-
tetramethylethylenediamine)
VWR 8 pi 8 pi 10 pi
Following polymerisation, the gel comb was gently removed and the glass cassette 
containing the gel was set up inside the vertical gel electrophoresis tank. The gel tank was 
filled with running buffer (see Table 2.10.1) and was then ready for the protein samples to be 
loaded. Protein samples (including pre-stained protein marker - NEB) were prepared for 
SDS-PAGE by being defrosted on ice and then boiled at 100°C for 5 minutes. The samples 
were then vortexed briefly before being centrifuged at 4°C for 4 minutes at 16,000 x g. The 
samples were kept briefly on ice before being promptly loaded into the wells of the 
polyacrylamide gel. The gel was run at 200 V for approximately 1 hour.
The next step was transfer the separated proteins from the polyacrlamide gel onto a 
nitrocellulose membrane using the Mini-PROTEAN®-3 system (BioRad) following the 
manufacturer’s instructions, typically for 1 hr at 100 V.
Once the transfer was complete, the membrane was stained with Ponceau S solution 
(0.1% (w/v) in 5% acetic acid - Sigma-Aldrich) for visualisation of proteins and to check 
whether the protein loading and transfer were even. The membrane was then incubated in
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PBS/Tween with 5% non-fat dry milk (BioRad) typically overnight at 4°C, or at least for 1 hr at 
RT before continuing with the immuno-blot. The membranes (with or without overnight 
storage in the fridge) were then blocked in the 5% milk solution with shaking (~ 60 rpm) at RT 
for at least 1 hour. In the meantime the primary antibodies were prepared in the 5% milk 
solution (see Table 2.10.4). Some antibodies did not tolerate freeze/thawing and therefore 
they were prepared fresh each time, whilst others could be frozen at -80°C and re-used. 
Once blocking was complete, the membranes were incubated with the appropriate primary 
antibody for 1 hour at RT with gentle agitation. Following incubation with the primary 
antibodies, the membranes were washed in PBS/Tween for 3 x 10 minutes. The membranes 
were then incubated with the appropriate secondary antibody for 1 hour at RT with shaking. 
Secondary antibodies (from Amersham/GE Healthcare) conjugated to horseradish peroxidise 
(HRP) were diluted in 5% milk solution as follows; 1:5,000 for anti-rabbit-HRP antibody and 
1:2,500 for anti-mouse-HRP antibody. After incubation with the secondary antibody, the 
membranes were washed again in 3 x 10 minutes with PBS/Tween.
Once all the washes were completed the membrane was then ready to be treated 
with the Western lightning chemiluminescence reagent plus (ECL reagent - Perkin Elmer). 
The ECL reagent was prepared by mixing the enhanced luminol reagent and oxidizing 
reagent together at a 1:1 ratio (require 0.1 ml per 1 cm2) and this was then pipetted over the 
membrane and allowed to incubate for 1 minute. Excess ECL reagent was dabbed off the 
membrane using a clean soft tissue on the edge of the membrane and then the membrane 
was arranged between two sheets of acetate. The luminescence signal was detected using a 
Kodak 1S4000MM image station.
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Table 2.10.4: Primary antibodies used in this project for Western blotting
Protein Antibody Source Raised in Working
concentration
p21 M19 Santa Cruz Rabbit polyclonal 1:200
p53 CMS Novacastra Rabbit polyclonal 1:1000
p-gal 0802 Calbiochem Mouse monoclonal 3 pg/ml
Actin C-2 Santa Cruz Mouse monoclonal 3 pg/ml
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2.11 RNA extraction methods
2.11.1 Preservation of RNA integrity bv RNA/aferstabiiisation solution
RNA/afer solution was purchased from Applied Biosystems and was used to prevent 
the degradation of RNA inside animal tissues, A major technical problem when isolating RNA 
from tissues is the presence of ribonucleases (RNases) that catalyse the breakdown of RNA 
and therefore need to be inhibited.
RNA/afer solution was used on freshly isolated mouse gut samples to preserve the 
integrity of RNA as follows; freshly isolated mouse gut samples (5 cm in length) were placed 
into 5 ml universal tubes which had been pre-filled with RNA/afer solution and incubated 
overnight at 4°C to ensure that the RNA/afer solution had permeated all the cells in the 
sample. The sample was then frozen and stored at -80°C whereupon the RNA should be 
preserved indefinitely.
To isolate RNA from a tissue preserved in RNA/afer, the tissue sample was removed 
from the -80°C freezer and allowed to defrost at 4°C overnight. The following day, once the 
RNA/afer solution had thawed completely, the tissue could be removed and utilised. Samples 
preserved in RNA/afer could be freeze/thawed multiple times without affecting the quality of 
RNA, therefore routinely, a small portion of the tissue (0.3 g) was removed for RNA isolation 
and the remaining tissue was returned to the RNA/afer solution and re-frozen. The next 
section describes RNA isolation from whole animal tissue with the QIAGEN RNeasy Mini kit.
2.11.2 Isolation of RNA from whole animal tissue
The QIAGEN RNeasy Mini kit was used to isolate RNA from whole animal tissues 
using a variation of the guanidine extraction method. Briefly; the samples were lysed in a 
buffer that contains guanidine thiocyanate (a powerful protein denaturant) to ensure 
immediate inactivation of RNases. Once lysed the samples are loaded onto a silica-based 
membrane within the RNeasy spin column (similar to QIAprep spin Miniprep kit used for 
isolation of plasmid DNA - see Section 2.3.2). Under the appropriate binding conditions (high 
salt and presence of ethanol) the silica-based membrane binds to the RNA. Once bound to
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the RNeasy spin column the RNA can be washed to remove any contaminants and then 
eluted in RNase-free water. The yield using this kit could vary depending on the starting 
material but typically produced 70-100 pg of high quality RNA.
The RNeasy Mini kit was used to isolate RNA according to the manufacturer’s 
guidelines essentially as follows; 30 mg of fresh tissue or 15-20 mg of RNA/afer stabilised 
tissue (since RNA/afer partially dehydrated the sample) was disrupted by using a pestle and 
mortar, with liquid nitrogen to facilitate the grinding. The liquid nitrogen was allowed to 
evaporate and 600 pi of buffer RLT was added to lyse the cells. The cell lysate was collected 
and transferred into a pre-cooled (in liquid nitrogen) 2 ml micro-centrifuge tube. The lysate 
was then homogenised by passing it through a 20-gauge (0.9 mm) needle at least 5-10 times. 
Once the lysate appeared homogenous it was then centrifuged for 3 minutes at maximum 
speed (16,000 x g) in a bench top centrifuge. The supernatant was promptly transferred to a 
fresh tube and 1 volume of 70% ethanol was added to the cleared lysate and the sample was 
mixed by pipetting (ethanol was added to promote binding of the RNA to the silica-based 
membrane). Addition of ethanol sometimes produced a precipitate which was ignored in the 
subsequent steps, since it did not affect the efficiency of RNA isolation. Up to 700 pi of the 
sample was loaded onto the RNeasy spin column which was placed inside a 2 ml collection 
tube. The RNeasy spin column was then centrifuged for 15 seconds at > 8000 x g and the 
flow-through was discarded. Samples which had a volume greater than 700 pi were simply 
loaded onto the same spin column, and centrifuged as before in successive aliquots. 700 pi 
of buffer RW1 was then applied and centrifuged as before. The flow-through was discarded 
and 500 pi of buffer RPE was added to the column and centrifuged as before. The flow­
through was discarded and another 500 pi of buffer RPE was applied to the RNeasy spin 
column. This time the RNeasy spin column was centrifuged at > 8000 x g, for 2 minutes to 
both wash and dry the membrane. To avoid transfer of residual ethanol (from wash buffer 
RPE) the RNeasy spin column was placed into a fresh 2 ml collection tube and centrifuged for 
a further 1 minute. The RNeasy spin column was then transferred into a fresh 1.5 mi 
collection tube and 30-50 pi of RNase-free water was applied directly to the silica-based 
membrane. The RNA was then eluted by centrifuging the spin column for 1 minute (> 8000 x 
g). The quantity of RNA was estimated by using a UV spectrophotometer (taking readings at
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230, 260 and 280nm) and the quality was assessed by running the samples on a non­
denaturing agarose gel (see Section 2.4).
2.11.3 Isolation of RNAfrom intestinal epithelial cell extraction
RNA was isolated from cell pellets which had been collected using the intestinal 
epithelial extraction protocol described in Section 2.13.4 by using a basic chloroform 
extraction/isopropanol precipitation protocol. The cell pellets were re-suspended 1:1 with 
TRIZOL reagent to preserve the integrity of RNA (TRIZOL reagent contains guanidine 
isothiocyanate - which inhibits the activity of RNases) and frozen prior to commencing this 
procedure.
RNA was extracted from ceil pellets frozen in TRIZOL as follows; the cell pellets in 
TRIZOL were defrosted on ice and homogenised by pipetting the samples through decreasing 
diameters of needles. Once the samples were homogenous they were centrifuged at 
maximum speed (16,000 x g) at 4°C for 10 minutes. The supernatant was promptly 
transferred to a fresh pre-chilled tubes and 200 pi of chloroform was added and mixed by 
inversion. The RNA extraction reaction was performed for 15 minutes on ice, with occasional 
inversion of the tube to mix. The samples were centrifuged as before and then the aqueous 
phase was transferred to a fresh tube containing 600 pi of isopropano!. The samples were 
mixed again by inversion and then were incubated on ice for at least 1 hour while the RNA 
precipitated. After the RNA had precipitated, the samples were centrifuged as before and the 
supernatant was carefully removed (RNA forms a pellet at base of tube). The RNA pellet was 
washed with 500 p! of pre-chilled 70% ethanol and then the pellet was allowed to air dry for 5- 
10 minutes. RNA was re-suspended in 100 pi of nuclease-free water and the quantity/quality 
checked by using a UV spectrophotometer (Section 2.4.1).
The RNA samples were then cleaned up to be of high enough quality for RNA 
microarray analysis as follows; 50 pi of each sample was treated with DNase I and cleaned 
up using the QIAGEN RNeasy Mini kit (Section 2.11.4). A PCR was then performed to check 
for any residual contaminating genomic DNA. The DNase I treatment, column purification
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and subsequent PCR check was kindly performed by Dr Dimitris Athineos (The Beatson 
Institute Glasgow).
2.11.4 Removal of contaminating DNA from RNA - treatment with DNase I
RNA samples which were contaminated with genomic DNA were treated with DNase 
I (QIAGEN) according to the manufacturer’s instructions. Once the DNA was digested the 
sample was reloaded onto an RNeasy spin column for RNA purification.
DNase I stock solution prepared in advance as follows; the lyophilized form of DNase 
I was re-suspended in RNase-free water and mixed by inversion (not vortexing - since DNase 
I is sensitive to mechanical stress) and then aliquoted and stored at -20°C. The DNase I 
treatment was then performed. The reaction components in Table 2.11.1 were mixed 
together and left to incubate at RT for 10 minutes.
Table 2.11,1: DNase / reaction components
Amount Components
87.5 pi RNA solution (contaminated with genomic DNA)
10 pi Buffer RDD
2.5 pi DNase I stock solution
RNA from the 100 pi DNase I reaction was then recovered using a modified version 
of the RNeasy Mini kit protocol as follows; to the 100 pi reaction 350 pi of buffer RLT was 
added and mixed well. 250 pi of 96-100% ethanol was then added and mixed well by 
pipetting. This 700 pi solution was then transferred to an RNeasy spin column with a 2 ml 
collection tube attached. The RNeasy spin column was centrifuged for 15 seconds at > 8000 
x g and the flow-through discarded. 500 pi of buffer RPE was applied to column and 
centrifuged as before. From here the protocol proceeds as for isolation from whole animal 
tissue RNeasy protocol (see Section 2.11.2).
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2.12 RNA microarray
2.12.1 Reverse-Transcriptase reaction for generation of cDNA
RNA samples were reverse-transcribed into cDNA {complementary DNA) using the 
RNA-directed DNA polymerase Moloney Murine Leukemia Virus (M-MuLV) reverse 
transcriptase (RT) from NEB. cDNA was synthesised according to the manufacturer’s 
instructions essentially as follows; in a sterile, nuclease free, 0.2 ml PCR tube (or for multiple 
samples a 96-well PCR plate was used) the initial reaction components were mixed together 
(see Table 2.12.1). The initial reaction components were then heated to 80°C for 5 minutes 
and placed promptly onto ice. The remaining reaction components were then added to the 
tube/s (for multiple reactions a master mix was prepared for ease of addition) and the reaction 
was performed at 42°C for 1 hour. A control reaction, without M-MuLV RT (known as minus 
RT), was also performed for each sample. The enzymes were then heat-inactivated by 
incubation at 90°C for 10 minutes and cDNA samples were stored at -20°C until required.
Table 2.12.1: Reverse-transcriptase reaction components.
Initial reaction contains heat-insensitive reagents, whereas final reaction contains the buffers 
and enzymes.
Component Amount Source
The following initial reaction components were mixed together and heat-denatured
RNA solution 0.5-2 pg Own material - used 0.5 pg
Primer: oligo dT 40 pM MWG Eurofins
dNTPs 2.5 mM each GE Healthcare
Nuclease-free water Up to 16 pi With M-MuLV Kit
Final reaction components were then added and RT reaction performed
X 10 RT buffer 2 pi With M-MuLV kit
10 U/ pi RNase inhibitor 1 pi NEB
M-MuLV reverse-transcriptase 1 pi NEB
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2.12.2 Quantitative Real-Time PCR (QRTPCm
Quantitative Real-Time PCR (QRTPCR) was performed on cDNA samples using the 
iQ™ SYBR® Green Supermix and iQ5 multicolor real time PCR detection system (BioRad). 
QRTPCR was used to determine whether the villus/crypt enrichment procedure, as performed 
in the small intestine epithelial extraction protocol (see Section 2.13.4), was successful. That 
is, would villus-specific genes be up-regulated in the ‘mostly villus’ fraction over the ‘mostly 
crypt’ fraction and vice-versa. To accomplish this, three different genes were examined, a 
villus specific gene (Max), a crypt specific gene (Lgr5) and a house-keeping gene to 
standardise the data (Hprtl).
QRTPCR was performed according a slightly modified version of the manufacturer’s 
guidelines as follows; working with one high profile, clear 96-well PCR plate at a time, a 
master mix containing all reaction components except for the template DNA (see Table 
2.12.2) was prepared for n reactions (n = number of reactions + 5). 15 pi of master mix was 
then pipetted into each assigned well using a multipipette® (Eppendorf) for speed and 
consistency. Once the master mix was dispensed, the 96-well PCR plate was sealed with a 
temporary plate sticker and placed to one side whilst the template cDNA and DNA standards 
were prepared.
Table 2.12.2: Standard components of a QRTPCR reaction.
Component /20 pi
X 2 iQ SYBR Green Supermix 10 pi
Forward primer (0.1 pg/pl) 0.4 pi
Reverse primer (0.1 pg/pl) 0.4 pi
h2o 4.2 pi
Template DNA 5 pi
The template cDNA was prepared by diluting the cDNA synthesised from the reverse 
transcriptase reaction (described previously in Section 2.12.1) 1 in 20 with H20. If cDNA 
samples were not already in a 96-well PCR plate they were transferred into one to simplify
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pipetting and storage. The DNA standards used were seven serial dilutions of known 
concentration of plasmid DNA which contained the PCR fragment being amplified (fragment 
was typically cloned into a TA vector such as pCR2.1). The starting dilution was 1000 amol 
(1 attomol = 1 x 10‘18 M) in 5 pi and this was diluted 1 in 10 until 1 zmol (1 zmo! ~ 1 x 10'21 M) 
was reached and see Table 2.12.3. The DNA standard serial dilutions were prepared fresh 
on the day in 1.5 mi micro-centrifuge tubes (10 pi into 90 pi H20) but were transferred into the 
wells of a 96-well PCR plate so a multichannel pipette could be used. The cDNA template 
and DNA standard reactions were each performed in triplicate, the minus-RT (negative 
control) was only performed in duplicate.
Table 2,12.3: Concentration of DNA standards for QRTPCR.
DNA Standard Amount in 5 pi
1 1000 amol
2 100 amol
3 10 amol
4 1 amol
5 100 zmol
6 10 zmol
7 1 zmol
Once the template DNA was ready, 5 pi of standard or sample was transferred into its 
corresponding well in the original 96-well PCR plate which contained the master mix. A 
multichannel pipette was used when possible for speed and consistency. Following addition 
of DNA, the reaction plate was sealed with an appropriate adhesive sticker (Microseal® ‘B’ 
film - BioRad) and plate sealer tool (to avoid marking the top of the plate). The plate was then 
centrifuged briefly to ensure that the contents was at the base of each well, before being 
placed into the iQ5 multicolor real time PCR detection system for the QRTPCR reaction to be 
run.
The QRTPCR reaction, including plate layout, was set up using the workshop in the 
BioRad iQ5 software. The standard cycling parameters of a QRTPCR is shown in Table
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2.12.4. Once a run was complete the results could be briefly analysed in the data analysis 
section, however for a more detailed analysis, the files were saved and sent to Dr Bryony 
Lloyd (The University of Liverpool).
Table 2.12.4: Standard cycling parameters of a QRTPCR
Initial Denaturisation 95°C 3 minutes
40 cycles
Denaturisation 95°C 30 s
Anneal Primer specific 45 s
Melt curve 95°C 50°C 1°C per 10 s
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2.13 Phenotype analysis
2.13.1 Animals
c-Rel^' knock-out mice (on a C57BU6 genetic background) were obtained from Dr 
J.C. Caamano from the University of Birmingham as described in [Mason et ai., 2002]. These 
mice retain wild-type p53 and thus have intact apoptotic responses and since these were 
readily available they were used to optimise conditions for immunohistochemistry (IHC). 
Conditionally floxed Mdm2 null mice were a kind gift from Dr O.J. Sansom, Beatson Institute, 
Glasgow, UK. These mice contain a ere gene under the control of the gastrointestinal specific 
promoter CYP1A1, which can be switched on by administrating lipophilic xenobiotics (such as 
(3-naphthoflavone) [Campbell et al., 1996]. A summary of the experiments performed in this 
thesis can be found in Table 2.13.1. All experiments were conducted under the authority of a 
valid UK Home Office project licence.
2.13.2 Exposure of animals to v-irradiation
12-13 week old female mice (c-Rel^) were exposed to 8 Gy y-radiation (Gammacell 
irradiator with a 137Cs source dose rate 2.6 Gy/min) and sacrificed at 4.5 hours by cervical 
dislocation. 8-10 week old Mdm2flox/flox or wild-type male mice were exposed to 14 Gy y- 
irradiation using a cobalt-60 source at the Beatson Institute and sacrificed at 6 hours by 
cervical dislocation.
2.13.3 Cre-mediated recombination by 3-naphthoflavone (BNF)
Various doses of (3-naphthoflavone (BNF) (Sigma, Dorset, UK) dissolved in corn oil 
were administered by gavage and/or injection to induce expression of ere. Note that since 
BNF is broken down by exposure to light it is necessary to dissolve BNF in an amber bottle 
and to freeze it in aliquots in amber bottles. BNF and corn oil were heated in a water bath set 
to 99.9°C. Large pieces of BNF were crushed using a glass rod and then the whole amber 
bottle was transferred to a heated stirrer set at 100°C and stirred for about 10 minutes. This
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process was continued (water bath to stirrer) until all the BNF has dissolved (takes about an 
hour). The BNF is then aliquoted and frozen. After 3 freeze-thaw cycles the remaining BNF 
is discarded. Following gavage with BNF mice were sacrificed either on day 1 or day 2 by 
cervical dislocation, or exposed to 14 Gy y-irradiation and then sacrificed see for Table 2.13.1 
Table 2.13.1 details.
Table 2.13.1: Summary of in vivo experiments
Experiment Animals Treatment Other details
Liverpool 6 x c-Rer ($) +/- 8 Gy y-irradiation sacrificed Small and large intestine
2007 4.5 hours for paraffin blocks
Glasgow 6 x Mdm2™ox Day 0 - 1 x 80 mg/kg dose of Small intestine and liver
2008 6 x Wild-type
(<?)
BNF (gavage)
Day 1 - sacrifice 3 x Mdm2flox/flox
& 3 x wild-type
Day 2 - sacrifice 3 x Mdm2flox/flox
& 3 x wild-type
for paraffin blocks
Glasgow 6 x Mdm2T,oxmox Day 0 - 3 x 80 mg/kg dose of Small intestine and liver
2009 6 x Wild-type BNF (IP injections at 9am, 12pm for paraffin blocks
(<?) and 5pm) + additional 1 x 80
mg/kg BNF (gavage 12pm)
Day 1 - +/- 14 Gy y-irradiation
sacrificed 6 hours
Small intestine frozen in
RNA/afer
Glasgow 3 x Mdm2T10X/T,0X Day 0 - 3 x 80 mg/kg dose of Performed intestinal
2010 6 x Wild-type BNF (IP injections at 9am, 12pm epithelial extraction -
(<?) and 5pm) + additional 1 x 80
mg/kg BNF (gavage 12pm)
Day 1 - 3 x wild-type + 14 Gy y-
irradiation sacrificed 6 hours.
Remaining animals also
sacrificed
collected 2 fractions
‘mostly villus’ and
‘mostly crypt’ - were
frozen in TRIZOL
reagent
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2.13.4 Isolation of epithelial cells from mouse gut
The epithelial extraction protocol described here is based on [Weiser, 1973]. During 
the procedure two cell fractions were collected; the first fraction was said to be ‘mostly villus’ 
whilst the second was said to be ‘mostly crypt’. For this experiment, a custom made piece of 
equipment was necessary - a 0.5 mm diameter spiral glass rod (made using a glass blower). 
The experiment was performed as follows; mice were sacrificed by cervical dislocation and 
their small intestine was promptly removed. The first 5 cm (from the stomach) was discarded 
and the next 10-20 cm was used for extraction. The gut was flushed with water then a suture 
was used to tie off ~ 1 cm of intestine. This ~ 1 cm of intestine was carefully threaded onto 
the curved end of the custom made helical glass rod so that the tie was flush with the tip of 
the glass rod. The remaining gut was then forced back over itself so that the intestine was 
inverted on the helical glass rod. The glass rod was then wedged inside the pipetteaid and 
lowered into a 50 ml Falcon tube containing 25 ml of 10 mM EDTA in HBSS (Ca and Mg free 
Gibco #14170-088). The 50 ml Falcon and EDTA/HBSS were pre-warmed to 37°C and were 
kept at 37°C for the duration of the extraction procedure. The pipetteaid was held in a retort 
stand and its expel button was taped down to create a gentle vibration which dislodges the 
cells from the intestine (see Figure 2.13.1). The first fraction was collected for 15 minutes, 
after which the glass rod with the inverted intestine was removed from the pipetteaid and 
given a quick shake (to dislodge loose cells and any remaining mucus) into the EDTA/HBSS. 
The glass rod was then reinserted into the pipette aide and was lowered into a fresh 50 ml 
Falcon with another 25 ml EDTA/HBSS to collect the second fraction. The second fraction 
was collected for 15 minutes and once finished; the glass rod was again shaken firmly to 
remove any remaining cells. The collected fractions were stored on ice until all the mice had 
been sacrificed.
When all the samples had been collected they were centrifuged at 3000 x g for 15 
minutes to pellet the cells. The supernatant was very carefully poured off and the cells re­
suspended in 1 ml TRIZOL reagent. The cells/TRIZOL suspension were transferred into a 
nuclease free 1.5 ml micro-centrifuge tube and frozen at -80°C until commencing RNA work 
(see Section 2.11.3).
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Figure 2.13.1: Intestinal epithelial extraction apparatus.
2.13.5 Immunohistochemistrv (IHC)
IHC was performed on formalin-fixed paraffin-embedded mouse intestinal tissue as 
described in [Wilson et al.t 1998]. Sections were cut in series on a microtome at 4 pm 
thickness and stained for Noxa (1:200) (rabbit polyclonal anti-Noxa, Anaspec), p21 (1:900) 
(rabbit polyclonal anti-p21 (M-19) Santa Cruz) and p53 (1:500) (rabbit polyclonal anti-p53 
protein (CMS) Novocastra).
Following de-waxing in xylene and hydration through 100%, 90% and 70% ethanol 
baths, the endogenous peroxidase activity in sections was blocked in buffer (1% H2O2 in 
methanol) for 12 minutes at room temperature (RT). Sections were then washed for 5 
minutes in distilled water. Antigen retrieval was carried out by boiling sections in 10mM citric 
acid buffer (pH 6.0) for 20 minutes in a microwave and then allowing them to cool for a further 
20 minutes. All antibodies were incubated for 2 hours at room temperature followed by a 30 
minute incubation with a horseradish peroxidise (HRP) labelled polymer which is conjugated 
with secondary antibodies (DAKO Envision Rabbit-Primary kit). 10 minute washes were 
carried out between each stage using TBS-Tween (0.05 M Tris-base, 0.15 M NaCI and 0.1%
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Tween 20). Staining was visualised with DAB (10 minutes) and counterstained with Gill’s 
haematoxylin (Vector Laboratories). Sections were dehydrated and clarified in xylene then 
mounted using VectaMount permanent mounting media.
2.13.6 Cell scoring
Normal cells, apoptotic cells and mitotic cells were distinguished based on their 
morphological characteristics (see Section 1.4.5.1 and Figure 2.13.2) and scored based on 
their cell position from the bottom of the crypt [Ijiri and Rotten, 1983]. 50 half crypts were 
counted from each mouse and the data was recorded and analysed using the WinScore 
programme [Roberts, 1996]. Mitotic cells can be differentiated from apoptotic cells by the 
absence of apoptotic bodies and in addition they appear displaced towards the gut lumen 
[Wilson et al., 1998].
Figure 2.13.2: Examples of cell scoring.
A) Base of a colonic crypt, the red arrows show strong immunoreactivity while the orange 
arrows show weak-to-moderate cell staining. B) The same colonic crypt, the red circles 
illustrate the apoptotic cells. C) & E) Photos of mitotic cells (green arrows) and D) Photo of an 
apoptotic cell.
Immunoreactivity for Noxa, p21 and p53 was classified based on signal intensity 
(weak-to-moderate versus strong) and scored using the same counting method as above. 
This approach, while subject to observer bias, has been shown to be both robust and
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reproducible [Wilson et al., 1998]. An equal number of crypts were counted from at least 
three circumferences of intestine to avoid bias where there might be areas of patchy staining.
A slightly different scoring protocol was used for scoring cells on the villi. Rather than 
scoring cells based on their absolute position (as for crypts), the total number of positive cells 
were recorded based on their general location (lower villus, mid-section and villus ‘tip’). This 
was because the villi are much longer than crypts and therefore are more difficult to cross- 
section accurately. 25 villi were scored from each mouse.
2.13.7 B-qalactosidase staining assay
In order to detect expression of p-geo (a fusion protein of p-galactosidase and 
neomycin) in the p21 gene-trapped ES cell line AM0998, a p-galactosidase (P-gal) X-gal 
staining assay was performed. In this assay X-gal (5-bromo-3-indoyl-p-D-galactopyranoside) 
substrate is cleaved by P-geo which has p-galactosidase activity fused to a neomycin 
resistance gene (see Figure 2.13.3) generating a product that when oxidised forms an 
insoluble blue product which can be observed inside cells.
Figure 2.13.3: X-gal reaction
X-gal is cleaved by P-galactosidase into A) galactose and B) 5-bromo-4-chloro-3- 
hydroxyindole. B) Becomes oxidised over time to produce C) 5,5'-dibromo-4,4'-dichloro- 
indigo which is responsible for the blue colour observed. Image was adapted from 
htto://en. wikioedia. orq/wiki/X-oal.
The p-gal staining assay was performed on cells as follows; the old media was 
removed from the tissue culture vessel and the cell monolayer was washed twice with 2 ml
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DPBS and incubated with 2 ml of fixing buffer (see Table 2.13.2 for composition - buffers 
were prepared fresh on the day) for 15 minutes at RT. Following incubation, the fixing buffer 
was removed and the cells were washed twice with DPBS. 4 ml of substrate buffer was 
added to the flask which was then returned to the 370C, tissue culture incubator for at least 
2.5 hours (was routinely left overnight) in order to let the blue colour develop. Once the 
reaction appeared complete, the substrate buffer was removed and the celts were washed 
twice with H20 and the flasks were inverted to dry. The colour (if any) could be photographed 
on a light microscope. The volumes above are suitable for a T25 flask, and should be scaled 
up or down accordingly for other tissue culture vessels.
Table 2.13.2: Composition of (3-Galactosidase assay buffers.
Buffer Composition Source
Fixing buffer 2% glutaraldehyde BDH
In DPBS Sigma-Aldrich
Substrate buffer 3 mM potassium ferrocyanide BDH
3 mM potassium ferricyanide BDH
1 mM magnesium chloride BDH AnalaR
0.5 mg/ml X-Gal Sigma-Aldrich
In DPBS Sigma-Aldrich
2.13.8 Luciferase assay
The Dual-Luciferase® Reporter Assay System from Promega was used to detect 
expression of firefly and Renilla luciferase constructs which had been transfected into 
mammalian cells (See Section 2.9.2.1). Firefly (Photinus pyraiis) luciferase is an enzyme 
which catalyses the oxidation of luciferin to produce oxyluciferin and light, whilst Renilla 
luciferase catalyses the oxidation of coelenterazin to produce coelenteramide and light (see 
Figure 2.13.4). Thus firefly and Renilla (Renilla reniformis, a sea pansy) luciferases utilise 
two distinct chemical pathways which both generate bioluminescence. The dual-luciferase 
reporter assay system exploits these two different biological pathways so that the activities of
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each enzyme can be measured in turn from a single sample. Briefly, cell lysates are first 
examined with LAR II (luciferase assay reagent II) to detect the activity of firefly luciferase. 
Then, once the luminescence had been measured, a second reagent is added and the 
luminescence measured again. The second reagent contains both a quencher (Stop+Glo 
reagent) to stop the luminescence generated by firefly luciferase and the Renilla substrate to 
initiate the second bioluminescence reaction. The protein concentration (to normalise the 
data) is also determined using a micro-Bradford assay (see Section 2.10.1).
The luciferase assay was performed according to a scaled down version of the 
manufacturer’s guidelines as follows; cells in a 48-well plate which had been transfected with 
luciferase constructs at least 24 hours prior had the old media removed and were washed 
with 300 pi of DRBS twice. 150 pi of passive lysis buffer (PLB - diluted 1 in 5 in H20 before 
use) was then added to each well and left to incubate for 10 minutes at RT with agitation (on 
a rocking table). The cell lysates were transferred into 1.5 ml micro-centrifuge tubes (one for 
each well) and centrifuged at maximum speed for 1 minute. The supernatant was transferred 
into a fresh 1.5 ml micro-centrifuge tube and examined for luciferase activity.
MO
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Figure 2.13.4: The firefly and Renilla luciferase bioluminescence reactions.
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Firefly luciferase activity was measured first as follows; 30 |jl of LAR II reagent was 
pipetted into a fresh 1.5 ml micro-centrifuge tube (Eppendorf). To the tube 6 pi of cell lysate 
was added and vortexed for exactly 1 second (without closing the lid) then placed into the 
luminometer and measured. When measuring the luminescence of the samples it was 
important to move at a steady speed to minimise variability. The luminometer (GloMax® 
20/20 Luminometer) was set to have no time delay prior to reading and an integration time of 
10 seconds. Whilst the sample luminescence was being measured 30 pi of the Renilla 
substrate/Stop+Glo reagent was taken up into a pipette tip ready for when the firefly 
luciferase reading was finished. Immediately upon completion of the reading the tube was 
removed from the machine and the second reagent added. This was then vortexed for 
exactly 5 seconds before being returned to the luminometer and measured again. The 
luminescence readings were recorded and the steps repeated for any remaining samples. 
The Renilla substrate/Stop+Glo reagent was prepared fresh on the day by diluting the Renilla 
substrate 1 in 50 into the Stop+Glo reagent.
In order to normalise the results a micro-Bradford assay was then performed in the 
cell lysates - see Section 2.10.1.
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Results
3.1 Investigating cell death in the mouse intestinal 
epithelium
3.1.1 v-irradiation of mice (cRel^'l
3.1.1.1 Immunohistochemistry
To determine whether p21 and Noxa levels reliably indicated a p53 response in the 
gastro-intestinal tract, mice were exposed to an 8 Gy dose of whole body ionising radiation to 
induce DNA damage and serial sections of the colon and small intestine were examined for 
p53, p21 and Noxa by IHC (Figure 3.1.1 & Figure 3.1.2 respectively). We used c-Rel^' mice 
for these studies because these were readily available and according to results from all of our 
available analyses they behaved indistinguishably from wild-type mice. The staining in the 
crypts was then compared to control mice that had not received whole body y-radiation. p53 
and p21 were up-regulated in intestinal cells as a result of whole body y-radiation as shown in 
Figure 3.1.1 and Figure 3.1.2 (and see (Pritchard et al., 1999)). Noxa appeared up-regulated 
as a result of ionising radiation in the colon; however its expression was relatively high 
regardless of irradiation status in the small intestine (see Figure 3.1.3).
p53 and p21-specific antibodies stained the nucleus of cells in a uniform pattern 
across the section, whereas Noxa staining was cytoplasmic, punctuated and often 
heterogenous across different gut circumferences within the section (see Figure 3.1.3). The 
observed pattern of expression is expected since p53 is a transcription factor that acts on 
DNA in the nucleus (Vousden, 2006), and p21 is also localised in the nucleus, where upon 
activation it binds to cyclin dependent kinases (CDKs) and induces cell cycle arrest 
(Coqueret, 2003). However Noxa is found in the cytoplasm of the cells, since it interacts with 
anti-apoptotic protein Mcl-1 at the mitochondrial surface (Willis and Adams, 2005). The 
pattern of dotted staining for Noxa matches that of other mitochondrial proteins such as 
cytochrome c (Payne et al., 2005).
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Figure 3.1.1: Immunoreactivity of p53, p21 and Noxa in mouse colon.
Colon was harvested from c-Ref^ (p53 wild-type) mice 4.5 hours post ± 8 Gy y-irradiation. 
Serial sections were probed with antibodies against p53, p21 and Noxa. Digital photographs 
were taken with x 20 objective. p53 and p21 expression (A, B, C and D) was increased upon 
irradiation, whilst there was no staining for Noxa (E and F) in this series. There was little or 
no staining for p53, p21 or Noxa in the colonic crypts of non-irradiated mice demonstrating 
that the response was dependent on y-radiation.
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Figure 3.1.2: Immunoreactivity of p53, p21 and Noxa in the small intestine.
Small intestine was harvested from c-ReFf' (p53 wild-type) mice 4.5 hours post ± 8 Gy y- 
irradiation. Serial sections were probed with antibodies against p53, p21 and Noxa. Digital 
photographs were taken with x 40 objective. p53, p21 and Noxa all appear to be up-regulated 
in response to ionising radiation, however Noxa staining was inconsistent and non-irradiated 
tissue also shows some areas of very strong staining. See also Figure 3.1.3.
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Figure 3.1.3: Comparison of Noxa staining in c-Ref'' mice.
A) Staining of Noxa in part of an irradiated mouse colon. Noxa staining appeared ubiquitously 
in this section of colon, however other areas were completely unstained (compare with Figure 
3.1.1). B) Noxa staining in non-irradiated small intestine; crypt and villi cells were both 
stained as strongly as irradiated animals (see Figure 3.1.2) despite a lack of stimulus.
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The specificity of the p53 (CMS) (BotchKarev et al., 2001, Midgley et al., 1995) and 
p21 (M-19) antibodies has been well documented (Canman et al., 1995, Chang et al., 2011). 
Relatively little, however, was known about the specificity of Anaspec anti-Noxa antibody.
3.1.1.2 Crypt cell scoring data
Cells in the crypt were scored for apoptosis and immunoreactivity to p53, p21 and 
Noxa in the serial gut sections prepared above. Apoptosis was characteristically high at the 
base of the crypt in both the large and small intestine 4.5 hours after 8 Gy of y-radiation (cell 
positions 0-5). This apoptosis peak was matched in the colon with high immunoreactivity for 
p53, p21 and Noxa. Of these proteins, p21 had the widest response and its up-regulation 
was significant until approximately half way up the crypt (cell position 33 - see Figure 3.1.4). 
In the small intestine only the p53 immunoreactivity matched the apoptosis peak, as p21 and 
Noxa had a more bell shaped distribution peaking at around position 15 (as opposed to 0-5). 
Noxa had a relatively high background in non-irradiated animals (see Figure 3.1.5), whilst p21 
was expressed towards the top (lumen) end of the crypt in non-irradiated mice. This mini­
peak of p21 expression coincided with migrating cells entering phase cell cycle arrest (el- 
Deiry et al., 1995) and was, most likely, associated with differentiation and maturation of 
intestinal cells (Yang et al., 2001).
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Figure 3.1.4: Cell scoring data for the colonic crypts of c-Rel-/- mice.
Apoptosis (top) and immunoreactivity of p53, p21 and Noxa (bottom) in irradiated and non- 
irradiated c-Ref' mouse colon. Apoptosis is significantly induced by whole body irradiation 
(significant up to cell position 12) as is p53, p21 and Noxa expression (significant up to cell 
position 32, 33 and 29 respectively).
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Figure 3.1.5: Cell scoring data for the small intestine of c-Rel-/- mice.
Apoptosis (top) and immunoreactivity of p53, p21 and Noxa (bottom) in irradiated and non- 
irradiated c-RefA mouse small intestine. Apoptosis is significantly induced by whole body 
irradiation (significant up to cell position 17) as is p53, p21 and Noxa expression (significant 
up to cell position 23 (p53), and between 10-20 & 11-19 (p21 & Noxa respectively)).
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3.1.2 Conditionally floxed Mdm2 null mice
3.1.2.1 Immunohistochemistry
To examine whether p53 and its downstream targets p21 and Noxa would be up- 
regulated following loss of Mdm2 (an essential negative-regulator of p53 (Jones et al., 1995)) 
in the small intestine, we took advantage of conditionally floxed Mdm2 null mouse strain: 
Mdm2?0*mox. Activation of Cre recombinase upon addition of BNF (|3-naphthoflavone) to these 
animals leads to conditional knockout of Mdm2 only in the small intestine (and liver). For 
these experiments, /Wd/772ftox/flox and wild-type mice were both administered with 1 x 80 mg/kg 
of BNF by gavage. Serial sections of small intestine from both groups were stained for p53, 
p21 and Noxa at day 1 and day 2 following treatment (see Figure 3.1.6).
p53 was strongly expressed in the crypt compartment of the small intestine at 24 
hours following loss of Mdm2, but less so at 48 hours. Indeed, p53 levels had returned to 
approximately wild-type levels in the crypt cells by day two. p21 up-regulation was less 
obvious in this system, since p21 staining appeared in both wild-type and Mdm2flox/ftox animals 
and background staining was generally high. Nonetheless p21 staining did appear to be 
more intense on day 1 following knockout of Mdm2. Noxa expression appeared to be up- 
regulated as a result of the gavage treatment itself, rather then as a consequence of loss of 
Mdm2 and the subsequent up-regulation of tumour suppressor gene p53, since all day 1 
sections stained equally strongly for Noxa regardless of genotype.
Interestingly, p53 protein up-regulation was not limited just to cells within the crypts. 
Following conditional knockdown of Mdm2, p53 was also up-regulated in epithelial cells on 
the villi, an observation that has been previously reported (see Figure 3.1.7. and (Valentin- 
Vega et al., 2008)). The observed p53 expression pattern on the villi was only present in 
MQfm2flox/flox animals and was thought to be genuine, not an artefact or a consequence of the 
migration of crypt cells onto the villus. We thought this for several reasons; the staining 
occurred in the nucleus of the cells as expected for a transcription factor such as p53 and 
therefore the pattern of staining appeared specific. In this experiment the first time point was 
24 hours which does not allow sufficient time for the whole intestinal gut epitheiia to turnover 
(typically takes 2-7 days (Brittan and Wright, 2004)), therefore the crypt-to-villus migration of
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cells can not account for all of the p53 positive cells - which occurred along the entire length 
of the villi (not just at the base or crypt-villus shoulder). Perhaps most convincingly, p21, a 
downstream target gene of p53, was also up-regulated on the villi of the Mdm2ilo^ox animals 
but not in wild-type animals. The up-regulation of p21 in cells on the villi was unambiguous 
since background staining was low and, unlike the cells within the crypt region, p21 positive 
cells rarely occurred on the villi of wild-type animals. p21 expression along the length of the 
villus indicated that not only was p53 present in cells on the villus, but that it was actively 
transcribing at least one of its downstream target genes - p21. Despite p53 up-regulation, 
however, there was still no apoptosis observed in cells on the villi
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Figure 3.1.6: Immunohistochemical analysis of time course following administration of 
p-naphthoflavone (BNF) in the small intestine of wild-type & Mdm2flox/flox mice.
Mdm2 conditionally null mice and wild-type mice both received 1 x 80 mg/kg of BNF by gavage on day 
0. Staining for p53, p21 and Noxa was carried out on serial sections 24 and 48 hrs following treatment. 
Photos were taken at x 40 magnification. p53 was very strongly expressed on day 1 but less so on day 
2. p21 appeared up-regulated in all animals and time points, though perhaps the staining was more 
intense on day 1 (see Figure 3.1.10). Noxa expression was patchy and very strong in some sections (I 
& J), but was independent of Mdm2 status.
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Figure 3.1.7: Immunohistochemical analysis of p53 expression on villi.
IHC using p53-specific antibody of a conditionally floxed Mdm2 null mouse small intestine 24 
hours post administration of 1 x 80 mg/kg BNF by gavage. Blue arrows indicate p53 positive 
cells. Since only 24 hours had passed from the administration of BNF, crypt to villus cell 
migration does not account for the presence of these p53 positive cells on the villi.
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3.1.2.2 Crypt cell scoring data
Cell scoring was performed as described in Section 2.13.6 for the experiment 
described above in order to quantify the IHC results. There was an unambiguous marked 
increase in both apoptotic and p53 levels 24 hours after loss of Mdm2, which had returned to 
basal levels by 48 hours (see Figure 3.1.8). The apoptosis level peaked at the base of the 
crypt, with p53 expression peaking further along from the base of the crypt at cell position 16. 
p53 up-regulation was coincident with the expression peak of p21 (also at approximately cell 
position 16 - see Figure 3.1.9), although the interpretation of p21 expression was less clear 
since there was much higher background staining present (also seen in IHC photos see 
Figure 3.1.6). This uncertainty was resolved when only the very strong staining levels were 
compared (see Figure 3.1.10). p21 was clearly up-regulated in a similar manner to p53 and 
the background was completely eliminated. There was no difference in Noxa expression 
between wild-type and floxed mice even when only strong immunoreactivity was compared. 
In addition, high background staining for Noxa made interpreting results quite difficult. Noxa 
up-regulation appeared instead to be temporally regulated, with expression on day 1 being 
considerably higher than that observed on day 2 in both wild-type and floxed animals. This 
may be a side effect of the gavage technique or an indication of a problem with the specificity 
of the antibody, which as discussed previously was unknown.
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Figure 3.1.8: Crypt cell scoring data for apoptosis and p53
Apoptosis (top) and p53 (bottom) levels on day 1 and day 2 after administration of 1 x 80 
mg/kg BNF by gavage to either conditionally floxed Mdm2 null or wild-type mice. Floxed day 
1 mice have an increased apoptotic response (significant up to cell position 21) and increased 
p53 expression (significant up to cell position 29).
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Figure 3.1.9: Crypt cell scoring data for p21 and Noxa.
p21 (top) and Noxa (bottom) protein levels on day 1 and day 2 after administration of 1 x 80 
mg/kg of BNF by gavage to either conditionally floxed Mdm2 null or wild-type mice. p21 
protein levels on day 1 only appeared marginally increased following knockout of Mdm2 (high 
background staining made analysis difficult). Noxa expression appears to be independent of 
Mdm2 status, but depended on time from treatment by gavage.
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Figure 3.1.10: Crypts cell scoring data of strong staining only for p21 and Noxa.
Examination of strong staining only for p21 (top) and Noxa (bottom) on day 1 and day 2 after 
administration of 1 x 80 mg/kg BNF by gas/age to either conditionally floxed Mdm2 null or wild- 
type mice. Strong immunoreactivity only occurs in floxed animals 24 hours after Mdm2 loss 
for p21, eliminating the background when weak-to-moderate and very strong staining were 
pooled together. Noxa may be reacting to Mdm2 loss as the peak for floxed day 1 appears 
considerably higher than wild-type day 1 but the back ground is still very high (note the scale 
on the Y axis).
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3.1.2.3 Villus cell counting data
In order to quantify the unusual cell staining observed on the villi for p53 and p21 
proteins, positive ceils were counted and compared for the different treatments as described 
in Section 2.13.6. Whilst p53 or p21 positive cells were rarely observed in wild-type animals 
(average 0-2 positive cells per villi), they were frequently seen in Mdm2n°mm animals 
(average 8-15 positive cells per villi) as shown in Figure 3.1.11. This was only statistically 
significant for p21 staining on day 1 (p-value = 0.006), because by day two p21 levels 
returned to wild-type levels. Presumably, the p53 staining was not significant due to the wide 
variability in cell count data. For example; the total number of p53 positive cells on day 1 in 
each floxed animal was 117, 278 and 718 compared with the three individual wild-type 
animals which was 0, 0 & 1 (p-value = 0.094). The observed variability could be a problem 
with the nature of scoring villi because getting a full cross section of the entire length of any 
one villi is extremely difficult and therefore quite often only part of a villus was scored. This 
may inadvertently lead to some bias in scoring, although since p21 staining was consistent 
and statistically significant it may also be a problem with p53 antibody optimisation. 
Regardless, whilst p53 immunoreactivity on the villi was not statistically significant there was 
still an obvious trend which requires further investigation, especially since, despite p53 up- 
regulation there was still no apoptosis observed on the villi.
Noxa immunoreactivity was also scored on the villi and compared for the different 
treatments (see Figure 3.1.11). Noxa positive cells appeared across all treatment groups, 
however there was significantly more staining on day one compared with day two (p-value = 
0.001). This villus scoring data concurs with the previous IHC and crypt scoring data, 
showing that Noxa staining appears higher as a result of administrating BNF rather than 
because of the knockout of Mdm2. Noxa generally appears to be an unreliable reporter of 
p53 apoptotic activity, since it is often up-regulated without stimulus and its up-regulation 
does not always lead to apoptosis.
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p53 p21 noxa
Figure 3.1.11: Villi cell scoring data in conditionally floxed Mdm2 null mice.
Bar chart plots of p53, p21 and Noxa immunoreactivity on the villus on day 1 and day 2 after 
administration of 1 x 80 mg/kg BNF by gavage to either conditionally floxed Mdm2 null or wild- 
type mice. p53 and p21 levels both increase following knockout of Mdm2 but start to 
decrease again by 48 hours. Noxa levels appear unaffected by knockout of Mdm2 but 
instead appear to be a side effect of treatment by gavage. 25 villi were scored from each 
animal, 3 animals per group the error bars are the SEM.
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3.1.3 v-irradiation of conditionally floxed Mdm2 null mice
As demonstrated in the above section, using the conditionally floxed Mdm2 null 
system, it was possible to induce p53 expression in cells on the villus. These p53 positive 
cells were able to up-reguiate p21] a downstream target gene of p53 involved in the cell cycle 
arrest response to genotoxic stress, but still appeared unable to undergo apoptosis. The 
absence of an apoptotic response in villi cells has been well documented (Grossmann et al., 
2002, Marshman et al., 2001, Watson and Pritchard, 2000); however previously it could have 
been argued that this was due merely to lack of p53 up-regulation. Obviously this was not 
entirely the case, since now even with p53 present on the villi there was still no apoptosis 
observed. We thought to try and induce apoptosis in these p53 positive cells on the villi by 
adding an additional stimulus in the form of whole body ionising radiation. Would the 
additional genotoxic stress signal finally induce apoptosis in cells on villi? We attempted to 
address this question with the experiment described next.
BNF was administered to 6 Wild-type and 6 Mdm2noxmox mice on day 0. The dosing 
system was slightly different to the previous experiment, here the mice received 3 x 80 mg/kg 
of BNF by three IP injections (given at 9am, 12pm and 5pm) and at 12pm mice also received 
an additional 80 mg/kg of BNF by gavage. This more intense dosing plan was used to ensure 
maximum induction of the Cre-recombinase gene and hence better knockout of Mdm2. In the 
morning of day 1, 3 Wild-type and 3 Mdm2f,ox/f,ox mice were each exposed to 14 Gy of whole 
body ionising radiation. In the afternoon, 6 hours post-irradiation, all the animals were 
sacrificed and the small intestine was taken for IHC and cell scoring analysis of the crypts and 
villus which is described next.
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3.1.3.1 Crypt cell scoring data
Cells in the crypt were scored for apoptosis and immunoreactivity to p53 and p21 for 
the experiment described above. Apoptosis was characteristically high at the base of the 
crypt (up to cell position 9) for the ‘flexed’, ‘floxed + 14 Gy' and the ‘wild-type + 14 Gy' 
treatment groups (see Figure 3.1.12). Apoptosis was induced to similar levels between these 
three treatment groups which demonstrated that knockout of Mdm2 alone or treatment with 
whole body y-irradiation alone was sufficient to induce a full apoptotic response. On the other 
hand, mitosis was only observed in the unstressed ‘wild-type’ treatment group as might be 
expected when p53 is up-regulated (Merritt et al., 1997, Pritchard et al., 1998). In 
concurrence with this observation, immunoreactivity for p53 was high at the base of the crypt 
for the ‘floxed’, ‘floxed + 14 Gy’ and the ‘wild-type + 14 Gy’ treatment groups but not in the 
‘wild-type’ control group as shown in Figure 3.1.13. Unlike the apoptotic levels, however, 
(which remained similar regardless of the stress stimulus) p53 staining was more intense and 
occurred further up the crypt in the ‘floxed’ and 'floxed +14 Gy’ treatment groups when 
compared to the ‘wild-type + 14 Gy’ treatment group. The increased levels of p53 expression 
in the Mdm2n°mo* mice was most striking when only very strong staining was analysed (see 
Figure 3.1.13 - bottom panel). The ‘wild-type + 14 Gy’ treatment group had negligible p53 
‘strong’ staining (comparable to ‘wild-type’ treatment group) whilst the ‘floxed’ and ‘floxed + 14 
Gy’ treatment groups had significantly increased p53 ‘strong’ straining (p53 up-regulation was 
significant up to cell positions 12 and 18 for ‘floxed’ and ‘floxed + 14 Gy’ respectitively).
The increased levels and wider range of p53 expression in the Mdm2flox/flox mice, with 
whole body ionising radiation treatment alone, was not completely unexpected since it is well 
documented that p53 up-regulation in response to ionising radiation is limited to the 
proliferative compartment of the crypt (Merritt et al., 1994, Pritchard et al., 1999). The 
conditional knockout of Mdm2, however, relied upon successful activation of Cre- 
recombinase and hence on delivery of BNF which was therefore not limited to a particular 
cellular compartment. Thus p53 expression could (and did) occur further up the crypt and 
indeed even on the villus (discussed in Section 3.1.3.2). The up-regulation of p21 is 
examined next.
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In accordance with our previous observations p21 expression appeared normally 
distributed with a bell shaped curve in the ‘floxed’, ‘floxed + 14 Gy’ and the ‘wild-type + 14 Gy’ 
treatment groups (see Figure 3.1,14). The peak of these expression curves was around cell 
position 9-10 for all three treatment groups. There were no statistically significant differences 
between these curves, nor did p21 staining appear more intense for any particular treatment. 
This raised some interesting questions since the observed increase in p53 expression in the 
floxed animals was not matched with either an increase in apoptosis or p21 expression. 
Perhaps this was due to the fact that p21 expression was already very high (85% at the peak 
of the curve) and therefore p21 could not physically be expressed any more then it already 
was. These results would also indicate that despite p53 not being induced as strongly in the 
wild-type mice when exposed to irradiation, the p53 present was sufficient to produce all the 
normal physiological responses - or rather extra p53 does not contribute any additional 
responses, (at least not in the crypt).
One last observation was the characteristic mini-peak of p21 expression towards the 
crypt-villus boarder (seen also in Figure 3.1.5 & Figure 3.1.9), observed in the control group 
(wild-type mice which had been administered with BNF but had not been exposed to y- 
irradiation). As discussed previously this p21 mini-peak was in part a result of exit of cells 
from the proliferative compartment and also of normal differentiation signals (Yang et al., 
2001, el-Deiry et al., 1995). The expression of p53 and p21 was also examined on the villi.
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Apoptosis
— Floxed +14 Gy
— Floxed
— Wild-type + 14 Gy
Wild-type
Cell position from base of crypt
Mitosis
— Floxed +14 Gy
2.5 -
— Floxed
— Wild-type + 14 Gy
— Wild-type1.5 -
0.5 -
Cell position from base of crypt
Figure 3.1.12: Cell scoring data for apoptosis and mitosis.
Apoptosis (top) and mitosis (bottom) levels were examined in the small intestine of 24 hours 
post induction of Cre-recombinase in either conditionally floxed Mdm2 null or wild-type mice ± 
14 Gy of ionising irradiation. Apoptosis is characteristically high at the base of the crypt in 
both groups of conditionally floxed Mdm2 null animals and in the irradiated wild-type control 
group (significant up to position 9). There were no statistically significant differences between 
the apoptotic rates in these animals. As expected only wild-type non-irradiated animals had 
cells undergoing mitosis. Cre-recombinase was induced by administrating 3 x 80 mg/kg of 
BNF by IP injections plus 1 x 80 mg/kg of BNF by gavage.
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p53
— Floxed + 14 Gy
— Floxed
— Wild-type + 14 Gy
— Wild-type_______
E 40 -
(/) 30-
V isj3 rfi np' rfe rp> ntjL' n^>
Cell position from base of crypt
p53 - strong staining only
— Floxed + 14 Gy
— Floxed
— Wild-type + 14 Gy
— Wild-type_______
Cell position from base of crypt
Figure 3.1.13: Cell scoring data for p53.
Comparison between all staining (top) and only very strong staining (bottom) of p53 in the small 
intestine, 24 hours post induction of Cre-recombinase in either conditionally floxed Mdm2 null or wild- 
type mice ± 14 Gy of ionising irradiation (sacrificed 6 hours later). Up-regulation of p53 was significant 
up to cell position 22, 25 & 14 for floxed + 14 Gy, floxed & wild-type + 14 Gy treatment groups 
respectively - with the strongest and widest responses from the floxed animal groups. Cre-recombinase 
was induced by administrating 3 x 80 mg/kg of BNF by IP injections plus 1 x 80 mg/kg of BNF by 
gavage.
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— Floxed + 14 Gy
— Floxed
— Wild-type + 14 Gy
— Wild-type_______
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p21 - strong staining only
— Floxed + 14 Gy
— Floxed
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— Wild-type_______
? 25 -
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Cell position from base of crypt
Figure 3.1.14: Cell scoring data for p21.
Comparison between all staining (top) and only very strong staining (bottom) of p21 in the small 
intestine, 24 hours post induction of Cre-recombinase in either conditionally floxed Mdm2 null or wild- 
type mice ± 14 Gy of ionising irradiation (sacrificed 6 hours later). Up-regulation of p21 occurred in a 
bell-shaped distribution which peaked at cell position 9-10 for both the floxed groups and the wild-type + 
14 Gy control group. There were no significant differences between these groups. The non-irradiated 
wild-type group had the characteristic mini-peak at cell position 13 towards the crypt-villus shoulder. 
Cre-recombinase was induced by administrating 3 x 80 mg/kg of BNF by IP injections plus 1 x 80 mg/kg 
of BNF by gavage.
179
3.1.3.2 Villus cell counting data
To investigate the effect of whole body y-irradiation, as an additional stress, on p53 
and p21 immunoreactivity on the villi, positive cells were counted and compared between 
wild-type and Mdm2fl05C/fl0X animals. As observed with our previous experiment, there were 
relatively few p53 or p21 positive cells observed in wild-type mice (average 0-1 positive cell 
per villi), whilst Mdm2*oxm°* mice frequently had p53 and p21 positive cells (average 18-25 
positive cells per villi) (see Figure 3.1.15). These differences were statistically significant for 
both p53 and p21 (p-values = < 0.001), even though there was considerable variability in cell 
scoring counts. One animal in particular seemed to contribute to the very wide error bars in 
the ‘Floxed + 14 Gy’ treatment group, since the IHC staining pattern observed was clearly 
uneven across the gut circumference. In this outlier the crypts were stained very strongly, 
whilst the villi were stained only very faintly. This may have also been a technical problem, 
perhaps due to the samples drying out during IHC or the section not being completely de­
waxed when IHC was commenced. Regardless of these problems, the results still 
demonstrated that p53 and p21 were up-regulated in this animal.
When the irradiation status was taken into consideration, there did not appear to be 
any additional up-regulation of p53 or its downstream target p21 on the villi in the Mdm!^omm 
mice. In other words, the additional DNA damage did not induce any extra p53 protein. This 
may not be completely unexpected since p53 protein is not normally up-regulated on the villi 
in response to genotoxic stress (Merritt et al., 1994, Pritchard et al., 1998, Leibowitz et al., 
2011). We were very interested, however, in whether the cells on the villi which were 
expressing p53 were then more prone to undergoing apoptosis. No convincing apoptosis was 
observed along the length of the villi, even when the animals were exposed to 14 Gy of y- 
irradiation. Apoptosis was defined by the characteristic appearance of cell shrinkage, 
membrane blebbing and the formation of nuclear bodies (Kerr et al., 1972). During the 
scoring of villi for this thesis no cells on the villi have ever completely matched this 
description, although some cells displayed some of the phenotypic features of apoptosis. For 
example there were occasional cells which were simply missing nuclei, or they had darkly 
stained circular bodies within their cytoplasm (nucleus was intact) or there were cell sized 
gaps in the epithelial lining of the villi. The occasional apoptotic cell on the villus tip could be
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explained by the normal physiological process of ceil shedding. Apoptosis was probably not 
more commonly observed on the villus tip purely because the likelihood of getting an entire 
cross section of a single villus, all the way to the ‘real’ villus tip, was relatively small 
(Marshman et al., 2001). The occasional apoptotic cell near the crypt-villus join region could 
perhaps be explained by an awkward cross section of a crypt. Only 5 cells were potentially 
apoptotic in the middle of a villus for all the animals examined in both wild-type {1 ‘cell’) and 
floxed mice (4 ‘cells’). None of these ‘apparently apoptotic’ cells appeared to entirely fit the 
profile of an apoptotic cell. Therefore, since none of these cells completely matched our 
definition of an apoptotic cell and since there were so few of them in both the wild-type and 
floxed animals, we concluded that there was no apoptosis along the length of the villi - even 
with the additional stress stimulus.
The immunoreactivity for p53 and p21 on the villi was then compared between the 
two conditionally floxed Mdm2 null experiments since a different BNF treatment regime was 
used for each. As shown in Figure 3.1.16, higher p53 and p21 cell positivity was observed 
following the more intense BNF dosing protocol. This was statistically significant for p21 
between the ‘floxed day T and ‘floxed’ treatment groups (p-value = 0.012). Therefore, in 
order to achieve maximum induction of Cre-recombinase and hence better knockout of Mdm2 
and up-regulation of p53/p21, the higher dose of BNF was chosen for any future experiments.
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Figure 3.1.15: Villi cell scoring data for p53 and p21.
Bar chart plots of p53 and p21 immunoreactivity on the villus, 24 hours post induction of Cre- 
recombinase in either conditionally floxed Mdm2 null or wild-type mice ± 14 Gy of ionising 
irradiation (sacrificed 6 hours later). *One animal in the “Floxed + 14 Gy” group displayed a 
very strong staining in the crypt region but did not stain very well in the villus region, therefore 
results with and without this outlier were included for comparison. p53 and p21 protein levels 
increase following Mdm2 knockout. Additional treatment with 14 Gy ionising radiation does 
not appear to increase the number of positive cells. Cre-recombinase was induced by 
administrating 3 x 80 mg/kg of BNF by IP injections plus 1 x 80 mg/kg of BNF by gavage. 25 
villi were scored from each animal, 3 animals per group (with the exception noted above) the 
error bars are the SEM.
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Wild- Wild- Floxed Floxed Wild- Wild- Floxed Floxed Floxed + 
type day type day day 1 day 2 type type + +14 Gy 14 Gy*
12 14 Gy
<-----------------------------------------------------------------------► ◄------------------------------------------------------------------------------------ ►
1 x 80 mg/kg by gavage 3 x 80 mg/kg by IP injection
+ 1 x 80 mg/kg by gavage
Figure 3.1.16: Comparison of p53 and p21 positivity on the villi.
Wild-type animals (regardless of irradiation status) have relatively low staining for p21 and 
p53 (1 or 2 positive cells per villi) whilst conditionally floxed mdm2 null animals have relatively 
high staining for p21 and p53 (up to 25 positive cells per villi). *One animal from the ‘‘Floxed 
+ 14 Gy” group was obviously less intensely stained than the others so results with and 
without this animal were included for comparison. The stronger BNF dosing regime appears 
to induce higher cell staining positivity. 25 villi were scored from each animal, 3 animals per 
group (with the exception noted above) the error bars are the SEM.
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3.1.4 Quality control of RNA samples extracted from epithelial cells
In order to investigate the differences in p53 up-regulation and activation along the 
crypt-villus axis in mice, an RNA expression array analysis experiment was designed (see 
Figure 3.1.17). The RNA was collected for micro-array analysis as follows; on day 0, six wild- 
type mice and three Mdm2flox/flox mice were each administered with high dose of BNF (see 
Section 3.1.3.2). In the morning of day 1, three of the wild-type mice were exposed to 14 Gy 
of y-irradiation and then in the afternoon, 6 hours post-irradiation all the animals were 
sacrificed. Epithelial extractions were performed on the small intestine (as described in 
Section 2.13.4) which provided a “villus enriched” sample and "crypt enriched” sample from 
which the RNA was extracted (see Section 2.11.3).
+BNF +BNF +m3y +BNF 
Wild-type Wild-type Mdm2f,0X/fl0X
/ \ / \ / \
Crypt Villus Crypt Villus Crypt Villus
Figure 3.1.17: Schematic diagram of RNA expression array experiment
See text for further details
Prior to sending this RNA for micro-array analysis, it was necessary to first check the 
purity and quality of the RNA and to check whether the crypt/villus enrichment process was 
efficient. In the first instance, the 260/280 ratio of the RNA was examined (results in Table
3.1.1) and a small (200 - 500 ng) aliquot of the RNA was run on an agarose gel (see Figure 
3.1.18) to assess the purity and quality of the RNA isolated. From the UV spectrophotometer 
analysis (shown in Table 3.1.1) the RNA quality and purity appeared good since the OD 
260/280 and 260/230 ratios were around 2.0 for the majority of samples. The quality of the 
RNA samples was then further examined by agarose gel electrophoresis. RNA quality was 
assessed based on the presence and ratio of the two rRNA subunit fragments, 28S and 18S 
(which should appear as two sharp bands at a - 2:1 ratio in un-degraded RNA - see Section
2.4.2) . In the RNA samples examined here there was a shift in the 2:1 ratio towards 1:1 (see 
Figure 3.1.18) which is indicative of partial degradation. One possible explanation for the
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slight RNA degradation observed might be that, due to the tedious nature of the tissue 
collection protocol, the extracted cells were not placed immediately into TRIZOL reagent (an 
RNase inhibitor) and hence there was a relatively long delay before RNA degradation was 
prevented. Part of the delay was because of the epithelial extraction protocol itseif (see 
Section 2.13.4) during which two cellular fractions were collected from whole gut by 
incubation in buffer with gentle agitation for 15 minutes (30 minutes in total). RNA, however, 
would begin to degrade from the moment the animal was sacrificed thus RNases would have 
the opportunity to degrade the samples during cell collection. On top of this, because of 
space limitations, only two animals could be processed at a time which meant that between 
the first and last animal 2-3 hours would have elapsed. This unavoidable delay presented a 
challenge when attempting to preserve the integrity of the RNA and hence these RNA 
samples can not be expected to appear as perfect as RNA extracted following other 
protocols, such as RNA extracted from whole gut tissue preserved in RNA/afer reagent for 
example.
On a more optimistic note the RNA samples were not contaminated with genomic 
DNA (which would appear as a high molecular weight smear on the agarose gel), nor was 
there any evidence of complete degradation of the RNA samples present (see Figure 3.1.18). 
If the RNA samples were completely degraded the two subunit bands would appear as a 
smear (if present at all) and there would also be an additional low molecular weight smear on 
the agarose gel. Therefore, the RNA was considered of good enough quality to continue with 
the validation experiment which is described next.
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Table 3,1.1: RNA samples extracted for micro-array analysis.
Sample ID identifies the mouse genotype, flox = Mdm2flox/f,ox mouse, WT = wild-type, the 
animal number (1-6) and the extraction fraction V = mostly villus & C = mostly crypt cells. 
High quality RNA should have an OD 260/280 ratio of 1.8 - 2.0 and an OD 260/230 ratio of 
1.8 or greater. Most of the RNA samples in this table meet those standards.
Sample ID ng/pl 260/280 260/230 Additional information
Flox1_V 929.16 2.04 1.34 3 x Mdm2T,0X/T,0X mice
Flox1_C 1089.54 2.03 1.84 Day 0 = administered with
Flox2_V 2089.94 1.98 2.02 3 x 80 mg/kg BNF by IP injection
Flox2_C 1436.37 1.98 1.59 + 1 x 80 mg/kg BNF by gavage
Flox3_V 1020.31 2.02 1.83 Sacrificed day 1
Flox3_C 2149.62 2.01 2.03
WT1_y 1188.85 2.03 1.87 3 x Wild-type mice
WT1_C 1818.34 2.00 1.93 Day 0 = administered with
WT2V 1370.45 2.02 2.06 3 x 80 mg/kg BNF by IP injection
WT2_C 1927.61 2.02 2.00 + 1 x 80 mg/kg BNF by gavage
WT3_V 1094.12 2.04 1.96 Sacrificed day 1
WT3_C 317.17 2.00 1.77
WT4V 1189.52 2.03 1.9 3 x Wild-type mice
WT4_C 1499.88 2.03 2,05 Day 0 = administered with
WT5V 304.73 2.00 1.23 3 x 80 mg/kg BNF by IP injection
WT5_C 843.65 2.04 1.97 + 1 x 80 mg/kg BNF by gavage
WT6_V 2124.99 2.01 1.95 Day 1 = exposed to 14 Gy y-radiation
WT6_C 1702.98 2.01 1.63 Sacrificed 6 hours later
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Figure 3.1.18: Agarose gel electrophoresis of RNA samples extracted for micro-array 
analysis.
RNA samples (200 - 500 ng) were run on a 1% agarose gel initially for 1 hour at 70 V (top) 
then permitted to run for longer (bottom). The RNA samples in this gel do not appear to be of 
the highest quality since the two ribosomal subunit fragments do not appear at an ~ 2:1 ratio 
and the bands appear a little fuzzy. However there is no genomic DNA contamination and it 
was unreasonable to expect that a very high quality RNA would be isolated due to the nature 
of the extraction process. Since the two bands are still clearly present in all the RNA samples 
and there are no low molecular weight smears (which would indicate mass degradation), the 
RNA quality was assessed as good enough for proposed experiments.
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3.1.5 Validation of crvot versus villus enrichment by QRTPCR
QRTPCR was performed on the RNA samples extracted for micro-array analysis to 
assess how efficient the enrichment for crypt/villus cells had been. To examine this, 
QRTPCR was performed for a crypt specific gene (Lgr5), a villus specific gene (Max) and a 
house-keeping gene to normalise the data (Hprtl) - see Appendix C.1. I performed the 
QRTPCR reactions; however all the analysis of data, including the figures was kindly 
performed by Dr Bryony Lloyd (Applied Cancer Biology Research Group, The University of 
Liverpool).
Figure 3.1.19 shows the Hprtl normalised transcript expression levels of Lgr5 (top) or 
Max (bottom) for the ‘mostly villus’ or ‘mostly crypt’ cell fractions from each animal. Analysis 
revealed that the villus specific gene Max was indeed enriched within the villi cell fraction (p- 
value = 0.01) as expected however, surprisingly, stem cell marker gene Lgr5 was also 
enriched in the ‘villus’ cell fraction (p-value = 0.017). Since Lgr5 had previously been 
validated as a crypt specific marker by QRTPCR (von Furstenberg et al., 2010) it seemed 
likely that our enrichment protocol had failed.
In one last attempt to make sense of the contradictory Lgr5 expression levels, a box 
and whisker plot analysis was also performed (Figure 3.1.20). We hypothesised that because 
the ‘Flox’ and ‘WT + 14 Gy’ treatment groups would have incurred p53-mediated cell death 
within the crypt compartment (particularly in the highly proliferative Lgr5 positive stem cells) 
that perhaps the Lgr5 villusxrypt ratio would be higher in these treatment groups (as 
compared to WT). Whilst there was a slight indication that this may be true for the Flox group 
this was not statistically significant. In addition, this explanation does not satisfactorily clarify 
why Lgr5 was not enriched in the intact crypts of the WT group. In conclusion, since these 
RNA samples are not sufficiently enriched for crypt or villus specific genes we decided not to 
examine them further.
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Figure 3.1.19: Transcript expression for Lgr5 and Max (normalised to Hprtl) in the 
small intestine.
Top panel: Lgr5 (stem cell marker gene) transcript expression on the villi and in the crypt 
(normalised to Hprtl) in the 9 animals. All samples were collected 24 hours post 
administration of BNF in Mdm2flox/f,ox (Flox) or WT mice. WT animals 4-6 also received 14 Gy 
of y-irradiation 6 hours pre-harvesting. QRTPCR was performed in triplicate, error bars are 
the SEM. Bottom panel: As above except for Max (villus specific gene marker). Both Lgr5 
and Max appeared enriched in the ‘mostly villus’ cell fraction (p-values = 0.017 & 0.01 
respectively). Performed by Dr Bryony Lloyd.
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Figure 3.1.20: Box and whisker plots of Hprtl normalised Lgr5 expression levels.
Top panel: Box and whisker plot of Hprtl normalised Lgr5 expression levels. Bottom panel: 
Box and whisker plot of Lgr5 villus:crypt ratio. The coloured ovals are the individual data 
points. The outlier animal WT5 was omitted from these analysis. The Flox treatment group 
may have an indication of decreased Lgr5 expression in the crypt as compared to WT, 
although this is not significant. Performed by Dr Bryony Lloyd.
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3.2 Gene-Trapping
3.2.1 £21
3.2.1.1 Evaluation and selection of gene-trapped ES cell lines
Three p21 gene-trapped ES cel! lines were identified using the search tool (key word 
“p21,r) on the IGTC website (http://www.qenetrap.org/ and see Table 3.2.1). These cell lines 
had been screened and localised to p21 by matching the sequence tag generated by 5’RACE 
to p21 exon/s. 5’RACE is a PCR based technique which enables sequencing of unknown 5’ 
termini from specific cDNA clones obtained from mRNA [Schramm et al., 2000, Methods, 
2005]. Briefly it was employed as follows: RNA was extracted from the ES cells and reverse- 
transcribed into cDNA using an anti-sense primer which was specific to the gene-trapping 
vector (within (3-geo). The enzyme terminal transferase was then used to add on a 
homopoiymeric tail onto the 3’ end of the cDNA clones (upstream of the unknown 5’ DNA 
sequence). PCR was then performed using a universal primer which annealed within the 3’ 
homopoiymeric tail and a second anti-sense primer specific to the gene-trapping vector. The 
resulting PCR fragments were cloned and sequenced to give rise to the sequence tag. 
5’RACE is a useful initial screening method since it simultaneously localises the gene­
trapping vector and demonstrates that it is being transcribed - this does not, however, 
demonstrate that the (3-geo transcript is also translated into a functional protein.
Table 3.2.1: Cell lines targeting p21 available on the IGTC website.
Identification status refers to what information is available on each cell line regarding the 
genomic localisation of the gene-trap vector. Localised data: sequence tag matched to a 
single genomic locus. Transcript data: full-length mRNA transcript for a single genomic locus.
Cell Line ID Identification Status Source Vector
AM0998 Localised & Transcript SIGTR pGTOIxr
PST004 Localised & Transcript BayGenomics pGTOTMp
YTC584 Localised & Transcript BayGenomics pGTOLxf
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Since all three ES cell lines identified had sequence tags which aligned to exon/s 
within p21 (see Figure 3.2.1), there did not appear to be any distinguishing features, at this 
stage, to select one clone in preference to another. There were difficulties, however, with 
gathering further information on the two ES cell clones which had been generated as part of 
the BayGenomics project. Information was difficult to obtain because the BayGenomics 
Project had closed. AM0998, the cell line generated by SIGTR was therefore selected since 
information regarding this cell line, including vector sequences and growth maintenance 
protocols, was readily available.
Wild-type p21
Exon
Wild-type DNA
ATG
IGTC gene-trapped p21 - sequence tag alignment
AM0998 
Vector pGTCHxr
BayGenomics gene-trapped p21 - sequence tags alignments
PST004 H-............................................... 1
Vector pGTOTMp ■ Tia ■
YTC584 H....... ...........
Vector pGTOLxf ft-geo
KEY
0
Coding Region
Non-Coding Region
Sequence tag
Splice Acceptor
Poly A Signal
Trans-membrane
domain
Vector Integration
AM0998 
Intron 1 •
PST004/YTC584 
Intron 2 WKk
a-M J-geo
Figure 3.2.1: Gene-trapped p21.
Schematic diagram illustrating the wild-type gene structure of p21 and the gene-trapped locus 
of p21 following vector integration. p21 has three exons with the ATG start codon located in 
exon 2. The sequence tag of AM0998, which was generated by 5’RACE aligned with exon 1 
- indicating that the fi-geo had integrated into intron 1. Cell lines PST004 and YTC584 had 
sequence tags which aligned with exons 1 & 2 indicating that in those cell lines the gene-trap 
vectors had integrated within intron 2.
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3.2.1.2 Verification of the identity and functionality of the p21 gene-trapped 
ES cell line AM0998
Upon receipt of the AM0998 ES cell line it was important to verify the genotype and 
test the expression of (3-geo. The genotype was confirmed by using a PCR screen and by 
sequencing the integration sites. The expression of [3-geo was confirmed initially by growing 
the cells under G418 selection (hence neomycin resistant genes must be present) and then 
by testing for expression of [3-gal using an X-gal assay. Expression of [3-gal was also tested 
by western blotting. Testing and confirmation of expression of [3-gal in the cell line was 
important as some 10% of gene-trapped ES cell lines do not show (3-galactosidase activity in 
vivo so pre-screening in vitro can help identify this potential problem [Voss et al., 1998]. 
Following successful identification and confirmation of the expression pattern (p21 is inducible 
following y-irradiation) it would then be appropriate to proceed to use the clone to create 
gene-trapped reporter mice. The PCR screen and sequencing results are described first 
followed by the phenotypic analysis of AM0998 cells.
3.2.1.2.1 PCR screen & sequencing
The sequence tag generated by 5’RACE in the ES cell line AM0998 indicated that the 
targeting vector pGTOIxr had integrated into p21 within the first 4.5 kb intron (see Figure 
3.2.1). A PCR screen was used to help localise pGTOIxr within the 4.5 kb intronic region as 
follows; p21 specific PCR primers were designed approximately every 1 kb along the length 
of the p21 intron 1, in both the forward and reverse directions. These p21 specific primers 
were then paired with vector specific primers (IstPCR and 2ndPCR designed by the SIGTR 
centre) in order to pinpoint the vector’s integration site. PCR was performed on genomic DNA 
isolated from AM0998 ES cells and on wild-type genomic DNA, which acted as a control to 
identify non-specific products. Several screening PCR reactions were performed (see 
Appendix B) until the presence of an AM0998 specific PCR fragment was identified (see 
Figure 3.2.2).
The vector integration site was localised to the fourth kilobase of intron 1 when PCR 
reaction D (from Figure 3.2.2), which used the primer pair2ndPCR & p21ln1+4kbR, produced
193
a PCR fragment of - 200 bp. Additional primers were designed within p21 intron 1 and 
pGTOIxr to confirm the 5’ integration site (see Figure 3.2.3). PCR was performed and the 
AM0998 specific DNA fragments were sent for sequencing.
Sequencing results revealed that the vector pGTOIxr had inserted at a position 4186 
bp into p21 intron 1. There were some minor rearrangements within the integration sites 
which are described next (and see Table 3.2.2). Within the vector there were small 13 & 11 
bp deletions at the 5’ and 3’ ends respectively. In addition to the small deletions in the vector 
there was also a small deletion of the p21 intron (10 bp - CCACGCCCGG) at the 3’ insertion 
site. At the 5’ integration site there were 4 bp of random DNA (TTTA) inserted between the 
upstream p21 intronic DNA sequence and downstream vector sequence. There was also a 
duplication of 15 bp of p21 intronic DNA at both the 5’ and 3’ integration sites. No major 
deletions or rearrangements were detected therefore the AM0998 ES cell line appeared to be 
as expected from its sequence tag. Next the AM0998 ES cell line was examined 
phenotypically by (3-galatosidase assay and western blotting to determine the expression of p- 
geo.
Table 3.2.2: DNA sequence of the integration sites of gene-trapping vector pGTOIxr 
into intron 1 of gene p21.
KEY: BLUE TEXT = p21 genomic DNA, GREEN TEXT = random inserted DNA,
PURPLE TEXT = pGTOIxr DNA, * = site where genomic DNA was deleted (CCACGCCCGG)
5’ integration site AGTGCTGGGATTAAAGGCGTGTGCCTTTAatgggaagag
3’ integration site tgtaaaacgaTTAAAGGCGTGTGCCAC*TGTCCAGGGT
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1
ATG
Gene-trapped p21 - AM0998
KEY: ■ Coding Region Non-Coding Region
Primers
2ndPCR & 
p21ln1+1 kbR
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p21ln1+2kbR
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p21ln1+2kbF & 
p21ln1+4kbR
Figure 3.2.2: Confirmation of the identity of the p21 gene-trapped ES cell line AM0998 
by PCR.
The top panel shows a schematic diagram of the wild-type p21 locus versus its gene-trapped 
counterpart. The PCR primers and their locations within p21/vector are shown next, followed 
by a photograph of an agarose gel displaying the results of PCR analyses. PCR reaction D 
using primers 2ndPCR & p21ln1+4kbR produced an AM0998 specific DNA fragment of - 200 
bp - localising the gene-targeting vector to the fourth kilo base of p21 intron 1.
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Figure 3.2.3: Sequencing of gene-trapped p21.
The top panel shows a schematic diagram of the primers designed to identify the 5’ 
integration site. PCR was performed and the reactions were run on an agarose gel (bottom 
panel). AM0998 specific DNA fragments were excised from the agarose gel and sent for 
sequencing.
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3.2.1.2.2 B-aalatosidase & western blotting
The second important task, prior to using the ES cell line AM0998 to generate a 
transgenic mouse was to test expression of the reporter construct - p-geo. Initially this was 
confirmed by growing the cell line in the presence of G418 (150 pg/ml) since only cells which 
had a functional neomycin resistant gene should survive. Next the expression pattern of p- 
geo was examined using a p-galatosidase assay. One aliquot of the AM0998 ES cell line 
was grown on gelatin only plates (without a MEF feeder layer) for several passages to allow 
the ES cells to differentiate. ES cells were allowed to differentiate for several reasons. First, 
there was no obvious benefit in maintaining the ES cells used for screening purposes in an 
undifferentiated state since these cells were only to be harvested for DNA/protein or fixed and 
stained, therefore growing those ES cells on MEF feeder layers would only waste the feeder 
layers. Another consideration was that the presence of feeder layers could make results 
difficult to interpret since they would contaminate the ES cell population and finally there was 
some ambiguity over whether undifferentiated ES cells express/respond to p53 induction 
[Aladjem et al., 1998]. The following experiments were therefore performed on differentiated 
ES cells. Differentiated ES cells were identifiable from undifferentiated cells by characteristic 
changes in morphology, such as loss of smooth cellular edges and better adherence to the 
culture vessel surface (see Figure 3.2.4).
Differentiated AM0998 ES cells (and a differentiated ‘wild-type’ ES cell line B6-C2 - 
described later in this section) were exposed to several doses of y-irradiation (6, 20 & 60 Gy) 
to induce p53 activation and were then fixed and stained using the X-gal assay at several 
time points (8, 24, 36 & 48 hours). A wide range of irradiation doses and time points were 
used in order ensure induction of p53 and sufficient time for production of p-geo. 
Disappointingly however, none of these conditions appeared to produce any positive cells. 
The lack of positive cells was not a fundamental problem with the reagents or staining 
protocol since positive cells could be identified with a LacZ transfected control plate. The 
expression of p-geo was then investigated further using western blotting.
Western blotting was performed on four cell lines AM0998, B6-C2, wild-type MEFs 
and p53 null MEFs. B6-C2 is an ES cell line selected from the laboratory cryostore of 
archived ES cell clones which had been previously cultured and expanded (in 2002) as part of
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other experiments, but which does not contain a p21 targeting event and thus can be used as 
a wild-type control for this screening experiment. Wild-type MEFs were included to act as a 
positive control for p53 induction and antibody reactivity, whilst p53 null MEFs were used to 
identify non-specific p53 antibody binding.
The cell lines either received 6 Gy of ionising radiation or were mock treated. Cells 
were harvested at 24 and 48 hours post-irradiation (to allow enough time for p-gal 
expression). Western blotting was performed to check for expression of p53, p21, p-actin and 
p-gal. It was hoped that this screen would determine whether or not p53 was induced in the 
ES cells, and whether activated p53 was up-regulating p21. If p21 was up-regulated then the 
obvious test would be to see whether or not p-geo could also be detected in the AM0998 ES 
cell line. Unfortunately this screen did not resolve any of the outstanding issues since the 
controls did not respond as expected (p53 null MEFs, which had previously been confirmed 
genetically to contain the p53 targeting event appeared to have a band at c. 53kD - data not 
shown). However, rather than investing more time and effort on these experiments to work 
we instead re-investigated how the ES cell line AM0998 was generated - specifically we 
wanted to determine whether it might be possible for the gene-trapped cells to have a 
functional neomycin gene and yet fail to express p-gal.
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Undifferentiated ES cells Differentiating ES cells
ES cells mock prepared for blastocyst 
Differentiated ES cells injection____________
Figure 3.2.4: Photomicrographs of embryonic stem cells growing in culture and when 
prepared for a mock blastocyst injection.
(A-C) Shows ES cells growing in culture, photos were taken using the x40 objective on a phase contrast 
microscope, however B has had the magnification increased 33% compared to A&C. The different 
colours are a reflection of the colour of the media. A) Undifferentiated ES cells are circular with a shiny 
nimbus around them and smooth edges. B) As ES cells begin to differentiate they lose their shape and 
the edges become scalloped (see top cell just beginning to differentiate (red arrow) vs the bottom cell 
that has very bubbly edges and is therefore more differentiated (yellow arrow)). C) Once completely 
differentiated the ES cell colonies spread outwards and small individual nuclei become visible (dark 
spots in the large colony as indicated by black arrows). D) Shows ES cells which were prepared for a 
mock blastocyst injection. ES cells were trypsinised and then the trypsin was inactivated in 10x the 
amount of media, the ES cells were then photographed. ES cells are small and round whereas feeder 
layers (MEFs) are large and amorphous. ES cells shown here appear to be of the quality required for 
blastocyst injection.
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3.2.1.2.3 The d21 gene-trap vector is integrated upstream of the endogenous ATG
When multiple attempts to detect expression of p-geo in vitro appeared negative we 
investigated why this might be. The initial screening method, 5’RACE, generated a sequence 
tag from the mRNA, hence p~geo was being actively transcribed in the AM0998 p21 gene- 
trapped ES celts. Also, AM0998 cells were resistant to G418 drug selection providing 
evidence that this transcript was being successfully translated into protein. However, despite 
this we could still not detect p-gal activity in vitro. What was happening then to the p-gal 
portion of p-geo? To answer this question we examined the layout of the gene-trapping 
vector pGTOIxr, specifically how were p-gal and neomycin fused together and could this 
explain why AM0998 cells were resistant to G418 but did not display any detectable levels of 
p-gal activity?
We discovered that p-gal and neomycin were fused together in that order and that 
essentially there was no upstream ATG to commence translation for the entire length of the p- 
geo cassette. Within the p-geo cassette there were several in-frame ATG sites which could 
potentially initiate the translation for the latter half of this fused transcript (hence cells were 
still resistant to G418). We had already sequenced the 5’ integration site therefore we knew 
that an ATG had not been introduced by chance. The first in-frame ATG site excluded the 
first 84 amino acids of the p-gal protein and it would appear that if that ATG site was used 
those first 84 amino acids were essential to p-gal activity. In conclusion the p21 gene-trapped 
ES cell line AM0998 could not be used for our purpose of generating a transgenic reporter 
mouse since it did not express any detectable levels of p-gal and, since this was not the 
endogenous ATG site it was unlikely to provide an authentic report of p21 activation.
At this point, the direction of this project changed from creating gene-trapped mice to 
generating our own DNA targeting constructs and targeting our own ES cells. The plan for 
the DNA targeting constructs was to return to the original concept - a dual fluorescent 
reporter system for p53 activation. However, for completeness an evaluation of the Puma 
gene-trapped ES cell lines is included in the next section.
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3.2.2 Puma - evaluation of gene-trapped ES cell lines
There were eight ES cell lines localised to Puma (Bbc3) available to view on the 
IGTC website see Table 3.2.3 search performed on the IGTC website using the key word 
"Bbc3” http://www.qenetrap.org/)). However upon further investigation none of these ES cell 
lines were suitable for the generation of transgenic mice, for reasons discussed briefly below. 
The TIGM (Texas Institute for Genomic Medicine) ES cell lines did not contain a vector in the 
correct orientation and the ESDB (ES Cells- Mammalian Functional Genomics Centre) cell 
lines used the vector U3NeoSV1 which did not contain a reporter construct [Hicks et al., 
1997],
A further two ES cell lines were identified on the MGI (Mouse Genome Informatics) 
website from Lexicon Genetics 0ST197510 & OST364Q98 (see Figure 3.2.5). These cell 
lines contained a gene-trapping vector with p-geo and a second cassette which was used to 
generate sequence tags by 3’RACE. 3’RACE is essentially the same as 5’RACE (see 
Section 3.2.1.1) except it identifies unknown flanking DMA sequences at the 3' termini. This 
means that 3’RACE can take advantage of the poly A tail present on all mRNAs to anchor its 
universal primer for PCR - rather than synthetically adding a homopolymeric tail as used in 
5’RACE. The sequence tags were analysed by BLAST to confirm the location of the gene­
trapping vector within the Puma locus (intron 2 and intron 3 respectively - downstream of the 
internal ATG site - and see Table 3.2.4). These ES cell lines were deemed suitable to use 
in the generation of transgenic mice, however, at a cost of $9500 (US dollars) per project we 
decided to design and create our own targeting DMA construct.
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Table 3.2.3: Cell lines localised to the Puma locus available to view on the IGTC
website.
Identification status refers to what information is available on each cell line regarding the 
genomic localisation of the gene-trap vector. Localised data: sequence tag matched to a 
single genomic locus.
Cell Line ID Identification Source Vector
Status
IST11193F7HMF1 Localised only TIGM Not specified
1ST 11317F12HMF1 Localised only TIGM Not specified
PST1671-1 Localised only ESDB U3NeoSV1
PST418-1 Localised only ESDB U3NeoSV1
PST418-3 Localised only ESDB U3NeoSV1
PST50-3 Localised only ESDB U3NeoSV1
PST908-3 Localised only ESDB U3NeoSV1
PST953-2 Localised only ESDB U3NeoSV1
Table 3.2.4: The sequence tags of the two Lexicon PUMA gene-trapped ES cell lines.
Red highlight indicates a mismatch, an asterisk * shows a missing base, while bright green 
and grey highlighting illustrate exon 3 and 4 respectively.
Clone Sequence Tag
OST197510
HIHHHHHHIHB?alacaalaa9a,3ca9catclacaccgaccctcaccctggaggg|catg
taca§tctcttcatgggactcctccccttacccHggatcctggagcccca|aaatggagcccaactaH|
gtgcctacacccgcccgggggacgt§ggagactt|gggggcaggacccccticgicttctgacaicctgg
ccagcgcggggga
OST364098 ccctlaccctggagggt§atgtacaatctcttcatgggactcctccccttacccagggatcctggagccc
capaaatgg*gcccaactaggtgcctacacccgcccgggggacgtcggag»ettggggggcaggacccec
tccgccttctgacaccctggccagcgcgggggactttttctgcaccatgtagcatact|ggactgccagc
cttgcccgtcccaggggcaggcaagggatgccactcgagcccgggcag§ctgggtgcactgatggagata
cggacttggggggaccctggcctcccgaaagccagggaagggagggctgaj|MMNUMNNI
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Figure 3.2.5: Gene-trapped Puma.
Schematic diagram of the wild-type gene structure of Puma and the gene-trapped structure of 
Puma in the ES cell lines OST197510 and OST364098. Puma has four exons and the coding 
region starts in exon 2. The gene-trapping vector contains a (3-geo fusion gene with upstream 
splice acceptor (SA) and downstream poly-A signal (pA) for simultaneous selection and report 
of targeted genes. The gene-trapping vector also contains a second cassette which has a 
ubiquitous murine ES cell promoter (such as Pgk - phosphoglycerate kinase) which 
expresses the first exon of Btk (Bruton agammaglobulinemia tyrosine kinase) followed by a 
splice donor site (SD). The second cassette is used to generate sequence tags by 3’RACE. 
Clone OST197510 is inserted into intron 2 whilst OST364098 is inserted into intron 3. There 
are areas of discrepancies between the sequence tags and the genome which were 
examined further in Table 3.2.4.
203
3.3 Generation of DNA targeting constructs
3.3.1 Brief overview
This project aimed to generate four different transgenic mouse strains by homologous 
recombination - also known as gene targeting. These strains were;
• p27-mCherry knock-in reporter
• Puma-E2Crimson knock-in reporter
• Mdm2 P2-mutant
• Mc/m2P1-null
The first stage of gene targeting was to design and create a DNA targeting construct 
for each desired transgenic mouse strain. Each DNA targeting construct was to contain a 
negative selectable marker, a positive selectable marker, a left and right arm of homology and 
the desired mutation (see Figure 3.3.1). Positive and negative selection was used to enrich 
for cells containing the desired recombination event [Mansour et al, 1988] and see Section 
2.9.2.2.4. The arms of homology were to be 4 - 5 kb in length and were made using isogenic 
DNA to improve homologous recombination frequencies [te Riele et al, 1992] and see Section 
1.5.2. The desired mutations were unique to each targeting construct and included variously 
knock-in of fluorescent proteins or more subtle specific point mutations. Completed DNA 
targeting constructs were then used to target undifferentiated embryonic stem (ES) cells (see 
Figure 3.3.2).
Targeting construct
Left arm of homology Right arm of homology
Tk' Yi rv.
Figure 3.3.1: General plan of a DNA targeting construct.
The targeting construct contains a negative selectable marker (thymidine kinase - TK), a left 
and right arm of homology (4 - 5 kb of wild-type genomic DNA) either side of the desired 
mutation (shown here in an orange box with an X) and positive selectable marker (self 
excision neomycin cassette (shown in red with green arrows)).
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Figure 3.3.2: Schematic diagram of gene targeting events.
Following a successful homologous recombination event the desired mutation X (orange box) 
had become incorporated into the genomic DNA of targeted ES cells. The self-excision 
neomycin cassette (shown in red box with green arrows) is then removed by activated Cre- 
recombinase in the first generation (F-,) of the heterozygous mice. Cre-recombinase is up- 
regulated from within the self excision neo cassette by a testis specific promoter (tACE) and 
thus becomes active in the testis of the chimeras. Recombination promoted by the Cre- 
recombinase results in removal of DNA located between the two LoxP sites (green arrows) - 
leaving behind only a single copy of the LoxP site (34 bp of foreign DNA). It is important to 
remove the positive selectable marker to avoid confounding the results that might arise as a 
consequence of a large independent expression cassette being inserted into the gene.
One of the major obstacles in the process of generation of transgenic mice is often 
the creation of the complex DNA targeting constructs. One major reason for this in the 
present project was that DNA targeting vectors contained large pieces of genomic DNA which 
were often repetitive and/or filled with complex secondary structures which made propagating 
the DNA in bacteria difficult and PCR virtually impossible (such as during cloning of the p21 
right arm of homology and the Puma left arm of homology - see Sections 3.3.3.7 and Section
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3.3.4.1). Another reason why generation of large DNA targeting vectors took a relatively long 
time was that there were many steps (see cloning overview in Figure 3.3.4 and Figure 3.3.44) 
which required sequential assembly - if a single cloning step was unsuccessful then it halted 
progression of the construct/project until it was completed (or redesigned to overcome the 
obstacle). Much of the work described in this thesis has consequently been concerned with 
overcoming these difficulties to successfully prepare DNA for targeting of ES cells. This 
results chapter describes how the four gene targeting vectors were finally successfully 
constructed. p2f-mCherry and Puma-E2Crimson are discussed first including the selection of 
fluorescent proteins; followed by Mdm2 P2-mutant and Mdm2 P1-null.
3.3.2 Selecting the optimum fluorescent proteins
Different fluorescent proteins were examined to determine which two would be the 
most appropriate to use in a dual fluorescent reporter system for p53 activation in vivo. The 
small animal imaging system (The FMT 2500™ LX quantitative tomography system - referred 
to as the FMT system) at the University of Liverpool contains two lasers which excite at 635 
nm and 750 nm. Originally, when it was not yet clear which imaging system would become 
available, we had planned to use a monomeric variant of Ds Red, mCherry (excitation peak 
587 nm) to replace one p21 allele and a red-shifted GFP protein, EGFP (excitation peak 488 
nm) to replace Puma [Shaner et al., 2005]. However it became obvious when the FMT 
imaging system was purchased towards the end of this project that we needed to re-evaluate 
those choices, especially for EGFP (since this fluorescent protein would in ail probability not 
be detectable in the FMT system).
Several important factors were considered prior to selecting the fluorescent proteins, 
including the feasibility of swapping proteins part-way through a cloning exercise. The ideal 
pair of fluorescent proteins would have limited toxicity in mammalian cells, be bright enough 
to overcome auto-fluorescence of tissues, have high photostability (for imaging), mature 
quickly and efficiently, have minimal cross-talk between the two proteins and possess two 
distinct emission spectra (to differentiate between the proteins) (reviewed in [Shaner et al., 
2005]). mCherry and EGFP were chosen initially since they appeared to meet these criteria,
206
Results
however once the FMT system was purchased there was an additional criteria to meet; the 
fluorescent proteins selected must have sufficient brightness when excited at 635 nm. On 
this decisive factor EGFP failed completely and mCherry was only capable of emitting at < 
2% of its maximum brightness (however subsequent studies with mCherry expressing cells 
have confirmed that the FMT does detect mCherry in xenografted cells). Therefore, a 
literature review was performed to determine whether other, possibly newer, far-red 
fluorescent proteins could be identified which might meet these requirements.
The far-red fluorescent proteins mKate, TagRFP657, E2Crimson and eqFP670 were 
identified and examined for suitability. The properties of each protein are summarised in 
Table 3.3.1 and their relative brightness is compared in Figure 3.3.3. mKate (and mKate2) is 
a monomeric version of Katushka but is only slightly brighter than mCherry when excited at 
635 nm (1.7 fold) [Shcherbo et al., 2009]. TagRFP657 was developed from mKate and is 
further red-shifted (excitation peak 611 nm) and hence found to be brighter than both 
mCherry and mKate when excited at 635 nm (7.7 fold brighter than mCherry). The 
maturation time of TagRFP657 however, was the longest out of all those examined (125 
minutes) [Morozova et al., 2010] and at the time of this study TagRFP657 was not 
commercially available. eqFP670 is a dimeric far-red shifted fluorescent protein which was 
found to be 4.3 fold brighter then mCherry when excited at 635 nm [Shcherbo et al., 2010]. 
eqFP670 was derived from Katushka-9-5, a variant of Katushka with lower cytotoxicity but 
was also not available commercially. The brightest far-red fluorescent protein in this 
comparison and also with the fastest maturation time (26 minutes) was E2Crimson. 
E2Crimson was 30 fold brighter than mCherry and 3.9 fold brighter then the next brightest 
protein (TagRFP657) when excited at 635 nm [Strack et al., 2009]. E2Crimson is a tetrameric 
protein developed from DSRed-Express2 and is supposedly non-cytotoxic to bacterial and 
mammalian cells [Strack et al., 2009]. One disadvantage of the tetrameric structure of 
E2Crimson is that we could not risk tagging it with a NLS (Nuclear Localisation Signal) since 
this may inadvertently interfere with tetramerisation which might reduce the sensitivity when 
observing single cells [Strack et al., 2009], E2Crimson also had a second bright blue peak 
within its emission spectra - although this should not interfere with detection in whole animals 
using the FMT system. Therefore, because E2Crimson was considerably brighter than all the
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other fluorescent proteins examined, it was deemed the most suitable candidate to replace 
EGFP.
It was decided to keep mCherry as the fluorescent protein for the p21 construct since 
the molecular cloning had already progressed past the point when it would be trivial to change 
plans. Also despite mCherry only able to be excited at < 2% of its maximal efficiency, 
preliminary work by other members of our research group demonstrated that mCherry could 
be detected in vivo (data not shown). However, since the emission spectra of mCherry and 
E2Crimson overlapped it would not be possible to differentiate between them at this stage. 
Although this development was not ideal and would prevent our ultimate aim of simultaneous 
detection of p21 and Puma up-regulation in vivo (for now), the proposed transgenic strains 
(p2f-mCherry and Pi/ma-E2Crimson) are still likely to provide useful tools with which to study 
p53 activation individually (discussed in detail in Section 4.4).
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Figure 3.3.3: Relative brightness of various far-red fluorescent proteins.
Values shown are relative to the brightness (BR) of E2Crimson at either its excitation maxima or to its 
excitation at 635 (the wavelength of the laser in our small animal imager). Top panel: Each data series 
is relative to either BR at the excitation maxima (blue bars) or BR at 635 nm (orange bars). Bottom 
panel: All data is shown relative to BR at maxima. Data was generated using the modest assessment of 
E2Crimson's quantum yield (QY = 0.12). E2Crimson was considerably brighter then all the other far-red 
proteins compared here, including mKate and mCherry, at both the excitation maximums and at 635 nm. 
When excited at 635 nm all of the proteins fluoresce at only a fraction of their potential. See also Table 
3.3.1.
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Results
3.3.3 p21- mCherrv 
3.3.3.1 Cloning strategy
Figure 3.3.4 shows the basic cloning plan for generation of the p27-mCherry and 
Puma-EGFP DNA targeting constructs. This plan relies upon PCR techniques to create the 
initial vectors (vectors 1-3 in Figure 3.3.4) and then on four unique restriction sites which 
would be used assemble the penultimate and ultimate vectors. These unique restriction sites 
would ideally be the same for p27-mCherry and Puma-EGFP (EGFP was later switched to 
E2Crimson - Section 3.3.2) so that some of the vectors and intermediate steps could be 
shared between the two cloning exercises, thus simplify the task of cloning. Whilst this was 
not completely achievable (sequences examined on NEBcutter tool - see Section 2.8.6), 
three suitable enzyme sites were identified as Fsei (GGCCGGCC), Sail (GTCGAC) and Pad 
(TTAATTAA). A further two restriction enzymes were identified that were suitable except for 
the fact that they cut somewhere in the other gene’s arms of homology. These were Asel 
(ATTAAT) for p27-mCherry and Asel (GGCGCGCC) for Puma-EGEP.
The selected restriction enzymes were then allocated to the planned unique 
restriction sites A-D in Figure 3.3.4 as follows; A, B & C were Fsel, Sail and Pad respectively 
which enabled vector 1 (the negative selectable marker) to be shared between the p27- 
mCherry and Puma-EGFP cloning exercises. D was Asel or Asel depending on the gene. 
Fsel/Pacl and Sall/Asel were paired together for the restriction digests since they had 
compatible buffers. Once the restriction enzymes had been chosen the primers for the 
numerous planned PCR reactions were designed and ordered.
There now follows a detailed description in Section 3.3.3 to Section 3.3.4.6 of how 
each component of the targeting vector was generated. As mentioned in the overview, whilst 
undertaking the task of generating multiple DNA targeting constructs we encountered many 
challenges and many modifications to this basic plan had to be made in order to complete the 
vectors. Despite this, the basic strategy outlined below provides an essentially correct 
summary of the planned sequence of events.
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Figure 3.3.4: Basic cloning strategy for the DNA targeting constructs p21-mCherry & 
Puma-EGFP.
Flow diagram of the construction of the targeting constructs. Vectors 1-3 were planned to be 
generated by various PCR techniques including PCR-mediated mutagenesis and fusion PCR. 
The final targeting vector would then be assembled using the unique restriction endonuclease 
sites (shown as letters A-D). A, B & C were Fsel, Sail & Pad respectively whilst D was Asel 
for p21-mCherry orAsd for Puma-EGFP.
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3.3.3.2 Negative selectable marker
A negative selectable marker was included in the design of our DNA targeting 
constructs since, when negative and positive selection are used in combination, they greatly 
enrich for positive clones [Mansour et al., 1988]. The basis for negative selection is that 
integration of a negative selectable marker into cells confers sensitivity to a particular 
treatment. In this project, the viral protein thymidine kinase (TK) was used as the negative 
selectable marker for all four DNA targeting constructs. TK sensitises mammalian cells to 
treatment with the antiviral drug Ganciclovir [Cannon et alM 1999] (see Section 2.9.2.2.4). TK 
was placed at one end of the targeting vectors (outside the arms of homology) so that during 
a targeted homologous recombination event TK would not be incorporated into the genome 
(see Figure 3.3.2). In the case of random recombination however, TK is more likely retained 
in the genome and hence those cells could be eliminated in the presence of Ganciclovir.
Cloning of the negative selectable marker (TK) is described next and an outline of the 
strategy is provided in Figure 3.3.5. The TK cassette containing the TK gene with poly A 
signal under the control of the MCI promoter was obtained from the pKO Scrambler NTKV- 
1902 vector by PCR-mediated mutagenesis (see Section 2.7.2.1) which added 5’ Fsel-Sall 
and 3’ Pad restriction sites for use in subsequent cloning steps. The PCR product was TA- 
cloned into vector pCR2.1 and the recombinant clones were screened for successful insertion 
of the TK fragment by an EcoRI digest (see Figure 3.3.5 - C). 9/10 clones appeared positive 
and two clones (TK1 & TK2) were sent for sequencing. Two clones were sent for sequencing 
because there were mismatches in the sequence alignment for the first clone (TK1). The 
second clone (TK2) also had the same mismatches so in order to confirm whether these 
differences were present in the original template sequence; this region of the parental plasmid 
DNA (pKO Scrambler NTKV-1902) was also sequenced. All three sequences (TK1, TK2 & 
pKO Scrambler NTKV-1902) were in agreement which does not match the published 
sequence. There were 9 mismatches in total (see Appendix D.1) of which 2 caused a 
missense mutation in TK (T133A & T232A), however since these mutations were not caused 
by PCR and the pKO Scrambler NTKV-1902 vector had been used previously in our 
laboratory for a different gene targeting experiment (which had been successful - manuscript 
in preparation) the clones TK1 & TK2 were deemed suitable for use.
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Ar M13-20RV+RE
Amp R
TK fragment amplified 
byPCR
Add on Pad, Sail and Fsel
Fsel Sail Pact
PCR product
B
PCR reaction
TK fragment 
5 2.1 kb 9,
T— <4--------------------------- »- 3-
GENECLEAW
<u
■O
■D
TA clone PCR product 
I Into pCR2.1 vector
TK in pCR2.1
6084 bp
-g TK in pCR2.1 clones 1-10- 
digested with EcoRi
^ 1 2 3 4 5 6 7 8 9 10
Figure 3.3.5: Cloning of the negative selectable marker - thymidine kinase (TK).
A) Flow diagram of the cloning strategy. 5’ Fsel-Sall & 3’ Pad restriction sites were added onto the TK 
fragment by PCR then cloned by TA-cloning into pCR2.1. B) The PCR product was run on an agarose 
gel to confirm it was the correct size (2.1 kb). C) The concentration of the DNA was determined 
following extraction from the previous gel. 10% of the total product was run. D) EcoRI digest of DNA 
extracted from bacterial clones transformed with the TK in pCR2.1 vector. Positive clones should have 
two fragments 2.1 & 3.9 kb in size.
214
Results
3.3,3.3 p21 left arm of homology
The p21 left arm of homology is 4.3 kb in length with the endogenous translational 
initiation codon (ATG) at the 3’ end followed by an inserted nuclear localisation signal (NLS). 
The NLS was added to localise mCherry expression within a cellular compartment to increase 
the local concentration of fluorescent protein and hence increase sensitivity when imaging 
cells [Fujii et al., 1999, Toby etal., 1998, Hadjantonakis etal., 2003].
Prior to successfully generating the p21 left arm of homology we had attempted to 
proceed directly from the BAG clone DNA to the second product (B in Figure 3.3.6), but this 
resulted in an unexpected complication. After sequencing one of these clones (p21NLS3) it 
was discovered that 72 bp were deleted from the region between 3 and 4 kb of p21 intron 1. 
A further 6 clones were sequenced all of which contained the same 72 bp deletion. In 
addition, a second problem emerged in which the incorporation of the NLS signal was not 
always 100% accurate and the primer region was frequently mutated - discussed in more 
detail later in this section. Since sequencing was relatively expensive and time consuming, a 
PCR screen was designed to distinguish the wild-type (811 bp) and mutated (739 bp) DNA 
(see Figure 3.3.7). This PCR reaction proved robust and could be used for PCR from 
bacterial colonies. 32 bacterial colonies were screened in total but none of these appeared to 
be wild-type. At this point it was decided to return to the BAG clone DNA and amplify the p21 
gene fragment in two rounds.
The p21 left arm of homology including the desired modifications (5’ Fsel-Pacl and 3’ 
NLS) was eventually generated by two steps of PCR (see Figure 3.3.6). The initial round of 
PCR amplified the p21 fragment only (no modifications) and used BAG clone bmQ-262p22 as 
a template. BAG clone DNA was used in preference to genomic DNA since the DNA used to 
create the BAG library from which the bmQ-262p22 plasmid was obtained, was derived from 
129SvE\/ mice (and so was isogenic to the AB2.2 ES cells we planned to use for gene 
targeting), but was only 102.6 kb in size (versus 3 x 106 kb) and therefore provided an 
enriched source of the p21 locus. The product from the first round of PCR (A in Figure 3.3.6) 
was TA-cloned into vector pCR-XL-TOPO and recombinant clones were screened for 
insertion of the correct sized product by Mlul/Notl digest (see Figure 3.3.7). 10/10 clones 
appeared positive and one (p21LA2) was sent for sequencing. The sequencing results
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matched the genomic sequence 100% (aligned using BLAST) and so this clone was used as 
the template DNA for the second round of PCR.
The second round of PCR was used to append the desired modifications, a 5’ Fsel- 
Pacl for downstream cloning steps and the 3’ NLS sequence. The template DNA was the 
previously described and sequenced clone p21LA2. The resulting PCR product (B in Figure 
3.3.6) was then cloned into pCR-XL-TOPO and screened first by a Mlul/Notl digest (13/13 
appeared positive - see Figure 3.3.7) and then by the PCR screen described above to 
determine if these clones contained the 72 bp region which had been previously deleted (7/13 
appeared wild-type - see Figure 3.3.7). I sequenced all 7 PCR positive clones using the 
MegaBACE method (see Section 2.7.2.6) at the 5’ and 3’ ends using the primers M13F, 
M13R and p21ln1+4kbF to check for successful incorporation of the restriction enzyme sites 
and the NLS. This screen was performed since previously we had encountered problems 
with the incorporation of these sequences. Of the 7 clones only 1 (p21NLS8b) had both the 5’ 
Fsel-Pacl and 3’ NLS sequences added correctly (the other clones either had confirmed 
mutations or reads were too short to confirm either way). Therefore this clone (p21NLS8b) 
was sent away for complete sequencing. The sequencing results for clone p21NLS8b 
matched the genomic DNA 100% except for a deleted T within the 5’ primer region (not part 
of the Fsel-Pacl region). Since this mutation was at location 16 bp of the p21 left arm of 
homology and therefore would probably not be incorporated into the genome during 
homologous recombination, it was decided that this clone was suitable to use for the next 
cloning stages (fusion PCR reaction with mCherry).
The 5’ oligonucleotide mutation described in clone p21NLS8b was unexpected 
since it was within the 40 bp p21ln1LA-Fw+RE primer region and therefore could only be 
mutated if the primer itself contained a mutation. This high mutation frequency (5/12) issue 
was brought to the attention of Eurofin MWG Operon (who synthesised all primers used 
during this project) and as a result another synthesis of this primer was sent to us for use in 
the next stage of cloning.
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Wild-type p2f
1 ♦
p21ln1LAfw
p21ln1LAfw+REs
Fsel Pad
B------
4 3 kb
ATG
p21 Ex2LArv
I
p21 left arm of homology 
amplified by PCR
<■
ATG
i
p21Ex2LA+NLS
5’ Fsel-Pacl and 3’ NLS added onto 
p21 left arm of homology by PCR
ATG
Figure 3.3.6: Flow diagram for cloning of the p21 left arm of homology.
The 4.3 kb DNA fragment of p21 (immediately upstream of the endogenous ATG site) was 
amplified from the BAC clone bmQ-262p22 by PCR. This product (A) was TA-cloned into 
vector pCR-XL-TOPO and sequenced. Once the correct sequence was confirmed 5’ Fsel- 
Pacl & 3’ NLS (nuclear localisation signal) sequences were added by PCR-mediated 
mutagenesis to produce PCR product B. B was then TA-cloned into vector pCR-XL-TOPO 
and sequenced.
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Figure 3.3.7: Cloning of the p21 left arm of homology.
A & B) Recombinant clones were digested with restriction enzymes Mlul and Notl to liberate 
the 4.3 kb genomic fragment of p21 from the vector pCR-XL-TOPO (backbone 3.5 kb). All 
clones here appeared positive. C) A schematic diagram of the PCR screen used to identify 
bacterial clones with wild-type p21 (primers p21ln1MUT & p21ln1+4kbR). D) Example 
agarose gel of the PCR results. Wild-type (WT) DNA produced an 811 bp product whilst 
mutated DNA produced a smaller product ~ 740 bp. The PCR results shown here 
demonstrate that clones 1-6 and clone 8 (7/13) appeared to retain the wild-type sequence.
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3.3.3.4 mCherry
mCherry was selected to be the fluorescent reporter gene for p21 activation in vivo. 
In order to capture authentic expression we planned to replace one copy of p21 with mCherry, 
so that the endogenous p21 ATG translational initiation site would represent the start of 
mCherry coding. An NLS sequence was also included (see Section 3.3.3.3) so that the 
mCherry protein would concentrate in the nuclei of cells to increase detection sensitivity 
[Hadjantonakis et al., 2003].
Figure 3.3.8 provides an overview of the cloning steps required to prepare the 
mCherry cassette before it could be fused with the p21 left arm of homology. The parental 
plasmid (pmCherry) did not contain a poly A signal therefore before any downstream cloning 
could take place a poly A signal needed to be added. The SV40 poly A signal from pEGFP- 
N1 was amplified (with the addition of 5’ EcoRI and 3’ Spel sites) by PCR and TA-cloned into 
vector pCR2.1. Recombinant clones were screened with an EcoRI/Spel digest to check for 
successful insertion of the 299 bp PCR product. 8/10 clones were positive and clone 5 
(polyA-5) was sequenced. The sequencing results were identical to the expected sequence.
Once the sequence of the SV40 poly A signal was confirmed it was digested and sub­
cloned into pmCherry using the common EcoRI/Spel sites. Positive clones were confirmed 
initially by restriction digest with enzymes Hindlil/Spel which resulted in a shift in the digest 
pattern from the parental clone 2500 & 844 bp to a targeted clone 2500 & 1085 bp. All 10 
clones appeared positive, but because the agarose gel had some additional bands present 
(which sometimes occurred when DNA quality was low) this positive result was further 
examined by digesting one clone (mCh-polyA1) with EcoRI/Spel (see Figure 3.3.9).
Clone mCh-polyA1 was then used as the template DNA for PCR-mediated 
mutagenesis which added the desired 5’ NLS & 3’ Asel-Sall sequences. The PCR product (B 
in Figure 3.3.8) was TA-cloned into pCR2.1 and positive clones were confirmed by digest with 
EcoRI (see Figure 3.3.9). One clone was selected for sequencing (mChNLSI), however the 
sequencing results indicated that there was a single T deletion within the NLS. The second 
clone (mChNLS2) was then sent for sequencing and fortunately was found to be identical to 
the expected sequence. Clone mChNLS2 was therefore selected for the downstream cloning 
steps which would fuse the p21 left arm of homology in-frame with mCherry.
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EGFPSV40fw+REV.5' MCS
3' MCS
1
SV40 poly A signal 
amplified by PCR 
5’ EcoRI and 3’ 
Spel sites added
EGF PSV40rv+R E
mCHEGFPfw+NLS
5’ MCS SV40 poly A signal
3' mcs cloned into
pmCherry via 
EcoRI & Spel sit 
in 3’ MCS
4
mCherryRv+RE
‘mCherry + poly A signal’ 
amplified by PCR _ 
5’ NLS & 3’ Asel-Sall 
sequences added
ATG
EcoRI Spel
KH
PCR product A 
cloned into pCR2.1
i
5' MCS
3' MCS
Asel,
PCR product B 
cloned into pCR2.1
Figure 3.3.8: Flow diagram for cloning of mCherry.
1. Since the plasmid pmCherry did not contain a poly adenylation (poly A) signal the SV40 
poly A signal was amplified from pEGFP-N1 (with additional 5’ EcoRI and 3’ Spel restriction 
sites) by PCR. This short PCR product (299 bp - A) was TA-cloned into vector pCR2.1 and 
sequenced. 2. Once the sequence had been confirmed the SV40 poly A signal was excised 
from pCR2.1 using the restriction sites EcoRI and Spel and cloned into the 3’ MCS (multiple 
cloning site) of pmCherry using the same sites. 3. Once a positive clone had been identified 
another round of PCR was performed to append 5’ NLS and 3’ Asel-Sall sequences to 
mCherry+pA. The resulting PCR product (B) was then TA-cloned into pCR2.1 and 
sequenced.
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mChpolyA clones 1-10 
Digested with HindiII & Spel
Recombinant Parental (pmCherry)
2500.1085 bp 2500, 844 bp
mCherry(+polyA)
B
mChpolyA-1 
Digested with
EcoRI & Spel
n 5' Asel-Sall & 3' NLS 
^ mChNLS clones 1 & 2 
Digested with EcoRI
Positive clones
3912,722,373 bp
Figure 3.3.9: Cloning of mCherry.
Restriction digests analysis to confirm positive clones. A) 10/10 clones appear positive for the 
size shift from the parental clone to recombinant clones (844 —► 1085 bp). B) The poly A 
signal was excised from the plasmid to further confirm clone mChpolyA-1. C) mChNLS 
clones 1 & 2 both appear positive following digestion with restriction enzyme EcoRI.
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3.3.3.5 Fusing the p21 left arm of homology with mCherry
The p21 left arm of homology was fused in-frame with mCherry by using the 
overlapping NLS sequence as the anchor for fusion PCR (described in Section 2..7.2.2) and 
see Figure 3.3.10). Since there had been difficulties with appending the NLS sequence to the 
ends of both the previous PCR stages, shorter primers were designed to attempt to prevent 
such a high mutation rate (which might have been associated with the length of the 
oligonucleotide). These primers were used in the two initial PCR reactions (PCR reaction 1 & 
2 in Figure 3.3.10) in combination with the previous end primers, that is p21ln1LAfw+RE (re­
synthesised by Eurofins MWG Operon - see Section 3.3.3.3) and mCherryRv+RE. The two 
initial PCR products were then used as the template DNA in PCR reaction 3 (see Figure 
3.3.10).
The final PCR product (see Figure 3.3.11) was TA-cloned into vector pCR-XL-TOPO 
and the resulting bacterial colonies were screened using the bacterial colony PCR described 
in Figure 3.3.7 to identify clones which had retained the ~ 70 bp region within p21 intron 1. 
6/56 clones appeared positive (p21mCh clones 10, 15, 42, 51-53) and I then sequenced 
these clones using the MegaBACE 1000 sequencer with the primers M13F, M13R, 
p21ln1+4kbF to check for successful incorporation of the desired modifications 5’ Fsel-Pacl 
and 3’ Asel-Sall as well as the p21 —+ mCherry join region. This screen was performed since 
previously we had encountered problems with the incorporation of these sequences.
Clone p21mCh10 was sent away for complete sequencing since our sequencing 
screen indicated it had successfully incorporated all the desired 5’ and 3’ restriction enzyme 
sites and the p21 -+ mCherry join region. However, further sequencing revealed that the 
p21mCh10 clone matched almost 100% with the expected sequence except for a long A 
homopolymeric run within the 3 - 4 kb region of p21 intron 1. This poly A run was 38 nt in the 
wild-type DNA (and indeed in our two previous clones p21LA2 & p21NLS8b) however in 
p21mCh10 this poly A run was only 36 nt. On the chromatogram these 36 A’s appeared as 
discrete peaks, evenly spaced without any “noise” that might be associated with polymerase 
slippage during the sequencing reaction (see Figure 3.3.11) we therefore had to conclude that 
this was a real difference. The remaining clones were then sequenced to attempt to identify a
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clone with the wild-type sequence. Of the six clones sequenced, three had 36 As, two had 37 
As and one had 40 As, none had the wild-type 38 As. In each case the differences appeared 
real when the chromatogram was examined, therefore, time being a factor the clone 
p21mCh10 with 36 A’s was selected as a compromise to continue with the cloning exercise.
Once the p21mCh10 clone had been selected there were still two additional cloning 
steps to be performed on the vector prior to its use in the final construct assembly (see Figure 
3.3.12). These two cloning steps removed un-wanted Asel and Fsel sites from the pCR-XL- 
TOPO backbone which would otherwise complicate downstream cloning steps. The two Asel 
sites were located between the pUC origin of replication and the 3’ end of p21/mCherry 
sequence and the Fsel site was located in the Zeomycin resistance cassette. The Asel sites 
were removed first by digesting p21mCh10 DNA with Mlul and Pcil. The DNA ends were 
then blunted (see Section 2.6.3) and the gel purified product was re-ligated to create a small 
(377 bp) deletion in the plasmid backbone. Positive clones were identified by two restriction 
digests which checked for an intact Mlul or Pcil site (see Figure 3.3.12- A & B).
Next, the Fsel site was removed from the ZeoR cassette by performing a partial digest 
with Fsel. A blunting reaction was performed (see Figure 3.3.12 - C) and the linearised 8.6 
kb DNA fragment was extracted from the gel and re-ligated so that the resulting plasmid 
should only have one intact Fsel site. To identify positive clones, which had the correct Fsel 
site destroyed, a restriction digest was performed on recombinant clones with Fsel and Asel 
(see Figure 3.3.12 - D). Perhaps surprisingly all 8/8 clones appeared positive for correct Fsel 
site deletion. These clones were then ready for the next downstream cloning step.
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PCR reaction 3
Fsel Pad
36 bp of overlap
mCherryRv+RE
4-------
' *•
p21ln1LAfw+RE
Fsel Pad i
Asel Sail
Asel Sail
PCR product cloned into pCR-XL-TOPO
Figure 3.3.10: Schematic diagram for the fusion of the p21 left arm of homology in­
frame with mCherry.
Fusion PCR was performed as described in Section 2.7.2.1. The 4.3 kb genomic fragment of 
p21 was fused to the 1 kb mCherry fragment so that the endogenous ATG was followed by a 
36 bp NLS then an in-frame mCherry coding sequence. The final product was cloned into 
pCR-XL-TOPO.
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Fusion PCR reaction between 
p21 left arm of homology with mCherry
B
PCR screen on p21-mCherry fusion clones 1-12
p21ln1MUT & o. p21ln1+4kbR
O T C TCAAAA/IAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAOTOCCCT
p21mCh10-sequenced using p21ln1+4kbR
Figure 3.3.11: Fusion PCR reaction for p21 left arm of homology and mCherry.
A) The fusion PCR product (~ 5.3 kb) was recovered from the gel (B) and (C) 10% was 
analysed to estimate the concentration. D) Example PCR screen (described in Figure 3.3.7) 
to identify recombinant clones which retained wild-type (WT) p21 sequence - clone 10 
appeared positive. E) Part of p21mCh 10 sequencing chromatogram to illustrate the poly A 
run (36 nt).
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Figure 3.3.12: Removing additional Asel/Fsel sites from the p21mCh10 clone
Top panel: schematic diagram of the cloning strategy used to remove the unwanted Asel and Fsel 
restriction sites from the pCR-XL-TOPO backbone. Bottom panel: A & B restriction digest analysis on 
the p21mCh10 clones with the Mlul-Pcil fragment deleted (and hence the two Asel sites were also 
removed). All clones appeared positive. C) The partial Fsel digest of a p21mCh10-Asel removed clone 
('optimised as 5 pg of DNA, with 5 U of Fsel, in 30 pi for 30 minutes at 37°C). Zral a single cutter (for 
linearised plasmid) and uncut DNA were included for comparison. D) Restriction digest analysis on 
bacterial colonies from the Fsel site removed ligation. Although the digest was quite inefficient (a lot of 
linearised plasmid is present at ~ 8.6 kb) the correct fragments were still visible. All 8 clones appear 
positive for the desired Fsel site deletion.
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3.3.3.6 Positive selectable marker
The positive selectable marker used in the generation of both the p27-mCherry and 
Piv/na-E2Crimson DNA targeting constructs was the self excision neomycin cassette from the 
pACN vector (see Figure 3.3.13). This positive selectable marker has the benefit of 
catalysing its own excision from the genome and thus there would be no need for additional 
ES cell selection protocols [Gu et al., 1993] or time consuming animal crosses [Schwenk et 
al., 1995] to remove the neomycin resistance genes [Bunting et al., 1999]. Residual positive 
selectable markers in the genome can have unpredictable effects in vivo and hence should be 
removed to avoid confounding the interpretation of results. This occurs because the 
expression of selection cassettes is usually driven by strong constitutive promoters/enhancers 
which may interfere with the neighbouring genes’ regulation [Olson et al., 1996] or effect the 
targeted allele itself [Meyers et al,, 1998],
The cloning of the positive selectable marker (Cre/NeoR) was essentially the same for 
both p27-mCherry and Puma-E2Crimson therefore the generation of both these vectors is 
described in this section. The Cre/NeoR fragment was amplified by PCR to add either a 5’ 
Asel (p27) or AscI (Puma) restriction enzyme site for downstream cloning steps (see Figure 
3.3.13). The PCR products were then TA-cloned into vector pCR-XL-TOPO and bacterial 
colonies were screened for positive clones using a Hindlll digest. 7/10 clones appeared 
positive for both cloning exercises and two clones (NeoA6 & NeoB3) were sequenced.
The sequencing results of clones NeoA6 & NeoB3 showed three mismatches within 
the Pol II promoter region, which were identical between both clones. Since the probability of 
two separate PCR reactions both incorporating identical errors would be extremely low it 
seemed logical to conclude that these ‘mismatches’ were present in the parental plasmid 
(pACN). Indeed, when we aligned the DNA sequencing results for our clones (NeoA6 and 
NeoB3) against the mouse genomic DNA the supposed mismatches were no longer 
apparent, indicating that the error probably lies within the published sequence for pACN 
rather than the plasmids. Therefore both these sequenced clones were suitable to use in 
downstream cloning experiments.
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Figure 3.3.13: Cloning of the positive selectable marker.
A) Schematic diagram of the self excision neomycin cassette. Image adapted from [Bunting et a!., 
1999]. The plasmid pACN contains the neomycin phosphotransferase cDNA driven by the RNA 
polymerase II large subunit promoter and Cre recombinase with nuclear localisation sequence and an 
intron from SV40 t-antigen. The cassette was flanked with two 34 bp loxP sites (green arrow heads in 
diagram). Cre recombinase is under the control of testis specific angiotensin-converting enzyme 
promoter (tACE) - hence upon passing through the germ line of male mice the entire 3.8 kb cassette 
would be removed leaving behind only a single loxP site at the targeted locus. B) Cloning strategy: The 
3.8 kb PCR product was amplified from the pACN vector using either primer pair pACNAselF & pACNRv 
(p21) or pACNAselF & pACNRv (Puma). The resulting PCR products either contained a 5’ Asel or Asel 
site respectively. C) These PCR products were cloned into pCR-XL-TOPO and recombinant clones 
were screened for successful insertion by Hindlll digest. *Clones A6 & B3 were sequenced.
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3.3.3.7 p21 right arm of homology
The p21 right arm of homology was designed to be 4 - 5 kb in length downstream of 
the coding region (~ 200 nt into p21 exon 3). The original plan for the generation this 
fragment was to use PCR-based techniques to amplify the genomic DNA region of interest 
from a BAG DNA clone (employing a similar strategy to that used to generate the left arm of 
homology). However following several attempts at performing this PGR with multiple primer 
pairs and under various reaction conditions (including touch-down PGR, a technique whereby 
the annealing temperature was the same as the extension temperature) it became obvious 
that there was a problem in amplifying DNA from this region since PGR products from these 
reactions always appeared as a smear when separated by agarose gel electrophoresis.
Upon closer examination it was revealed that the DNA sequence immediately 
downstream of the p21 gene was extremely repetitive. The repetitive region was comprised 
of several slight variations of a short (10-20 nt) sequence repeated in tandem which stretched 
on for approximately 12 kb (according to the C57BL/6 genomic reference assembly 
database). At approximately 5 kb into this repetitive region there was a slight lapse in the 
repetitive elements, where the PrimerS program selected several sequences as suitable for 
PGR primers, however if even if these primers were annealing correctly there was still 
apparently a problem with polymerase slippage during the DNA replication step of the PGR.
Since the repetitive region of DNA commenced immediately downstream of exon 3 
(the end of p21) this only left 1.3 kb of genomic DNA sequence to use for the right arm of 
homology if PGR was to be used. Considering the wealth of literature advising against short 
arms of homology for gene targeting experiments [Hasty et aL, 1991, Deng and Capecchi, 
1992] the possibility of extracting a suitably sized fragment using the BAG clone DNA was 
investigated.
A suitable BAG fragment would be greater then 4 kb in length, would not contain any 
of the unique restriction sites required for construct assembly (Fsel, Pad, Sail or Asel) and 
should also ideally be readily distinguishable from other BAG restriction fragments following 
digestion. Following sequence analysis of the p21 right arm region and BAG clone 262p22 
DNA using the NEBcutter tool only one DNA restriction fragment met these requirements; an 
EcoRV-Hindlll fragment of predicted size 12,054 bp. In order to differentiate the EcoRV-
229
Hindlll fragment from other contaminating bands an additional restriction enzyme was used in 
the digest (Nsil). The final cloning strategy and identification of positive clones is shown in 
Figure 3.3.14, however prior to achieving this several other strategies and rounds of cloning 
had been attempted. These failed attempts are detailed briefly in Appendix C.2
Cloning of the p21 left arm of homology was eventually achieved following digestion 
of BAG clone bmQ-262p22 DNA with EcoRV, Hindll and Nsil. The top band (~10 kb) was 
cloned into vector pBluescript II SK+ via the Smal (blunt) and Hindlll sites within the multiple 
cloning site (MCS). When this ligation reaction was initially transformed into TOP10 E. coli (a 
routine cloning strain) the DNA extracted from the resulting bacterial colonies appeared to 
have undergone recombination since the digest patterns were apparently random. However, 
when the same ligation reaction was transformed into MAXstbl.2 E. coli (a bacterial strain for 
growing unstable DNA sequences), the DNA extracted from the resulting bacteria behaved as 
might be expected (the backbone was at least present at the correct size). 10/24 colonies 
appeared positive and two of these clones (p21RASK+ 23 & 24) were sequenced using 
primers T7 & M13R to confirm the 5’ and 3’ ends.
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Figure 3.3.14: Cloning of the p21 right arm of homology.
A) BAC clone bmQ-262p22 was digested in silico to determine whether restriction fragments containing the p21 right 
arm (red circle) would be distinguishable from other fragments, followed by a restriction digest of the BAC DNA to 
confirm in silico predictions. NB. The apparently 12 kb fragment resolved at ~ 10 kb. B) The p21 right arm fragment 
was cloned into vector pBluescript II SK+ via the Smal and Hindlll sites. The MCS also had a 3' Sail and two 
additional unique sites (Notl and Sacll) which were utilised during assembly of the p21 right arm with the neo 
cassette. C) Initial cloning of the p21 right arm resulted in strange digest patterns in which even the backbone was 
re-arranged, typical of recombination. Once the ligation reaction was transformed into MaxStbl.2 E. Coli the 
diagnostic digest was performed again and despite several lanes being overloaded the expected digest pattern was 
observed. Clones 23 & 24 were apparently positive.
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3.3.3.8 Fusing the positive selectable marker to the p21 right arm of 
homology.
In order to join the Cre/NeoR cassette with the p21 right arm of homology without 
using PCR as originally planned (since the p21 right arm of homology was extremely 
repetitive and unable, in our hands, to be amplified) the cloning strategy had to be revised. 
The new cloning plan was based on the availability of unique restriction sites in pBluescript II 
SK+, that is the availability of restriction endonuclease recognition sites that did not cut within 
the p21 right arm or the within Cre/NeoR cassette. pBluescript II SK+ is a commonly used 
cloning vector and was chosen since it enabled directional cloning of the -10 kb EcoRV- 
Hindlll BAG digest DNA fragment into its Smal and Hindlll sites and left a downstream Sail 
site required for final assembly of the DNA targeting construct (see Figure 3.3.4 & Figure 
3.3.14). The pBluescript II SK+ MGS also had a further two unique restriction sites (Sacll and 
Notl) upstream which were used to insert the Cre/NeoR cassette into the p21RASK+24 
plasmid (see Figure 3.3.15).
Inserting the positive selectable marker into the p21 right arm of homology vector was 
performed in two stages. The first stage added the necessary Sacll site to the NeoA6 
plasmid whilst the second stage assembled the DNA fragments together in the correct 
orientation. Since the NeoA6 vector did not contain a Sacll site, a pair of adaptor 
oligonucleotides were designed to convert the 5’ Kpnl site. 1/17 bacterial colonies were 
identified as containing the Sacll site by restriction digest with Sacll (clone A610). The 
Cre/NeoR cassette was then cloned into p21RASK+24 using the now mutual Sacll and Notl 
sites. Note that the backbone of clone A610 was 3.5 kb whilst the insert was 3.8 kb therefore 
to successfully separate these fragments agarose gel electrophoresis was performed slowly 
for a relatively long time. Contamination with the backbone however was not a major concern 
since the parental vector pCR-XL-TOPO contains a Kanamycin resistance gene rather than 
Ampicillin used for selection of pBluescript II SK+ plasmid. Following transformation of the 
ligation reaction into MAXstbl.2 E. coii, colonies were screened for successful insertion of the
3.8 kb Cre/NeoR cassette by Sacll and Notl digest. 1/5 clones appeared positive, out of the 
negative clones two contained the correct insert size (3.8 kb) however the backbone
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(containing the -10 kb of repetitive DNA) size varied - demonstrating that this DNA was 
unstable. No additional sequencing was required because no PCR had been performed and 
therefore this clone (2410-5) was ready for the next stage of cloning - final assembly of the 
vectors.
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Figure 3.3.15: Cloning the Cre/NeoR cassette into the p21 right arm of homology
1. The 5’ Kpnl site in NeoA6 was mutated to create a Sacll site. 2. This allowed directional 
cloning of the Cre/NeoR cassette into p21 RASK+24 via their now mutual Notl & Sacll sites. 
The ligation reaction was transformed into MAXstbl.2 bacteria since the DNA was known to
be unstable. 3. One positive clone was identified (2410-5) when the DNA from bacterial 
clones was screened by Sacll & Notl restriction digest.
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3.3.3.9 Final construct assembly
Assembly of the penultimate and ultimate cloning vectors was performed as originally 
planned (see Figure 3.3.4 and Figure 3.3.16) - albeit with some difficulty. The penultimate 
step combined the p21 left arm of homoIogy-mCherry with the Cre/NeoR-p27 right arm of 
homology to create Vector 4. The last step of cloning then inserted the TK cassette into 
Vector 4 to generate the final DNA targeting construct (Vector 5). The first of these two final 
steps progressed as expected, however the final step of cloning took several attempts to 
complete. The main reason for this was probably because of the very repetitive region of 
DNA within the p21 right arm of homology - discussed in detail later in this section. Cloning 
of Vector 4 is described first followed by the generation of the evasive Vector 5.
Vector 4 was generated by inserting the -13.9 kb Asel-Sall DNA fragment from 
“Vector 3’’ (2410-5) into the Asel and Sail sites in “Vector 2" (p21mCh-FselR). This moved 
the ‘Cre/NeoR-p2f right arm’ DNA fragment into “Vector 2” in the correct orientation for gene 
targeting. The ligation reaction was transformed into MAXstbl.2 E. coli because of the known 
unstable DNA elements within the p21 right arm of homology. 2/6 of the resulting colonies 
appeared positive by an initial test digest with restriction endonucleases Asel and Sail which 
excised the -13.9 kb insert (Figure 3.3.17 - A). The positivity of these clones (V4-1 and 3) 
was then further confirmed by three additional restriction digests with EcoRV, EcoRI and Xhol 
(Figure 3.3.17 - B). Since all the DNA fragments appeared at their expected size and 
stoichiometric ratios, at this stage both clones V4-1 and V4-3 were deemed suitable for use in 
the final stage of cloning.
The final stage of cloning the p2-/-mCherry DNA targeting construct was to insert the 
2.1 kb TK negative selectable marker cassette into the main construct (Vector 4) via their 
common Fsel and Pad restriction sites. As alluded to earlier, this proved challenging since E. 
coli, even the MAXstbl.2 strain (which was optimised to grow unstable DNA), struggled to 
stably propagate the very repetitive region of DNA within the p21 right arm of homology. In 
fact even previously positive clones such as V4-3 could (and would) frequently “lose” varying 
amounts of this repetitive arm during overnight culture. Cloning of the ultimate vector then, 
was not entirely straightforward and is described in detail in Appendix C.3.
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The problem with the maintenance of the unstable DNA in the p21 right arm of 
homology was never completely resolved however, eventually, following advice from 
Invitrogen (who supplied the MAXstbl.2 strain) to grow the E. coli at 27°C (rather then 30°C) 
some (3/24) apparently positive clones were identified as shown in Figure 3.3.18, Upon 
further examination (and additional overnight culture) by restriction digest analysis with Xhol, 
Smal, Alel and BsrGI one of these clones had already “lost” part of the repetitive region. The 
other two clones however (V5h-7 and V5h-21) retained the region (see Figure 3.3.19) and 
these were prepared as a midi-prep (see Section 2.3.3) in order to have sufficient DNA for 1 - 
2 attempts at gene targeting. One clone was selected (V5h-21) and sent for further 
sequencing which confirmed the DNA sequences at the cloning junctions between the 
assembly vectors and at important locations such as the p21 left arm of homology into 
mCheny. We also sequenced parts of the p21 right arm of homology (where primers would 
anneal) and compared it with p21RASK+24 DNA sequence (since this was our first clone to 
successfully maintain the repetitive DNA region) to be confident that the DNA appeared as 
expected. The clone V5h-21 was therefore determined to be, to the best of our knowledge, a 
whole and accurate DNA targeting construct for the generation of a p2'/-mCherry knock-in 
transgenic reporter mice and was deemed suitable for use in gene targeting of ES cells.
This should have been the end of this cloning exercise however, since the first p21 
gene targeting experiment was unsuccessful (discussed in Section 3.4.1) more DNA needed 
to be generated. Unfortunately re-growing the E. coli from glycerol stocks was plagued with 
the same recombination issue as described previously - namely that the ~10 kb repetitive 
DNA region in the p21 right arm of homology was lost to varying degrees between clones. 
20/20 clones had lost the part of the region and this deletion occurred typically within the first 
5 kb (since the 4.5 kb fragment which should have been generated by a BsrGI digest 
frequently appeared missing in these clones). The desired DNA was eventually regenerated 
by retransformation of MAXstbl.2 E. co//with V5h-21 DNA (see Figure 3.3.20). 6/10 colonies 
were apparently positive for the p21 right arm region and two of these clones (V5h-21-25 and 
V5h-21-30) were selected for additional confirmation digests (see Figure 3.3.21). Since all 
the digests appeared as expected clone V5h-21-25 was then prepared as a Mega-prep. This 
DNA was then used for the second round of ES cell gene targeting for p21.
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Figure 3.3.16: Final assembly of p21-mCherry DNA targeting vector.
1. The positive selectable marker and p21 right arm of homology was inserted in to the vector 
containing the p21 left arm of homology and mCherry by their mutual Asel and Sail restriction 
sites. 2. Next, the negative selectable marker was added to the resulting vector (Vector 4) 
using the Fsel and Pad sites.
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Figure 3.3.17: Cloning of the penultimate p21-mCherry vector (vector 4)
A) Initial screen of vector 4 transformants was performed by restriction analysis with Asel and 
Sail. 2/6 clones appeared to contain the - 13.9 kb insert DNA. B) Further analysis of vector 
4 clone 3 (V4-3) with additional digests including restriction enzymes EcoRV, EcoRI and Xhol.
The digest patterns appear at the expected sizes. (The lower molecular weight bands have 
been digitally enhanced in this figure to make them easier to identify). C) The glycerol stock 
for V4-3 was re-streaked onto a fresh LB-Agar (Kan) plate and the resulting colonies were 
screened by Smal digest. Only 2/10 colonies appear to have kept the repetitive region 
(clones 3 and 6 - circled region) compared to the original p21 right arm clone (p21 RASK+24 
- see Figure 3.3.14).
238
Results
V5e-77 has correct 
low molecular weight 
fragments - however 
the ~13.2 kb fragment 
shows evidence of 
recombination
V5e-88 appears as 
parental clone
B
V5f clones Xhol digest
Si 234 5678 9 10 11 12 J.3 14
(DOO
3
3
a
o3
Xhol
V4 V5 V5f
•13.2 kb -13.2 kb “16 2 kb
4.3 kb 4.3 kb 4.3 kb
3.7 kb 3.7 kb 3.7 kb
1.3 kb 3 4 kb 1.3 kb
c V5h clones Xhol digest oo
CO
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 5
mm mm m
mm mt
Figure 3.3.18: Cloning of the p21-mCherry final DNA targeting construct.
Restriction digestion analysis of potential clones from various cloning experiments. A) An 
example of an unsuccessful attempt (V5e). Most DNA digestion patterns appear as random 
single fragments with a high molecular weight smear (probably bacterial genomic DNA). One 
clone (V5e-77) displays the correct low molecular weight fragments however the high 
molecular weight fragment appears lower than expected - indicating that some of the DNA is 
missing. B) Another unsuccessful cloning attempt (V5f) with clear evidence of loss of the 
large DNA fragment. Instead of there being one discrete large molecular weight band - 
multiple bands appear at various sizes. C) Successful cloning attempt (V5h) clones 1, 7 and 
21 appear positive.
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Figure 3.3.19: Confirmation digests of positive clones V5h-7 & 21.
A) p21-mCherry DNA targeting constructs V5h-7 & 21 were digested with multiple enzymes to 
identify any unwanted recombination events - specifically those which might affect the length 
of the very repetitive region of DNA within the p21 right arm of homology. Digest patterns 
appeared as expected for both clones when compared to previous clones - therefore one 
clone (V5h-21) was selected for sequencing. B) Schematic diagram of the restriction digest 
fragments for the p21 right arm of homology. The predicted sizes of the DNA fragments 
based on C57BU6 genomic DNA are shown first followed by the actual approximate size of 
the fragment (129SvEv strain) as determined by the experimental digests.
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Figure 3.3.20: Re cloning the p21-mCherry DNA targeting construct.
Following re-transformation of the original positive clone (V5h21) into MaxStbl.2 E. coli the 
resulting clones (21-30) were then examined for retention of the repetitive DNA fragment 
present in the p21 right arm of homology. A) Sail digest releases the gene targeting construct 
from the pCR-XL-TOPO backbone. DNA fragment sizes were compared to the original DNA 
(V5h21). B) The most promising clones (21, 25, 26, 28, 29 & 30) were then digested with 
BsrGI which cuts the vector within the repetitive region and hence is diagnostic for where 
recombination is taking place. Since all the clones (with the exception of 22, included for 
comparison only) contain the doublet at 4.8/4.5 kb all would be suitable for further growth and 
digests. Clones 25 and 30 were selected for further growth and analysis. C) Schematic 
diagram showing BsrGI sites in Vector 5 and expected fragment sizes.
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Figure 3.3.21: Confirmation of re cloned p21-mCherry DNA targeting constructs.
Re-transformed clones V5h21 -25 & -30 were compared side by side with the original p21- 
mCherry DNA targeting construct V5h21 to examine the size and stoichiometry of the 
restriction fragments when the samples were digested with multiple restriction enzymes. With 
the exception of the Alel digest, all restriction digests appeared very similar (if not identical). 
The reason(s) why V5h21 did not cut as well when digested with Alel is not obvious, since 
previously Alel was able to digest this DNA (see Figure 3.3.19).
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3,3.4 Puma-E2Crimson
3.3.4.1 Puma left arm of homology
The Puma left arm of homology was designed to contain 4 - 5 kb of 129SvEv 
genomic DNA immediately upstream of the endogenous start codon (ATG). We initially 
aimed to generate this genomic DNA fragment by two rounds of PCR, similar to the method 
used to generate the p21 left arm of homology (see Section 3.3.3.3). However despite 
several attempts to optimise this PCR reaction (as described in Section 2.7.1 and see 
Appendix B) no satisfactory results were achieved - that is, we observed either no product, 
wrongly sized product and/or multiple bands of an incorrect size (see Figure 3.3.22). The 
reason or reasons for the failure of PCR to amplify this region was or were unclear. We were 
confident that the template DNA (either BAG clone bmQ-397h22 or bmQ-207e13) contained 
at least part of the Puma locus and was an appropriate template to use for PCR since PCR of 
the Puma right arm of homology had been successful (see Section 3.3.4.4). We reasoned 
that given the size of the average BAC clone (100-300 kb) it seemed highly probable that the 
rest of the Puma locus should be present since the regions were only separated by ~ 2 kb. In 
addition, other than being slightly GC rich (-60%) and containing a few microsatellite repeats 
there did not appear to be any inherent problems with the primary DNA sequence (unlike the 
p21 right arm of homology - see Section 3.3.3.7). Whatever the reason(s), because PCR 
was problematic we decided to investigate the possibility of isolating a suitable DNA fragment 
by restriction digestion of the BAC clone DNA (as for the p21 right arm of homology - see 
Section 3.3.3.7).
Following sequence analysis of the Puma left arm region and BAC clone bmQ- 
397h22 DNA using the NEBcutter tool an Ncol-Ncol fragment with an expected size of 5865 
bp was identified. This 5865 bp fragment was considered suitable for our purpose since it 
was > 4 kb and did not contain the restriction sites Fsel, Pad, Sail or AscI - also discussed in 
Section 3.3.3.7. The desired Ncol-Ncol fragment was distinguishable from other 
contaminating digest fragments in silico due to the presence of two additional restriction 
enzymes sites, EcoRI and Hindlll, however when this triple digest was performed the 
restriction fragments did not match the expected sizes, nor were the anticipated stoichiometric
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ratios of bands observed (see Figure 3.3.23). For example, the highest molecular weight 
fragment should have been 7.1 kb however in the triple digest there were two DNA bands 
clearly visible at approximately 10 and 12 kb. The individual digest patterns for EcoRI, Hindll 
and Ncol were also analysed, but as seen in the triple digest, whilst there might have been 
some identifiable fragments (for example the triplet at ~5 kb in the Ncol digest), the majority of 
these patterns did not match the predicted patterns of bands. The same digest analysis was 
performed on the other ‘Puma’ BAG clone (bmQ-207e13) with similar results. At this point the 
idea to use the 5.9 kb Ncol-Ncol BAG restriction digest fragment as the Puma left arm of 
homology was abandoned in favour of returning to a PCR-based strategy.
in order to establish whether the Puma left arm region was present within either of the 
‘Puma’ BAG clones, several additional primers were designed. These additional primers 
would be expected to produce smaller PGR products (< 1 kb) and hence the PGR reactions 
should be more efficient and the products easier to amplify. Indeed it was possible to detect a 
few correctly sized PGR products using these new primers; however some regions (including 
the central 1.4 kb) still failed to amplify products of the expected size (see Figure 3.3.24). We 
therefore designed additional primers in order to break up the problematic section of DNA into 
easier to manage smaller sections, with the ultimate aim being to ‘stitch’ (ligate) the smaller 
DNA products together by fusion PGR and recreate the required 4 - 5 kb for the arm of 
homology.
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Figure 3.3.22: Long range PCR of the Puma left arm of homology.
Top panel shows a schematic diagram of the Puma left arm of homology and the primer 
annealing sites. Bottom panel shows the PCR results. Agarose gel lanes were loaded from 
PCR reactions +/- template DNA (bmQ-397h22) for each annealing temperature (50-60°C). 
None of the PCR reactions attempted here (A-D) showed products of the expected size. PCR 
reactions shown here were performed using Phusion (Hot Start) DNA polymerase and the GC 
rich buffer, for 30 cycles.
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Figure 3.3.23: Puma BAC clone bmQ-397h22 restriction digests analysis
A) In silico digest of the 119 kb BAC clone DNA for restriction enzymes EcoRI, Hindlll and 
Ncol. B) Actual digest pattern observed for the same restriction enzymes when 1 or 2 pg of 
BAC clone DNA was digested overnight and resolved slowly by agarose gel electrophoresis. 
It was hoped to be able to identify the 5.9 kb Ncol-Ncol fragment to use as the Puma left arm 
of homology however the digest patterns did not appear as expected.
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Figure 3.3.24: PCR of the Puma left arm of homology - 1
Top panel: Schematic diagram of the Puma left arm of homology region, with primer 
alignments. New primers (red arrows) were designed in order to amplify smaller PCR 
products (< 1 kb) to determine if PCR within the Puma left arm region was possible (since 
previous long range PCR had failed). Ticks and crosses indicate whether that primer pair 
produced a correctly sized product. Bottom panel: PCR results, example agarose gels for the 
9 PCR reactions (A-l). Successful PCR reactions (A, C, D, E & G) amplified a single DNA 
fragment of the correct size. Unsuccessful PCR reactions (B, F, H & J) either produced no 
product or multiple non-specific fragments. PCR reactions were performed with either BAC 
clones bmQ-397h22, bmQ207e13, genomic DNA (gDNA) or H20.
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The difficult to PCR, 1.4 kb DNA region situated immediately downstream of Puma 
exon 1, was eventually amplified by dividing the region into three smaller sections as shown 
in Figure 3.3.25. The trickiest PCR product to obtain was the middle 355 bp region. This 355 
bp fragment required very strict PCR reaction conditions in order to produce the correct sized 
product with a reasonable yield and without too many non-specific bands contaminating the 
agarose gel (see Figure 3.3.25 - C and Appendix B for reaction conditions). One reason for 
the difficulty in amplifying DNA from the Puma left arm region may be the increased GC 
content (for the 355 bp section the GC content was 76%). High GC content can cause 
problems during PCR because of formation of secondary structures (such as hairpins) which 
may result in non-specific truncated products [Frey et al., 2008]. With the whole Puma left 
arm region now able to be amplified by PCR in sections the task of fusing all the separate 
PCR fragments together could now be completed.
Fusion PCR was performed according to the reaction scheme detailed in Figure 
3.3.26. For the most part this proceeded as expected however there were some minor 
complications which are detailed next. The first potentially problematic observation was that 
the sequencing data for the Puma locus did not match with the C57BL/6 genomic DNA 
database. There were 52 mutations in the non-coding DNA sequence, including 28 base pair 
substitutions, 9 deletions, 9 insertions and 6 changes at microsatellite regions. This relatively 
frequent variability in the DNA sequence was also observed when we sequenced the 4.5 kb 
Puma right arm of homology. In the Puma right arm of homology there were 53 mutations in 
the non-coding DNA sequence including 27 base pair substitutions, 6 deletions, 12 insertions 
and 8 changes at microsatellite regions. These observed differences might be explained by 
mouse strain variation since we used 129SvEv genomic DNA and not C57BL/6 which was the 
strain the reference assembly database was based on. To provide more convincing evidence 
that that was indeed the case, multiple clones for each PCR product were sequenced 
(typically 2-3). Therefore, since sequence analysis from multiple clones agreed with the 
observed changes we concluded that these differences were genuine for the 129SvEv mouse 
strain and were not introduced by PCR. The amended 129SvEv consensus genomic DNA 
sequence for both the Puma left and right arm of homology is included in Appendix D.3 & D.4.
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Figure 3.3.25: PCR of the Puma left arm of homology - 2
Top panel: Schematic diagram of the 1.4 kb DNA region immediately downstream of Puma 
Exon 1, with primer alignments. Since previous primers (black arrows) had been unable to 
amplify this difficult region, new primers (red arrows) were designed in order to break it into 
easier to manage smaller sections. Bottom panel: PCR results, example agarose gels for the 
4 primer pairs (A-D). Primer pair A failed to product a correct sized product so the 5’ 798 bp 
region was further divided into two smaller fragments of 446 & 355 bp (D & C respectively). D 
produced a single DNA fragment of the expected size whilst C required additional 
optimisation (use of GC rich buffer + 3% DMSO) to generate the desired fragment. PCR 
Reactions were performed with BAC clone bmQ-397h22 DNA.
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Figure 3.3.26: Fusion PCR of the Puma left arm of homology.
Schematic diagram of each individual PCR reaction performed to construct the 4.6 kb Puma 
left arm of homology. Almost all PCR products were TA-cloned into either pCR2.1 (product < 
2.1 kb) or pCR-XL-TOPO (product >2.1 kb) and then sequenced, before being used as the 
template DNA for their next round of PCR. The exceptions to this were the PCR products B & 
C which were gel purified and used immediately as DNA templates in the fusion PCR reaction 
which produced PCR product F. Product F was then cloned and sequenced as for the other 
products. Dotted red lines indicate areas of sequence overlap (typically 20 bp) which were 
used as the anchors for fusion PCR. Bacterial colonies were screened initially by restriction 
digest with EcoRV & Spel, which excised the PCR product from the vector backbone, and 
then by sequencing.
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The other minor complication during fusion PCR of the Puma left arm of homology 
was a 30 - 100 bp deletion which was detected when the PCR products A and F were fused 
together to generate PCR product G (see the overview in Figure 3.3.26). The deletion was 
present in the Puma promoter region just upstream of exon 1, where the p53 REs are 
situated. Since the first cloning attempt only produced two bacterial colonies, both of which 
contained deletions in this region (50 bp and 100 bp), this fusion PCR step was repeated. On 
the second attempt, more colonies were generated (60 +) and 10 of these were screened by 
restriction digest with EcoRV and Spel to excise the 2841 bp PCR product G. Resolution of 
these restriction fragments was facilitated by extended agarose gel electrophoresis in order to 
distinguish between clones which might have a deletion (see Figure 3.3.27). Using this 
screen 3/10 clones appeared to contain a larger insert fragment and so these clones were 
sent for sequencing. Whilst one of these clones contained a 30 bp deletion the other two 
appeared correct therefore one of these was used as the template DNA for the final fusion 
PCR reaction which successfully generated the full 4.6 kb Puma left arm of homology (see 
Figure 3.3.28).
Once the Puma left arm of homology had been cloned into pCR-XL-TOPO and its 
sequence confirmed, there was one last additional cloning step to make this vector ready for 
assembly with E2Crimson. Fortuitously, the Puma start codon and the E2Crimson start 
codon, both contain Ncol (CCATGG1 sites. We therefore intended to assemble the Puma left 
arm of homology in frame with E2Crimson without performing any additional fusion PCR. 
However since both vector backbones pCR-XL-TOPO and pCR2.1 (into which E2Crimon 
would be cloned - see Section 3.3.4.2) contained several Ncol sites a different vector would 
be needed. pBluescriot II SK+ was chosen since it did not contain any Ncol sites and had 
other restriction sites suitable for vector assembly. The 4.6 kb Puma left arm of homology 
was then moved from pCR-XL-TOPO into pBluescript II SK+ via using mutual EcoRV and 
Hindlll sites (see Figure 3.3.29). 10/10 bacterial colonies were positive by EcoRV and Hindlll 
restriction digest analysis. These vectors (PumaLASK+) were all suitable for use in the next 
downstream cloning step.
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Figure 3.3.27: Penultimate fusion PCR step for the Puma left arm of homology.
Left panel: Schematic diagram of the penultimate fusion PCR reaction. Previous PCR 
products A and F were amplified together (with appropriate end primers - not shown here) to 
generate the 2841 bp PCR product G - taken from the overview in Figure 3.3.26. Right 
panel: Since there was a known problem with a 30 -100 bp deletion within PCR product G, 
recombinant clones were screened by restriction digest with EcoRV & Spel and the fragments 
were allowed to separate until a difference in the size of the insert fragment was noticeable. 
'These clones were sent for sequencing.
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Figure 3.3.28: Ultimate fusion PCR step for the Puma left arm of homology
Top panel: Schematic diagram of the ultimate fusion PCR step to generate the Puma left arm 
of homology. Bottom panel (left): PCR reactions for the two starter products G and H (as 
annotated in Figure 3.3.26). Since there were some non-specific products contaminating H, 
this reaction was separated by agarose gel electrophoresis until the contaminating lower 
molecular weight DNA fragments had been run off the bottom of the gel (H-2). I, the final 
round PCR product also had some non-specific products; however the desired 4.6 kb was 
also present. Bottom panel (right): Gel purified PCR product I was then TA-cloned into pCR- 
XL-TOPO and the resulting colonies were screened by restriction digest with EcoRV and 
Spel. 3/5 products appeared positive and one was selected for sequencing (Puma4.6-5).
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Figure 3.3.29: Cloning of the Puma left arm of homology into pBluescript IISK+.
A) Schematic diagram of the Puma left arm of homology and the multiple cloning site of 
pBluescript II SK+. The 4.3 kb Puma left arm region was moved from its pCR-XL-TOPO 
backbone into pBluescript II SK+ via their mutual EcoRV and Hindlll sites. There was also a 
downstream Sail site for the subsequent cloning steps. B) The resulting vector PumaLASK+ 
and C) restriction digest analysis of bacterial clones. 10/10 clones appeared positive by 
digestion with EcoRV and Hindlll.
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3.3.4.2 E2Crimson
Cloning of E2Crimson for the Pt//??a-E2Crimson DNA targeting construct was 
relatively straightforward since the template DNA already contained a poly A signal (unlike 
mCherry - see Section 3.3.3.4) and a 5’ Ncol site for in-frame fusion with the upstream Puma 
sequence. Therefore only the 3’ Ascl-Sall restriction sites needed to be appended onto 
E2Crimson before it could be used in the final construct assembly. This was performed by 
PCR mutagenesis using the pE2-CrimsonN1 vector as the template DNA and the primers 
CrimsonF and CrimR+Ascl-Sall (see Figure 3.3.30). The resulting 1 kb PCR product was 
then TA-cloned into pCR2.1 and recombinant bacterial clones were screened by restriction 
digest analysis with EcoRV and Hindlll. 6/10 clones appeared positive and one (Crim9) was 
sent for sequencing. The sequencing results matched 100% with the expected sequence and 
therefore this clone was ready for the next stage of cloning.
3.3.4.3 Fusing the Puma left arm of homology in frame with E2Crimson
In order to avoid an additional round of fusion PCR which would require optimisation 
and then further sequencing, we instead planned to take advantage of the naturally occurring 
Ncol site at both the start codons of Puma and E2Crimson to combine the cloned products in 
these vectors. E2Crimson was therefore inserted into PumaLASK+ via their mutual Ncol and 
Sail sites to create the vector PumaLACrimSK+. The resulting recombinant clones were 
screened for successful introduction of E2Crimson by restriction digest with Ncol and Sail. 
10/10 colonies appeared positive and any one of these would be suitable for the next stage of 
cloning.
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Figure 3.3.30: Cloning of E2Crimson.
Schematic diagram of the cloning plan for E2Crimson: 3’ Ascl-Sall restriction sites were
appended to the 3’ end by PCR mutagenesis and the resulting PCR product was TA-cloned 
into pCR2.1. Bacterial transformants were screened for the 1 kb E2Crimson insert by 
restriction digest with EcoRV and Hindlll. 6/10 clones appeared positive (Crim- 1-2, 4, 8-10) 
and one of these was sent for sequence analysis (Crim9).
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Figure 3.3.31: Cloning E2Crimson in-frame into the Puma left arm of homology.
E2Crimson was cloned in-frame with the endogenous ATG site in Puma exon 2 by taking 
advantage of the naturally occurring Ncol site in the initiation codons of both of these genes. 
The 1 kb Ncol-Sall DNA fragment from Crim9 was cloned into the same sites in PumaLASK+. 
Positive clones were identified by a restriction digest with Ncol and Sail. All clones shown 
here appeared positive.
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3.3.4.4 Puma right arm of homology
The Puma right arm of homology contained 4.5 kb of 129SvEv genomic DNA which 
commenced 719 bp into Puma intron 3 and ended 788 bp downstream of Puma exon 4 (see 
Figure 3.3.32). This region was cloned by two rounds of PCR similar to the method used to 
generate the p21 left arm of homology (see Section 3.3.3.3). The resulting vector 
(PumaRA+Sall2) contained the 4.5 kb region of homology and 5’ 20 bp of sequence overlap 
with the NeoB3 vector (containing the Cre/NeoR cassette - described in Sections.3.3.6) and a 
3’ Sail site. The 20 bp of Cre/NeoR overlap was included since originally we had planned to 
join the Puma right arm of homology with the Cre/NeoR by fusion PCR. This original plan was 
later amended to avoid unnecessary PCR steps and is discussed in the next section. Cloning 
of the Puma right arm of homology was quite straightforward and progressed smoothly with 
only one minor issue concerning high sequence variation from the C57BL/6 genomic 
database which was resolved following sequencing of additional clones (discussed in detail in 
Section 3.3.4.1).
3.3.4.5 Fusing the positive selectable marker (Cre/NeoR) with the Puma right 
arm of homology
The Cre/NeoR cassette from vector NeoB3 (described in Section 3.3.3.6) was 
inserted into the 5’ EcoRV site in the vector PumaRA+Sall-2 by blunt ended cloning (see 
Figure 3.3.33). Since the Puma right arm of homology (clone PumaRA+Sall-2) had 
recombined into pCR-XL-TOPO in the reverse orientation this meant the EcoRV site in the 
vector backbone was at the 5’ end of the cloned sequence and hence could be used to insert 
the Cre/NeoR cassette upstream. In order to excise the 3.8 kb Cre/NeoR cassette from 
NeoB3, a triple digest was performed with Kpnl, Notl and Zral. Kpnl and Notl were sufficient 
to excise the positive selectable marker however since the backbone was a similar size at 3.5 
kb contamination was a likely problem. Therefore, Zral was also included in the digest since 
this enzyme cleaved the pCR-XL-TOPO backbone approximately in half and hence would 
allow better resolution of these fragments during agarose gel electrophoresis.
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Figure 3.3.32: Cloning of the Puma right arm of homology.
Top panel: Flow diagram for cloning the 4.5 kb DNA fragment of the Puma right arm of 
homology by PCR. PCR was performed using the BAC clone bmQ-397h22 DNA as a 
template. The first stage amplified the Puma right arm only. This product (A) was TA-cloned 
into vector pCR-XL-TOPO, screened by restriction digestion and then sequenced. Once the 
sequence was confirmed in two separate bacterial clones the second round of PCR was 
performed. The second round of PCR annealed 5’ ‘20 bp overlap sequence to Cre/NeoR & 3’ 
Sail restriction site to generate PCR product B. B was then TA-cloned into vector pCR-XL- 
TOPO, screened by restriction digest and sequenced. Bottom panel: corresponding 
restriction digests. *These clones were sent for sequencing.
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Figure 3.3.33: Cloning the Cre/NeoR cassette into the Puma right arm of homology.
The Cre/NeoR cassette was inserted into the EcoRV site in the PumaRA+Sall-2 vector by 
blunt end cloning. The resulting bacterial clones were screened by restriction digest analysis 
with Hindlll - which could determine the orientation of Cre/NeoR (see blue box for expected 
restriction digest fragment sizes). 4/7 clones contained the Cre/NeoR cassette in the correct 
(forward) orientation. A second digest with Sail was also performed to confirm the vector
size.
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Since blunt ended cloning was used, insertion of the Cre/NeoR cassette into the 
Puma right arm of homology could occur in either orientation, however for downstream 
cloning steps we required only the forward orientation. The resulting bacterial clones 
therefore were screened with Hindlll which could determine the orientation (see Figure 
3,3.33). 4/7 clones were positive for Cre/NeoR in the correct (forward) orientation and one 
(NeoPumaRA-4) was selected for the final construct assembly.
3.3.4.6 Final construct assembly
Assembly of the penultimate and ultimate Pu/r?a-E2Crimson cloning vectors was 
performed according to a slightly altered version of the original cloning plan (see Figure 
3.3.4). In the new cloning plan, shown in Figure 3.3.34, the TK cassette was inserted into 
vector Pumal_ACrimSK+ first, rather than last and by blunt end cloning rather than directional 
cloning using Fsel and Pad restriction sites. This was done because we had forgone an 
additional round of PCR which would have also appended 5’ Fsel-Pacl sites to the Puma left 
arm of homology. Since the 5’ Fsel-Pacl unique restriction sites were absent we utilised the 
5’ EcoRV site present in the pBluescript II SK+ backbone (see Figure 3.3.29) to insert the 
blunted TK cassette. The TK cassette had to be inserted prior to adding the Cre/NeoR-Puma 
right arm of homology fragment because the Cre/NeoR cassette contained an EcoRV 
restriction site which would otherwise disrupt the cloning. Once the TK cassette was added, 
the ‘Cre/NeoR-Puma right arm of homology’ fragment from vector NeoPumaRA was then 
inserted using the mutual AscI and Sail sites.
The TK cassette was excised from TK2 (Vector 1 see Figure 3.3.34) by digestion with 
restriction enzymes Pad and Sail. The digested TK fragment was then blunted and inserted 
into the EcoRV site in vector PumaLACrimSK+. Sail was used instead of Fsel so that the 
Sail recognition sequence would be destroyed during cloning, thus maintaining the unique 
Sail site (3’ to E2Crimson) required for the final stage of cloning. Orientation of TK should not 
matter for the purposes of gene targeting, however the only positive clone was in the forward 
orientation when screened by Ncol restriction digest and so this clone was used in the final 
cloning step.
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The final cloning step for generation of the Pu/77a-E2Crimson DNA targeting construct 
inserted the ‘Cre/NeoR-Puma right arm’ fragment from NeoPumaRA (Puma Vector 3) into the 
TKPumaLACrim vector by their mutual AscI and Sail sites. The resulting bacterial clones 
were screened by both Ncol and Notl restriction digests to doubly confirm positive clones {see 
Figure 3.3.35). 5/10 colonies appeared positive and one of these (PumaU-6) was sent for 
further sequencing to confirm the DNA sequences at the cloning junctions between the 
assembly vectors and at important locations such as the Puma left arm of homology into 
E2Crimson. The clone PumaU-6 was confirmed in this way to represent a full and accurate 
DNA targeting construct for the generation of a Pt/ma-E2Crimson knock-in transgenic reporter 
mouse suitable for use in gene targeting of ES cells.
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Pad
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CATGG
Figure 3.3.34: Final assembly of the Puma-E2Crimson DNA targeting vector.
1. The negative selectable marker (TK) was inserted into the 5’ EcoRV site in 
Puma LA CrimSK+ by blunt end cloning. 2. Lastly the ‘Cre/NeoR-Puma right arm’ fragment 
was inserted into the resulting vector TKPumaLACrim using the mutual AscI and Sail sites.
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Figure 3.3.35: Cloning of the ultimate Puma-E2Crimson DNA targeting construct.
Restriction digest analysis of potential clones by Ncol and Notl. 5/5 appeared positive for 
insertion of the Cre/NeoR cassette. Lanes A & B correspond to the parental plasmids 
TKPumaLACrim and NeoPumaRA respectively.
264
Results
3.3.5 Mdm2 Constructs
In order to address fundamental questions regarding the regulation of p53 and Mdm2 
in vivo, we proposed to generate two strains of transgenic mice which would contain either a 
deletion in the Mdm2 constitutive (P1) promoter or mutate the p53 RE within the p53- 
responsive Mdm2 (P2) promoter (as discussed in Section 1.4.2). The first of these strains 
(Mdm2 P1-Null) will determine if constitutive/p53-independent up-regulation of Mdm2 is 
essential for viability whilst the second strain {Mdm2 P2-Mutant) will determine if 
inducible/p53-dependent up-regulation of Mdm2 is essential for viability. In other words can 
the deletion of either one of these promoter regions be rescued/compensated for by the 
remaining promoter region? Additional studies of these strains would also reveal (if viable) 
the contributions of these processes, p53-dependent and p53-independent, with regards to 
the role(s) of Mdm2 in normal development, tumour susceptibility and in response to a wide 
variety of cellular stresses. This results chapter describes the design and in vitro testing of 
each of these mutations followed by a description of the strategy that led to the successful 
cloning of the gene targeting constructs required for generation of the proposed transgenic 
mouse lines.
3.3.5.1 Design of Mdm2 promoter region mutations
Mdm2 is an important proto-oncogene, with both p53-dependent [Oliner et al., 1992] 
and p53-independent [Ganguli and Wasylyk, 2003] roles in carcinogenesis. Reflecting this, 
Mdm2 has two promoter regions, including an upstream constitutive promoter (P1) and a p53- 
inducible (P2) promoter which is situated in intron 1 (as discussed in Section 1.4.2 and see 
Figure 3.3.37). Part of the work for this thesis then, was to investigate the relative 
contributions of each of these promoters to the regulation of Mdm2 and in turn, on the Mdm2 
negative regulation of p53. To accomplish this, we designed and created two DNA targeting 
constructs which would either delete the P1 region or mutate the p53 RE sequences in P2 to 
abrogate their p53 responsiveness. The design and in vitro testing of these mutations is 
described next.
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During the Mdm2 P1/P2 mutation design process, several important factors needed 
to be considered in order to generate the optimum mutational sequences - that is to introduce 
mutations which would effectively disrupt the desired promoter whilst leaving other features 
(such as other transcription factor binding sites) within the locus unaffected. The first 
consideration was whether there were any other genes (validated or hypothetical) at the 
Mdm2 locus which might be affected by the planned introduction of mutations to the region. 
Disruption of genes other than Mdm2 could confound interpretation of the results due to 
unintended non-specific affects. Originally when this project started in 2007, there was 
indeed a small (612 bp) hypothetical gene, EG668154, on the positive strand (Mdm2 is on the 
negative strand) which overlapped with the Mdm2 P2 promoter region. EG668154 had a 
predicted translation initiation codon within the p53 RE region and the predicted transcript ran 
until part way through Mdm2 exon 1. The presence of this hypothetical gene greatly 
complicated the design of mutations within the P2 region since only base pair changes which 
did not affect the hypothetical amino acid sequence could be used. Fortunately however, part 
way through this project, the EG668154 gene record was withdrawn from the MGI and 
RefSeq databases. EG668154 had been originally identified by a computational analysis 
however during the process of curation of such hypothetical genes the judgement was made 
that EG668154 was not a gene and the record was discontinued in 2009 [email 
communication with MGI]. Therefore, since Mdm2 did not appear to have any other bona fide 
overlapping genes and the nearest upstream gene was ~ 23 kb away we were fairly confident 
that any mutations we introduced would only affect the Mdm2 gene (see Figure 3.3.36). The 
P1/P2 specific design aspects are discussed next.
Chromosome 10 - HC 000076.5
[116940692 ^ [117229761 ^
I------------------------------------------------------------------------------------------------------------------------------------------------1
WfcSc-ps — cpm — ----------^—> S1c35e3
Gm9004 Mdm2 |\j|jpiQ7 ^.-=^========0
Figure 3.3.36: The genomic context of Mdm2.
Section of chromosome 10 with the alignment of Mdm2 and other genes. No other genes 
overlap with Mdm2 and the closest 5’ gene (S1c35e3) is ~ 23 kb upstream of Mdm2 exon 1. 
Image was exported from the NCBI website htto://www.ncbi. nlm.nih. aov/aene/17246.
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Deletion of the Mdm2 P1 promoter region was relatively simple in design (compared 
to the Mdm2 P2-Mutant - discussed later in this section), since we intended to completely 
eliminate the functionality of P1 and were not concerned about retaining any specific features 
in this region. Therefore, to ensure maximum disruption of P1, the entire minimal essential 
region was deleted as well as the first 22 bp of Mdm2 exon 1 (163 bp in total) (see Figure 
3.3.37). This deletion would remove many of the conserved features between the mouse and 
human P1 promoter region including several GC rich regions, putative transcription factor 
binding sites and a CCAAT box [Phillips et al., 2006]. Since the transcriptional initiation site 
was also removed, even if there was somehow residual activity of the P1 promoter this should 
not be transcribed into mRNA. The P1 promoter region would be deleted by replacing the 
163 bp region with a self-excision positive selectable marker (described in Section 3.3.5.3), 
therefore in the Fi heterozygote mice (and all subsequent progeny) the P1 region will be 
replaced with 132 bp of spacer DNA which will include a single LoxP site (see Figure 3.3.38). 
The activity of the Mdm2 P1-Null region was also assessed in vitro to confirm reduction in P1 
activity and to check that deletion of P1 did not affect p53-dependent induction of the Mdm2 
P2 promoter (discussed in further detail in Section 3.3.5.2).
Disruption of the p53 responsive elements within the Mdm2 P2 promoter region was 
slightly more complex, owing to the additional known and putative TFBS within the region 
(see Figure 3.3.39 and Figure 3.3.41). In order to create a P2-Mutant which was 
unresponsive to p53 but otherwise unaffected at the other TFBS, subtle point mutations were 
introduced. These point mutations, typically affecting the most conserved residues of the p53 
consensus binding sequence, were analysed using the online MAPPER tool to help 
determine the optimum sequence (method described in Section 2.8.2). The optimum 
sequence (that is, the sequence that had the smallest number of mutations, which 
successfully prevented p53 binding whilst altering as few other TFBS within the region as 
possible) was derived and is shown in Figure 3.3.40. Whilst creating a P2 mutated sequence 
that did not introduce any changes other than deletion of the p53 RE was not completely 
achievable, the optimum sequence derived for this thesis only introduced 6 alterations and 
only 2 of these were in mammalian TFBS (see Table 3.3.2 and Figure 3.3.41). The two 
alterations in the mammalian TFBS were addition of an NFKB1 (also known as p50) site and
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deletion of an ELK1 site. It would be theoretically possible to test the functionality of these 
sites by performing co-transfection experiments with the promoter regions ± murine Nfkbl or 
Elk1 however since these predicted TFBS did not have a high alignment score and were from 
the human sequence models, rather than mouse, it seems unlikely to impact on the promoter 
region.
One final design consideration with the Mdnr>2 P2-Mutant sequence is the 
incorporation of a restriction endonuclease site (or deletion of one) for screening purposes. 
Indeed, it was possible to introduce an Ncol site within the 13 bp spacer region between the 
two p53 RE sites, without compromising any of the previously optimised features (see Figure 
3.3.40). The inclusion of an Ncol site, however does raise its own concerns, namely that 
creating an Ncol site (CCATGG) introduces an ATG site which aligns well with the Kozak 
consensus sequence (ACCATGG) [Kozak, 1978] and therefore it may potentially act as a 
translational initiation site. However, upon further consideration, this concern would appear to 
be unfounded since the Ncol site is within intron 1 and will be spliced out during mRNA 
processing. The Mdm2 P2-Mutant sequence was also analysed by a splice site predictor tool 
(see Section 2.8.3) to ensure that we had not inadvertently simultaneously introduced a splice 
acceptor site which might enable alternative splicing of Mdm2 and hence create an alternative 
transcript where the ATG introduced by the Ncol site could feasibly be utilised. Importantly, 
the only splice acceptor site recognised by either the wild-type or P2-Mutant Mdm2 promoter 
region was the endogenous AG at the Mdm2 intron 1 - exon 2 boundary. Therefore to the 
best of our knowledge in silico the Mdm2 P2-Mutant promoter region effectively abrogates 
p53-responsiveness with minimal impact on the surrounding features. The activity of the 
Mdm2 P2-Mutant promoter region was then examined in vitro along with the previously 
designed Mdm2 P1-Null promoter region.
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Table 3.3.2: Alterations in the putative transcription factor binding sites (TFBS)... 
...between the wild-type and mutant p53 RE region of the Mdm2 gene (+/- 40 bp). Oryza 
sativa is Asian rice and Triticum aestivum is common wheat. The score value is a statistical 
measurement of how well the model matches the actual DNA sequence (the higher the value 
the higher the significance). The E (expect) value is a measure of how often it might be 
expected to see this sequence purely by chance hence the higher the value the lower the 
significance - compare with the genuine murine p53 RE sites.
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Deleted T01806 p53 + 41 60 9.9 0.6 Mus
musculus
Inserted MA0105 NFKB1 + 50 60 2.9 7 Homo
sapiens (p50)
Inserted MA0023 Dl_2 50 59 0.8 19 Drosophila
melanogaster
(DorsalJ?)
Inserted MA0105 NFKB1 50 60 2.7 7.8 Homo
sapiens (p50)
Deleted M00507 TRAB1 - 50 59 3.1 7.7 Oryza sativa
Deleted T01098 EmBP-1b 54 59 2.4 20 Triticum
aestivum
Deleted MA0028 ELK1 56 62 2.2 14 Homo
sapiens
Deleted T01806 p53 + 79 98 8.9 1.2 Mus
musculus
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Wild-type Mdm2 P1-P2 locus
The murine PI region is the 
145 bp immediately upstream 
of exon 1
The P2 region is the 237 bp 
immediately upstream of 
exon 2, including the EtsA & 
B, and API sites (Ras 
activated) and the p53 REs.
Mdm2 PI-Null
The PI region is deleted (163 bp total including 22 bp of Exonl)
In mice will be replaced with 132 bp of spacer-DNA including foxP sites
Mdm2 P2-Mutant
Exonl
8 bp substitutions, including 5 bp in the p53 RE itself and 3 bp in spacer
Figure 3.3.37: Design of the Mdm2 promoter mutations.
Schematic diagrams of the wild-type, P1-Null & P2-Mutant Mdm2 promoter regions. The 
details of each region are described underneath each one. The Lox P site is shown as a 
green arrow head. The red stripe in the P2 region in the Mdm2 P2-Mutant represents the 
mutated p53 REs. The sequence detail and alignment of specific features of the wild-type, 
P1-Null and P2-Mutant promoter regions are shown in Figure 3.3.39, Figure 3.3.38 & Figure 
3.3.40 respectively.
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Wild-type Afcfrn2 i^I?9i£n_ _ _ _ I essential region_________________
GTTTCGAGCG GTAAACACAA CCGCGCGGCC CCTCCCCACC TCCTGCGCGC TCCGGCACCG -103
GGCGGCCGCT AAGCCCCGCC CCCCGCCTCC TATTGGTCCA GGAGGCGGCG TCGGGCGTGC -43
-----------------------------------------------------------------------------------------------------Exon 1
GCGCGCGCAC GCCCCGATGC CCGGATGGCC CGTGGCTTCC GGCGTTCTCT CCGCGGACGG 17
Sfll
TAGGGGGCGC TCGTCACAGA ACTCTGCTTT GTTAACGGGG CCTCCGGGGC CAGCGTAGCC 77
Mdml PI-Null I
The entire essential PI region is deleted (163 bp total including 22 bp of Exonl) 
In mice will be replaced with 132 bp of spacer-DNA including ioxP site
GTTTCGAGCG GTAAACACAA CCctcqagga attccgatca tattcaataa cccttaatat -94 
_________________ LoxP site______________________
aacttcgt at aatqtatqct atacqaagtt attaggtctg aagaggagtt t acgtccage -34
Exon 1
Caagctagct tggctgcagg tcgagtaccc cgggGGCGCT CGTCACAGAA CTCTGCTTTG 26 
________ Sfil________
TTAACGGGGC CTCCGGGGCC AGCGTAGCCT AGGAGCGGCC GGTGAGGAGC CGCCGCCTTC 86
Figure 3.3.38: Sequence detail following deletion of the Mdm2 P1 promoter.
Top panel: The wild-type Mdm2 P1 promoter region is the 145 bp upstream of exon 1 shown 
in purple text as defined by [Chang et al., 2004], The P1 minimal essential region was inferred 
from the conserved features between human and mouse Mdm2 [Phillips et al., 2006], Bottom 
panel: The predicted DNA sequence at the P1 region following deletion in transgenic mice. 
The P1 minimal essential region will be replaced with 132 bp of spacer DNA, leaving only 4 
residual bp of the original promoter region.
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Essential PI region
GTTTCGAGCG GTAAACACAA CCGCGCGGCC CCTCCCCACC TCCTGCGGGC T CCGGCACCG -103
GGCGGCCGCT AAGCCCCGCC CCCCGCCTCC TAT TGGTCCA GGAGGC GGC G TCGGGCGTGC -43
GCGCGCGCAC GCCCCGATGC CCGGATGGCC CGTGGCTTCC GGCGTTCTCT CCGCGGACGG 17
Sfil
TAGGGGGCGC TCGTCACAGA ACTCTGCTTT GTTAACGGGG CCT CCGGGGC CAGCGTAGCC 77
T AGGAGCGGC CGGTGAGGAG CCGCCGCCTT CTCGTCGCTC GAGCTCTGGA GCGACCATGG 137
TCGCTCAGGC CCCGGCCGCG GGGCCTCCGC GCTCCCCGTG AAGGGT C GGA AGAT GCGCGG 197
IECS
GAAGT AGC AG GTACCCGCTC CGTGGGCGGC GGAGAGTCCC GATCATTCCC TCTTTTCCGC 257
GCCCTCCGGG GCCTACTCGT AACCCGGGCC GGCTCGTGGG GTCGCGGGGC ACGAGGCT GG 317
GCGACCGTTT GCCCGCGCTG GGCCCTGATG TCATTCTGCG GCCGGGGGT G TGCGTGTGGG 377
TGGGAGTGGG GGGTGGGGTG GGAGATGGCG CGGTTAGCAC GGCGCATGCG CGGGAGGGGA
P2
437
CGGAGGGAGG GGGAGGAGGG AAGAGCGGGG GTCTCCCAGC AGGCCCCGCG CGCGGGGGGC 497
CCGCTCCGGG GTCGCGCTGG
•t-------
GCTCGTTGCT
EtsA
GGGGTCCAGG AGGTGACAGG TGCCTGGTCC
AP-1
557
CGGACTCGCC
EtsB
-4-----------------------
GGGATGCGGC TTCCGGGACG
p53RE
GGTGGGACTG GGCTGGGCCG AGTTGACTCA 617
GCT^TG TGGGGCTGGT CAAGTTGGGA CACGTCCGGC 
4 TATA BOX
GTCGGCTGTC GGAGGAGC T A
..Exon2
CAGCCGTCTG
677
AGTCXTTGACA TGTCTCCAGC T GGGGTTATT TAAACGCTGC CCCGTTTCCG 737
CTGGGCGAGC GGGAGACCGA CCGGACACCC CTGGGGGACC CTCTCGGATC ACCGCGCTTC 797
TCCTGCGGGC CTCCAGGTAA GGGACAGCTC GCCGACGTCG TTTTGCATTT GAGAGCTATT 857
GCCGAAAGAC GTTTTCTGTC TCCTTCX5TAA ATGCATGTAT CTATTTGTCC CTTTTCGTAG 917
Exon 3
ATGTTTTATA ATTTCAAGTT TTTATCGTGT GTGTTGTTGT TTTTTTTCTA CTTGTAGGCC 977
AATGTGCAAT ACCAACATGT CTGTGTCTAC CGAGGGT GC T GCAAGCACCT CACAGATTCC 1037
AGCTT CGGAA CAA.GAGACTC TGGTTGGTAT TTCTGCCTCG AGTGTGTAAA TATAGCTTGT 1097
SexAl
TTTACCAGGT AATCGAGGAA ACAAAAT T GA AACC 1157
Figure 3.3.39: Sequence detail and features at the Mdm2 P1 - P2 locus.
Based on [Phelps et ai, 2003]. The 1294 nt Mdm2 DNA sequence including the 145 nt 
upstream of exon 1 which contains the essential region for the Mdm2 P1 promoter (purple 
text) and the 273 nt P2 region (dashed red line). Exons are shown in green text, the p53 REs 
(red text) and other features are also shown including IECS (Brown), EtsA, EtsB (blue) AP-1 
(orange), AP-4 (pink) and putative TATA BOX. The ATG translational initiation site is within 
exon 3.
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* Separated by 0-13bp
Consensus 5' -PuPuPuCWWGPyPyPy*PuPuPuCWWGPyPyPy-3'
Common
Bases
Mdm2 left GGTCAAGTTGGGACACGTCC
Match COHSSnSUS aajjaaaaaa^aaaaajcaaaa 
OUR MUTATIONS -
Mdm2 right AGCTAAGTCCTGACATGTCT
Match CODS0DSUS aaj^j^aaaaaa^aaaaaaaaa
OUR MUTATIONS
p53RE
GGTCAA TTGGGA AC
tGC gtc ggc t gtc gga :
iGGCGTCGGCTGTC cat
p53RE
MUTATIONS INTRODUCED
Ncol 
Site introduced MUTATIONS INTRODUCED
Figure 3.3.40: Specific point mutations introduced to Mdm2 to create the P2-Mutant.
Figure based loosely on [Wei et a!., 2006]. From the top line down: the consensus p53 RE 
site followed by the most common bases and then the actual Mdm2 p53 RE sequences (left 
then right). Mutations were systematically introduced in order to render the p53 RE sites 
inactive, starting with the most conserved bases (see methods Section 2.8.2). 8 base pair 
mutations were introduced in total; 5 bp substitutions were introduced to the p53 RE site and 
a further 3 mutations were placed in the spacer region (to create an Ncol site for screening 
targeted ES cells/transgenic mice).
KEY Pu = purine (A/G), Py = Pyrimidine (C/T), W = Weak (A/T).
273
Wild-type Mdm2p63 RE region +/- 40 bp
e-rrs
Tallb*4«-C47S
(*>-« LBP-l mr~2
P2-Mutant Mdm2p53 RE region +/- 40 bp
Figure 3.3.41: Putative transcription binding sites at the Mdm2 P2 locus
The Mdm2 p53 RE sites +/- 40 nt were analysed by MAPPER to identify putative transcription 
factor binding sites (TFBS) [Marinescu et al., 2005]. This figure shows the graphical output 
from these searches, arrows are indicative of a predicted binding site. A) The wild-type Mdm2 
p53 RE region and B) The mutated Mdm2 p53 RE region generated for this thesis. The P2- 
mutant sequence has lost its p53 REs but still contains the known upstream TFBS Ets and 
AP-1 and downstream AP-4. The TFBS p50 and Dorsal-2 have been added whilst the TFBS 
TRAB1, EmBP-1b and Elk-1 have been deleted, summarised in Table 3.3.2.
274
Results
3.3.5.2 In vitro validation of the Mdm2 promoter region mutations
To determine whether the previously described mutations (see Section 3.3.5.1) 
introduced to the Mdm2 P1/P2 promoters had significantly impacted on the activity of these 
promoters an in vitro luciferase assay was performed. To perform this analysis the whole P1- 
P2 promoter region (-1600 bp including 300-400 bp of upstream and downstream sequence) 
was cloned into pGL4.11 (a simple promoterless luciferase plasmid) and transfected into p53 
null cells with and without murine p53. The cloning of these vectors is described in Appendix 
C.4. The luciferase assay was performed in p53 null human non-small cell lung carcinoma 
cell line H1299 and p53 null MEF in triplicate wells of a 48-well plate as described in Section 
2.13.8 and the results are shown in Figure 3.3.42 and Figure 3.3.43.
Following co-transfection with murine p53, the WT (wild-type) and P1-Null luciferase 
plasmids both had a massive increase in luminescence in both H1299 (45 and 83 fold, p- 
values = 0.009 and 0.003 respectively) and p53 null MEFs (5.5 and 18 fold, p-value = 0.004 
and < 0.001 respectively). On the other hand, the Mdm2 P2-Mutant promoter had its p53- 
dependent response completely abrogated in both H1299 and p53 null MEF cells (p-value = 
0.009 and 0.002). There was a trend for the P2-Mutant to also have slightly lower basal 
luminescence (without co-transfection with murine p53) although this was not significant (p- 
values = 0.051 (H1299) and 0.104 (p53 null MEF)). Importantly, for generation of the Mdm2 
P1-Null mouse, there were no significant differences between the p53-dependent expression 
values of the WT and P1-Null plasmids (p-value = 0.695 (H1299) and 0.918 (p53 null MEF)). 
This indicates that the absence of Mdm2 P1 promoter does not interfere with the p53 
dependent up-regulation from the Mdm2 P2 promoter.
The positive control plasmid pp53-TA-Luc, was also induced following co-transfection 
with murine p53. The increase in luciferase expression was less than the WT or P1-Null 
constructs in both H1299 (~ 14 fold reduction) and p53 null MEFs (~ 7 fold reduction) which 
may be due to the slightly different luciferase genes. pp53-TA-Luc contains the standard 
Luciferase gene, whereas pGL4.11 contains Luc2, a mammalian codon optimised version of 
Luciferase for more efficient translation and expression in mammalian cells.
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As might be expected the effects of deleting of the Mdm2 P1 promoter were more 
subtle however these differences were significant. The Mdm2 P1-Null had a 1.6 and 3.1 fold 
reduction in luciferase compared to WT in H1299 (p-value = 0.015) and p53 null MEF (p- 
value = 0.015) respectively. When the P1-Null basal luminescence levels were compared 
with the P2-Mutant this was also significantly different in the murine system (p-values = 0.643 
(H1299) and 0.002 (p53 null MEF)). The murine system is probably more sensitive since we 
are using the murine Mdm2 promoter regions which may be associated with more efficient up- 
regulation of the WT Mdm2 P1 promoter in mouse cells due to increased specificity of mouse- 
mouse transcription factor DNA binding interactions. The relatively higher basal 
luminescence in murine cells provides one explanation as to why the fold changes in the p53- 
dependent up-regulation of luciferase appeared greater in the human H1299 cells (45-80 fold 
compared with 5-18 fold increase).
In conclusion, since the Mdm2 P2-Mutant was not p53 responsive and had 
comparable baseline expression, this indicates that the mutations designed are ideal to use in 
a transgenic model to study the p53-dependent up-regulation of Mdm2. Also, since the 
Mdm2 P1-Null had compromised basal expression but still had comparable p53-dependent 
induction of expression, this too indicates that the P1 promoter deletion has worked as 
designed and would therefore be suitable to use in a transgenic model to study the p53- 
independent up-regulation of Mdm2. This thesis will now go on to describe how the two DNA 
targeting constructs for each of the Mdm2 promoter mutant mice were generated.
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Figure 3.3.42: In vitro testing of the Mdm2 promoter mutations.
A luciferase assay was performed on H1299 cells transfected with the indicated plasmids. Empty vector is the 
pGL4.11 plasmid (negative control) and pp53-TA-Luc is a luciferase gene under the control of a consensus p53 
binding site [Komarova et al., 1997] (positive control). WT, P2-Mutant and P1-Null are the various promoter regions 
cloned into promoterless luciferase plasmid pGL4.11. +p53 indicates co-transfection with murine p53. Values shown 
here are luminescence corrected for protein concentration. Readings were obtained from triplicate wells of a 48-well 
plate and Error bars are the SEM. The bottom panel shows the same data without the ‘WT +p53’ and ‘P1-Null +p53’ 
treatment groups in order to expand the scale for better comparison.
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Figure 3.3.43: In vitro testing of the Mdm2 promoter regions
A luciferase assay was performed on p53 null MEF cells transfected with the indicated 
plasmids, as detailed in Figure 3.3.42.
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3.3.5.3 Cloning strategy
Figure 3.3.44 shows the basic cloning plan for the generation of the Mdm2 P1-Null 
and Mdm2 P2-Mutant DNA targeting constructs. This plan utilises the natural ability of yeast 
cells to perform high efficiency homologous recombination between relatively short (200-400 
bp) regions of identical DNA [Storck et al., 1996]. Short recombinogenic arms (RA) are 
inserted either side of a yeast/mammalian positive selectable marker which when excised 
from its bacterial plasmid backbone (pRAY-Cre) acts as the donor DNA. The donor DNA 
recombines precisely in yeast cells where there is sequence overlap with the shuttle vector to 
introduce the positive selectable marker (pRAYNeoR). The shuttle vector contains 11 kb of 
genomic DNA around the Mdm2 promoter region, so that following insertion of the positive 
selectable marker, the resulting vector will contain two 4-6 kb arms of homology and could be 
used as the gene targeting vector. The genomic DNA would be obtained from a suitable BAG 
clone restriction digest and cloned immediately into the vector containing the negative 
selectable marker (TK2 - see Section 3.3.3.2), therefore, this method does not involve the 
labour intensive steps to generate the arms of homology as the previous method for p21- 
mCherry and Puma-E2Crimson did (see Section 3.3.3.7 and Section 3.3.4.1).
For generation of the Mdm2 P1-Null DNA targeting construct, the plan was to simply 
replace the P1 promoter region with the positive selectable marker. This could be effectively 
accomplished in just a few steps of cloning by selecting RAs either side of the P1 region since 
any DNA between the two RAs would be deleted [Storck et al., 1996]. For the Mdm2 P2- 
Mutant DNA targeting construct the point mutations were added to the shuttle vector first, by 
reconstructing the region through PCR-based techniques (see Figure 3.3.49). The 
pRAYNeoR cassette was then introduced ~700 bp downstream through homologous 
recombination in yeast. The construction of these vectors is described next.
3.3.5.4 Shuttle vector construction
The shuttle vector was required to contain an 8-15 kb section of 129SvEv genomic 
DNA isolated from a suitable restriction digest fragment from a BAG clone. A suitable DNA 
fragment would contain the Mdm2 P1-P2 promoter region and sufficient DNA sequence
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upstream and downstream to create at least two c. 4 kb arms of homology. The BAC 
restriction digest fragment would also ideally contain two unique restriction sites around the 
Mdm2 P2 site (or one restriction site twice) so that the region could be manipulated more 
easily. The BAC fragment should also be distinguishable by in silica digestion and ideally be 
cloned immediately into the negative selectable marker plasmid (TK2 - see Section 3.3.3.2) 
to avoid additional rounds of cloning.
Following sequence analysis of the ‘MdmZ BAC clone bmQ-305J12 DNA using the 
NEBcutter tool a 10,994 bp Pacl-Acll restriction digest fragment was identified (see Figure 
3.3.45). This Pacl-Acll fragment was cloned into a modified version of vector TK2 (named 
TK-Acll) as shown in Figure 3.3.46. The TK2 vector was modified to remove the two Acll 
sites in the AmpicillinR cassette and to introduce a new Acll site just downstream of the Pad 
site. The removal/addition of the Acll sites in TK2 allowed the 11 kb Pacl-Acll BAC restriction 
digest fragment to be cloned directly into the negative selectable marker (TK-Acll). The 
transformation reaction was performed using the bacterial strain MAXstbl.2 to avoid any 
potential problems that might arise in association with cloning a large section of genomic DNA 
(such as DNA instability as seen with the p21 right arm of homology - see Section 3.3.3.7). 
4/39 colonies appeared positive through a Notl & Sail digest and Mdm2 specific PCR screen 
(see Figure 3.3.47). The positivity of these 4 promising clones (Mdm2TK-16, 22, 25 & 31) 
was then further confirmed by three additional restriction digests with Kpnl, Sacl and Xhol 
(see Figure 3.3.47 - C). Since all the DNA fragments appeared at their expected size and 
stoichiometric ratios, at this stage all the clones were deemed suitable for use in the next 
stage of cloning.
The next stage of cloning was to move the 13.1 kb JK-Mdm2 DNA fragment into the 
yeast-E. coli shuttle vector pRS414 via their common Sail and Spel sites. This cloning took 
four attempts to complete without obvious reasons for failure (detailed in Appendix C.5). The 
cloning was finally accomplished by using the TOP10 bacterial strain (rather than the 
MAXstbl.2 strain). 5/5 colonies appeared positive when bacterial colonies were screened by 
restriction digestion with Sail and Notl (see Figure 3.3.48). The positivity of two of these 
clones (pRSmdm2TK) was then further confirmed by two additional digests with Kpnl and 
Sacl. At this stage these clones (pRSmdm2TK-2 and 5) were both considered suitable for the
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next round of cloning. In the case of the Mdm2 P1-Null DNA cloning exercise, this DNA 
(pRSmdm2TK-2 or 5) could be used immediately in co-transformation in yeast cells; however 
for the Mdm2 P2-Mutant additional rounds of cloning in bacteria were required first. The 
additional rounds of cloning were required to reconstruct the P2 region to include our desired 
point mutations. As alluded to earlier, there are two unique restriction sites around the Mdm2 
P2 region, Sfil and SexAl, which define a 1024 bp DNA fragment {see Figure 3.3.39). This ~1 
kb DNA fragment was amplified by PCR to introduce the desired point mutations as outlined 
in Figure 3,3.49. Briefly, the DNA fragment was amplified in two sections which separated the 
p53 RE sites and allowed the mutations to be introduced by use of specially designed 
‘mutating’ primers. These two initial PCR products A and B in Figure 3.3.49 were TA-cloned 
into pCR2.1, screened by restriction digest with EcoRV and Spel, then sequenced to ensure 
successful incorporation of the desired base pair substitutions. Once the DNA sequences 
had been confirmed, a further round of PCR was performed to fuse these two sections 
together. The resulting PCR product (C in Figure 3.3.49) was then also TA-cloned into 
pCR2.1 and screened by EcoRV and Spel restriction digest (see Figure 3.3.48 - C). 10/10 
clones appeared positive for the P2-Mutant region and one clone (10) was sent for 
sequencing. The DNA sequencing results were identical to the expected sequence and 
therefore this clone was used in the next step of cloning the P2-Mutant shuttle vector.
In order to create the Mdm2 P2-Mutant shuttle vector, the P2-Mutant Sfil-SexAl DNA 
fragment was then inserted into the pRSMdm2TK shuttle vector, however since the restriction 
enzyme SexAl was blocked by overlapping Dcm methylation the two vectors were first 
retransformed into Dcm/Dam negative bacterial strain “C2925” (see Figure 3.3.50 for an 
overview). The Mdm2 P2-Mutant region was then inserted into the shuttle vector by using 
their common Sfil and SexAl sites. 3/3 clones were positive when screened using an Ncol 
and Nhel restriction digest (see Figure 3.3.48 - D) and of these one was selected (pRSm-P2- 
1) for co-transformation in yeast cells. This report will now go on to describe the cloning of 
the Mdm2 P1-Null and P2-Mutant donor DNA.
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Intron from SV40 Simplified in 
other
diagrams to
pRAYNeoR
B
Short
recombinogenic 
arms 200-400 bp 
(PCR product)
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Figure 3.3.44: Basic cloning strategy for the DNA targeting constructs Mdm2 P1-Null and Mdm2 P2-Mutant.
A) Schematic diagram of the yeast/mammalian self excision positive selectable marker pRAYNeoR. pRAYNeoR 
contains the neomycin phosphotransferase cDNA driven by the Tk promoter, yeast selectable marker URA3 and the 
Cre recombinase gene as described in Figure 3.3.13 and [Bunting et al., 1999]. The cassette was flanked with two 34 
bp Lox P sites (green arrow heads in diagram). B) Schematic diagram of the pRAY-Cre vector adapted from [Storck 
et al., 1996]. pRAY-Cre contains the pRAYNeoR cassette with two multiple cloning sites either side which are used to 
introduce the recombinogenic arms. C) The donor DNA and D) The shuttle vector are co-transformed into yeast cells 
and homologous recombination occurs where there is sequence overlap. E) The resulting vector.
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Figure 3.3.45: Cloning the Mdm2 genomic DNA fragment.
A) BAC clone bmQ-305J12 was digested in silico to determine whether the restriction 
fragment containing the 11 kb Mdm2 fragment (red circle) would be distinguishable from other 
fragments, followed by an actual digest to confirm. The actual restriction digest pattern 
appears to accurately resemble the results predicted in the virtual gel. B) Schematic diagram 
of the 11 kb Pacl-Acll Mdm2 fragment. Since the regions of interest, the Mdm2 promoters P1 
(purple box) and P2 (orange box), are located approximately in the centre of this genomic 
DNA fragment, this provides two substantial flanking regions to act as the arms of homology 
for gene targeting (4.2 -6.7 kb).
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Figure 3.3.46: Flow diagram for the cloning of the Mdm2 shuttle vectors.
1. The 2 Acll sites in AmpR were removed from TK2 by digestion with Acll, followed by blunting and 
religation. 2. The resulting vector then had a new Acll site introduced at the unique Spel site. The Spel 
site was maintained for downstream cloning. 3. The 11 kb Pad-Acll BAC digest fragment was inserted 
into the vector TK-Acll using the mutual Pad & Acll sites. 4. The whole negative selectable marker 
(TK) and Mdm2 genomic region were then transferred into the yeast-E. coli shuttle vector, pRS414, via 
their mutual Sail & Spel sites. This shuttle vector (pRSMdm2TK) was then ready for use in co- 
transfection experiments in yeast to generate the P1-Null DNA targeting construct (P2-Mutant required 
additional cloning steps - see Figure 3.3.50).
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Figure 3.3.47: Confirmation of positive Mdm2TK clones.
A) Restriction digest analysis of Mdm2TK clones 1-19 with Notl & Sail. B) PCR screen with Mdm2 
specific primers - BAC clone 305J12 DNA was included as a positive control. * Clone 16 appeared 
doubly positive (for restriction digest and PCR). C) The 4/39 doubly positive promising clones were then 
examined further by additional restriction digest analysis with Kpnl, Sacl and Xhol. All four clones 
tested (16, 22, 25 & 31) had restriction fragments at the correct sizes therefore all four would be suitable 
for the next stage of cloning.
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Figure 3.3.48: Cloning of the Mdm2 shuttle vector.
Restriction digestion analysis of pRSMdm2TK clones. A) Initial test digest with Sail and Notl. 
5/5 clones appear positive. B) Further digests on clones 2 & 5 with Kpnl and Sacl. All DNA 
fragments appeared at the expected sizes and stoichiometric ratios. C) The mutated Mdm2 
P2 promoter region was TA-cloned into pCR2.1 (see Figure 3.3.49). 10/10 clones were
positive when screened with EcoRV and Spel. D) The P2-Mutant region was then inserted 
into the shuttle vector pRSMdm2TK. 3/3 clones appeared positive by restriction digest with 
Ncol and Nhel. Expected sizes of DNA restriction digest fragments are shown in boxes.
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Figure 3.3.49: Generating the Mdm2 P2-Mutant promoter region by fusion PCR.
Right panel: Schematic diagram of the fusion PCR steps to create the Mdm2 P2-Mutant 
region. PCR products A and B were TA-cloned into pCR2.1 and sequenced prior to use in 
the next round of PCR to create PCR product C. The primers P2Mutant5’ and P2Mutant3’ 
contained the desired point mutations which would be introduced following the first round of 
PCR. Left panel: Corresponding agarose gel photographs.
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Figure 3.3.50: Flow diagram of the cloning the Mdm2 P2-Mutant shuttle vector.
The plasmids pRSMdm2TK and P2-Mut-10 were retransformed into Dcm/Dam C2925 E. coli 
to allow the methylation sensitive restriction enzyme SexAl to cleave the DNA. The Mdm2 
P2-Mutant region was then inserted into pRSMdm2TK via their common Sfil and SexAl sites. 
Bottom left corner, the agarose gel which resolved the backbone (pRSMdm2TK ~ 17 kb) and 
insert (P2-Mutant ~1 kb) DNA.
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3.3.5.5 Donor DNA construction
The donor DNA was designed to contain the yeast/mammalian self-excision positive 
selectable marker pRAYNeoR flanked by two short (200-400 bp) genomic DNA fragments 
known as recombinogenic arms (RAs). These RAs were generated by PCR and were 
inserted into the relevant multiple cloning site of the plasmid pRAY-Cre (see Figure 3.3.44). 
In the case of the Mdm2 P1-Null cloning exercise, these RAs would determine which section 
of the P1 promoter and Mdm2 exon 1 would be deleted (see Figure 3.3.51). For the Mdm2 
P2-Mutant cloning exercise, the RAs would insert the pRAYNeoR cassette 715 bp 
downstream of the p53 RE point mutations (see Figure 3.3.52).
The cloning of the donor DNA plasmids was performed according to the cloning plan 
detailed in Figure 3.3.51 (P1-Null) and Figure 3.3.52 (P2-Mutant). All PCR products were first 
TA-cloned into pCR2.1, screened by EcoRV and Spel restriction digestion and then 
sequenced (see Figure 3.3.53 - A & B). Once the sequences were confirmed the RAs were 
then inserted sequentially into the pRAY-Cre vector using the indicated restriction enzymes. 
Positive clones were identified for successful integration of the RA by restriction digestion with 
various enzymes as shown in Figure 3.3.53 C-E. The exception to this was insertion of the 
P2 5’ RA, since this was inserted using unidirectional cloning and therefore an addition PCR 
screen was performed to determine the orientation (see Figure 3.3.53 - F). The final donor 
DNA plasmids were P1B2-3 and P2C3-8 for the P1-Null and P2-Mutant cloning exercises 
respectively. These vectors were then prepared for co-transformation into yeast cells by 
releasing the donor DNA fragment from the backbone by restriction digestion with Sail and 
Notl. Identification of positive yeast colonies and re-transformation of the recombined DNA 
back into bacteria is described next.
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Figure 3.3.51: Cloning of the Mdm2 P1-Null donor DNA.
The two RAs were amplified by PCR using the mdm2TK2-16 DNA as a template. Since the 
P1 region and first 22bp of Mdm2 exon 1 lie between the two RAs, this 163 bp region will be 
deleted during homologous recombination in yeast. The P1 5’ RA was introduced to the 
pRAY-Cre vector first, followed by the P1 3’ RA by the indicated common restriction sites. 
Once constructed, the donor DNA could be excised from its backbone plasmid P1B2-3 by 
restriction digestion with Sail and Not!.
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Figure 3.3.52: Cloning of the Mdm2 P2-Mutant donor DNA.
The two P2 RAs were amplified by PCR using the mdm2TK2-16 DNA as a template. There is 
no gap between the two RAs, hence the only modification in the F1 heterozygous mice should 
be the accumulation of ~ 100 bp of spacer DNA (including 34 bp LoxP stie) in Mdm2 intron 3. 
The pRAYNeoR cassette is 715 bp downstream of our P2-Mutated sequence since we did not 
wish to disrupt the promoter region other than in the p53 RE sites. Once constructed, the 
donor DNA could be excised from its backbone plasmid P2C3-8 by restriction digestion with 
Sail and Notl.
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Figure 3.3.53: Cloning of the Mdm2 donor DNA.
The RAs were amplified by PCR and TA-cloned into pCR2.1. A-B) Restriction digestion 
analysis with EcoRV and Spel to screen for positive clones (expected DNA fragment size is 
indicated at top of gel). *These clones were sent for sequencing. Once the sequence was 
confirmed the RAs were inserted into pRAY-Cre via their common restriction sites. C-E) 
Positive clones were identified by restriction digestion analysis with the indicated enzymes, 
expected DNA fragments are indicated underneath each gel. All clones shown here are 
positive. F) PCR reaction to determine the orientation of the P2 5RA once inserted into P23’-
Cre. Primer pair A indicates the correct orientation, whilst B is the incorrect orientation and C
is the positive control reaction. The PCR reactions were tested using clone P2C3-8 and 
fortunately this clones was positive (no further clones screened).
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3.3.5.6 Assembly of final constructs
Final assembly of the Mdm2 P1-Null and P2-Mutant DNA targeting constructs was 
intended to be performed by homologous recombination in yeast as described in Section 
3.3.5.3 however, due to unforeseen complications several additional cloning steps (in E. coll) 
were required to successfully complete the cloning of these two DNA targeting constructs. 
The main reason for the initial failure of homologous recombination in yeast (or rather the 
retransformation of correctly recombined yeast DNA back into bacterial cells) was primarily 
because we did not take into account the presence of the TK promoter within the pRAYNeoR 
cassette. The TK promoter (which drives expression of the neomycin phosphotase cDNA) 
shares significant sequence homology with the MCI promoter (which drives expression of TK) 
within the shuttle vector DNA. In fact analysis of the MCI and TK promoters revealed that 
they were virtually identical, except that the MCI promoter also contains a polyoma enhancer 
[Thomas and Capecchi, 1987]. As a result there existed a 275 bp identical sequence overlap 
between the TK and MCI promoters which was potentially sufficient to allow the yeast cells to 
perform homologous recombination between these sequences. This unwanted recombination 
event was found to be not only a potential, but an actual problem since it simultaneously 
deleted the TK cassette and the 4-5 kb region intended to be the Mdm2 left arm of homology 
and the resulting smaller vector was preferentially propagated when yeast DNA was 
retransformed into E. coll.
This cloning strategy setback was overcome in two different ways; therefore the 
cloning of the P1-Null and P2-Mutant DNA targeting constructs are discussed separately. 
Cloning of the Mdm2 P2-Mutant DNA targeting construct is described first, since this was 
completed without amending the original P2-Mutant shuttle vector whilst the Mdm2 P1-Null 
DNA targeting construct is discussed afterwards, since this cloning exercise (which took 
longer to complete), also required redesigning of the P1-Null shuttle vector (pRSMdm2TK).
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3.3.5.6.1 Mdm2 P2-Mutant
Following co-transformation of the P2 shuttle vector (pRSm-P2mutant) with the P2 
donor DNA (excised from P2C3-8) in yeast, 100 + yeast colonies were obtained after 2-3 
days of growth on Trp'/Ura' (“drop out”) plates (see Section 2.2.1). 10 of these colonies were 
screened for successful integration of the donor DNA (and hence the positive selectable 
marker pRAYNeoR) by several PCR reactions (see Figure 3.3.54). Plasmid DNA isolated from 
the most promising yeast clones (P2Y1, P2Y5 & P2Y7) was then used to transform bacterial 
cells. This step, namely the transfer of the DNA targeting construct back into E. coli was 
required to generate sufficient quantities of high quality plasmid DNA for gene targeting 
experiments. It was also important to isolate individual plasmids since within a yeast ceil 
multiple copies of the shuttle vector can be propagated and it is possible that not all copies 
will contain the correct homologous recombination event (or indeed any homologous 
recombination event).
The yeast DNA was initially transformed into TOP10 cells (since this was the strain in 
which the shuttle vector was maintained) however despite screening ~20 clones we did not 
obtain any restriction digest patterns which matched with either the desired DNA targeting 
construct or the shuttle vector (see Figure 3.3.55 - A & B). These restriction digest patterns 
contained DNA fragments with very uniform sizes which perhaps indicated contamination with 
some unknown vector DNA. At this point we did not consider there to be a problem with the 
yeast-E. coli plasmid DNA since all the PCR screens (which had been repeated on the DNA 
extracted from the yeast cells) indicated that the desired homologous recombination event 
had occurred. The yeast colonies were re-streaked and fresh DNA was extracted and 
transformed into bacteria again nevertheless the same uniform digest pattern was observed. 
To attempt to resolve this problem, which we speculated might be due to difficulty in 
propagating the relatively large DNA construct in TOPIOs, various other E. coli strains were 
utilised including MaxStbl.2, CopyCutter, SURE, XL1-blue and DH5a. However the majority 
of restriction digestion patterns appeared much the same as for TOPIOs except for the 
occasional bacterial colony which had either a random digest pattern or seemingly uncut 
DNA. One of these occasional rare bacterial colonies (P2Y1a2) appeared to have at least
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some of the correctly sized DNA fragments and so was selected for further restriction digest 
analysis (see Figure 3.3.55 B & C).
Upon further analysis it emerged that the bacterial clone P2Y1a2 had somehow 
incorporated the pRAYNeoR cassette twice in the forward orientation. Fortuitously there is a 
unique restriction site (Cla!) within pRAYNeoR which was used to rescue the Mdm2 P2- 
Mutant DNA targeting construct as outlined in Figure 3.3.56. The resulting plasmid (P2TCIal) 
was confirmed by multiple restriction digests (see Figure 3.3.55 - C) and then sequenced in 
its entirety. The sequencing results for P2TC!al were identical to the expected sequences, 
therefore this clone was determined to be, to the best of our knowledge, a whole and accurate 
DNA targeting construct for the generation of a Mdm2 P2-Mutant transgenic mouse strain and 
was deemed suitable for use in gene targeting of ES cells (as described in Section 2.9.2.2).
It was during sequencing of this clone (P2TCIa!) that the 275 bp sequence overlap 
between the TK and MCI promoter regions became apparent. This unwanted region of 
homology enabled yeast cells to perform a second homologous recombination event which 
would result in the loss of the TK cassette and Mdm2 left arm region. Whilst the loss of this ~ 
7 kb region, did not completely explain the uniform restriction digest patterns observed during 
screening of bacterial transformants it did indicate that we needed to redesign the cloning 
strategy to increase the probability of obtaining the desired homologous recombination event. 
This redesigned P1-Null cloning strategy is detailed next.
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Figure 3.3.54: Yeast colony PCR screen for Mdm2 P2-Mutant
Top panel: Schematic diagram of the un-recombined and recombined Mdm2 P2-Mutant 
region, with alignment of primers (black arrows). PCR reactions were performed to test for 
the successful incorporation of the 5.2 kb pRA YNeoR cassette by homologous recombination 
in yeast. Primers were designed outside of the RAs so that generation of a correctly sized 
PCR product only occurred following successful integration. Bottom panel: Example agarose 
gels for the indicated primer pairs. Yeast colony PCR was quite sensitive (indeed, the use of 
too many yeast cells easily inhibits the PCR reaction) therefore a negative result does not 
always reliably indicate the absence of the target DNA region. From these screens P2Y 
clones 1, 5 & 7 were selected for retransformation into E. coli.
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Figure 3.3.55: Cloning the Mdm2 P2-Mutant DNA targeting construct.
A) Example of a typical restriction digest pattern observed when yeast DNA was
retransformed into various strains of E. coli (XL1-blue and TOP10 shown here). B) Another
restriction digest screen of retransformed yeast DNA, this time in DH5a. Only clone 2 
(P2Y1a2) appears to contain some of the correct sized DNA fragments. C) Restriction 
digestion analysis of bacterial clones P2Y1a2, P2TCIal, and P2 shuttle vector (pRSm- 
P2mutant) with various enzymes as indicated to confirm the positivity of P2TCIal. All DNA 
restriction fragments appear at the expected sizes and stoichiometric ratios, therefore vector
P2TCIal was sent for complete sequencing.
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Figure 3.3.56: Final assembly of the Mdm2 P2-Mutant DNA targeting construct.
Flow diagram for the final step in cloning the Mdm2 P2-Mutant DNA targeting vector. The 
double insertion of the pRA YNeoR cassette could be rescued by digesting with Clal and re­
ligating the 22.4 kb backbone.
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3.3.5.6.2 Mdm2 P1-Null
Cloning of the Mdm2 Pi-Null DNA targeting construct had been previously hindered 
by the unintentional inclusion of an additional region of homology between the shuttle vector 
and donor DNA (discussed in Section 3.3.5.6). Therefore the cloning strategy was 
redesigned to remove the TK cassette (containing one of the unwanted regions of homology) 
from the shuttle vector before homologous recombination in yeast and then to reintroduce it 
afterwards (see Figure 3.3.57 and Figure 3.3.58).
The TK cassette was removed from the P1 shuttle vector (pRSMdm2TK) by digestion 
with restriction enzymes Sail and Paci, the DNA ends were then blunted and the vector 
reiigated to create a smaller plasmid (pRSm-TK). 4/4 bacterial transformants appeared 
positive for removal of the 2.1 kb TK region when screened by restriction digestion with Kpnl 
and Sacl (see Figure 3.3.57). One of these clones (pRSm-TK1) was selected to be the 
shuttle vector in a second round of homologous recombination in yeast.
Following co-transformation of the new shuttle vector (pRSm-TK1) and donor DNA 
(excised from P1B2-3) in yeast, 100 + yeast colonies were obtained. DNA was extracted 
from 12 yeast clones and screened for successful incorporation of the pRAYNeoR cassette by 
several PCR reactions as shown in Figure 3.3.59. The most promising clones (P1YB-5, 11 
and 12) were then transformed into £. coli strain SURE. SURE bacteria were used since they 
were readily available and previously had demonstrated high transformation efficiency with 
DNA prepared from yeast cells (see Section 2.7.2.5 for method). 5/14 transformants 
appeared to contain the correct DNA fragments when screened by an initial test digest with 
Hindlll. All five of these clones were from the transformation of yeast clone P1YB-5. 
Following additional restriction digests to further confirm the positivity of these clones with 
Ncol, Notl, Kpnl and Sacl (see Figure 3.3.60 - A & B) one clone (P1 Target-1) was selected 
for the final stage of cloning.
The ultimate step in cloning the Mdm2 P1-Null DNA targeting construct reintroduced 
the negative selectable marker to allow for double selection (positive and negative) during 
gene targeting in ES cells as discussed in Section 2.9.2.2.4. The TK cassette was excised 
from TK2 by double digestion with Fsel and Pad, blunted and then inserted into the blunt 
Swal site within the TRP1 gene of the P1Target-1 vector (see Figure 3.3.58). 1/5 of the
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resulting colonies appeared positive for insertion of TK by restriction digestion with Kpnl and 
Sacl (see Figure 3.3.60) and this clone (P1Target+TK-3) was sent for sequencing to confirm 
the DNA sequences at the cloning junctions between the assembly vectors. The sequencing 
results for P1Target+TK-3 were identical to the expected sequences, therefore this clone was 
determined to be, to the best of our knowledge, a whole and accurate DNA targeting 
construct for the generation of a Mdm2 P1-Null transgenic mouse strain and was deemed 
suitable for use in gene targeting of ES cells.
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Figure 3.3.57: Re-cloning of the Mdm2 P1-Null shuttle vector.
A) Flow diagram for the removal of the TK cassette from the original shuttle vector 
pRSMdm2TK. The 2.1 kb TK cassette was removed by digestion with Sail and Pad. The 
DNA ends were blunted then the plasmid was religated to form pRSm-TK. B) Restriction 
digestion of pRSMdm2TK. The 15.7 kb backbone DNA fragment was extracted from the gel 
for generation of the pRSm-TK vectors. C) 4/4 clones appeared positive when screened by 
two different restriction digests Kpnl and Sacl. P stands for the parental vector, in this case 
pRSMdm2TK.
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Figure 3.3.58: Final assembly of the Mdm2 PI-Null DNA targeting construct.
Flow diagram of the ultimate step in cloning the Mdm2 P1-Null DNA targeting construct. The 
negative selectable marker (TK) was reintroduced to the targeting vector to enable both 
positive and negative selection during ES cell targeting experiments. The TK fragment 
released from TK2 by digestion with Fsel and Pad, this was blunted and then inserted into 
the blunt site Swal within the TRP1 gene (a yeast selectable marker) of the P1 Target vector. 
The resulting vector P1Target+TK could be linearised by restriction digestion with Sail.
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Figure 3.3.59: Yeast DNA PCR screen for Mdm2 P1-Null.
Top panel: Schematic diagram of the un-recombined and recombined Mdm2 P1-Null region, 
with alignment of primers (black arrows). Bottom panel: Example agarose gels for the 
indicated primer pairs. PCR reactions were performed on DNA extracted from yeast clone 
liquid cultures. + indicates a positive control, the negative controls (H20) were combined 
post-PCR and run together. From these screens P1YB clones 5, 11 & 12 were selected for 
retransformation into E. coli (SURE strain).
303
P1-Null targeting vector clones digested with various enzymes
Sacl
3
4 ^ CL c 
I 2. Q. U
Kpnl
P1 Target 
11116 bp 
9016 bp
pRSm-TK 
11116 bp 
4624 bp
Sacl
P1 Target 
13362 bp 
6519 bp 
251 bp
pRSm-TK 
9221 bp 
6519 bp
P1-Null DNA targeting construct +TK
r
p
Kpnl
A
12 3 4 5 z. r~p 1
Sacl
A
2 3 4 5
Kpnl
P1T a rg et +TK (F w/R v) 
13260 bp 
9016 bp
PI Target (Parental) 
11116 bp 
9016 bp
Sacl
P1Target+TK(Fw) 
12347 bp 
6519 bp 
3159 bp 
251 bp
PITarg et+TK(Rv) 
12029 bp 
6519 bp 
3477 bp 
251 bp
P1 Target (Parental) 
13362 bp 
6519 bp 
251 bp
Figure 3.3.60: Confirmation of positive Mdm2 P1-Null DNA targeting construct.
A) Further restriction digests identify positive clones for retransformation of the yeast DNA 
into E. coli with Ncol and Notl. Despite low concentration of DNA loaded into the agarose gel, 
the correct sized DNA fragments were just visible on the Ncol digest (the 2.3 kb band has 
been digitally enhanced to be visible in this figure). B) Further confirmation of the P1 Target 
clones 1 & 2 by Kpnl and Sacl digests. C) The TK cassette was then reintroduced to the 
P1 Target construct and 1/5 clones appeared positive when screened by restriction digestion 
with Kpnl and Sacl (P1Target+TK-3).
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3.4 ES cell gene targeting
3.4.1 p21-mCherrv 1181 attempt)
The first attempt at targeting ES cells with the p21-mCherry DNA targeting construct 
was unsuccessful. Following electroporation and selection protocols there were only a few, 
very small (only visible under a microscope) ES cell colonies to pick off of the dishes at day 
11 of selection. These colonies grew very slowly, if at all. The reason or reasons for the slow 
ES cell growth was or were initially unclear since the preparation of the DNA targeting 
construct appeared to proceed as expected (see Figure 3.4.1) and the ES cells appeared 
healthy prior to electroporation. Further investigation, however, indicated that the failure of 
this first attempt at gene targeting might be due to the set-up of the GenePulser II during the 
electroporation since the actual recorded time constant (RC) was sub-optimal suggesting that 
the discharge might have been too rapid. Another factor that might have contributed to the 
slow growth of ES cells was the quality of our FBS. Although we were already using an ES 
cell approved FBS (HyClone), the batch that we used was only quality controlled by the 
supplier/manufacturer. Previous successful gene targeting had been performed using FBS 
from a batch tested and approved by the Bradley laboratory at the The Wellcome Trust 
Sanger Institute in Cambridge. According to their experts the batch-to-batch quality and ES 
cell suitability of FBS can vary tremendously [email communication with The Wellcome Trust 
Sanger Institute]. Fortuitously the The Wellcome Trust Sanger Institute had just finished 
batch testing a new lot of FBS (Invitrogen) which was of a high quality therefore it was 
decided to order fresh FBS from this batch and repeat the gene targeting experiment.
Southern blotting was necessary to locate where mCherry had integrated into the 
genome. Figure 3.4.2 contains an outline of the Southern blot strategy for identification of 
correctly targeted ES cells and genotyping the subsequent transgenic mice. However, initial 
testing of the 790 bp DNA fragment intended to act as the p21 Southern blot probe 
demonstrated that this probe was not specific enough. Instead of detecting a single DNA 
band this 790 bp probe detected a smear (see Appendix C.6). Therefore for future screening
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this probe needs to be redesigned. We therefore, in the meantime attempted to screen these 
slow growing colonies by PCR.
Despite the slow growth some (51 out of 140 picked) ES cell colonies did eventually 
reach confluence and these were screened for insertion of mCherry by PCR (see Figure 
3.4.3). 4/51 clones (20, 23, 34 & 36) appeared positive for insertion of mCherry however 
since these DNA bands were very faint when visualised by UV on an agarose gel we 
attempted to improve the PCR product yield (and perhaps identify other positive clones) by 
optimising the reaction conditions (see Figure 3.4.3 - C). Optimisation of the reaction 
conditions identified conditions using 2 pi of template DNA for 35 cycles. Unfortunately when 
the number of cycles was increased, this resulted in an unexpected and persistent 
contamination problem in the negative controls (the genomic DNA, the water, mCherry 
control) in both the mCherry specific and the positive control PCR reactions. The 
contamination was clearly on issue of technical competence since it was possible to generate 
clean controls. In the future it would be better to rely on Southern blotting (which is the better 
screen - since PCR is unable to localise an insert within the genome) to circumvent this 
problem.
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—* pv VH5-21 p21 -mCherry
^Vh5-21 p21 -mCherry ^ 500 ng test
500 ng test following DNA cleanup
Fsel Uncut Fsel Uncut
p21 right arm | backbone
Figure 3.4.1: Preparation of the gene targeting vector for ES cell electroporation.
A) 60 fjg of the p21-mCherry DNA targeting construct (Vh5-21) was digested overnight with 
Fsel to linearise it. B) Schematic diagram of the linearised gene targeting vector. C) Agarose 
gel electrophoresis was performed on 500 ng of the Fsel cleaved Vh5-21 vector to check for 
complete digestion. D) A second 500 ng sample was examined by agarose gel 
electrophoresis post DNA clean up (by PCI extraction see Section 2.3.10) to confirm that 
everything appeared as expected. An uncut control sample was included for comparison.
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Targeting construct EcoN1
mCherry
Wild-type genomic DNA
EcoN1
Wild-type 11,541 bp
Targeted genomic DNA - ES cells and Chimeras
EcoN1 nQ^Dc
probe .
790b p 1 mCherry
Recombined 16,349 bp
F, heterozygote progeny
EcoN1
Cre-mediated removal of Cre/NeoR 12,721 bp
Figure 3.4.2: Southern blot strategy for p21-mCherry.
Following a successful homologous recombination event in ES cells, the self-excision 
neomycin cassette (Cre/NeoR -shown in red with green arrows) is integrated into intron 1 of 
p21 (exons blue boxes shown numbered). The Southern strategy utilises restriction enzyme 
EcoN1 which cuts only once inside the targeting construct and relies on a specific upstream 
EcoN1 site to generate products of the expected size. Since the probe hybridises outside of 
the targeting construct (upstream of p21), the recombined fragment only occurs in the event 
of successful recombination. The same Southern blot strategy could potentially be used to 
genotype the first generation (F^ mice following the removal of Cre/NeoR by Cre-recombinase 
(see Section 3.3.3.6).
308
Results
ES Cell colony PCR screen on clones 33-51
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Optimisation of ES Cell colony PCR. Increase template and increase cycles. 
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Figure 3.4.3: ES cell colony PCR screen.
PCR results for p21-mCherry ES cell clones 33-51. A) mCherry specific PCR and B) positive 
control reaction (to determine if DNA was extracted and whether it was acceptable quality for 
PCR). *Clones 34 & 36 appeared positive although these bands were very faint. C) 
Optimisation of the ES cell colony mCherry specific PCR reaction to improve yields. 
Optimised PCR reaction conditions used 2 pi of template DNA (see Section 2.3.12 for DNA 
extraction method) for 35 cycles. However contamination was a problem when 35 cycles 
were used (wild-type genomic DNA also produced an apparent mCherry specific product- red 
circle). Primers were; pmChPROBEF & pmChPROBER for mCherry specific PCR reaction 
and p21ln1+2kb & p21ln1+3kbR for the control reaction.
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3.4.2 Mdm2 P2-Mutant
The second attempt at gene targeting was performed using the Mdm2 P2-Mutant 
DNA targeting construct. This round of ES cell targeting proceeded much more smoothly 
then the previous attempt and there were large numbers of easily visible ES cell colonies by 
day 9 of selection. Approximately 600 (6 x 96-well plates) ES cell colonies were picked for 
expansion and screening. Potential positive clones would be identified initially by using 
Southern blot analysis and then by sequencing of PCR products (to ensure successful 
incorporation of the point mutations within the P2 region).
Figure 3.4.4 shows the outline of the Southern blot strategy designed to screen for 
successful incorporation of the positive selectable marker (pRAYNeoR) in targeted ES cells. 
Using this screen, 10/208 colonies have so far been identified as containing pRAYNeoR 
cassette correctly integrated at the Mdm2 locus (see Figure 3.4.5). The homologous 
recombination efficiency in clones screened to date is ~ 4.8%. Whilst this is encouraging, it 
does not unequivocally demonstrate that the P2 mutation has been incorporated. This is 
because the positive selectable marker is ~ 700 bp downstream of the P2 point mutations 
therefore there is a small chance that the homologous recombination event has occurred 
within that region and if so, our desired mutations would not have been integrated into the 
genome. Also, even if the P2 point mutations have been successfully incorporated the 
aforementioned Southern blot strategy is unable to detect random recombination events 
which may have occurred simultaneously during ES cell targeting. These issues will need to 
be resolved prior to use the of these ES cell clones in micro-injection experiments for the 
generation of chimeras. These issues will be addressed in two separate ways which are 
discussed next.
In order to determine whether the P2 mutations have been incorporated into the 
genome the P2 region (of the ES cells clones which are positive by Southern blot analysis) 
will be amplified by PCR and sequenced. Since the template DNA will also contain the wild- 
type allele we will be looking for mixed peaks on the chromatogram at the expected mutated 
base pairs. Alternatively the P2 region PCR product could be cloned into pCR2.1 and 
transformed into E. coli, to enable single PCR products to be sequenced and reduce the 
ambiguity surrounding mixed peaks.
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In the meantime the Southern blot screen will be repeated but instead of using a 
Southern probe that detects a region outside of the DNA targeting construct, we will use one 
designed to anneal within the pRAYNeoR cassette to create a single fragment of 12.7 kb. If 
non-specific bands appear during this Southern blot analysis it would be indicative of an 
additional unwanted random recombination event{s). This screen was not performed 
originally since without a probe based outside of the DNA targeting construct, an expected 
size shift alone does not guarantee integration at the correct loci (since the correct expected 
sizes could occur purely by chance). Due to time constraints these important controls have 
yet to be performed.
The restriction enzyme Ncol which was introduced by the P2 point mutations will be 
used to help genotype transgenic mice, rather than correctly targeted ES cells (see Figure 
3.4.6).
In conclusion, since we already have 10 pRAYNeoR positive colonies, it is highly 
likely that one or more of these contains the correct homologous recombination event and 
therefore we are in an excellent position to continue on and make the Mdm2 P2-Mutant 
transgenic mouse.
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Figure 3.4.4: Southern blot strategy for Mdm2 P2-Mutant - ES cells.
Following a successful recombination event, the self-excision neomycin cassette (pRAYNeoR 
shown in yellow with green arrows) is integrated into intron 3 of Mdm2 (exons green boxes 
shown numbered). The Southern strategy utilises restriction enzyme Ahdl which cuts only 
once inside the targeting construct and relies on a specific downstream Ahdl site to generate 
products of the expected size. Since the probe hybridises outside of the targeting construct 
(in intron 4 of Mdm2), the recombined fragment only occurs in the event of successful 
recombination.
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Figure 3.4.5: Southern blot analysis of targeted ES cells.
Example Southern blot film following a 3 day exposure. Southern probe hybridises to 
genomic Mdm2 region (outside of the targeting construct). Wild-type genomic DNA should 
yield a band at 8180 bp, whereas a correctly targeted clone will have both an 8180 bp band 
and a larger recombined band at 12741 bp. *One clone shown here is positive. The signal of 
the recombined fragment should be detected at approximately a 1:1 ration with the un­
recombined fragment band.
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Figure 3.4.6: Southern blot strategy for Mdm2 P2-Mutant - transgenic mice.
Following a successful recombination event, pRAYNeoR is integrated into intron 3 of Mdm2 
(exons green boxes shown numbered). The Southern strategy utilises restriction enzyme 
Ncol which is introduced by the specific point mutations of the P2-Mutant and by the positive 
selectable marker. Since the 1655 bp recombined fragment near the P2 locus is also present 
within the DNA targeting construct, this screen was not suitable to identify correctly targeted 
ES cells. However, following Cre-mediated removal of pRAYNeoR the resulting DNA 
fragments can be distinguished. The Ncol screen will therefore be used to help genotype 
transgenic mice.
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3.4.3 p21-mCherrv (2nd attempt)
The p21-mCherry gene targeting experiment was repeated as soon as new targeting 
construct DNA had been generated (see Section 2.3.5) and taking advantage of the, now 
proven, Sanger Institute ES cell —tested batch of FBS. This second attempt (the third ES cell 
targeting experiment) appeared much more successful than the first and like the Mdm2 P2- 
Mutant gene targeting experiment there were many (100 + colonies per 10 cm dish); large, 
rapidly growing, undifferentiated ES cell colonies, visible by day 10 of selection. 
Approximately 600 ES cell colonies were picked (6 x 96-well plates) however, due to time 
restraints these ES cell colonies have yet to be screened. Nonetheless, given the high 
homologous recombination frequency observed for the Mdm2 P2-Mutant construct we have 
every reason to believe it will be possible to isolate p21-mCherry positive clones.
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4.1 Investigating cell death along the crypt-villus-axis 
(CVA)
In order to study key aspects of p53 activation and regulation in vivo we examined the 
expression of p53 target genes p21 and Noxa along the CVA in response to DNA damage 
and also changes in p53 levels by using conditionally floxed Mdm2 null mice. We aimed to 
determine whether p21 and/or Noxa could be reliably used as reporters of p53 activity and 
thus assess their suitability for use in a dual p53 cell cycle arrest/apoptosis reporter system. 
The gastrointestinal tract was used as a model system since it has a well defined molecular 
and hierarchical cell structure (reviewed in [van der Flier and Clevers, 2009]) with dramatic 
differences in regards to cell death susceptibility within the tissue [Marshman et al., 2001, 
Leibowitz et al., 2011]. In this system, cycling cells within the crypt compartment readily and 
rapidly undergo massive p53-dependent apoptosis, whilst cells which are arrested in 
phase of the cell cycle and migrate onto the villus rarely respond to a wide variety of 
apoptogenic stimuli. As it has been demonstrated in this report, this lack of apoptosis on the 
villi is not simply due to a lack of p53 up-regulation, since even when p53 is induced in cells 
on the villi in the presence of genotoxic stress, these cells remain refractory to apoptosis. We 
therefore also aimed to investigate the uncoupling of p53 activation from apoptosis in cells on 
the villi by RNA expression array analysis.
In order to develop a dual cell cycle arrest/apoptosis p53 reporter system we planned 
to target p53 responsive genes using a targeted knock-in approach so that one allele of each 
selected gene would be replaced with a reporter gene (such as LacZ or florescent protein). 
An ideal target gene would preferably be exclusively activated by p53, invoke a specific 
response programme (such as cell cycle arrest or apoptosis) and would also not display any 
haploinsufficiency. Whilst the latter may not be completely achievable, we have set out to 
generate two reporter strains that would enable differential monitoring of p53 activation 
leading to cell cycle arrest and/or apoptotic responses.
In the case of cell cycle arrest, p21 appears to be an ideal reporter of p53 activity in 
the gut as identified by both our own experiments and previously reported work on p21 
expression in the intestinal epithelium following different stress stimuli [Pritchard et al., 1998,
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Wilson et al., 1998]. Indeed, consistent with previous findings, p21 up-regulation was 
demonstrated by IHC and confirmed by cell scoring data in the crypt region of c-Ref1 mice 
following exposure to 8 Gy of ionising irradiation in both the colon and small intestine (see 
Figure 3.1.1, Figure 3.1.2, Figure 3.1.4 and Figure 3.1.5). p21 protein was also strongly up- 
regulated in the crypt in response to p53 up-regulation by conditional knock-out of Mdm2 as 
shown by IHC (see Figure 3.1.6) and cell scoring data (see Figure 3.1.10 and Figure 3.1.14). 
The up-regulation of p21 was typically greater (as indicated by a higher scoring index) than 
up-regulation of p53 (see Figure 3.1.8 and Figure 3.1.13). In addition, in wild-type (including 
c-Ref1') animals which had received whole body irradiation, p21 also had a wider response 
than p53 (p21 expression was significant further along the crypt in comparison to p53). The 
expression of p53 coincided with the apoptosis curve in the crypt and peaked around cell 
positions 3-6, whilst the expression of p21 had a more bell shaped normal distribution and 
peaked around cell position 9-10 in the small intestine. The distribution pattern of p21 fits well 
with its known role as an inducer of cell cycle arrest and its pro-survival activities that 
generate conditions which favour repair of DNA damage rather than induction of apoptosis 
[Leibowitz et al., 2011, Cmielova and Rezacova, 2011]. In Mdmf°mox mice, p53 expression 
was generally increased over that of wild-type animals that had received whole body 
irradiation (see Figure 3.1.13) and p53 therefore had a comparable response to p21 up- 
regulation. Interestingly, the up-regulation of p53 and p21 in Mdm^°^ox mice was not limited 
to within the crypt compartment (as observed with wild-type mice), but also extended onto the 
villi (see Figure 3.1.7 and Figure 3.1.16 - discussed in more detail later in this section). 
These experiments have demonstrated that p21 expression is induced across the entire gut, 
in the colonic epithelium as well as the small intestine in response to ionising radiation and an 
increase in p53 levels when using conditionally floxed Mdm2 null mice. In conclusion, since 
p21 is essential for Gi phase p53-induced cell cycle arrest and is readily up-regulated by DNA 
damage in the gastrointestinal tract in a p53 dependent manner ([Wilson et al., 1998] and our 
own data) p21 would appear to be ideal surrogate indicator of p53 activity.
Noxa, on the other hand, may not be an ideal reporter of p53 activity since up- 
regulation of Noxa neither recapitulated an apoptotic response nor was Noxa reliably induced 
following various stress stimuli in the small intestine. Following exposure of c-Ref'' mice to 8
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Gy of whole body ionising radiation Noxa expression did appear to accurately report p53 
induction in the colon as shown by IHC (see Figure 3.1.1) and supported by cell scoring data 
(see Figure 3.1.4). However, in the small intestine Noxa was expressed at relatively high 
levels regardless of irradiation status as shown by IHC (see Figure 3.1.2 and Figure 3.1.3) 
and supported by cell scoring data (see Figure 3.1.5). Fei et al. have also shown that 
expression of Noxa (analysed by in situ hybridisation) can be independent of irradiation and 
p53 status in the small intestine [Fei et al., 2002], supporting the idea that Noxa may not be 
an ideal reporter of p53 activity in this context. Furthermore, when Noxa expression was 
examined in Mcfm2flox/fiox mice, Noxa up-regulation was dependent upon time from treatment 
rather than on p53 up-regulation. This Noxa up-reguiation may be a side effect of the gavage 
technique or may be triggered by BNF itself by an unknown pathway. It is also worth 
mentioning here that the observed staining for Noxa could well be an indication of a problem 
with the specificity of the antibody (anti-Noxa Anaspec) since we have been unable to find 
adequate citations for this product. Nevertheless, the expression pattern we observed 
(relatively high background in the small intestine regardless of irradiation status) was also 
reported by Fei et al. who examined this tissue for Noxa expression by in situ hybridisation 
with and without irradiation on both a p53 wild-type and p53 null genotype [Fei et al., 2002].
The apparently p53-dependent expression of Noxa in the colon paired with high 
background staining for Noxa in the small intestine (without a known stimulus) is somewhat 
reminiscent of another BH3-only protein; Bid. Bid was also examined for suitability to act as a 
downstream reporter of p53 apoptotic activity, however since Bid is expressed constitutively 
in the small intestine (albeit in a p53-dependent fashion) [Fei et al., 2002] it would not be an 
appropriate reporter gene. It is interesting to note similarities between these two BH3-only 
proteins which both bind selectively to pro-survival Bcl-2 family members (see Figure 1.4.10) 
and are speculated to act as sensitizers of cell death in this tissue [Shelton et al., 2009, 
Ploner et al., 2008] (discussed in Section 1.4.5.3). In conclusion, since Noxa does not reliably 
indicate neither p53 status nor an apoptotic response, it should not be used as the 
counterpart to p21 in a dual cell cycle arrest/apoptosis p53 activity reporter system.
Since Noxa turned out to be less than ideal candidate gene to act as a reporter for the 
p53-dependent apoptotic response to DNA damage, other p53 downstream target genes
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have been investigated (including Bax, Bid and Puma - see Section 1.4.5.3). The current 
literature indicates that Puma may be the best gene to compliment p21 in our dual cell cycle 
arrest/apoptosis p53 reporter system, since Puma is a key p53 target gene that mediates 
p53-induced apoptosis not just in the gut but also in other tissues, such as the spleen 
[Michalak et al., 2008]. We have not yet examined Puma up-regulation following y-irradiation 
in detail, however others have shown this to be dependent on p53 (at least in the Gl tract) 
[Qiu et al., 2008, Leibowitz et al„ 2011]. One obvious confounding factor in using Puma in a 
p53 activity reporter mouse is that Puma also has many p53-independent functions, including 
a role in oxidative stress induced apoptosis along the length of the villi [Wu et al., 2007] and 
during chronic colitis [Dirisina et al., 2011]. Nevertheless p53-dependent Puma-mediated 
apoptosis could be readily distinguished from p53-independent Puma induced apoptosis by 
the use of p53-null mice.
To summarise hitherto, past studies [Pritchard et al., 1998, Wilson et al., 1998] and 
more recent studies [Leibowitz et al., 2011] as well as our own data reaffirm that p21 is 
potentially an ideal reporter of p53 activation in the gut. Whilst initially there was no similarly 
straightforward downstream target gene for the apoptotic response to p53 activation in the 
gastrointestinal tract, our current literature search indicates that Puma (out of the others 
examined - see Sections 1.4.5) may be the best gene to compliment p21 in a dual cell cycle 
arrest/apoptosis p53 activity reporter system [Qiu et al., 2008, Leibowitz et al., 2011], 
However, since during the early stages of this project evidence for Puma’s role in p53- 
dependent activation of apoptosis was contradictory [Qiu et al., 2008, Fei et al., 2002] and we 
had yet to validate or investigate Puma expression ourselves (due to a lack of a reliable 
antibody), our research concentrated on developing the gene-trap p21 lacZ mouse in the first 
instance (see Section 1.5.1). The ultimate aim would be to develop a dual fluorescent 
apoptosis/celi cycle arrest p53 reporter system which would have wide-reaching applications 
in cancer research and for studying normal development.
We envision using these mice in the first instance to examine the long standing 
molecular phenomenon occurring in intestinal gut epithelium, in which cells on the villi display 
an uncoupling of p53 activation and apoptosis [Marshman et al., 2001, Leibowitz et al., 2011, 
Watson and Pritchard, 2000] (see Section 1.2.6). As stated earlier this lack of apoptosis on
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the villi is not simply due to a lack of p53 up-regulation, since even when p53 is induced in 
cells on the villi by conditional knock-out of Mdm2 these cells do not undergo apoptosis (see 
Figure 3.1.17 and Section 3.1.2.3). Furthermore, p53 positive cells on the villi still failed to 
undergo apoptosis even when an additional stress stimulus (14 Gy whole body irradiation) 
was applied (see Section 3.1.3.2). Why is there this apparently black and white switch in the 
cells behaviour along the CVA? One possible explanation for this may be that p53 on the villi 
is inducing cell cycle arrest instead of apoptosis. In line with this theory, cell cycle arrest gene 
p21 was up-regulated on the villi in Mdm2floxinm mice (both with and without irradiation see 
Figure 3.1.11 and Figure 3.1.15), however it is difficulty determine whether this interpretation 
(p53 induces cell cycle arrest) is accurate since no similar analysis was performed for a 
reliable p53-responsive apoptotic gene. In instances like these, where antibodies are 
unreliable (as for Puma), the use of an in vivo p53 activity reporter system as proposed by 
this thesis could provide a valuable tool with which to analyse the actions and outcomes of 
p53 up-regulation.
The unusual up-regulation of p53 on the villi has been reported previously by another 
group who also used a conditional Mdm2 knock-out system to study p53-mediated cell death 
in the intestinal epithelium [Valentin-Vega et al., 2008]. However, whilst we observed no 
increase in apoptosis along the length of the villi as a result of Mdm2 knock-out, conversely 
Valentin-Vega et al. report a small (0.06 -► 0.9 apoptotic cells/villi) but significant increase in 
apoptosis in the terminally differentiated cells of the villi. The reason or reasons for these two 
different results are investigated next. One major contributing factor might be that whilst 
methods used in these two reports may seem similar, the mechanism for conditional knock­
out of Mdm2 was fundamentally different between these experiments. Valentin-Vega et al. 
utilised the VHCre trans-gene to control activation of Cre-recombinase (and subsequent loss 
of Mdm2) rather then the CYP1A1 promoter region as in our Md/r?2flox/f,ox mouse system. The 
impact of this is that since the VHCre trans-gene [Madison et al., 2002] is active throughout 
mouse development the transgenic mice (denoted Mdm2'ntA) are born deficient in Mdm2 
which resulted in abnormal gut architecture due to excessive p53-mediated cell death (this 
phenotype was completely rescued on a p53 null background) [Valentin-Vega et al., 2008]. 
Therefore the villi examined by Valentin-Vega et al. by their own observation were atrophied,
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often inflamed, full of abnormal vacuole-like structures and had lost cell polarity which makes 
it difficult to compare them to villi found in a healthy, well organised adult gut. On the other 
hand, the CYP1A1-Cre trans-gene (in Mdm2?]0*Wox mice), is only induced by administration of 
aryl hydrocarbon compounds such as BNF [Campbell et al., 1996, Ryding et al., 2001] and 
therefore provides a model in which to study the effects of p53 up-regulation in 
morphologically normal adult gut. These fundamental structural differences may explain why 
Valentin-Vega et al. reported a significant increase in apoptosis along the length of the villus 
as a result of Mdm2 knock-out whilst we do not. For instance, since the Mdm2!nt* small 
intestine tissue is disorganised in structure it may be difficult to determine what constitutes a 
villi, or crypt/villus boarders may be less strict (possible given the loss of cell polarisation). In 
addition, as the villi are atrophied (and hence shorter) there may be bias for cross sectioning 
the villus tips more often and thus perhaps the increased apoptosis detected by Valentin- 
Vega et al. is simply a result of increased detection of p53-independent DICD. Finally, given 
the loss of the cell hierarchy the villi like protrusions in Mdm2!ntA mice are unlikely to reflect 
true villi, therefore we are confident that in morphologically normal adult Gl tract, p53 up- 
regulation and the apoptotic response on the villi remain uncoupled and require further 
investigation.
In order to investigate the differences in p53-mediated cell death along the CVA we 
performed an RNA expression array analysis on epithelial ceil fractions enriched for either 
crypt or villus cells. The experimental design was to include WT mice with and without 
irradiation in order to determine which genes are differentially regulated along the CVA as a 
result of DNA damage and an Mdm2f,ox/f,ox treatment group in order to determine the p53 
response independent of irradiation/DNA damage (outlined in Figure 3.1.17). The epithelial 
cell fraction collection and RNA extraction experiments were performed in collaboration with 
The Beatson Institute in Glasgow according to their previously optimised protocol (see 
Section 2.13.4). Prior to sending RNA samples for micro-array analysis, it was necessary to 
first check the purity and quality of the RNA and second to check whether the crypt/villus 
enrichment process was efficient. The initial quality control checks performed on the RNA 
samples, including UV spectroscopy and agarose gel electrophoresis, indicated that the RNA 
was of adequate purity and quality for micro-array analysis (see Table 3.1.1 and Figure
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3.1.18). However, the second quality control check, which utilised QRTPCR to validate the 
epithelial cell extraction procedure, indicated that there may be a problem.
Crypt/villus enrichment was determined by examining the fold changes in expression 
of known and validated crypt- {Lgr5 — [Barker et al., 2007, von Furstenberg et al., 2010]) or 
villus- (Max - [Mariadason et al., 2005]) specific genes. Whilst for the villus-specific gene 
Max, the enrichment protocol appeared successful (because Max was significantly increased 
in the villus fraction, p-vaiue = 0.01), this was not the case for the crypt-specific gene Lgr5 
(see Figure 3.1.19). Contrary to the expectation Lgr5 was also significantly enriched in the 
villus fraction (p-value = 0.017 - see Figure 3.1.19) most likely as a result of some 
contaminating crypt cells present in the villus fraction. Therefore we must conclude that the 
epithelial extraction protocol was unable, in our hands, to sufficiently fractionate cells along 
the CVA and on this decisive factor the cell extraction protocol used appeared to have failed. 
The reason or reasons for the failure of the enrichment process are discussed next.
Upon further investigation, it became apparent that the basic cell extraction method 
used in this thesis was inadequate to satisfactorily resolve epithelial cells along the CVA. The 
original CVA fractionation procedure developed by Weiser in 1973 for use in rats and most 
subsequent mouse friendly adaptations feature collection of multiple cellular fractions (5-10 - 
rather than just 2) over an extended time period (up to 115 minutes - rather then only 30 
minutes) [Weiser, 1973, Ferraris et al., 1992, Flint et al., 1991]. These methods also included 
a wash step (5-15 minutes in length), the purpose of which was to remove calcium from the 
tissues (by chelating agents - such as EDTA) in order to reduce protein mediated cell 
adhesion and facilitate cell shedding [Ferraris et al., 1992]. Increasing the number of cellular 
fractions may provide a mechanism for better separation of crypt and villus cells since there 
will be less overlap/ambiguity surrounding the contents of the first (mostly villus) and last 
(mostly crypt) samples - although this may have the disadvantage of generating lower RNA 
yields per fraction. Another potential drawback might be that the extended cell collection 
times at 37°C could adversely affect the integrity of the RNA samples [Flint et al., 1991]. 
Since the length of incubation presented in these methods is a concern when extracting RNA, 
it is worth noting that Mariadason et al. have successfully used one of these methods to 
perform gene expression profiling along the CVA [Ferraris et al., 1992, Mariadason et al.,
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2005]. This indicates that the increased length of collection time at 37°C does not appear to 
affect the quality of the RNA samples and hence this protocol seems compatible with our 
planned intention of performing RNA micro expression array analysis. Therefore, in 
conclusion, if the RNA expression array experiment (outlined in Figure 3.1.17) was to be 
repeated, the Ferraris et al. validated extraction procedure should be used instead [Ferraris et 
al„ 1992].
Potential experimental design drawbacks...
One potential criticism of the analysis of apoptosis in this thesis is that we were 
relying solely on identification of the morphological characteristics of apoptosis (such as cell 
shrinkage, membrane blebbing and the formation of nuclear bodies [Kerr et al., 1972]) as 
visualised by H&E (haematoxylin and eosin) staining. This may be a concern when 
attempting to detect apoptosis along the length of the villi, since cells only appear 
morphologically apoptotic once they begin to detach from the basement membrane 
[Shibahara et al., 1995]. However apoptosis may have already been initiated in 
morphologically normal cells and therefore the total amount of cells undergoing apoptosis 
may be underestimated. Marshman et al. have investigated this possibility by comparing the 
traditional H&E scoring method with two other commonly used methods for identification of 
apoptotic cells within the gastrointestinal epithelium. These were; IHC using activated 
caspase-3 antibody for staining and terminal deoxynucleotidyl transferase dUTP-mediated 
nick end labelling (TUNEL) method [Marshman et al., 2001]. In their study quantification of 
apoptosis by H&E staining compared favourably with activated caspase-3 staining within both 
the crypt and villi. In comparison, identification of apoptosis by TUNEL staining detected 
twice as many positive cells within the crypt compartment and was generally unreliable for 
detection of apoptosis along the length of the villi. TUNEL binding may overestimate 
apoptosis since non-specific nicks in DNA may also occur as a result of DNA damage 
induced by irradiation [Marshman et al., 2001, Ansari et al., 1993]. Importantly, since scoring 
apoptosis by H&E staining alone was as effective as activated caspase-3 staining it is unlikely 
that we have underestimated the apoptosis on the villi [Marshman et al., 2001].
324
Discussion
Another potential criticism of the experiments performed on the Gl tract to investigate 
the p53-dependent cell death for this thesis is that these experiments were not performed 
using p53 null mice which would definitively confirm whether the effects observed were truly 
p53-dependent. However, with regards to the selection of p21 and Puma for use in the dual 
cell cycle arrest/apoptotic p53 activity reporter system, their p53-dependence has already 
been repeatedly demonstrated [Leibowitz et al., 2011, Qiu et al., 2008, Wilson et al., 1998]. 
The apoptosis as a result of conditional knock-out of Mdm2 cells has also been demonstrated 
to be dependent on p53 [Valentin-Vega et al., 2008]. Therefore, for our purposes it was not 
strictly necessary to include those controls.
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4.2 Gene-trapping
Following selection of p21 as a suitable candidate gene to reliably indicate p53 
activation in the Gl tract our research was initially concentrated on developing a p21-LacZ 
reporter mouse. To accomplish this, we planned to take advantage of the gene-trapped ES 
cell lines available from the IGTC in the first instance because gene-trapping had the potential 
by-pass many of the complex and labour intensive molecular cloning stages involved in both 
the design and construction of DNA targeting constructs (see Section 1.5.1). The possibility 
of obtaining a Puma gene-trapped ES cell line was also investigated since according to our 
literature review Puma is a major p53 target gene for apoptosis in the Gl tract [Leibowitz et 
al., 2011, Qiu et al., 2008] and may be the most appropriate gene to complement p21 in our 
dual cell cycle arrest/apoptosis p53 activity reporter system. Generation and evaluation of the 
p21-LacZ and/or Puma-LacZ transgenic mouse lines would provide proof in principal that our 
targeted knock-in approach recapitulates an authentic report of expression in these genes. 
Assuming these transgenic mice respond to genotoxic stress in the expected manner we 
would then go on with our ultimate goal and target these loci with two different fluorescent 
markers to create an elegant in vivo system for monitoring p53-dependent programmed cell 
death and cell cycle arrest.
Unfortunately this relatively simple concept - to utilise the pre-targeted ES cell lines 
and rapidly create a proof in principal transgenic mouse strain - became a rather 
unproductive exercise which cost this project valuable time. Briefly, the p21 gene-trapped ES 
cell line which we had selected (AM0998 - generated by SIGTR) was intrinsically flawed from 
the outset since the gene-trapping vector (containing p-geo) had integrated upstream of the 
endogenous translational initiation site. This fundamental error meant that the LacZ portion of 
the P-geo was not detectably expressed in vitro and furthermore even if the LacZ had been 
expressed, we could not expect these cells to replicate authentic activation.
At this point in the project given the unavailability of an appropriate/affordable gene- 
trapped ES cell line, we returned to our original plan - that is a dual fluorescent cell cycle 
arrest/apoptosis p53 reporter system. This would be undertaken by generating our own novel 
DNA targeting constructs and performing gene targeting in ES cells.
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4.3 Generation of large DNA targeting constructs
4.3.1 Major obstacles
The bulk of the research project described in this thesis was spent undertaking the 
task of generating four separate DNA targeting constructs. As mentioned in Section 3.3.1 a 
molecular cloning exercise of this size is extremely labour intensive and time consuming 
owing to several contributing factors which are outlined below.
1) Large (4-12 kb) pieces of genomic DNA were included in the design of each gene 
targeting vector to be the arms of homology, however these could be;
a. Repetitive in nature and therefore impossible to PCR (such as the p21 right 
arm of homology see Section 3.3.3.7).
b. Repetitive in nature and therefore and extremely unstable in E. coli (see 
Section 3.3.3.9).
c. GC rich, which created problems for PCR (for example the Puma left arm of 
homology - see Section 3.3.4.1).
2) Reliance on PCR based techniques - whilst essential and a powerful mutagenesis 
tool - using PCR did have some drawbacks. These were;
a. PCR required optimisation and careful primer design - which was not always 
straightforward (such as the Puma left arm of homology see Section 3.3.4.1).
b. Sequencing had to be performed on each cloned PCR product to ensure that 
the DNA polymerase had not introduced any mutations.
c. Errors in the synthesis of long oligonucleotides (see Sections 3.3.3.3 - 
3.3.3.5) - resulting in incorrect incorporation of desired sequences.
3) DNA targeting constructs required many stages of sequential assembly so that failure 
of one step could halt progression of the whole cloning exercise until it was 
completed or redesigned to overcome the obstacle. This occurred at many stages of 
cloning and these are summarised (together with the solutions arrived at) in Table 
4.3.1.
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Table 4.3.1: Cloning issues encountered during the construction of large DNA targeting
constructs.
Cloning issues encountered Solutions arrived at
Negative selectable marker Since these mismatches were present in the parental vector
(TK) - sequencing revealed 9 (which had been used previously in our laboratory) this was
mismatches compared with the deemed suitable to use. (see Section 3.3.3.2 and Appendix
published sequence D.1).
p21 left arm of homology - Rather than amplify the p21 left arm of homology from the
deletion of ~ 70 bp when BAC clone DNA in one step, we amplified it in two steps
amplified by PCR. and pre-screened clones with a PCR reaction to identify
clones lacking the deletion (see Section 3.3.3.3 and Figure
3.3.7).
p21 left arm of homology - The NLS and restriction enzyme sites were not always
mutations within the primer incorporated correctly. These were screened by
regions. sequencing (see Section 3.3.3.3) and shorter primers were
designed for the subsequent cloning step.
mCherry-NLS sequence was Another clone was sequenced - which fortunately was
not incorporated correctly. identical to the expected sequence (see Section 3.3.3.4).
Shorter primers were designed for the next cloning step.
p21 left arm of homology fused Many clones (-60) were pre-screened by bacterial colony
in-frame with mCherry - PCR in order to identify 6 clones which did not contain the
deletion of - 70 bp and deletion. These 6 clones were then sequenced to check for
incorrect incorporation of successful incorporation of the NLS sequence and 5’ & 3’
primer sequences. restriction enzyme sites.
p21 left arm of homology fused A long homopolymeric run of As within the 3 - 4 kb region
in-frame with mCherry - a poly of p21 intron 1 which was 38 nt in the wild-type sequence
A run was mutated in all clones was observed to occur in various sizes in the 6 above
sequenced (6 in total). mention clones (36, 37 and 40 nt). One clone with 36 nt
was chosen as a compromise to continue with the cloning
exercise (see Section 3.3.3.5).
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Cloning issues encountered Solutions arrived at
Positive selectable marker These 3 mismatches were not present in the mouse
(Cre/NeoR) - sequencing genomic DNA RefSeq database and therefore these clones
revealed 3 mismatches were deemed suitable for downstream use to act as the
compared with published positive selectable marker (see Section 3.3.3.6).
sequence.
p21 right arm of homology - DNA was extremely repetitive. The right arm fragment was
PCR failed. cloned from a suitable restriction digest fragment of a BAC
clone instead (see Section 3.3.3.7).
p21 right arm of homology - Initially this appeared to have been solved by the use of
unstable DNA, resulting in specialised E. coli strain MAXStbl.2 (see Section 3.3.3.7)
random recombination of however the problem was never fully resolved. Growing the
plasmid. bacteria at 27°C rather then 30°C helped reduce
recombination. In order to confirm the positivity of bacterial
transformants extensive screening by bacterial digests was
performed to check for any loss of this ~10 kb repetitive
region (see Section 3.3.3.9).
p27-mCherry final construct Since Fsel and Pad were side by side in Vector 4 (see
assembly - inefficient double Appendix C.3), efficient double digest was only achieved if
digestion of Fsel-Pacl. plasmid was digested with Fsel, DNA purified, then
digested with Pad.
Puma left arm of homology - Long range (4-5 kb) PCR reactions were unsuccessful (see
difficult to PCR and restriction Figure 3.3.22), we then attempted to use a suitable BAC
digest of BAG clone DNA did restriction digest fragment however this was also
not appear as expected. unsuccessful - since the restriction digests did not produce
fragments of the expected sizes or stoichiometric ratios. In
order to amplify the entire 4.6 kb left arm region, the
problematic section of DNA was broken into smaller, easier
to manage pieces which were then ‘stitched’ together by
fusion PCR. 9 rounds of PCR in total - see Section 3.3.4.1.
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Cloning issues encountered Solutions arrived at
Puma left arm of homology - Cloning step repeated and additional clones screened until
30-100 bp deletion during the a wild-type clone was obtained (see Section 3.3.4.1).
penultimate round of PCR
Puma left and right arms of Multiple differences were observed (~50 in each arm of
homology - DNA sequences homology) which were identical between different bacterial
did not match the RefSeq clones - therefore these differences were assumed to be
database due to differences between C57BU6 and 729SvEv strains
rather than introduced by PCR (see Section 3.3.4.1).
Moving the MdmZTK fragment No obvious reason for failure. Using TOPIOs rather than
into the yeast-E. coli shuttle MAXstbl.2 appeared to solve the problem (see Appendix
vector took four attempts. C.5).
Final assembly of Mdm2 P2- Yeast DNA was retransformed into various strains of
Mutant DNA targeting bacteria to produce the final DNA targeting construct.
construct - double integration However, following screening of many bacterial clones
of pRAYNeoR cassette. (-60) which mostly contained an unknown vector - one
clone was identified which had double integration of the
positive selectable marker. This was rescued by using a
restriction enzyme which only cut the pRAYNeoR once to
recreate the desired targeting construct (see Section
3.3.5.6.1).
Final assembly of Mdm2 P1- The unwanted homologous recombination event occurred in
Null DNA targeting construct - yeast cells due to an unanticipated additional region of
unwanted homologous homology within the shuttle vector DNA - therefore this
recombination events in yeast. additional region of homology was removed to increase the
probability of generating the correct homologous
recombination event (see Section 3.3.5.6.1). The removed
region (the TK cassette) was then reintroduced once the
plasmid was propagating in bacteria.
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In addition to the reasons listed above it is also important to bear in mind that each 
individual cloning exercise typically took a week complete (or longer if sequencing was 
required). This was because of multiple unavoidable overnight steps in the cloning procedure 
including ligation of DNA fragments, selection of transformants and outgrowth/re-growth of 
clones (see Figure 4.3.1). Thus realistically, if a cloning step had failed, it would not become 
apparent until day 4 or 5 of the experiment. In addition, the reason or reasons for failure of a 
cloning exercise were not always immediately obvious and therefore the solution was 
sometimes decidedly unforthcoming (such as during cloning of the p21 right arm or Puma left 
arm of homology - see Sections 3.3.3.7 & 3.3.4.1). Particularly difficult stages of cloning 
where multiple (4-8) attempts had failed actually represents months of work and greatly 
contributed to the overall time taken to complete construction of the DNA targeting vectors.
Reflecting on the relative complexities of each of the cloning exercises the overall 
time spent generating these DNA targeting constructs was 17-25 months. The construct 
which took the longest time to complete was P/7/r?a-E2Crimson owing mainly to the difficulty in 
amplifying the Pi/ma-left arm of homology. This is an example of how GC-rich genomic DNA 
and reliance on PCR techniques can drastically slow down a cloning exercise. The delay was 
caused since each cloned PCR product (and there were 7 in total - once we had found PCR 
reactions which actually produced the correct products!) required sequencing to check that 
the DNA polymerase had not inadvertently introduced unwanted mutations. Whilst the return 
of sequencing reads was usually fairly fast (2 days) not all sequencing reactions were 
successful (could fail on some technical level) and if clones contained mutations then 
additional sequencing was required which created a further delay. In addition, during the UK 
postal strikes in late 2009 the sequencing turnaround time (for Eurofins MWG Operon) was 2- 
3 weeks (if samples arrived at all) which caused major delays in cloning. Later in this project 
we switched to using GATC Biotech since they employed a courier service to collect 
sequencing samples directly (see Section 2.7.2.7).
The DNA targeting construct which took the next longest time to generate was Mdm2 
P1-Null (22 months). The major delay in this cloning exercise was associated with undesired 
homologous recombination events during the final vector assembly step in yeast cells (to 
insert the positive selectable marker - pRAYNeoR). This resulted in a truncated plasmid
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being the predominant cloning event when the DNA extracted from yeast cells was re­
transformed into E. coli (see Section 3.3.5.6). Conversely, although the same problem was 
apparent during cloning of the Mdm2 P2-Mutant gene targeting vector, purely by chance, a 
bacterial clone was identified which contained a rare double integration event (pRAYNeoR 
had inserted twice). The double integration could be rescued (see Section 3.3.5.6.1) and 
hence cloning for Mdm2 P2-Mutant was completed 5 months ahead of Mdm2 P1-Null. 
Indeed, cloning of the Mdm2 P2-Mutant construct was completed in the fastest time (17 
months) although since the cloning of the Mdm2 constructs was commenced following our 
inventive and successful use of BAG clone restriction digests for the p21 right arm of 
homology (see Section 3.3.3.7), the Mdm2 P2-Mutant DNA targeting construct was finished 
after the p27-mCherry DNA targeting construct. Hence, the first ES cell gene targeting 
experiments were performed for generation of the p2f-mCherry knock-in reporter strain.
Cloning of the p2f-mCherry DNA targeting construct was initially completed in 18 
months; however re-growth of this DNA took a further 2 months to accomplish since 
identification of a stable positive clone was tricky. The major cloning obstacle for generation 
of the p2f-mCherry DNA targeting construct was therefore associated with the maintenance 
of the large (10 kb), extremely repetitive p21 right arm of homology in E. coli (see Section 
3.3.3.9). This is an example of how highly repetitive genomic DNA sequences can create 
delays in cloning, since its inherent instability made it difficult to propagate efficiently in 
bacteria (recombination occurred frequently which resulted in variable loss (3-8 kb) of the 
region). Construction of the p2f-mCherry gene targeting vector also had its share of 
PCR/sequencing related idiosyncrasies, as occurred for example during cloning of the p21 left 
arm of homology in-frame with mCherry (see Section 3.3.4.1). Several issues arose; 
including a major deletion (~70 bp), a minor deletion/addition (1-2 bp in a long A 
homopolymeric run) and frequent failure to successfully incorporate the 5’ additional 
sequences during PCR mutagenesis (see Table 4.3.1). The last of these problems was 
probably due to the length of oligonucleotides used (48 - 61 nt) since errors are likely to 
accumulate with increasing length of oligonucleotide sequence (due to limitations in the 
synthesis procedure). Where possible we re-designed primers to be shorter and therefore 
circumvent this problem.
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Despite the various and numerous cloning chailenges encountered during this thesis, 
inventive redesign, use of different E. coli strains and persistence eventually enabled 
successful construction of all four desired DNA targeting constructs. As these cloning 
exercises proved extremely complex and time consuming we must consider whether 
alternative cloning methods (or combinations of same) may have finished the task more 
quickly and efficiently. These alternative cloning strategies are discussed next.
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DAY 1 & 2 ( +
Insert 
DNA
backbone PREPARATION OF PLASMID DNADNA digested (typically overnight) and resolved 
by agarose gel electrophoresis. DNA fragments 
are then gel purified and a ligation reaction is set 
up overnight
Resistance gene 
e g. Amp/Kan
DAY 3 TRANSFORMATION
By electroporation or heat-shock
DAY 4
SELECTION
PLATE out onto LB-Agarwith appropriate 
antibiotic
Incubate at 37°C O/N 
Resistant colonies should appear
OUTGROWTH
DAYS
t
Colonies are "picked" from LB-Agar plate into 5 
ml starter LB culture (+ antibiotic) 
Incubate at 37°C O/N with shaking ~230 rpm
DNA EXTRACTION
4 ml of Bacteria are harvested the following 
morning by centrifugation at ~ 7000 x gfor5 
minutes. From cell pellet extract plasmid DNA
ANALYSIS
Perform restriction digest on DNA and confirm it 
is correct by running on an agarose gel
RE-GROWTH
Once plasmid DNA has been confirmed re-grow 
bacterial colony and use a fresh O/N culture to 
create a glycerol stock (frozen 1:1 LB:50% 
glycercol). And (if necessary) perform high 
quality DNA preparation for sequencing.
Figure 4.3.1: Overview of a molecular cloning experiment.
The plasmid DNA is typically prepared using standard cloning techniques such as digestion with 
restriction enzyme(s) or amplification of insert DNA by PCR which could take 1-2 days depending on the 
complexity of the cloning exercise. The plasmid DNA with selectable marker (usually antibiotic 
resistance) is introduced into a suitable competent E. coli strain. Transformed bacteria are grown under 
selective conditions O/N on an LB-agar plate containing an appropriate antibiotic. Recombinant clones 
are then screened by extracting their DNA and performing a restriction digest. DNA digest patterns are 
examined by agarose gel electrophoresis and positive clones re-grown to generate glycerol stocks for 
long term storage.
DAYS
j
-/
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4.3.2 Alternative cloning strategies
The field of molecular biology is fast paced with new discoveries and technologies 
continuously being developed which can refine and revolutionise the basic tool-set of a 
molecular biologist. Molecular cloning techniques are no exception and newer, more efficient, 
simpler and/or more intelligent cloning procedures are constantly evolving. With the wide 
range of old and newer molecular cloning techniques available it is almost a certainty that the 
cloning exercises performed for this thesis could have been accomplished in numerous ways. 
Thus an important question to ask ourselves before, during and after generation of the novel 
DNA targeting constructs described here, is what cloning strategy/cloning techniques should 
we use(?), could we have used(?) and were there any other, potentially better methodologies 
to complete the same task?
Addressing the last of these questions - are there any newer (or missed) alternative 
cloning strategies that could have completed the construction of the DNA targeting constructs 
in a radically improved way? - In essence, at the time of writing this thesis, I think the short 
answer is no. None of the other commonly used molecular cloning techniques such as 
GATEWAY cloning, direct restriction digestion of PCR products, in gel cloning or blunt end 
PCR product cloning, provide a significant time or labour saving advantage over the 
standard/specialised techniques which were utilised for the cloning within this thesis - 
summarised in Table 4.3.2.
Of the newer, less routinely used cloning techniques the alternative cloning strategy 
with the most potential to circumvent some of the problems associated with the generation of 
the p27-mCherry and Puma-E2Crimson constructs is “recombineering” (recombination - 
mediated genetic engineering) [Ellis et al., 2001]. Briefly, recombineering exploits the 
recombination proteins present within bacteriophage A to effectively allow efficient 
homologous recombination between very short arms of homology (~ 50 bp) in bacteria. The 
apparent advantage of such a cloning system is once you have an appropriate BAG clone you 
can in theory insert, with accuracy any desired mutational event (complete with positive 
selectable marker) without the need for traditional ‘cut and paste’ recombinant DNA 
techniques [Narayanan and Chen, 2011]. The resulting modified BAG clone - dubbed a BAG 
trans-gene (BAC-Tg) can then be used immediately as a DNA targeting construct. The
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recombineering strategy therefore does have a certain appeal, particularly since generation of 
the arms of homology, introduction of the desired mutations and final construct assembly 
would be simultaneous. However, upon further inspection a variety of problems are 
associated this scheme - first and foremost, the use of recombination competent bacteria 
would have been disastrous for maintaining the p21 right arm of homology (which included 
-10 kb of extremely repetitive and unstable DNA). Second, BAG clones are typically 100-300 
kb in size, thus it is highly probable that the BAC-Tg will contain additional genes and/or 
regulatory elements which will inevitably confound interpretation of the results due to 
unintended non-specific affects. Furthermore, given the size of the BAG clone and the high 
efficiency at which homologous recombination can take place, depending on the DNA 
sequence I would expect there to be a significant amount of background recombination 
events which, again, would confound interpretation of the results.
Whilst use of an entire BAG clone for direct cloning could be less than ideal (for the 
reasons detailed above) we found that restriction digestion of the BAG clone to excise 
particular regions of interest worked reasonably well (for example during cloning of the Mdm2 
promoter mutant DNA targeting constructs). This strategy of course has its own drawbacks - 
namely reliance on availability of suitable restriction enzyme sites - however on a gene-by­
gene basis it could potentially be very helpful, especially when combined with homologous 
recombination in yeast. That is, if a suitable BAG clone fragment exists it could be inserted 
directly into a yeast-E. coli shuttle vector and then used to create the arms of homology 
following homologous recombination in yeast with an appropriately designed donor DNA. It is 
worth noting here the similarities between recombineering in bacteria and homologous 
recombination in yeast as cloning strategies.
Whilst it would be virtually impossible and considerably beyond the scope of this 
thesis to discuss every alternative cloning strategy available an effort has been made to 
highlight some of the more relevant molecular cloning techniques that may (or may not) have 
been useful. In vitro validation of the DNA targeting constructs is the next topic discussed 
below.
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Table 4.3.2: Evaluation of other commonly used cloning techniques.
Common cloning method Considerations
Invitrogen GATEWAY cloning - uses specific High start up cost - more applicable to high
DNA sequences and specialised enzymes to through-put cloning, rather than the unique
shuffle target sequences in and out of various and complex cloning steps involved in
pre-generated vectors generation of gene targeting vectors.
Direct restriction digestion of PCR products - Restriction enzymes work with varying
appends restriction enzyme sites during PCR efficiency on terminal sections of DNA
then digests with those restriction enzymes therefore an additional 10 nt cap may be
and clones the fragment directly into the required to be added to primers, which may
desired vector (no intermediate TA vector) increase non-specific products during PCR.
Potential time saved may be lost if restriction
enzymes are unable to cleave the DNA ends.
In gel cloning - performs ligation reactions Not attempted. No major time saving
within the GTG low melting temperature advantages since gel purification kits are
agarose gel. fairly rapid.
Blunt ended PCR cloning kits - similar Since we used Phusion DNA polymerase
principal as the TA-cloning kits except for which created a blunt ended DNA product
blunt ended PCR products. this kind of kit may have been beneficial -
however A-tailing reactions are fairly quick
and simple to perform and worked reliably in
our hands (see Section 2.6.6.1).
Oligonucleotide directed mutagenesis of Even high fidelity DNA polymerases can only
vectors - sometimes referred to as site- amplify ~ 10 kb. Only a few point mutations
directed mutagenesis. A primer is designed in close proximity can be introduced at a
which contains the desired point mutations time, therefore if more mutations are required
and then the whole vector is amplified by a multiple rounds of targeting are required. As
high fidelity DNA polymerase (such as with all PCR-based techniques any construct
Phusion). The new vector (with desired generated this way will require complete
mutations) is then isolated and cloned. sequencing.
337
4.3.3 In vitro validation of DNA targeting constructs
Where possible, testing of the desired gene modifications should be performed prior 
to ES cell gene targeting. This is because ES cell gene targeting is also an extremely labour 
intensive process that requires diligent care and planning during both the ES cell culture and 
the subsequent ES cell screening protocols. Therefore before investing considerable time 
and resources into an ES cell gene targeting experiment, it is essential to know that firstly, the 
DNA targeting construct is a full and accurate representation of the expected DNA sequence 
and secondly, it is desirable to know whether it is likely to produce the designed responses in 
vivo. The former was confirmed for all four DNA targeting constructs by sequencing and 
restriction digest mapping whilst the latter was addressed when possible by in vitro analysis.
For the Mdm2 P1-Null and P2-Mutant promoter regions in vitro testing was essential 
to validate the introduced disruptions (see Section 3.3.5.2). Importantly, the modified 
promoter regions behaved exactly as expected - that is the Mdm2 P1-Null promoter region 
had significantly reduced basal expression but equal p53-responsiveness whilst the Mdm2 
P2-Mutant promoter region had comparable basal expression but completely abrogated p53- 
responsiveness. These mutations would therefore be suitable for generation of transgenic 
mouse strains with which to study the relative contributions of the p53-independent and p53- 
dependent regulation of Mdm2 (discussed further in the Section 4.4).
In vitro validation of the p2f-mCherry DNA targeting construct prior to ES ceil 
targeting was not possible since the p21 left arm of homology (which commenced 228 bp in to 
p21 intron 1) did not contain the p21 promoter region. The murine p21 promoter region and 
specifically the two p53 RE sites are located approximately 2.8 and 1.9 kb upstream of exon 1 
[el-Deiry et ai., 1995] and hence were not present within our gene targeting vector. We did 
not attempt to include the p21 promoter region with our DNA targeting construct because that 
would have created a much larger p21 left arm of homology (~ 8 kb) which was not necessary 
for ES ceil targeting and would have been much more difficult to PCR successfully. Without 
the endogenous p21 promoter region it unfortunately would not be possible to determine 
whether mCherry is reliably induced by p53 in vitro until mCherry has successfully 
incorporated at the p21 locus in targeted ES cells.
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However, along the same line of thought, since the Puma-E2C rim son DNA targeting 
construct does contain the endogenous Puma p53 REs (~110 bp upstream of exon 1 [Yu et 
al., 2001]) it should be possible to determine if E2Crimson is reliably induced following p53 
activation in vitro, prior to lengthy ES cell gene targeting procedures. In vitro validation will be 
performed by co-transfection experiments of the PumaLACrimSK+ vector in p53 null MEFs 
with and without murine p53.
One final comment on the matter, each DNA targeting construct designed and 
created for this thesis is completely novel and totally unique - such that, even if another group 
attempted to create these transgenic mouse strains it would be unimaginable that they would 
have designed the exact same mutations and/or reached the same end result.
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4.4 ES cell targeting
The main aim of this thesis was to generate four different transgenic mouse strains by 
homologous recombination in ES cells in order to study novel aspects of p53 regulation, 
activation and function. These strains included the p2f-mCherry and Puma-E2Crimson 
knock-in fluorescent reporter mice which are hoped to provide valuable tools with which to 
monitor p53 activity in vivo. The study of such mice would be useful for studies where careful 
in vivo analysis of p53 activation is necessary or desired for example during the DNA damage 
response in the Gl tract. Radiosensitivity in the Gl tract is of particular relevance to cancer 
since radiotherapy is one of the most effective and commonly used treatments for a wide 
variety of cancers. However, one of the major limiting factors in radiotherapy (and 
chemotherapy) is unwanted cytotoxicity in highly proliferative tissues, such as the Gl tract 
(known as Gl syndrome) which can cause adverse side effects such as nausea, vomiting, 
diarrhoea, dehydration and in severe cases death [Qiu et al., 2010, Qiu et al., 2008, Kirsch et 
al., 2010]. In order to mitigate the potentially lethal Gl syndrome it has been proposed to pre­
treat patients undergoing radio- or chemotherapy with protective agents which either block 
induction of the acute apoptotic response [Burdelya et al., 2008] or promote tissue 
regeneration [Zhang et al., 2010]. Since the p53-dependent activation of both Puma and p21 
have been shown to play key roles in regulating Gl syndrome [Leibowitz et al., 2011] having 
an in vivo tool with which to monitor these p53-responses in real time as proposed by this 
thesis would enable researchers to determine what molecular responses their treatment(s) 
are inducing with superior temporal and spatial detail than is currently possible. The 
advantages of such an in vivo reporter system are numerous, including;
• Real time - provides additional temporal information for acute treatment effects 
(might be particularly beneficial for easily accessed organs such as the skin/colon).
• Whole animal can be imaged at once - provides additional spatial information, 
including identification of p53-responses in unintended targets (improve traditional 
toxicology studies).
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• Non-invasive imaging — allows for long term studies (for chronic effects of 
treatment(s) and/or disease progression), which ultimately permits a reduction in 
animal numbers since the animals can be imaged multiple times.
• More sensitive/accurate detection may be possible - since not relying on 
antibodies or other lengthily optimisation/visualisation procedures.
• More authentic report of p53 activity - since knock-in targeted approach uses the 
endogenous reporter gene locus (not affected by positional bias).
• Differential monitoring of p53 activity - demonstrate not only that p53 is activated, 
but which genes/responses it is attempting to elicit.
To date, no other such dual p53 activity system exists. Thus, we envision that the 
fluorescent reporter mouse strains described here could find many applications in the field of 
cancer studies including preclinical testing of radio-protective agents, characterisation of 
acute/chronic p53-responses to chemotherapy and long term gene-regulation during cancer 
development.
The next two transgenic mouse strains we intend to generate are the Mdm2 P1-Null 
and Mdm2 P2-Mutant which will be used to answer fundamental questions relating to the p53- 
dependent and p53-independent regulation of Mdm2 and ultimately addressing whether p53 
mediated regulation of Mdm2 is a component of the essential negative regulation of p53. 
Since p53 is one of the most important tumour suppressor genes, and loss of function of p53 
is considered to be a critical event in the development of almost all known cancers, involving 
many of the cellular responses to DNA damage (and other stress stimuli - see Section 1.4), it 
is not surprising that p53 is one of the most extensively studied genes in cancer biology (see 
Section 1.1). However, despite considerable advances in knowledge there are still 
substantial gaps in this competitive field of cancer research - such as, is the p53-dependent 
up-regulation of its essential negative regulator Mdm2 required for viability? And/or - is 
constitutive (p53-independent) up-regulation of basal Mdm2 required for viability? These 
questions have remained unanswered for nearly 17 years, since the role of Mdm2 as an 
essential negative regulator of p53 first became apparent in 1995 [Montes de Oca Luna et al., 
1995, Jones et al., 1995]. Therefore, the transgenic mice proposed for this thesis are
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expected to have a significant impact in the field of cancer biology regardless of the 
phenotype (viable or lethal).
It is worth noting at this point - before speculating on the phenotypes of the Mdm2 
P1/P2 mutant mice - that a hypomorphic allele of Mdm2 (~ 30% less Mdm2) resulted in mice 
which were smaller, with defects in lymphogenesis and had increased radiosensitivity - 
presumably due to increased constitutive p53 activity [Mendrysa et aL, 2003], These mice 
(denoted Mdm2?uro), aged normally and were resistant to tumour formation demonstrating that 
reduced levels of Mdm2 can have anti-tumourigenesis properties in vivo [Mendrysa et al., 
2006]. This study, however, cannot discriminate between the p53-dependent and p53- 
independent regulatory contributions to Mdm2 expression. At the other end of this 
extraordinarily sensitive feedback mechanism, it has been shown that a single SNP 
polymorphism which affects the human MDM2 P2 promoter (T>G nucleotide 309 in intron 1) 
increases MDM2 protein expression by approximately 4-fold and significantly accelerated the 
rate of tumour onset in Li-Fraumeni patients [Bond et al., 2004]. Whilst this study indicates 
that increased MDM2 levels can contribute to cancer development (as evident by the high 
rate of MDM2 amplification in cancers in general [Oliner et al., 1992, Nie and Tian, 2009]) it 
cannot however, discriminate between the p53-dependent and p53-independent regulatory 
contributions of MDM2 to tumourigenesis. In another relevant study, Mdm2'/' mice with a 
hypomorphic allele of p53 (denoted p53515C) were unable to survive beyond postnatal day 13 
due to a failure to cope with elevated ROS in hematopoietic cells [Abbas et al., 2010]. Thus, 
taken together, these studies demonstrate an overwhelming need to further investigate the 
relative contributions of p53-dependent and p53-independent functions of Mdm2. 
Furthermore these studies indicate that the mutations we have designed for the Mdm2 
promoter regions are likely to generate dramatic phenotypes in vivo with relevance to normal 
development, in response to genotoxic stresses and cancer susceptibility.
Following on from this, in the first instance the design of the proposed experiments 
involving the Mdm2 P1-Null and P2-Mutant strains are very simple since there are only two 
outcomes - life or death. It is anticipated that either outcome (viable/lethal) and additional 
studies will provide significant insights into the p53/Mdm2 negative feedback loop. These 
additional experiments are discussed next.
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If the genotypes of the Mdm2 P1-Null and/or P2-Mutant lead to lethality, an important 
additional experiment would be to cross the heterozygote mice onto a p53 null background - 
thus demonstrating that lethality is as a result of de-regulated p53 activity. Further attempts 
could be made to rescue the lethality of these mice by intercrossing onto mice with either 
compromised apoptotic responses (such as Puma'1' or Bax1') or cell cycle arrest genes (such 
as p2f/') to determine which downstream p53 target or targets is or are responsible for the 
lethality1. Additional intercrosses to rescue lethality could include a hypomorphic p53 allele 
(as such p53515C described by [Abbas et al., 2010]) which might enable the phenotypes of 
such animals to be examined. In the future, for the Mdm2 P2-Mutant it would also be 
interesting to determine if increased basal expression of Mdm2 could rescue this genotype 
(perhaps by designing a hyperactive P1 promoter - or a more efficiently translated P1 
transcript).
On the other hand, if the genotypes of the Mdm2 P1-Null and/or P2-Mutant are viable 
this will give us a unique opportunity to determine - exquisitely and unequivocally - the 
relative p53-dependent and p53-independent contributions of Mdm2 up-regulation in a wide 
variety of developmental, homeostatic control, stress induced and tumour susceptibility 
scenarios. This would be examined by several approaches including;
• Complete characterisation of the organs to determine any developmental issues.
• Exposure to different stress stimuli (such as y-irradiation) to analyse p53 activity in 
vivo - including the strength and magnitude of p53 signal and up-regulation of its 
major downstream genes such as p21, Puma and Mdm2.
• Long term studies to establish if there is any increase/decrease in cancer formation 
or any affects on aging.
If the Mdm2 P1-Null strain is viable (as I would predict) given the developmental 
defects apparent in the Mdm2puro mouse strain it would seem logical to predict that the Mdm2 
P1-Null strain might also have some developmental problems. In addition since Mdm2 basal 
expression is compromised the resulting animals might be more sensitive to various
1 This is another example of where the p21-mCherry and Puma-E2Crimson p53 activity 
fluorescent reporter mice could be beneficial - since they could provide an authentic report of 
p53 activity and double knock-ins (p21mCh+/+ and PumaE2Crim+/+) would also compromise 
gene function - as might be appropriate in this instance.
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genotoxic stresses due to higher basal activity of p53. This may lead to immediate problems 
in the neonates associated with inappropriate/excessive p53 activity in tissues, which if 
severe enough could result in early postnatal death (as observed in the p53515C). If mice 
recover from this and/or are able to cope with the various cellular stresses then there will be 
long term implications regarding their susceptibility to tumour formation (which I expect would 
be reduced) and other late onset conditions. In addition, since there is still some controversy 
surrounding the effect of high p53 levels and aging (some studies indicate mice age normally 
[Mendrysa et al., 2006, Garcia-Cao et al., 2002] whilst others indicate premature aging 
[Gannon et al., 2011]) this will also be characterised.
If the Mdm2 P2-Mutant strain is viable then this would indicate that the p53-mediated 
up-regulation of its own essential negative regulator, Mdm2, is dispensable for absolute 
control of p53 activity. In other words, basal levels of Mdm2 are sufficient to keep p53 activity 
in check and prevent death from excessive p53 activity observed in Mdm2‘A mice. This would 
have significant implications for our understanding of the underlying biology of the p53/Mdm2 
feedback loop. In this case it would then be imperative to examine the stress-responses in 
these mice to determine if they are able to cope with sustained p53 activity across a wide 
variety of tissues. Similar to the Mdm2 P1-Null mice, the increased constitutive activity of p53 
in the Mdm2 P2-mutant mice will have further implications for their longevity, general 
health/development and tumour susceptibility.
In retrospect, as a novice to molecular cloning, this was an ambitious project! 
Notwithstanding, all four gene targeting constructs have been successfully created and ES 
cell targeting was performed for the p2f-mCherry knock-in reporter and the Mdm2 P2-Mutant 
transgenic strains with some promising success. In each round of ES cell targeting (despite 
an initial setback - see Section 3.4.1) a large number of rapidly growing, easily visible, 
undifferentiated ES cell colonies were obtained. Whilst time was a limiting factor to this 
project and therefore complete screening of these clones was not possible the initial 
screening by Southern blot analysis for the Mdm2 P2-Mutant transgenic strain has already 
yielded positive ES cell clones (10/208 colonies were positive for integration of the self­
excision positive selectable marker see Section 3.4.2). Thus we are in a very good position to
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continue with the generation of the proposed mouse strains which are likely to be in high 
demand within the cancer biology field.
4.5 Future work
There are a number of obvious experiments that need to be performed and for brevity 
some of these are listed below:
• Screening of the p2'/-mCherry knock in reporter ES cell colonies including:
o Southern blotting to confirm integration of mCherry and the Cre/NeoR positive 
selectable marker
o Phenotypic analysis of cells to determine mCherry functionality
o Additional Southern blotting to check that there are no additional unwanted 
random recombination events
• Further confirmation of the Mdm2 P2-Mutant ES cell clones including;
o Sequencing to unequivocally confirm the introduction of the desired point 
mutations.
o Additional Southern blotting to check that there are no additional unwanted 
random recombination events.
• Generation of p2-/-mCherry and Mdm2 P2-Mutant transgenic mice by blastocyst 
injection.
• In vitro validation of the Puma-E2Crimson DNA targeting construct.
• ES cell targeting with the Mdm2 P1-Null and Pt/ma-E2Crimson DNA targeting 
constructs and subsequent screening of ES cell clones.
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APPENDIX A OLIGONUCLEOTIDES
Table A.1: Oligonucleotides designed for this thesis.
Primers are arranged alphabetically. KEY: Yellow highlight indicates the mutating nucleotides 
to be incorporated by the oligonucleotides at the Mdm2 P2 promoter.
Primer name SEQUENCE
Le
ng
th
G
C
% p
s1-
IstPCR AGTATCGGCCTCAGGAAGATCG 22 55 57
2ndPCR ATTCAGGCTGCGCAACTGTTGGG 23 57 59
AdapKpnlSacIM GAGAGACCGCGGGTAC 16 69 57
AdapKpnlSacll2 CATGCTCTCTGGCGCC 16 69 57
AdapSpe-AcM CTAGTAACGTTGAGAGA 17 41 48
AdapSpe-Aci1 CTAGTCTCTCAACGTTA 17 41 48
CrimR+AscISali TCTCGTCGACAGGCGCGCCTGAGTTTGGACAAACCACA
AC
40 60 55
CrimsonF TAGCGCTACCGGACTCAGAT 20 60 55
EGFPSV40fw+RE GAGAGAATTCACATGGTCCTGCTGGAGTTC 30 50 60
EGFPSV40RV GAGAACTAGTTGAGTTTGGACAAACCACAAC 31 42 59
EzrEIF ATACTCGGGACTGCGGAGCG 20 65 58
EzrE2R CACCCGGACGTTGATTGGCTT 21 57 58
Hprt-F AGCTACTGTAATGATCAGTCAACG 24 42 58
Hprt-R AGAGGTCCTTTTCACCAGCA 20 50 58
Lgr5-F GAGTCAACCCAAGCCTTAGTATCC 24 50 58
Lgr5-R CATGGGACAAATGCAACTGAAG 22 45 58
LoxP-Fw ATAACTTCGTATAATGTATGCT 22 27 51
LoxP-Rv ATAACTTCGTATAGCATACATT 22 27 51
M13-20RV+RE GAGAGTCGACAACACTGGCCGTCGTTTTAC 30 38 60
M2-P2regio5’-2 TCGAGGCAGAAATACCAACC 20 50 60
M2“P2regio5’-3 TTGTTCCGAAGCTGGAATCT 20 45 60
369
Primer name SEQUENCE (5’-^3’)
Le
ng
th
G
C
%
(0.) W1
M2-P2region3’-2 GCTCGTCACAGAACTCTGCTT 21 52 60
MaxE1/2F ACATCGAGGTGGAGAGCGACGC 22 64 61
MaxE2F AGCGGGCTCACCATAATGCACT 22 55 59
MaxE3R TGTCTAGGATTTGGGCCCGGG 21 62 58
mChEGFPfwNLS GAGAATGGGTGCTCCTCCAAAAAAGAAGAGAAACGTAG
CTCCAGTGAGCAAGGGCGAGGAG
61 53 62
mCherryRv+RE GAGAGTCGACATTAATTCACCGTCATCACCGAAAC 35 46 62
mChNLSendF ATGGGTGCTCCTCCAAAAAAG 21 48 58
MDM2 P2region 3’ CTGGGCCCTGATGTCATTCT 20 55 59
MDM2 P2region 5’ TAGACACAGACATGTTGGTATTG 23 39 57
mdm2-1kbF TGGGCCCTCAAGATGACTAA 20 50 61
Mdm2-5upF1+Sall GAGAGTCGACGTGGCGTGAGTGACTGAAAA 30 53 60
Mdm2-5upR1+Xhol GAGACTCGAGGGTTGTGTTTACCGCTCGAA 30 53 61
Mdm2E1F1+Smal GAGACCCGGGGGCGCTCGTCACAGAACT 28 67 60
Mdm2E3F+Hindlll GAGAAAGCTTTGCAAGCACCTCACAGATTC 30 47 60
Mdm2ln1F1 AGTCCCGATCATTCCCTCTT 20 50 60
Mdm2ln1R1 AAGAGGGAATGATCGGGACT 20 50 60
Mdm2ln1R1+Notl GAGAGCGGCCGCAAGAGGGAATGATCGGGACT 32 63 61
Mdm2ln1R2 GCCCGGGTTACGAGTAGG 18 67 60
Mdm2ln3F1.6kb TGGAGAGATGGCTCAGAGGT 20 55 60
Mdm2ln3F1+Smal GAGACCCGGGTTGTGAGGATTTTAGTTATGAGAGG 35 49 58
Mdm2ln3F1kb GCCCCATTGAAGGTATCAAA 20 45 60
Mdm2ln3F2.4kb TCCACAGAAGTGGTGGTCTG 20 55 60
Mdm2ln3F3.7kb AGCTGAGGGCTGTGATTGTA 20 50 59
Mdm2ln3F3kb CTGGGCTCACTAGCTGCTTT 20 55 60
Mdm2ln3R1+Hindlll GAGAAAGCTTAAAGCACGGATGCTTCTATGA 31 42 60
Mdm2ln3R2 GAGGGCTGGCAATATTCGT 19 40 60
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Primer name SEQUENCE (5^3’)
Le
ng
th
G
C
% p
£H
Mdm2ln3R2+Notl GAGAGCGGCCGCTGCTGAGCAGAGTGAGCAGT 32 66 60
Mdm2ln4F CAGAACTGAGGGGTGGAGAG 20 60 60
Mdm2ln4F775bp GCCGATTTCTGAGTTCAAGG 20 50 60
Mdm2PROBE-F1 CAAGTTCTTGTGGCAGGTTAGGGGC 25 56 60
Mdm2PROBE-R2 AACTCCCCGCAGAGAGCAGGAG 22 64 60
Mdm2R-2.5kb CATTGGGGTGGGGATGGGGGA 21 67 60
Mdm2SexA1 R TGCGATAATCCAGGTTTCAA 20 40 60
Mdm2SfilF GCTCGTCACAGAACTCTGCTT 21 52 61
mdm2up-1,7bkF ATCCCATGAAACTGCACACA 20 45 60
mdm2up-4kbF GTCCTTCCCCTAGCTCATCC 20 60 60
Mdm2-up-F2 TGCTCATGGAGACCAGAAGA 20 50 60
Mdm2upF-2.4kb ACCCAGTTTGTGGCTTTCAC 20 50 60
Mdm2upF-3.2kb ATGCCCTCTTCTGGTGTGTC 20 55 60
Mdm2upR-1kb GGCCTAGTCCCCTTAACTGC 20 60 60
p21Ex2LA-Rv CATGGTGCCTGTGGCTGAAA 20 55 60
p21 Ex2LA-Rv+NLS GAGATGGAGCTACGTTTCTCTTCTTTTTTGGAGGAGCA
CCCATGGTGCCTGTGGCTGAAA
60 50 60
p21 Ex3RA2-Fw ATCCCGACTCTTGACATTGC 20 50 57
p21Ex3Rv CTTAGCCCCCAAGACACCAT 20 55 61
p21ln1+1kb ACACCCAGTGTAGGAAGGTG 20 55 57
p21ln1+1kbR CACCTTCCTACACTGGGTGT 20 55 57
p21ln1+2kb TGTCTTCCCTTCCTTCCTCT 20 50 58
p21ln1+2kbR AGAGGAAGGAAGGGAAGACA 20 50 58
p21ln1+3kb TAGCCAAGGTAGACCCTGAA 20 50 57
p21ln1+3kbR TTCAGGGTCTACCTTGGCTA 20 50 57
p21ln1+4kb ATCACCAAGACAGCAGGGTA 20 50 58
p21ln1+4kbR TACCCTGCTGTCTTGGTGAT 20 50 58
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Le
ng
th
G
C
%
(a.) "i
p21ln1Fw1 TCAAATAGGGAGCCCAGAGA 20 50 60
p21 ln1Fw2 GTATGCTGCCACAACCACAC 20 55 60
p21ln1LA-Fw GAAGGCTTCGTTTGTTGGAG 20 50 57
p21ln1LA-Fw+RE GAGAGGCCGGCCTTAATTAAGAAGGCTTCGTTTGTTGG
AG
40 50 57
p21ln1mutkb CCTGGGAGAGAGCCTTAACC 20 60 61
P21LF-300 TAGTCCTTCCCACAGTTGGT 20 50 57
p21NLSendR TGGAGCTACGTTTCTCTTCTTT 22 41 57
P21PR0BE-F1 AGCAGAGCTGTGGGAAGCCTGT 22 59 60
P21PROBE-R2 CTTGTACGACAGGCAGGGAGCAT 23 56 59
p21RA10KbRv CAGTAGGGCACAAGGGGTAA 20 55 60
p21RA12kbF CGGGGACCAACTGTGTTAAG 20 55 60
p21RA12kbR CCAGTTGCCAGTTCCAAAAT 20 45 60
p21 RA2-Rv CCATCGCTGAGAGAGTTCTACA 22 50 60
p21RABsrGIF GTGATGGAGTTGTACAAT 18 39 45
p21RABsrGIR CACTGAGAATTGTACAAC 18 39 43
P2mutant3-44 GaTgGACAGCCGACGCCGGAgGTcTCCCAAgTTGACCA
GCCCCAC
45 67 >
75
P2mutant5-50 TCCGGCGTCGGCTGTCcAtGGAGCTAAaTCCTGAtATG
TCTCCAGCTGGG
50 58 >
75
P2PR0BE-F1 ATCCTGATATGTCTCCAGCTGGGG 24 54 57
P2PROBE-R2 CTGCGTCAGGGGAAGGGCTG 20 70 59
pACN1552F ATGCATAAGGCAGGCAAGAT 20 45 60
pACN2273F CCCGGCAAAACAGGTAGTTA 20 50 60
pACN2978F CGGTCAGTAAATTGGACACCT 21 48 59
pACN770F TCGTCCTGCAGTTCATTCAG 20 50 60
pACNFwAscI GAGAGGCGCGCCTCACTATAGGGCGAATTGGAG 33 61 59
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Primer name SEQUENCE
Le
ng
th
G
C
% p
pACNFwAsel GAGAAT TAATTCACTATAGGGC GAAT TGGAG 31 39 59
pACNRv TAGATCTCGAGCTCGCGAAA 20 50 57
pGT01xrRv1 TCTAGGACAAGAGGGCGAGA 20 55 60
pGT01xrRv2 CCTGGCCTCCAGACAAGTAG 20 60 60
pK05527Fw+RE GAGAGGCCGGCCTTAATTAATTTTTGTGATGCTCGTCA
GG
40 61 60
PolyAF CCCCCTGAACCTGAAACATA 20 50 60
pRAYCreFI AAGCTGAGCGGCAATAAAAA 20 40 60
pRAYcreF2 AACGAAGGAAGGAGCACAGA 20 50 60
pRAYCreFS CGTACTGACGGTGGGAGAAT 20 55 60
pRAYCreRI GGGGTTTGCTCGACATTG 18 55 60
pRAYCreRS CCCAGCCTGCTTTTCTGTAA 20 50 60
pRAYneoFI AGACAATCGGCTGCTCTGAT 20 50 60
pRAYURA3F1 GATGACAAGGGAGACGCATT 20 50 60
Primer 1 AACTTAATGTCCTTGCTCATTAC 23 35 55
Primer 2 TCAGTTCTGCTCACCTCTTTC 21 48 58
Primer 3 CAATACCAACATGTCTGTGTCTA 23 39 57
Primer 4 TTACTCCACAGAGCAGTAACC 21 48 58
Primer 5 GTACCTTTGTATACACGGTAAAC 23 39 57
Primer 6 GGAGAGATGGCTCAGCAATAA 21 48 58
PrimerIF GTAATGAGCAAGGACATTAAGTT 21 48 60
Puma-0.6kbR AGGGACACACACTCCAATCC 20 55 60
Puma-1.6kbR TCTCCAAGCCCATTTTTGAG 20 45 60
Puma129F1 CTTTTGGGATGGGATGTCAC 20 50 57
PumaATGLARv CATGGCGCTCCCTGGAGC 18 72 63
PumaExiF GTGATCCGGACACGAAGACT 20 55 60
PumaEx1LARv1n GCAAAGGCTGCAGGATACAG 20 55 60
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Primer name SEQUENCE (5’^Z’)
Le
ng
th
G
C
% O
z1-
PumaExIR AGTCTTCGTGTCCGGATCAC 20 55 60
PumaEx4-1F CCAGAAATGGAGCCCAACTA 20 50 60
PumaEx4-2F TGTGACCACTGGCATTCATT 20 45 60
Pumaln1F.3 GCTAGTGAGACCTGGGAGGA 20 60 59
Pumaln1F.6 GTTTGGCTCCCGAGTTTGTA 20 50 60
Pumaln1F1.2 CCAGGCTATGTGTCATGTGG 20 55 60
Pumaln1F1.6 TTGAGATGATGGTGGTGCAT 20 45 60
Pumaln1F2,5 TCTGCGCTCTTCTCTGTTGA 20 45 60
Pumaln1R.3 TCCTCCCAGGTCTCACTAGC 20 60 59
Pumaln1R.6 TACAAACTCGGGAGCCAAAC 20 50 60
Pumaln1R1.2 CCACATGACACATAGCCTGG 20 55 60
Pumaln1R2.5 TCAACAGAGAAGAGCGCAGA 20 50 60
Pumaln3-1R CCAACCAAACAAAAGGCTGT 20 45 60
Pumaln3-2F TTAACGGCTGAGCCATCTCT 20 50 60
Pumaln3-3F GGGCTAGTTCTGGGCATGTA 20 55 60
Pumaln3-4F CTCTACCACCAGGGATCGAA 20 55 60
Pumaln3Fw+Neo GAGATTTCGCGAGCTCGAGATCTATCCTCCATCTCCTT
CATTGG
44 50 57
Pumaln3RAFw TCCTCCATCTCCTTCATTGG 20 50 57
PumaLAFwIn CTGCTGGGATTTTGTCAGGT 20 50 57
PumaLAFw2n GCTGAATGCTCCAAGGTCTC 20 55 60
PumaRARv CCAGAAGAGGGCATTGGATA 20 50 57
PumaRARv+RE GAGAGTCGACCCAGAAGAGGGCATTGGATA 30 53 57
TACE-RV ACAGCACCATTGTCCACTTG 20 50 60
TK+700bp TACCCGAGCCGATGACTTAC 20 55 60
TK1900F TTTATGGTTCGTGGGGGTTA 20 45 60
TK525F CGATACCTTATGGGCAGCAT 20 50 60
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Primer name SEQUENCE (5’—>3’)
Le
ng
th
G
C
% U
E
1-
TKpoiyAF CTGGCACTCTGTCGATACCC 20 60 61
Viilin2F GTTTAAATTCCGGGCCAAGT 20 45 60
Villin2R ACCCAGACTTGTGCATTTCC 20 50 60
375
A
PP
EN
D
IX
 B
 POLYM
ER
A
SE
 C
H
A
IN
 R
EA
C
TI
O
N
S
£
O
+3
0)
(0
CM
m
05
c'o
c
0)
o
cr05
(0
04-
0
0W5ro
o
k:
I-
O)
£
co
o
Ek_
0
it:0
Y-C\l
Q.
05
co
o
CMQ.
05c
'E_g
O
CO
_1
Z
CO
o3
o
0CL■
0COu_in
0
c05
'co<
o
Q.
05£
£
O
O
CO
z
LO
+
&
0g
S
05£
Eo
O
0COI
0
co<
CO
CM
a
a:
oCL
£
O
'0
O>+—
■O£
Oo 0
c£0
0g
e
«©
o
S' in n m
05£
0©
E
£<
oo
a.E©
in
©
2
©E
>«o
Q.
a.
X5
Nt-CD
Q.
£}
CM
N.00
Q.XJ
CD
m
a,
n
'5^
'O'
r^ CM
Q.
jO
X—COCO"Cf
Cl
jO
00CO"'fr
Q.X5
0505CM
CLX5
CO
CL
X5
00CO
Cl
JO
CO
O
o
CL
>QCI—
X
T—o
I—
o
Q.
5
CL
o
0
CL
(2
O
I—0
CL
S.
5
CM
XLUT—CM
Cl
CO
+
<
CMXLUt—CM
CL
LU
CL+>
CL
L_0
sz
O
E
CM
CL
LU
CL+>
CL
b
L_0JZ
O
CM
CL
5
LL
CMa.
LL
T—£
CM
CL
‘S
LL
<Q.
LU
tL+
£
LL
I"-CMinin
O
Za.
CM
CL CM
Cl
W
CM
CL



£
O'<£O
0)(0
o o o o
£0
E
£
3
cr0u.
15co
'•B
•o<
D5l—
TO
I
O)c
co
O
oS
£
o
Q.JD
O
CNJ,
LO
COw
bo
Eco_ro
Cl
LO
o 3
cm
o
CL
££o
0J=■*->D)E"eo
O
•g
EW)i5Q.
v~t:Q.
X
0coooH—’■O
0Q.
E
I
■oI
U)0Q.
a:o
CLI—Xa
00
■0
0
0Cgoo-t-*
•0
0Q.
E
0
S
•0
E
00
Q.
a:o
CL
DCO
0
0
0g
■q.
0o
M
i—
0>
%o
0
0O
o
O)
£
to
0
£
£<
o
o
a
E
0
0
0
2
0
E>
o
CL
Cl
XJ
CO
N-uo
Cl
JD
CO
a.
oo
CM
CL
-Q
CD
O
CM
Q.
X3
■M*
CD
CLXI
DC
■G
Ol
DC■
■c
Q.
X
DC
CM
LUL.
N
LU
LL
•G
03
LL
it
CL
X
LL
t—
LJJ
s= IM
> LU
c
TJ« co 't in m in in inn B iri in in in in in in inWo o d CO CO CO CO CO CO CO CO(A </> CO CO CO CO CO to CO COOQ
tf)
c CM CM CL s0) □. Q_ <
E
£
3
©
c©
oQ.1—
CLOQ_
CLOCL
OCL
co■«
a"DC3
2
in
5
CO
S
In
S
CO
0x:-i—< inCMO’
£
(0c
E
EoUu
a:
a©JZ
T3
E©
co©
■O <C
co«
■O CD
b
C03
s:
0x:
K
0A
CM0.
0A-4—«
CMCL
0A-t-j
L—
£
c00
Ql
o
co
2
oo 0 CD 03 c •A—» c o -f-s O) CD CD CD O +-• >c Q. 3 c 3 c 3 c C C C © CO <■o c X 2 © 2 © © c c c c c3 oO
©
2 fAT™
3
2 to
3
2
CLl CM0.
o
a
o
o
o
O
o
o oQ_
0
o
Cl
c
w Wo> ©A
E u o in m in m in in in oo CO T- CM co
z *+•o
c0
W © © © « © w © « m ©c E o m m o in in in in oB CO T™ T— CO T” T— T™ COKHI
o>c o
« 0 o m m in in in in in in©cc
<
E©**
r- m in in in in in in m
©©© c c £= c c c c c cha o o O o o o o o ow © w © © © w © ©E 3 3 3 3 3 3 3 3 3>* x: A x: A ■C x: x:
o CL CL CL CL CL CL D_ CL CLCL
+*o Q. Q. CL CL CL a. a. Cl3 © A X2 XI XI XI X5 A in CO"D
2
H CD CM I"- o> in O) CO m 1 CO© CM S I-- ■O’ CD CO CD COCL ■'t T- CO CM CO CO
_ _ — __
© UT C£ 'T
CL
<
CL
<
-CX+
oZ+
c
if
•H-ioz+ > >
Tic
X
£© 'ST©E
COLUx
c«
X0CO
X0CO CL CL
+
5
CMCLCO
CL1CL
CL
a.
+
X<D © 3 CM CM in
CM
c CO c X X CO
& a ECM ETJ E~o CME
c
CM CME
o o c
CMCL 2 2 E TD E T3 E"O
2 2 TD2 2
TJ
2
—
"ro © — © “o CO E XJ E TJ c TJ
"S LL jL
in
in LL + CO+
c
X CO+
C
ir X+
C
X©% £©
CMLU coCM c© COCM
LLQ. LL +LL LL +UL +LLCou.
E•e CD2 TD 3E
E"D inCM LUCM
COLUCM
COc
CM
COLUCM
CO_c
COLUCMa. 2 CM 2 E E E E £ CME ELi- TJ TJ TD TJ ■o TJ
2 2 2 2 2 TJ2 2

cT3 c
0> o 'tA s CO io IO
c
o
Ore d d d d
iS (0«
Q
(0
c
o
E to iCNJ
to
c
o
05 c C
o
Zi 05 L_ 05 z
□
cr
cre
E
a
X)
c
L_L.
<D
05
£
o
a
D
o
cre 05
£ E
o
CO
I—
oE oCO CO oE
a
2
(0
c
0
vs
o
o
$
05
C
£a
4-'
c
oo
LU 05
■O
a
<
CM 05
■
CMa
CM
a
ci_
05a■5
■q
c
o
CO t—
CM
a
a
o
1 a
o
i
< O 2 a 5 a 5 CO
(A
0 re
A
E
s
o
S' 25 L0 IO toT“
z **-o
c 0)o
(A re o CO « CA
C E o o Oo E CO CO CO
K
LU T“
O)
C O
T5 CO o o o9 a io CO CO COcc
<
Ere**
0
tore c c. c cu o o o oo <0 (0 C/5 (0E 3 o 3 3
>i A a ao a a a aa.
o Q. a a a
s re A a a
■o
g
N
«
o
CO
CO
o05 COr-a f"- CO m
CMcc CMa1
LUCQ
oa
a
re£re&
wT
re
E
i
oCO
CM
LUCOOaa
a
LU
CQ
oa:Q£ Q. E■o aCMa
CME■o
a
CMa
re £
reCO+
lln
a
LUm
T—a■
LU
CQO
a■
LU
CQre o O a oo E in a a aa u CM a CM aa E"O CMa ET5 CMa2 2
Appendices
APPENDIX C ADDITIONAL CLONING
C. 1 QRTPCR control plasmids
This section describes the cloning of the control plasmids used in the QRTPCR 
reactions. Control plasmids contained a short (100-200 bp) PCR product derived from a 
cDNA of the genes of interest; Hprtl, Lgr5 and Max. These products were amplified by PCR 
using the indicated primer pairs and whole gut cDNA as the template. The resulting PCR 
products were then TA-cloned into pCR2.1 and positive clones were identified by restriction 
digestion with EcoRI. Once the DNA sequence was confirmed these plasmids were ready for 
use.
Table C.1: Summary of QRTPCR validation genes.
Gene Purpose in assay Forward primer Reverse primer Product size
Hprtl House-Keeping Hprt-F Hprt-R 200 bp
Lgr5 Stem cell marker Lgr5-F Lgr5-R 131 bp
Max Villus-specific MaxE2F MaxE3R 126 bp
Prior to selecting Max as the villus-specific gene we had initially attempted to amplify 
regions from ViHin2 (also known as Ezr). This was unsuccessful since the first product tested 
(using primer pair Villin2F & Villin2R ~ 206 bp) was contaminated with non-specific products. 
The second product (using primer pair EzrEIF & EzrE2R - 164 bp - these primers were 
designed using primerBLAST - which also scans the genomic/transcript databases for 
specificity) was not amplified successfully. The lack of product may be due to the fact that the 
second set of primers annealed ~ 3 kb from the 3’ end of the Villin2 mRNA/cDNA and hence 
maybe the cDNA synthesis reaction had not progressed to that point. Since all specific Vii!in2 
primers identified were localised to the 5’ end of the gene it was decided to select another 
villus-specific gene for analysis. Max was chosen since it had been previously identified by 
another RNA expression array and had been shown to be up-regulated on the villus 
[Mariadason et a!., 2005]. There was however one further delay in the cloning of this vector,
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which was that the original primer pair for Max (MaxE1/2F & MaxE3R) unfortunately, did not 
take into account the two splice variants of Max and hence two different sized DNA fragments 
appeared when the PCR reaction was analysed by agarose gel electrophoresis. New primers 
were designed which were not affected by the mRNA variants.
HPRT1 Standard curve Amplification Chart
cr 2000
o 1500
 67.77
Figure C.1: Hprtl Standard curve.
Serial dilutions are spaced evenly apart, demonstrating that the technique worked in principle. 
The uneven lines towards the top of the chart indicate where the reaction was in plateaux 
phase.
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C.2 p21 right arm of homology
This section describes the failed cloning attempts during the generation of the p21 
right arm of homology.
Table C.2: Unsuccessful cloning attempts of the p21 right arm of homology.
Attempt Description Result
1st Following digestion of BAG 262p22 clone DNA (10 pg)
the EcoRV-Hindlll fragment was gel purified by
GENECLEAN, A-tailed and cloned into pCR-XL-
TOPO.
5 colonies -
random digest pattern
Following digestion of BAG clone DNA (10 pg) the
EcoRV-Hindll fragment was gel purified by
GENECLEAN and cloned into Smal & Hindlll sites of
pBluescript II SK+.
10 colonies -
random digest pattern
gfa As above except 30 pg of DNA digested and
attempted to gel purify by phenol-chloroform
extraction.
DNA extraction failed.
-----4^ As above except 10 pg of DNA digested and
attempted gel purified by using the genomic sized
fragment protocol of the GENECLEAN kit.
No DNA after clean up.
Column became blocked
with cooling gel.
5th As with 2nd attempt except used the other BAG clone
bmQ448e21.
BAG digest pattern did
not match up!
6^ As with 1st attempt except scaled up to 30 pg of DNA. No colonies.
As with 2nd attempt except scaled up to 30 pg of DNA. 12 colonies -
random digest pattern.
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C.3 Final assembly of p21-mCherry
This section provides a more detailed account of the final stage of cloning the p21- 
mCherry DNA targeting construct. Table C.3 summarises the various attempts made to 
create the ultimate p21-mCherry DNA targeting vector. Eight attempts (a-h) were made in 
total and several issues had to be resolved in order to complete the cloning exercise. The 
first issue, which accounted for two of the failed attempts (a & c) was the apparent 
reformation of the TK2 plasmid DNA in recombinant clones. It was not obvious how 
contamination with TK2 plasmid had occurred although one possible explanation might be 
that the pCR2.1 backbone fragment was accidentally transferred during excision of the insert 
fragment (TK cassette) from the agarose gel. With the backbone fragment contaminating the 
ligation reaction this would lead to religation of the TK2 vector and hence the resulting 
bacterial clones would preferentially propagate this smaller plasmid (rather than the large 
DNA targeting vector). This TK2 contamination problem was easily resolved; digested TK2 
DNA fragments were simply separated for longer during electrophoresis and extra care was 
taken when excising the desired DNA fragments from gels.
Fsel Pad
Fsel - assume require 6 bp for cleavage Pad - 1 bp from end 76% cleavage efficiency
Figure C.2: Fsel and Pad restriction sites in Vector 4.
The second problem, which accounted for another two failed cloning attempts (b & d) 
was incomplete double digest with restriction enzymes Fsel and Pad. An incomplete digest 
of the parental vector meant that the desired ligation reaction could not occur and hence any 
rare resulting plasmids would contain random recombination (as observed in attempts b & d). 
Double digest with Fsel and Pad was a problem in Vector 4 since these restriction sites were 
side by side (see Figure C.2). As a general rule, restriction enzymes typically required 6 bp of 
double stranded DNA from the edge of their recognition sequence in order to cleave
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efficiently. Some enzymes, however (such as Pad), were more efficient at cleaving their 
recognition sequence and could still efficiently cut DNA with only 1 bp from the end [NEB 
technical reference guide]. Since Pad could still cleave 76% efficiently with only 1 bp from 
end, Vector 4 DNA was digested with restriction enzyme Fsel first and then with Pad second. 
This digestion order was important because if the Vector 4 DNA was cut with Pad first, this 
meant Fsel could not cut at all (digestion with Pad left a 3 bp margin whilst Fsel required 6 bp 
to cleave DNA effectively). With that in mind, the cloning attempts b - d digested the 
backbone vector (V4) with Fsel first for several hours, then fresh Pad enzyme was added 
(plus supplements) to the reaction to allow the second digest to occur. The second reaction 
with Pad was typically incubated overnight to allow complete digestion.
Despite careful planning however there were still relatively few bacterial colonies to 
screen using the above method and the colonies which did appear had random DNA digest 
patterns - which could be consistent with an incomplete double digest of parental vector (V4). 
Therefore to address this issue a single digest was performed on Vector 4 (using Pad), and 
the DNA ends were blunted to attempt unidirectional cloning (TK cassette was digested with 
Fsel/Pacl and then blunted). The resulting transformation (attempt e) produced 70+ bacterial 
colonies, some of which (5/72) contained evidence of the correct ligation event when 
screened by restriction digest with Xhol. Whilst none of the clones from this cloning attempt 
(e) were truly positive (for reasons discussed later), it did demonstrate that maybe the 
previous cloning attempts had in part failed because of inefficient double digest of the 
backbone vector (since the only major difference between the cloning attempts V5d and V5e 
was the cloning strategy: directional cloning versus unidirectional blunt ended cloning). 
Similar amounts of backbone and insert DNA were used in each ligation reaction and the 
transformation efficiencies were also similar (~1 x 108 c.f.u. per pg of pUC19 DNA), however 
there were many more bacterial colonies using the blunt ended cloning reaction (see Table 
C.3). Since blunt ended cloning did not depend on double digestion of the vector backbone 
this may explain the increase in recombinant clones.
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Table C.3: Vector 5 (V5) final construct cloning attempts.
Attempt Description Result
V5a Fsel/Pacl double digest in NEBuffer 4
50 ng of backbone to 10 ng of insert
9 colonies
- TK2 vector contamination?
V5b Fsel digest first for several hours, then fresh
Pad (+ buffers) added for digest overnight.
50 ng of backbone to 10 ng of insert
1 colony
- Random pattern
V5c As above except
50 ng of backbone to 250 ng of insert
3 colonies
- TK2 vector contamination?
V5d As above except
180 ng of backbone to 180 ng of insert
4 colonies
- Random patterns
V5e Digest with Pad only then blunt DNA ends for
unidirectional cloning.
250 ng of backbone to 250 ng of insert
72 colonies
- 5/72 had correct low molecular
weight fragments but incorrect
size of repetitive region
V5f Digest with Fsel, ethanol precipitate DNA,
digest with Sail (attempt to move V4 into
TK2). 50 ng backbone (TK2) to 175 ng insert
62 colonies
- repetitive region was
recombining
V5g Digest with Fsel, ethanol precipitate DNA,
digest with Pad.
250 ng backbone to 250 ng of insert
34 colonies
- repetitive region was
recombining
V5h As above except with re-streaked V4-3-3
DNA. E. coli were grown at 276C.
250 ng backbone to 250 ng insert
100 + colonies
3/24 appeared positive
The next two cloning attempts (f & g - performed in parallel) therefore aimed to 
improve the double digest efficiency by two different methods. Attempt V5f used different 
restriction enzymes, Fsel and Sail, which would move the main targeting construct containing 
‘p21 left arm-mCherry-Cre/NeoR-p21 right arm’ into the TK2 vector. It was hoped that the 
different enzymes would work more efficiently together. Digest was performed with Fsel first
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as with previous attempts (b - d) followed by an ethanol precipitation of the DNA to clean up 
the enzymatic reaction then the DNA was digested with Sail.
Cloning attempt V5g used the original restriction enzymes Fsel and Pad however 
rather than just adding fresh Pad (and buffer) to the old Fsel digestion reaction (in NEBuffer 
4), the DNA was ethanol precipitated and a fresh reaction was set up for the second digest 
with Pad (in NEBuffer 1). Previously enzymatic clean up had not been performed since 
according the NEB technical reference guide, restriction enzymes Pad and Fsel both had 
100% activity in NEBuffer 4 therefore an additional clean up reaction seemed unnecessary 
and would result in lower DNA yields. However given the suspected problem with the double 
digest efficiency and that Pad was expected to cleave DNA which only had a 2 bp margin we 
thought using Pad’s optimum buffer (NEBuffer 1) might improve the efficiency of digestion.
The unidirectional blunt ended cloning strategy was not immediately reattempted 
because a large number of colonies (72) had already been screened without success. 
Repeating the same cloning exercise therefore seemed rather futile and hence the different 
directional cloning strategies (f & g) detailed above were tried instead.
Both cloning attempts V5f and V5g had respectable numbers of bacterial 
transformants (62 and 34 respectively) indicating that the new DNA double digest methods 
were indeed more efficient at cleaving the backbone Vector 4. However, whilst this resolved 
the outstanding problem of double digest efficiency once these recombinant clones were 
screened (by Xhol restriction digest analysis) a separate problem was emerging. This 
problem was, whilst various clones contained the correct lower molecular weight fragments 
during Xhol restriction digest analysis, including the expected size shift (1.3 —*■ 3.4 kb) for 
successful TK insertion (in e and g), the higher molecular weight fragment (~13.2 kb (e and g) 
or ~16.2 kb (f)) was always smaller than expected and typically appeared as multiple bands. 
The large molecular weight fragment contained the p21 right arm of homology and hence it 
seemed likely that the repetitive region was recombining in the bacteria. This third issue 
accounted for three of the failed cloning attempts (e - g) and meant that due to the extreme 
instability of the p21 right arm of homology within E. coli, varying portions of this region were 
lost during cloning.
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The instability of this repetitive DNA region had been observed previously when the 
original ~10 kb EcoRV-Hindlll BAG DNA digest fragment was cloned into pBluescript II SK +. 
This recombination problem was resolved then by using the specialised bacterial strain 
MAXstbl.2 to propagate the DNA. However, this time, since we were already using this strain 
a solution to the problem was not immediately obvious. To exacerbate the situation, when 
more of the penultimate Vector 4 DNA was grown and extracted from the glycerol stock, this 
too had the tell tale signs of recombination. Indeed only 2/10 clones picked from glycerol 
stock re-streak of Vector 4 appeared to keep the original size of the p21 right arm region 
demonstrating once again how unstable the DNA was.
The problem with the maintenance of the unstable DNA in the p21 right arm of 
homology was never completely resolved however growing the E. coli at 27°C (rather than 
30°C as recommended by the manufacturer) helped reduce recombination enough to achieve 
success.
C.4 P1-P2 Promoter regions
This section describes the cloning of the various Mdm2 P1-P2 promoter regions 
which were used during the in vitro luciferase assays (see Section 3.3.5.2). These promoter 
regions were to contain either;
• WT (wild-type) DNA or
• P2-Mutant (containing the desired 8 point mutations) DNA or
• P1-Null (containing the DNA sequence which would remain in the genome 
following activation of Cre-recombinase and removal of the self-excision 
neomycin cassette in the first (and all subsequent) generations of Mdm2 P1-Null 
transgenic mice) DNA.
The whole P1-P2 Mdm2 promoter region (-1600 bp including 300-400 bp of 
upstream and downstream sequence) was cloned into pGL4.11 (a promoterless luciferase 
plasmid) for each promoter region. The basic method for all three luciferase plasmids was 
briefly; amplification of the region by PCR, TA-clone the resulting product into pCR2.1 or 
pCR-XL-TOPO and sequence bacterial clones which appeared positive by restriction
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digestion. Once the sequence was confirmed the promoter region was then inserted in the 
correct orientation into pGL4.11, whereby positive clones were identified by another restriction 
digest.
The WT and P2-Mutant regions were cloned by performing a single PCR reaction 
using the primer pair Mdm2-5’upF1+Sall and Mdm2SexA1R with either the pRSMdm2TK or 
pRSmP2-Mutants vectors as the template DNA respectively. However, since the P1-Null 
region did not yet exist, in order to create the P1-Null promoter region that would appear in F1 
heterozygote mice, this section of DNA was ‘stitched’ together from various plasmids using 
fusion PCR - as outlined in Figure C.3. The resulting PCR products were TA cloned into 
pCR-XL-TOPO and positive clones were identified by restriction digestion with EcoRV and 
Hindlll. Once the sequence was confirmed in each clone (wholeWT-9, wholeMut-7 and 
wholeP1-1 - which were all conveniently in the reverse orientation within pCR-XL-TOPO) the 
promoter region was directionally inserted into pGL4.11 by using their common restriction 
sites EcoRV and Hindlll. Successful insertion of the promoter region was confirmed by 
restriction digest with EcoRV and Hindlll. These clones (WhWTIuc-4, WhMUTIuc-5 and 
WhP1Nullluc-3) then ready for the luciferase assay.
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Template DNA - P1B2 
Mdm2-5'upF1+Sall
P1 5‘ RA
LoxP-Fw
P1 3' RA
— pRAYNec^^^ t—i |
LoxP-Rv 
__ )
Mdm2ln1 R1+Notl
427 bp
V
333 bp
I
Mdm2-5'upF1+Sall
*----- 4— I B
Template DNA - pRSMdm2TK
Mdm2ln1F1
; P2 2 3
A&—
V__
726 bp
Mdm2ln1 R1 +Notl 
J
\
Mdrr^-S’upFI+Sall
Mdm2SexA1 R
J
um 3| D
Mdm2SexA1 R
1613 bp
i
|P2 |2j
Figure C.3: Fusion PCR of the Mdm2 P1-Null promoter region for luciferase assay.
Schematic diagram of each individual PCR reaction performed to construct the Mdm2 P1-Null 
promoter region. PCR products A & B were fused together to create product C. Product C 
was then TA-cloned into pCR2.1 and the resulting bacterial colonies were screened by 
restriction digest with Spel before being sequenced. Once the sequence of C was confirmed 
it was re-amplified and used in a further fusion PCR reaction with PCR product D to produce 
E. E was then TA-cloned into pCR-XL-TOPO, screened by restriction digest with EcoRV & 
Hindi 11 and confirmed by sequencing.
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C.5 Mdm2 shuttle DNA construction
This section describes the failed cloning attempts during the generation of the Mdm2 
shuttle vector.
Table C.4: Cloning attempts for inserting the Mdm2TK DNA fragment into the yeast-E. 
coli shuttle vector pRS414.
Attempt Description Result
1 Overnight Spel digest, followed by liquid
GENECLEAN and Sail digest for 3-4 hours.
50 ng of backbone to 90 ng of insert. MAXStbl.2.
0 colonies
2 As above except
50 ng of backbone to 225 ng of insert.
~ 30 colonies however these
grew very lumpy and DNA
could not be extracted.
3 As above except
50 ng of backbone to 180 ng of insert
0 colonies
4 As above except transformed into TOP10 bacteria 5 colonies - all positive!
C.6 Generation of Southern probes
This section describes the generation of the 300-800 bp genomic specific PCR 
products which were used as probes for Southern blots. The primers were designed using 
primerBLAST (to minimise non-specific annealing of the probe) and the products were 
amplified by PCR using the indicated primer pairs and BAG clone DNA as the template (see 
Table C.5). The resulting PCR products were then TA-cioned into pCR2.1 and positive 
clones were identified by restriction digestion with EcoRI. The DNA sequence was confirmed 
and then Southern probes were prepared by digestion of the plasmid with EcoRI to excise the 
probe fragment from the pCR2.1 backbone. The DNA fragments were gel purified and eluted 
to be at ~ 50 ng/pl for radioactive labelling.
A test Southern blot was performed in order to validate the specificity of the Southern 
probes to ensure that they would be able to recognise the expected DNA fragments and
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determine the sensitivity of each probe. Having an accurate and sensitive Southern probe 
was important for correct identification of potential positive ES cell colonies since there would 
be limited starting material and due to the nature of gene targeting experiments we could only 
expect 0.5 copies of the targeting construct (transgene) per cell. Both the Mdm2 Southern 
probes appeared to be both specific and sensitive (able to detect 0.01 copies of the “trans­
gene” and the expected genomic size fragment) however the p21-mCherry 790 bp probe was 
very non-specific and a new one will need to be designed for future experiments (see Figure 
C.4).
Copy number was calculated using the following equation; where haploid content of a 
mammalian genome is 3 x 109 bp and assuming 10 pg of genomic DMA available.
Mass of trans-gene =
N bp trans-gene
3 x 109bp genomic DMAv J
x 10 pg genomic DMA
Table C.5: Southern probes.
Construct Restriction Forward primer Reverse primer Product
Enzyme size
p21-mCherry EcoNI P21PROBE-F1 P21PROBE-R2 790 bp
Mdm2 P1-Null Ahdl Mdm2PROBE-F1 Mdm2PROBE-R2 378 bp
& P2-Mutant
Mdm2 P2-Mutant Ncol P2PROBE-F1 P2PROBE-R1 571 bp
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Figure C.4: Southern probe validation.
2 day exposure of test Southern blot analysis for each Southern probe. 10 pg of genomic 
DNA was digested overnight with the indicated enzyme and run on an agarose gel with 0.01, 
0.1, 1 and 10 copies of the “trans-gene” (the plasmid containing the probe). The linearised 
plasmid was ~ 4.4 kb in each case. The p21 probe was unable to detect a single band at 
11.5 kb in the genomic DNA and instead appeared as a smear, indicating that the probe was 
too non-specific. Both Mdm2 probes were able to detect a single fragment of the correct size 
in the genomic DNA and were able to just detect 0.01 copies of the “trans-gene” (does not 
show up very well on this scanned copy of the film - however is much more apparent on the 8 
day exposure - data not shown). Additional bands present on the 10 copies lane were from 
star activity of the enzyme (EcoRV) used to linearise the plasmid containing the probe.
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APPENDIX D ALTERED SEQUENCES
D.1 Consensus Sequence of pKO (TK2)
(Sequences compared with each other and changes noted below)
Pink = MCI Promoter, Green = TK, Orange = PolyA signal
tttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggtt|tgg 
ccttttqcBcqqaccqtaqaqtcqaqcaqtqtqqttttcaaaaqqaaqcaaaaaqcctctccacccaqqcct 
qqaaLqtttccacccaatqtcqaqcaqtqtqqttttqcaaqaqqaaqcaaaaaqcctctccacccaqqcctq
qaatqt-t-tccacccaatqtcqaqcaaaccccqcccaqcqtcttqtcattqqcqaattqqaacacqcaqatqc
aqtcqqqqcqqcqcqqtcccaqqtccacttcgcatattaaqqtqacqcqtqtqqcctcqaacaccqaqcqac
cctgcaqcqacccqc ttaacaqcqtcaacaqcqtqccqcacatcttaataacataaaactcccanannl-.nM-
actaaacct j____.cggaccggtaaaacgacggccagtgtt
Confirmed changes in order
-C, +A, A>G, A>G, C>T, T>A, +G, +C, G>C,
Comparison of Protein Sequences (TK)
Protein sequence (Consensus)
>Frame 1
MASYPGHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRPEQKMPTLLRVYIDGPHGM
GKTTTTQLLVALGSRDDIVYVPEPMTYWRVLGASETIANIYTTQHRLDQGEISAGDAAVVMTS
AQITMGMPYfVTDAVLAPHIGGEAGSSHAPPPALTLIFDRHPIAALLCYPAARYLMGSMTPQA
vlafvalipptlpgtnivlgalpedrhidrlakrqrpgerldlaml|airrvygllantvrylq
GGGSWREDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAPNGDLYNVFAW
ALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMIQTHVTTPGSIPTICDLARTFAREMG
EAN
Protein sequence (Original Published)
>Frame 1
MASYPGHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRPEQKMPTLLRVYIDGPHGM
GKTTTTQLLVALGSRDDIVYVPEPMTYWRVLGASETIANIYTTQHRLDQGEISAGDAAVVMTS
aqitmgmpy|vtdavlaphiggeagsshapppaltlifdrhpiaallcypaarylmgsmtpqa
vlafvalipptlpgtnivlgalpedrhidrlakrqrpgerldlaml|airrvygli_antvrylq
GGGSWREDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAPNGDLYNVFAW
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ALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMIQTHVTTPGSIPTICDLARTFAREMG
BAN
Two changes to amino acid sequence
T133A & T232A, Threonine > Alanine, polar uncharged side chain vs. hydrophobic side chain
D.2 pACN self excision cassette - corrected sequence
Jeomycin phosphotrar 
M polymerase II large subunit promoter
)re gene with
Testis specific angiotensin-converting enzyme promoter (tACE)
Self-excision Neo-Cassette (consensus sequence from sequencing)
+T, -T, -A (highlighted in red)
cacctaaattgtaagcgttaatattttgttaaaattcgcgttaaatttttgttaaatcagctcattttt 
taaccaataggccgaaatcggcaaaatcccttataaatcaaaagaatagaccgagatagggttgagtgt 
tgttccagtttggaacaagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgt 
ctatcagggcgatggcccactacgtgaaccatcaccctaatcaagttttttggggtcgaggtgccgtaa 
agcactaaatcggaaccctaaagggagcccccgatttagagcttgacggggaaagccggcgaacgtggc 
gagaaaggaagggaagaaagcgaaaggagcgggcgctagggcgctggcaagtgtagcggtcacgctgcg 
cgtaaccaccacacccgccgcgcttaatgcgccgctacagggcgcgtcccattcgccattcaggctgcg 
caactgttgggaagggcgatcggtgcgggcctcttcgctattacgccagctggcgaaagggggatgtgc 
tgcaaggcgattaagttgggtaacgccagggttttcccagtcacgacgttgtaaaacgacggccagtga 
attgtaatacgactcactatagggcgaattggagctcgagatctagatatcgatgaatt(
ctcagctttacagtgacaatgacggctgg 
cgactgaatattagtgcttacagacagcactacatattttccgtcgatgttgaaatcctttctcatatg 
tcaccataaatatcaaataattatagcaatcatttacgcgttaatgg|
cgcaccattgcccctgtttcactatccaggttacggatata 
ccaccagcttgcatgatctccggtattgaaactc 
gcactgtgtccagaccaggccaggtatctctgac
399
iggccgca
ggaaagcagagccctgaagctcccatcaccggccaataagagccaagcctgcagtgtgacctcatagag
caatgtgccagccagcctgaccccaagggccctcaggcttgggcacactgtctctaggaccctgagaga
aagacatacccatttctgcttagggccctgaggatgagcccaggggtggcttggcactgaagcaaagga
cactggggctcagctggcagcaaagtgaccaggatgctgaggctttgacccagaagccagaggccagag
gccaggacttctcttggtcccagtccaccctcactcagagctttaccaatgccctctggatagttgtcg
ggtaacggtggacgccactgattctctggccagcctaggacttcgccattccgctgattctgctcttcc
agccactggctgaccggttggaagtactccagcagtgccttggcatccagggcatctgagcctaccagg
tccttcagtacctcctgccagggcctggagcagccagcctgcaacacctgcctgccaagcagagtgacc 
actgtgggcacaggggacacagggtggggcccacaacagcaccattgtccacttgtccctc 
aagaactctagggttgcggggggtgggggaggtctctgtgaggctggtaagggatatttgcctggccca
tatcgatac^^^JJctcgagggggggcccggtacccagcttttgttccctttagtgagggttaattt
cgagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacaca
acatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattg
cgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaac
gcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcgg
tcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcagggg
ataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgc
tggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggc
gaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttc
cgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagct
cacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccg
ttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttat
cgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttct
tgaagtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccag
ttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggttttt
ttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacgg
ggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatct
tcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggt
ctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatag
ttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaa
tgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccg
agcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagag
taagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgct
cgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgt
tgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttat
cactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtga
ctggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgt
caatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcgg
ggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaact
gatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa
aaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagca
tttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaatagggg
ttccgcgcacatttccccgaaaagtgc
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D.3 Puma left arm of homology actual sequence
Exon 1, mat. Exon 4
gctgaatgctccaaggtctctcactgtctgcagattgtccagTgtgggttattttaaatttaattgtgt
gtgagtatgTGtgtgtgtgtgtgtgtgtgtgtgtgtgtacgtgagtgtgtggacaTggacgcaggtctc
tcaggaggccaggagcatcagattccctgAagctagggttacatatccaggcacaagatgtaggtactg
ggaacagaacacaggtccttccttgggaagagctgtaagcactcttaatcactgagttctcTccccccc
TTccccAcacttgcttcgttttttgaaaaagatcacttgctgtgctcaaaaatgggcttggagagccgg
gcatggtggcgcacgcctttaatcccagcactcgggaggcagaggcaggaggatttctgagttcgaggc
cagcctggtctacaaagtgagttccaggacagccagggctacacacagaaaccctgtctcaaacaaaca
aacaaacaaaTaaacaaaaaagctggacagtggtggtgcatgcctttaatcccagcacttgggaggcaa
aggcaggtagatttctgagtttgaggccagcctggtctacaaactgagttccaggacaGccagggctac
acagagaaaccctgtcttgaaaaaccaaaaaaaaaaaaaagggggggggggcctggaactcactatgta
actcagacagactccaaccttgcaaccacCttcctgcttCatcctctgAaagtgctgggaagacaggtg
CaagtCactGtgtttatttctttaacaagtgtcttatctcacatggctgtgtgacaccctttcacagcg
ggccagtgctgggcacccataggtaagtaatatactcagtaagtttggtgacagtttgggtgagacaga
gagtctgtcaagtgccgtgagagatgtctacggcttgggaggaggaagggtcactgtttcaaaagggaa
gggaaataaatgacttttagaaaagggaaaggaaacagaaacaacagacaggatgaaatagggtgcagg
gggctgcccgggcatgtcCgtgccaggagcGcagggctgcctcttccccatttgtccagtgccagatgg
gtattacgccaggcgggccaggtgtttaagttcacgagtgtaacccgccatcaagccatttagcaggaa
cctgtctcaggagtgactttgtgagcacaggtctgggctcagtttcttctgtatgtgactggcatgttt
tgtagggtcagccagtgcagtctagtggctgtgcttcagctattgcgggtgtcagcctgagagtgctat
ttggattggagtgtgtgtccctctgaacctgccaggaagttgttctgagaaggggtcagcctttagtgt
agtgtgaatgccAtaggcatctggggacacgggtttgtgAgtcggagactgtttgaatattgtttgtgc
aactacgttttgggttgtcactgtctgtgtgtgacccagtgagccagtaagtaagataatctggatgtc
tgggtctgtgtgagctTgtgtgGccaggcccttgtccCgatgtgtatctgtgcctctggtctgactttg
tgtccctgtggctcagtcatcactgactcagtgcaccctggcgtgccagtccgttagtctgagcgtact
cctcaggtgtgggtgtgggtcccagtcagtgtgtcagtgtgtcaagcgtgtgtccggacaccctaggtc
tgggctgtccccacgctgctcctcctgcctggaccaggcctcgccccgcccctctggctgccgggaaac
cccccgcgccgaggtagggggcgcggcgcccgactgcaagccccgacttgtccccagccgcgggcgggg
ccctggcgtcacgcgggggcggggcgtgggagccagcgagaggcggggcggggcggGGCGGccgccgag
cgagcggggcccggggatctgccgggaggcctgagacgcggcatagagccacatgcgagcggggagccc
aggaggcggcggcgacaccagcaagcaagcagcagcagcggtgatccggacacgaagactccGgaagca
gcagcagtcactgcagttagagcagcaggagcagcagcaaggtgcctcaatagcaacccactcggcggg
cgagccctccagaaggcaaccgcccgccaccccatcgcctcctttctccggagtgttcatgcccccggg
gtgagtgagcaccccgattcccgaagctgTttacgagcggcaaggcccggagggctccctggaggaggt
gacggggtgcacgggccgataggacggtcgccttgcattcccgcagcttgtgccccagctttcatcact
gggactaaggctgggccaggcgggcgggaaggaagcacctgggactcagggcgccctgtctgggcgcac
aggtgccacagcggtctggcgggtttgtttacaaacaatggggttcgggctcgcccgcgccccctggtg
gctagtgagacctgggaggagcgtggccccgggctcgctcgagtcccccgagtcccactgcgggagggt
tggggtggggggtggcaccgaggatcggccacacccagagcgcgcgcccgccgggggcggcgacagggg
gcggcggaggctgtggctcccgcgggcgggggctgcgccccagcaacagccggttattggccccgcgcg
cgctgggcgggcggggcgggcgcacgtggcggcgtcgagggggggggGctgtgacagcggaggggcggc
ggggaccgcgcgtgcggggctgtggatctgcaggtgtctcgcctgggtgtgtgtgctcgtgtttggctc
ccgagtttgtatccctacaccgagatgttggcgtttgtcacccggaggggtgtctgcgtgagtccttgc
ccgcgtgtctgcggggtggggtgcacctgtccgtttacgggtgtgggtggccaccccccaaaccagagt
tgtatacgtgtgctcttaaggggtgaaaaggggatctgtatctgtcgcttgcctggtagtgctggtggt
ggtggtgcggacgaccggggcacttgagctgtgtttgtgtgtcgcttgagtgagctgtgttgctgtgca
ggggtctcgcccaagtgtgcgctgcgTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
GTGTGTGTGTATGCGCGCGCGCGCGTGCTGTCTCTGGGTGTCTCCAAGACAAGCATCTGCTGTACCCAG
CTTTTGGGATGGGATGTCACCCAGTGCCTGATCGCTCGCTGGGTGACTTCTGAGCAGCAAAAGGCACAC
AAGGCACGCTGAGCATGAAGGGCTTTGGGGGTGGGGGGGATCTAGCGGGTTCAGTGCCAGCCCCTCTCT
CTGCATGCAGTGTGTGTGTGTGTGTGTGTGTGTGTGAAAGAGAGAGAGAGGGGGGGGTGAGAGTGAGTT
TTGGGTCTGAGGGGTTTGTCTCTGTGATCcaggctatgtgtcatgtggtgctctctctctgtagtgttt
ataccagtcacgtgaggccagtgttttctgtctctgcattaggtgtgtgtgctgctgggctctgtgtgt
gtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgttttctggggctgacagttggctgtggtgt
attggggctgagagtagaggctggacctatggcttctaccagctgcggctggtgcctcccgatgtggct
gcccccgcactcgaggggggatgatgtatctggatatgatgacttgtgtctatgtgtggctgttgtgtc
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ccaggagctcaaagttggggCgggggtgcacattcaggtgtgttttgagatgatggtggtgcatgtgct
aaggaatagtaaggggggtgtctttgggttgtctgtgtgtatgcgggagaaacacgttgaagacttgag
tctgttgtgcttcagtgtgtgacggctgcattgtgggcgggtgagcgctggcatgtcagcagcgggtca
gtgtgagactggtgtaaatatgttgaaagggctctggatggctgtgtgtgcatgtctgtgtccccatgt
gtttctgggtgagacacctcactgggggagcgggaggggcggtaaagttggacacttctctgagttcac
tggtgtcttcccattACACACACACACACACACACACACACACACACACACACACACACACACACACAC
ACACAAACACACACACACACggttctctgacagcaccgtgtatcctgggagccccagcaccccttctgc
gctcttctctgttgagaaagttctccctggcccaagccctgagagtagtaggcagttttcctggtgggt
tttgctacaaaccccagacgcagtctgtgcgcccctcaccatgtgtcccggccaggctgtccctggggt
catcccttcctgggtgggagtgacttccaggcagggtgtctgcgaggtggggtcctgcagccccccccc
cgcagtcgccccactgacctcccgccgtgtcccgcag^^^^^BB^^^BI^^BBjj^M^^W
aggagggGagctctccggagcccgtagagggtctagcccgcgacagtccgcgccccttcccgctcggcc
tgtatcctgcagcctttgc
D.4 Puma right arm of homology, actual sequence
tttcgcgagctcgagatctaTCCTCCATCTCCTTCATTGGTTACCACTGAGCAAATCCTAGAGACTAGG
CAAGTAGCATGGCCTGGTGGCAGCATCCCGTAATCCCACCTACTCAGGGAGGGAGAAAGAAAGTTCAAA
GCCAGCCTGGGCAACCTAGTGAGTGATATTCTGCTTCAGAAATAGTCTTTGAAGTGGCTCAGAGGATAA
AGGTGCTTGCTACCAAAACTGATGAACAGAGTTCGATTCCCAGGACCCACTTAGTAAAAGTCAAGAGTC
TAATCTTACATAGTGTTCTCTAACCTCCACATGTGCACACACAAATCCCCCCCCCCTCTCTTTCTCATA
CACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACGTTA
ATGGTTAAGAGAACTCTTACAGAGAACCAGGGTCAGGTTCCCAGCTGACAACTGCCTGTAATTCCAGGT
CCAGGGATCCAATGCCTTCTGGTATTTGCCAGCACGTACACATTAGTTTGTTTGTTAGTTAGTTTGTTT
TTTAAAGATTTATTTATTTTATGTTTAATGAGTACACTGTTGCTGTCTTCAGACACAGGAGAAGAGGGC
ATCAGATGGTTGTGAGTCACCATGTGGTTGCTGGGATTTGAACTCAGGACCTCTGGAAGAGCAGTCAGT
GCTCTTAACGGCTGAGCCATCTCTCCAGCCCACATATTATTATTTTTTAAGTTTTATTTATTTACTTAT
TTATAATTCAGGGGAGGCTGATGTAGCTCAGTTGGTAGAGTGCTTGCCTAGGAGAGAGACACTGACCCT
TAGGTCTGTGGGTCAAGGTCACCCTCAAATACAGTTTCAGTTCCAGGACATCCTGTGCGACATGAGGTG
AGGTCTCAAAAACAGGAAGATTTTTTTCTTTTTTTTtCTTTTGTTTTTTCGGGACAGGGTTTCTCTGTG
TAGTCCTGGCTGTCCTGCAACTCACTCTGTAGACTAGGCAAACTGGCCGGGAACTCAGAGGTTCTCTCC
TCCTGCCCTTCCCCCACTCAAGTGCTGGGCTTAAAGGTTCCACTCAGCTGAGCTTTTTTTTTTTTtAAA
ACACATGCCTGGAATCCACCAGTGAGTGGCAAAAGGTGTGGCTTAGCAGCAAACATTGTCTAGCATTAG
TCTTTTCTCCTCTTTTCTAAGAGATGGCCATCTCTGGCTTGGCCCATGTGCTGTTGTCTTCAGAGTGAA
CACCCAGGGCTCCGTGCTCCCCCTAATAGGCTAAGTATAATGATAGTGAACTCACAAGGTGGCATCCAC
CACCTCGCCCAGTTGCAAGGAGGAGGAGGGCACAGGAGGCCTGGGCTAGTTCTGGGCATGTACTCCAAT
AGGGTCATTAGCCTGACATCTTCCAAATGGATTACATTCTTCACAACCAAGAACATGAGCCCGGTGGAT
CTGCTTGGCCACATAACCAGTGGAAGGATCAAGTAAAAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
CTCTTCCGTTCTTCCTTCCTTCCTTTCTCCCTTCCTTTCTTTCTCTTTCTTTTCTTTTCTTTtctTTTc
tTTTCTTTTCTTTTCtTTTCTTTTCTTTTCTTTTCTTTCTTtCcTTcTCTCTTTCTTTCtTTCTCTCAC
TCTCCCTCCCACCCTCCCTCTcCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTACCTTCCTtcCTT
CTTTCCTTCCAACACTGGCTGTCCTAGAACACACTATGTAGACCACCATGCTAGCCTTGAATTCTCAGA
GATCTGCCTGCCTCTGCCTCACAAGTTCTAAGATTAAAGATGTGAGCTACCACACCCAGCATTCTTTCT
TTCTCTCTCTCTCTCTTTCTCTCTTTCTTTTTCTCTTTTCCTTTTTTTTTtCTTTCTTTCCTTTTCTTT
CTTTTTCtTTTTTTTTTTTTTTAGGCTGGCTCTTAATAAGCTGTTCACACTGGCTTTGAACTCACTCTA
TAGCTCAGACAGGCTTTGAACTTTTGTCTTCCTGCCTCAGCCTCCTGAGTCGCTGGGATTACAGGCCTG
TGCCATCACAGAAGAAATCTAGATGCTACATCACACTTTTTCTCTACCACCAGGGATCGAACAAGAGTT
TCCCTGAAGCCAGCATTGCCAAGAGACACCTTCTCTcAGCCTTGCTGGCATGGccTGCTgTtCTcAaCC
CTCTTCCGGGgTGGTTTGAGAACTGCTTAGGCTGTCGGGCTGCTCCTTACTCTCTCTCATGTCCCAACA
GCCTTTTGTTTGGTTGGTTTGATTTTTCCAGTTAGGAGCCTGTGCTCTAGCACAAATTTAGTGAGGCAC
GCTAAGATGAGGAGTACGAGCCACCACGCCTGTCTCTCGCCTTGAGTGGGCTGCGTTTCAGCCCACCCC
TTAGAGCCCTTGTGATTCATAGGGTGTGTGTGCTAGGCTCTATGCTATGGGAATTCTGCCCCAGCCCCT
TCCCACCTAGATTGGGAGAGTGTGACGTGGTGAGTGAGGGGCTGAAAAATGGCTGGTAAGAGGGTTGCG
CACAGTTTTGGGACCGATCTCGAACCCACACCTTTTGCTCACTAACCCACTGTCTGCGGGTCCAAGCTA
ATTCCTACTTCCTCCTCTCCCCAGAGACAAGAAGAGCAGCATCGACACCGACCCTCACCCTGGAGGGTC
ATGTACAATCTCTTCATGGGACTCCTCCCCTTACCCAGGGATCCTGGAGCCCCAGAAATGGAGCCCAAC
TAGGTGCCTACACCCGCCCGGGGGACGTCGGAGACTTGGGGGGCAGGACCCCCTCCGCCTTCTGACACC
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CTGGCCAGCGCGGGGGACTTTTTCTGCACCATGTAGCATACTGGACTGCCAGCCTTGCCCGTCCCAGGG
GCAGGCAAGGGATGCCACTCGAGCCCGGGCAGCCTGGGTGCACTGATGGAGATACGGACTTGGGGGGAC
CCTGGCCTCCCGAAAGCCAGGGAAGGGAGGGCTGAAGGACTCATGGTGACCGAGGGGGTGGGGACCGAG
CCGCCCGCCTCTGCCGCCCACCACCATCTCAGGAAAGGCTGCTGGTGCTGGCTGCCCGTTCCAGCTGCA
GGggGGACGCTgGGGGTGTCCCCAGTGCGCCTTCACTTTgGGCCTggCCTCAGGCCCCTgGTgCttCCC
CCCCTCCTCCTGAGGAGGGGGTCTGTGAAGAGCATATGAGCCAAACCTGACCACTAGCCTCCTGGAGCC
AGAGAATGGGGGGCGTGTGAAGGCCTTCTTAACCCAGTGCCCAGCCATCTTCCCTGAGCCGCCGGCGGG
CGGTGAACGATGCCTGCCTCACCTTCATCTGGGGGTGTCCAGGAGGGGTCCAGACTGTGAATCCTGTGC
TCTGCCCGGGACCACCCcACACCCCCAATCCCCATCCATCTCATTGCATAGGTTTAGAGAGAGCACGTG
TGACCACTGGCATTCATTTGGGGGGTGGGAGATATTGGCGGAAGCCACCCCAGCCTTAGTCCCCAGGGC
AAAGCGCTGGGGAGGAAGATGGGGAGTCAGGGAGGGGGGAAGTCTCAGAAGAGGGAGGAGTCTGGGAGC
GGGGAGGGACGGCCCAGCCTGTAAGATACTGTACATGCACTGCTGTAGATATACTGGAATGAATTTTCT
GTACATGTTTGGTTAATTTTTTTTGTACATGATTTTTGTATGTTTCCTTTTCAATAAAATCAGATTGAA
CAGTGAACACTCTTTTTGTTAGCTTTACCAGTGACAGAGCATCTGGCACTACCTGTGAGGACATGAAAG
AAACGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGA
GAGAGAGAGAGAGAGAGAGAAATGGCTCAGTGGTTAAGAGCACTGACTGCTCTTCCAGAGGTCCTGAGT
TCAAATCCCAGCAACCACATGGTGGCTCACAACCATCATAATGAGATCAGACACCCTCTTCTGATATGT
CTGAAGGCAGCTACAGTGTACTTACATATAACAATAAATAAATGTAAAAAAGAGAAAGAAAGAAAGAAA
CTGGAACTTTTGGACTCTTAAGGGGCAGTCATACTAAAAGGTAAGCTAGAGGCTGGTCTGGTGGCACAG
GCCTGTCGTAGCTAGTTGGAAGGCCTGAGCAACTGAGACCCAGTCTCAGCAATGGGGAGGGGACAGGTG
GAGGGGACAGGCGGAGCGCTGGCTCAGCAGGTAGAAGTATGGGCTGTTCTTCAAGAGGATCTGCATTTA
GGTCCCAGCACCCATGCTGCAGCTCACACTCTGTAACTCAAGTTCCAGATCTGATACCTCCTGGCCTGC
GGGTACCAGGCATGTGCACAGGGCCCATTCCATGCGGACAAGGAAACCCAAAACCCCAAAAACACATAT
GCACATAAAATAGGTAAATGTGCCAGGGAGGTGGCTCAACTGTGAAGAGCACCAGCCGTTCTTCCAGAG
GTCCTGAGTTCAATTCCCAGCTACCACATGGTGGCTCACAACTATGTATAATGTTATCCAATGCCCTCT
TCTGGgtcgac
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